(12) STANDARD PATENT (11) Application No. **AU 2005267161 B2**
(19) AUSTRALIAN PATENT OFFICE

(54) Title
Substituted aryl-amine derivatives and methods of use

(51) International Patent Classification(s)
C07D 401/12 (2006.01)
A61K 31/4427 (2006.01)
A61K 31/443 (2006.01)
A61K 31/4439 (2006.01)
A61K 31/444 (2006.01)
A61K 31/4725 (2006.01)
A61P 35/00 (2006.01)
C07D 217/02 (2006.01)
C07D 401/14 (2006.01)
C07D 403/12 (2006.01)
C07D 405/12 (2006.01)
C07D 405/14 (2006.01)
C07D 413/14 (2006.01)
C07D 417/14 (2006.01)
C07D 471/04 (2006.01)

(21) Application No: **2005267161** (22) Date of Filing: **2005.07.20**

(87) WIPO No: **WO06/012374**

(30) Priority Data

(31) Number	(32) Date	(33) Country
11/185,556	**2005.07.19**	**US**
60/590,544	**2004.07.22**	**US**

(43) Publication Date: **2006.02.02**
(44) Accepted Journal Date: **2009.02.12**

(71) Applicant(s)
Amgen Inc.

(72) Inventor(s)
Patel, Vinod F.;Yuan, Chester Chenguang;Huang, Qi;Li, Aiwen;Harmange, Jean-Christophe;Riahi, Babak;Yang, Kevin;Nomak, Rana;Askew, Jr., Benny C.;Vanderplas, Simon;Potashman, Michele

(74) Agent / Attorney
Shelston IP, 60 Margaret Street, Sydney, NSW, 2000

(56) Related Art
WO 2004/007481 A
WO 2001/085715 A
WO 2004/005279 A2

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
2 February 2006 (02.02.2006)

PCT

(10) International Publication Number
WO 2006/012374 A1

(51) International Patent Classification:

C07D 401/12 (2006.01)	*C07D 471/04* (2006.01)
C07D 413/14 (2006.01)	*A61K 31/443* (2006.01)
C07D 401/14 (2006.01)	*A61K 31/4427* (2006.01)
C07D 405/12 (2006.01)	*A61K 31/4439* (2006.01)
C07D 405/14 (2006.01)	*A61K 31/444* (2006.01)
C07D 217/02 (2006.01)	*A61K 31/4725* (2006.01)
C07D 403/12 (2006.01)	*A61P 35/00* (2006.01)
C07D 417/14 (2006.01)	

(21) International Application Number:
PCT/US2005/025800

(22) International Filing Date: 20 July 2005 (20.07.2005)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

60/590,544	22 July 2004 (22.07.2004)	US
11/185,556	19 July 2005 (19.07.2005)	US

(63) Related by continuation (CON) or continuation-in-part (CIP) to earlier application:
US 11/185,556 (CIP)
Filed on 19 July 2005 (19.07.2005)

(71) Applicant *(for all designated States except US)*: **AMGEN INC.** [US/US]; M/S 28-2-C, One Amgen Center Drive, Thousand Oaks, CA 91320-1799 (US).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **YUAN, Chester Chenguang** [US/US]; 1416 Geyser Court, Newbury Park, CA 91320 (US). **YANG, Kevin** [US/US]; 8871 Camino Real Avenue, San Gabriel, CA 91775 (US). **VANDERPLAS, Simon** [NL/CA]; 21 Shaughnessy Cres, Kanata, Ontario K2K 2P2 (CA). **RIAHI, Babak** [US/US]; 6141 Kenwater Avenue, Woodland Hills, CA 91367 (US). **POTASHMAN, Michele** [US/US]; 217 Harvard Street, Apt. GR-R, Cambridge, MA 02139 (US). **PATEL, Vinod F.** [US/US]; 3 Mossy Lane, Acton, MA 01720 (US). **NOMAK, Rana** [TR/TR]; Ucaksavar Loj. B Blok D:20, Bogazici University, 34342 Etiler Istanbul (TR). **LI, Aiwen** [CN/US]; 660 Via Colinas, Westlake Village, CA 91362 (US). **HUANG, Qi** [CN/US]; 12308 Willow Forest Drive, Moorpark, CA 93021 (US). **HARMANGE, Jean-Christophe** [FR/US]; 57 William Street, Andover, MA 01810 (US). **ASKEW, JR., Benny C.** [US/US]; 266 Arrowhead Road, Marshfield, MA 02050 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US (patent), UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:
— *with international search report*
— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments*

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: SUBSTITUTED ARYL-AMINE DERIVATIVES AND METHODS OF USE

(57) Abstract: The present invention provides classes of compounds, including-their pharmaceutically acceptable derivatives, useful for treating angiogenesis and related diseases such as cancer. Formula I and II wherein R is a 9- or 10-membered heterocyclyl ring selected from 7-isoquinolinyl,.2-methyl-3-oxo-2,3-dihydroindazol-6-yl, [1,6]-naphthydrin-3-yl, [1,7]-naphthydrin-2-yl, 1-oxo-2,3-dihydrobenzofuran-4-yl, 3-oxo 2,3 dihydrobenzofuran-5-yl, dihydro-benzodioxinyl, 6-quinazolinyl, 2-amino-6-quinazolinyl, 4-methylamino-6-quinazolinyl, 2,4-diamino-6 quinazolinyl, 3-oxo-3,4 dihydro-1,4-benzoxazin-6-yl, 2,2 difluoro-l;3-benzodioxol-5-yl and 2,2,3,3 tetrafluoro-2,3-dihydro-l,4-benzodioxin-6-yl, each of which is optionally substituted with one or more substituents selected from halo, haloakyl, C_{1-6} alkyl, C_{2-8} alkenyl, C_{2-8} alkynyl, N-dimethylamino-C_{1-6}-alkyl, N-dimethylamino-C_{1-6}-alkoxy, amino, alkyl-carbonylamino, morpholino-sulfonyl, amino-sulfonyl, oxazolyl, pyrrolyl,4 morpholinyl, carboxyl, cyano, and acetyl; wherein R^1 in formula I is selected from unsubstituted or substituted phenyl, 5-6 membered heteroaryl, 9-10 membered bicyclic heterocyclyl and 11-14 membered tricyclic heterocyclyl, and R^1 in formula II is selected from specific bicyclic heterocycles.

WO 2006/012374 A1

SUBSTITUTED ARYL-AMINE DERIVATIVES AND METHODS OF USE

This application claims the benefit of U.S. Provisional Application No. 60/590,544 filed July 22, 2004, which is incorporated by reference herein.

FIELD OF THE INVENTION

This invention is in the field of pharmaceutical agents and specifically relates to compounds, compositions, uses and methods for treating cancer and angiogenesis-related disorders.

BACKGROUND OF THE INVENTION

Any discussion of the prior art throughout the specification should in no way be considered as an admission that such prior art is widely known or forms part of common general knowledge in the field.

Protein kinases represent a large family of proteins which play a central role in the regulation of a wide variety of cellular processes maintaining control over cellular function. A partial list of such kinases includes abl, Akt, bcr-abl, Blk, Brk, Btk, c-kit, c-met, c-src, CDK1, CDK2, CDK3, CDK4, CDK5, CDK6, CDK7, CDK8, CDK9, CDK10, cRafl, CSF1R, CSK, EGFR, ErbB2, ErbB3, ErbB4, Erk, Fak, fes, FGFR1, FGFR2, FGFR3, FGFR4, FGFR5, Fgr, flt-1, Fps, Frk, Fyn, Hck, IGF-1R, INS-R, Jak, KDR, Lck, Lyn, MEK, p38, PDGFR, PIK, PKC, PYK2, ros, tie, tie2, TRK, Yes, and Zap70. Inhibition of such kinases has become an important therapeutic target.

Certain diseases are known to be associated with deregulated angiogenesis, for example, ocular neovascularisation, such as retinopathies (including diabetic retinopathy), age-related macular degeneration, psoriasis, hemangioblastoma, hemangioma, arteriosclerosis, inflammatory disease, such as a rheumatoid or rheumatic inflammatory disease, especially arthritis (including rheumatoid arthritis), or other chronic inflammatory disorders, such as chronic asthma, arterial or post-transplantational atherosclerosis, endometriosis, and

neoplastic diseases, for example so-called solid tumors and liquid tumors (such as leukemias).

At the center of the network regulating the growth and differentiation of the vascular system and its components, both during embryonic development and normal growth, and in a wide number of pathological anomalies and diseases, lies the angiogenic factor known as Vascular Endothelial Growth Factor"(VEGF; originally termed 'Vascular Permeability Factor", VPF), along with its cellular receptors (see G. Breier et al., Trends in Cell Biology, 6, 454-6 (1996)).

VEGF is a dimeric, disulfide-linked 46-kDa glycoprotein related to "Platelet-Derived Growth Factor" (PDGF); it is produced by normal cell lines and tumor cell lines; is an endothelial cell-specific mitogen; shows angiogenic activity in *in vivo* test systems (e.g. rabbit cornea); is chemotactic for endothelial cells and monocytes; and induces plasminogen activators in endothelial cells, which are involved in the proteolytic degradation of extracellular matrix during the formation of capillaries. A number of isoforms of VEGF are known, which show comparable biological activity, but differ in the type of cells that secrete them and in their heparin-binding capacity. In addition, there are other members of the VEGF family, such as "Placenta Growth Factor"(PlGF) and VEGF-C.

VEGF receptors (VEGFR) are transmembranous receptor tyrosine kinases. They are characterized by an extracellular domain with seven immunoglobulin-like domains and an intracellular tyrosine kinase domain. Various types of VEGF receptor are known, e.g. VEGFR-1 (also known as flt-1), VEGFR-2 (also known as KDR), and VEGFR-3.

A large number of human tumors, especially gliomas and carcinomas, express high levels of VEGF and its receptors. This has led to the hypothesis that the VEGF released by tumor cells stimulates the growth of blood capillaries and

the proliferation of tumor endothelium in a paracrine manner and through the improved blood supply, accelerate tumor growth. Increased VEGF expression could explain the occurrence of cerebral edema in patients with glioma. Direct evidence of the role of VEGF as a tumor angiogenesis factor *in vivo* is shown in studies in which VEGF expression or VEGF activity was inhibited. This was achieved with anti-VEGF antibodies, with dominant-negative VEGFR-2 mutants which inhibited signal transduction, and with antisense-VEGF RNA techniques. All approaches led to a reduction in the growth of glioma cell lines or other tumor cell lines *in vivo* as a result of inhibited tumor angiogenesis.

Angiogenesis is regarded as an absolute prerequisite for tumors which grow beyond a diameter of about 1-2 mm; up to this limit, oxygen and nutrients may be supplied to the tumor cells by diffusion. Every tumor, regardless of its origin and its cause, is thus dependent on angiogenesis for its growth after it has reached a certain size.

Three principal mechanisms play an important part in the activity of angiogenesis inhibitors against tumors: 1) Inhibition of the growth of vessels, especially capillaries, into avascular resting tumors, with the result that there is no net tumor growth owing to the balance that is achieved between cell death and proliferation; 2) Prevention of the migration of tumor cells owing to the absence of blood flow to and from tumors; and 3) Inhibition of endothelial cell proliferation, thus avoiding the paracrine growth-stimulating effect exerted on the surrounding tissue by the endothelial cells which normally line the vessels. See R. Connell and J. Beebe, Exp. Opin. Ther. Patents,11,77-114 (2001).

VEGF's are unique in that they are the only angiogenic growth factors known to contribute to vascular hyperpermeability and the formation of edema. Indeed,

vascular hyperpermeability and edema that is associated with the expression or administration of many other growth factors appears to be mediated via VEGF production.

Inflammatory cytokines stimulate VEGF production. Hypoxia results in a marked upregulation of VEGF in numerous tissues, hence situations involving infarct, occlusion, ischemia, anemia, or circulatory impairment typically invoke VEGF/VPF-mediated responses. Vascular hyperpermeability, associated edema, altered transendothelial exchange and macromolecular extravasation, which is often accompanied by diapedesis, can result in excessive matrix deposition, aberrant stromal proliferation, fibrosis, etc. Hence, VEGF-mediated hyperpermeability can significantly contribute to disorders with these etiologic features. As such, regulators of angiogenesis have become an important therapeutic target.

Schipper US patent 3,226,394, issued Dec. 28, 1965, describes anthranilamides as CNS depressants. Japanese patent JP2000256358 describes pyrazole derivatives that block the calcium release-activated calcium channel. EP application 9475000, published 6 October 1999, describes compounds as PGE_2 antagonists. PCT publication WO96/41795, published 27 December 1996, describes benzamides as vasopressin antagonists. WO01/29009 describes aminopyridines as KDR inhibitors. WO01/30745 describes anthranilic acids as cGMP phosphodiesterase inhibitors. WO00/02851, published 20 Jan 2000 describes arylsulfonylamnoaryl amides as guanylate cyclase activators. WO98/45268 describes nicotinamide derivatives as PDE4 inhibitors. WO98/24771 describes benzamides as vasopressin antagonists.

US Patent No. 5,532,358, issued July 2, 1996, describes the preparation of 2-(cyclopropylamino)-N-(2-methoxy-4-methyl-3- pyridinyl)-3-pyridinecarboxamide as an intermediate for HIV inhibitors. Triazine-substituted

amines are described for their aggregating ability (J. Amer. Chem. Soc., 115, 905-16 (1993). Substituted imidazolines were tested for their antidepressant activity in Ind. J. Het. Chem., 2, 129-32 (1992). N-(4-Pyridyl)anthranilic amides were described in Chem Abstr. 97:109837 (1981). PCT publication WO99/32477, published 1 July 1999, describes anthranilamides as anti-coagulants. US patent 6,140,351 describes anthranilamides as anti-coagulants. PCT publication WO99/62885, published 9 December 1999, describes 1-(4-aminophenyl)pyrazoles as antiinflammatories. PCT publication WO00/39111, published 6 July 2000, describes amides as factor Xa inhibitors. PCT publication WO00/39117, published 6 July 2000, describes heteroaromatic amides as factor Xa inhibitors. PCT publication WO00/27819, published 18 May 2000, describes anthranilic acid amides as VEGF inhibitors. PCT publication WO00/27820 published 18 May 2000, describes N-aryl anthranilic acid amides as VEGF inhibitors. 7-Chloroquinolinylamines are described in FR2168227 as antiinflammatories. WO01/55114, published 2 Aug. 2001, describes nicotinamides for the treatment of cancer. WO01/55115, published 2 Aug. 2001, describes nicotinamides for the treatment of apoptosis. WO01/85715, published 15 November 2001, describes substituted pyridines and pyrimidines as anti-angiogenesis agents. PCT publication WO01/85691 published 15 November 2001, describes anthranilic amides as VEGF inhibitors. PCT publication WO01/85671 published 15 November 2001, describes anthranyl amides as VEGF inhibitors. PCT publication WO01/81311 published 1 November 2001, describes anthranilic amides as VEGF inhibitors. U.S. Patent No. 6,462,075, issued October 8, 2002, describes chalcone and its analogs as agents for the inhibition of angiogenesis and related disease states. U.S. Patent No., issued August 19, 2003, describes the preparation of 6-methyl nicotinamides as anti-

viral agents. U.S. Patent Publication No. 2002111495, published August 15, 2002, describes the preparation of nicotinamides as PDE4 D isozyme inhibitors. U.S. Patent Publication No. 2003073836, published April 17, 2003, describes the preparation of biphenylcarboxylic acid amides as inhibitors of microsomal triglyceride transfer protein (MPT). U.S. Patent Publication No. 20040053908, published March 18, 2004, describes nitrogen containing aromatic derivatives as VEGF inhibitors. U.S. Patent Publication No. 20040067985, published April 8, 2004, describes nicotinamides as inhibitors of angiogensis and are useful for treating cancer. However, the compounds of the present invention have not been previously described as inhibitors of angiogenesis and are useful for treating angiogenesis-related diseases such as cancer.

SUMMMARY OF THE INVENTION

According to a first aspect, the present invention provides a compound, wherein the compound is 2-(7-isoquinolinylamino)-N-(3-methyl-4-(1-methylethyl)phenyl)-3-pyridinecarboxamide, or a pharmaceutically acceptable salt or derivative thereof.

According to a second aspect, the present invention provides a compound of the following formula:



,

or a pharmaceutically acceptable salt thereof.

According to a third aspect, the present invention provides a pharmaceutical composition comprising a compound according to the first or second aspect and a pharmaceutically acceptable carrier.

2005267161 30 Jan 2009

According to a fourth aspect, the present invention provides a method of treating cancer in a subject, said method comprising administering to the subject an effective amount of a compound according to the first or second aspect or a pharmaceutical composition according to the third aspect.

According to a fifth aspect, the present invention provides a method of treating angiogenesis in a subject, said method comprising administering to the subject an effective amount of a compound according to the first or second aspect or a pharmaceutical composition according to the third aspect.

According to a sixth aspect, the present invention provides a method of a method of treating a VEGFR-related disorder in a subject, said method comprising administering to the subject an effective amount of a compound according to the first or second aspect or a pharmaceutical composition according to the third aspect.

According to a seventh aspect, the present invention provides a method of treating a proliferation-related disorder in a subject, said method comprising administering to the subject an effective amount of a compound according to the first or second aspect or a pharmaceutical composition according to the third aspect.

According to an eighth aspect, the present invention provides a method of reducing blood flow in a tumor in a subject, said method comprising administering to the subject an effective amount of a compound according to the first or second aspect or a pharmaceutical composition according to the third aspect.

According to a ninth aspect, the present invention provides a method of reducing tumor size in a subject, said method comprising administering to the subject an effective amount of a compound according to the first or second aspect or a pharmaceutical composition according to the third aspect

According to a tenth aspect, the present invention provides a method of treating diabetic retinopathy in a subject, said method comprising administering to the subject an effective amount of a compound according to the first or second aspect or a pharmaceutical composition according to the third aspect.

According to an eleventh aspect, the present invention provides use of a compound according to first or second aspect for the preparation of a medicament for treating cancer.

According to a twelfth aspect, the present invention provides use of a compound according to first or second aspect for the preparation of a medicament for treating angiogenesis.

According to a thirteenth aspect, the present invention provides use of a compound according to first or second aspect for the preparation of a medicament for treating a VEGFR-related disorder.

According to a fourteenth aspect, the present invention provides use of a compound according to first or second aspect for the preparation of a medicament for treating a proliferation-related disorder.

According to a fifteenth aspect, the present invention provides use of a compound according to first or second aspect for the preparation of a medicament for reducing blood flow in a tumor.

According to a sixteenth aspect, the present invention provides use of a compound according to first or second aspect for the preparation of a medicament for reducing tumor size.

According to a seventeenth aspect, the present invention provides use of a compound according to first or second aspect for the preparation of a medicament for treating diabetic retinopathy in a subject.

Unless the context clearly requires otherwise, throughout the description and the claims, the words "comprise", "comprising", and the like are to be construed in an inclusive sense as opposed to an exclusive or exhaustive sense; that is to say, in the sense of "including, but not limited to".

DESCRIPTION OF THE INVENTION

In one or more preferred embodiments, the present invention provides classes of compounds, including their pharmaceutically acceptable derivatives useful for treating angiogenesis and related diseases such as cancer. One class of compounds are defined by general Formula I



wherein R is a 9- or 10-membered heterocyclyl ring containing at least one nitrogen or oxygen atom, the

ring selected from 7-isoquinolinyl, 2-methyl-3-oxo-2,3-dihydroindazol-6-yl, [1,6]-naphthydrin-3-yl, [1,7]-naphthydrin-2-yl, 1-oxo-2,3-dihydrobenzofuran-4-yl, 3-oxo-2,3-dihydrobenzofuran-5-yl, dihydro-benzodioxinyl, 6-quinazolinyl, 2-amino-6-quinazolinyl, 4-methylamino-6-quinazolinyl, 2,4-diamino-6-quinazolinyl, 3-oxo-3,4-dihydro-1,4-benzoxazin-6-yl, 2,2-difluoro-1,3-benzodioxol-5-yl and 2,2,3,3-tetrafluoro-2,3-dihydro-1,4-benzodioxin-6-yl, each of which is optionally substituted with one or more substituents selected from halo, haloakyl, C_{1-6} alkyl, C_{2-8} alkenyl, C_{2-3} alkynyl, N-dimethylamino-C_{1-6}-alkyl, N-dimethylamino-C_{1-6}-alkoxy, amino, alkyl-carbonylamino, morpholino-sulfonyl, amino-sulfonyl, oxazolyl, pyrrolyl, morpholinyl, carboxyl, cyano, and acetyl;

wherein R^1 is selected from unsubstituted or substituted

phenyl,

5-6 membered heteroaryl,

9-10 membered bicyclic heterocyclyl and

11-14 membered tricyclic heterocyclyl,

advantageously, R^1 is selected from phenyl, 3-isoxazolyl, 3-pyrazolyl, 2-thiazolyl, 1,3,4-thiadiazol-2-yl, thienyl, 3-pyridyl, pyrimidinyl, pyridazinyl, 1,2-dihydroquinolyl, 1,2,3,4-tetrahydroquinolyl, 1,2,3,4-tetrahydro-isoquinolyl, 2-oxo-1,2,3,4-tetrahydroquinolyl, 2-oxo-1,2,3,4-tetrahydroquinolyl, 1-oxo-1,2,3,4-tetrahydro-isoquinolyl, 1',2'-dihydro-spiro[cyclopropane-1,3'-[3H]indol]-6'-yl, isoquinolyl, quinolyl, indol-6-yl, 6-isoindolyl, 3,4-dihydro-2H-benzo[1,4]oxazin-6-yl, 3-oxo-3,4-dihydro-2H-benzo[1,4]oxazin-6-yl, 2,3-dihydro-1H-indol-6-yl, naphthyridinyl, 2-oxo-3,4-dihydro-1H-[1,8]naphthyridin-7-yl, 3,4-dihydro-[1,8]naphthyridinyl, 1,2,3,4-tetrahydro-[1,8]naphthyridinyl, quinozalinyl, 2-oxo-chromen-7-yl, benzo[d]isothiazolyl, 3,4-dihydro-quinazolinyl,

2,3,4,4a,9,9a-hexahydro-1H-3-aza-fluorenyl, 5,6,7-trihydro-1,2,4-triazolo[3,4-a]isoquinolyl, 5,6-dihydro-[1,2,4]triazolo[3,4-a]isoquinolin-9-yl, indazol-6-yl, 2,1,3-benzothiadiazolyl, benzodioxanyl, benzothienyl, 2,3-dihydro-benzofuran-6-yl, benzofuranyl, benzimidazolyl, dihydro-benzimidazolyl, benzoxazolyl and 5-benzthiazol-5-yl,

more advantageously, R^1 is selected from phenyl, 1,2,3,4-tetrahydroisoquinol-7-yl, 2,3-dihydro-1H-indol-6-yl, 1,2,3,4-tetrahydro-[1,8]naphthyridinyl, 1',2'-dihydro-spiro[cyclopropane-1,3'-[3H]indol-6'-yl, tetrahydroquinolin-7-yl, 3-isoxazolyl, 3-pyrazolyl, 1,3,4-thiadiazol-2-yl, 3-pyridyl, 2-oxo-1,2,3,4-tetrahydroquinol-7-yl, 2-oxo-tetrahydroquinolin-7-yl, 1-oxo-1,2,3,4-tetrahydro-isoquinol-7-yl, indol-6-yl, 3,4-dihydro-2H-benzo[1,4]oxazin-6-yl, 3-oxo-3,4-dihydro-2H-benzo[1,4]oxazin-6-yl, 2-oxo-3,4-dihydro-1H-[1,8]naphthyridin-7-yl, 2-oxo-chromen-7-yl, 5,6-dihydro-[1,2,4]triazolo[3,4-a]isoquinolin-9-yl, indazol-6-yl, 2,1,3-benzothiadiazolyl, 2,3-dihydro-benzofur-6-yl, and 5-benzthiazol-5-yl, and

even more advantageously, R^1 is phenyl substituted with one or more substituents selected from methyl, propyl, isopropyl, n-butyl, isobutyl, tert-butyl, methoxy, hydroxyl, phenyl, chloro, ethyl-2-propanoyl, 2-methyl-2-(1-methylpiperidin-4-yl)ethyl, methylsulfonylamino, dimethylaminomethylcarbonylamino, piperazine-methyl, 4-methylsulfonyl-1-piperazine-methyl, 1-pyrrolidinyl-CH_2-C(=O)-NH-, 1-methyl-pyrrolidinyl-CH_2-O-, 1-isopropyl-pyrrolidinyl-CH_2-O-, 1-acetyl-pyrrolidinyl-CH_2-O-,2-hydroxy-3-pyrrolidinyl-propoxy, 4-morpholinyl-CH_2-C(=O)-NH-, 1-pyrrolidinyl-CH_2CH_2O-, pyrrolidinyl-propyl,

piperidinyl-propyl, 1-methyl-1,2,3,6-tetrahydro-4-pyridinyl, 1-pyrrolidinyl-1-butenyl, 3,3-dimethylamino-1-propynyl, 4-methyl-1-piperazinyl, piperazinyl, 4-methyl-1-piperazinyl-methyl, morpholino-propyl, 1-N-methyl-piperidinyl-CH_2-, 1-piperidinyl-propyl, hydroxyethylamino, 3-tetrahydrofuryl-O-C(=O)-NH-, 3-tetrahydrofuryl-CH_2O-, trifluoromethyl, pentafluoroethyl, tetrafluoroethoxyl, 1,1-di(trifluoromethyl)-1-hydroxymethyl, 1,1-di(trifluoromethyl)-1-(pyrrolidin-2-ylmethoxy)methyl, 3-tetrahydrofuryloxy, 1-methylcarbonyl-pyrrolidin-2-ylmethoxy, 1-methyl-pyrrolindin-2-ylmethoxy, piperidinyl-amino, N,N-dimethyl-glycyl-amino, isopropyl-piperidinyl-methoxyl, isopropyl-piperazinyl, benzoxyl, 4-N-methyl-piperazinyl-propyl, 4-N-propyl-piperazinyl, methylsulfonyl, and methylsulfonylaminoethoxy,

yet even more advantageously, R^1 is selected from 4,4-dimethyl-3,4-dihydro-2-oxo-1H-quinolinyl, 4,4-dimethyl-1,2,3,4-tetrahydro-1H-quinolinyl, 4,4-dimethyl-3,4-dihydro–2-oxo-1H-[1,8]naphthyridinyl, 3,3-dimethyl-2,3-dihydro-1H-indol-6-yl optionally substituted with one or more substituents selected from pyrrolidin-1-yl-carbonyl, pyrrolidin-1-yl-methyl, 1-methyl-4-piperidinyl, 1-methyl-4-piperidinyl-methyl, 1-4-piperidinyl, tetrahydro-2-furanylcarbonyl, acetyl, N,N-dimethylglycyl, methylcarbonyl, and methylsulfonyl, 4,4-dimethyl-1,2,3,4-tetrahydro-1H-isoquinolin-7-yl, and

4,4-dimethyl-1,2,3,4-tetrahydro-2-oxo-1H-isoquinolin-7-yl;

where R^1 is substituted with one or more substituents, the substituents are selected from halo, optionally substituted C_{1-6}-alkyl, optionally substituted C_{3-6}-cycloalkyl, optionally substituted phenyl, optionally substituted phenyl-C_{1-4}-alkylenyl, C_{1-2}-haloalkoxy, optionally substituted phenyloxy, optionally substituted 4-6 membered heterocyclyl-C_{1-6}-alkyl, optionally substituted 4-6 membered heterocyclyl-C_2-C_4-alkenyl, optionally substituted 4-6 membered heterocyclyl, optionally substituted 4-6 membered heterocyclyloxy, optionally substituted 4-6 membered heterocyclyl-C_{1-4}-alkoxy, optionally substituted 4-6 membered heterocyclylsulfonyl, optionally substituted 4-6 membered heterocyclylamino, optionally substituted 4-6 membered heterocyclylcarbonyl, optionally substituted 4-6 membered heterocyclyl-C_{1-4}-alkylcarbonyl, optionally substituted 4-6 membered heterocyclylcarbonyl-C_{1-4}-alkyl, optionally substituted 4-6 membered heterocyclyl-C_{1-4}-alkylcarbonylamino, optionally substituted 4-6 membered heterocyclyl-oxycarbonylamino, C_{1-2}-haloalkyl, C_{1-4}-aminoalkyl, optionally substituted C_{1-4}-aminoalkylcarbonyl, nitro, amino, C_{1-3}-alkylsulfonylamino, hydroxy, cyano, alkylthio, haloalkylthio, arylthio, aralkylthio, aminosulfonyl, C_{1-2}-alkylsulfonyl, C_{1-2}-alkylsulfonylamino, C_{1-2}-alkylsulfonylamino-C_{1-4}-alkoxy, halosulfonyl, C_{1-4}-alkylcarbonyl, amino-C_{1-4}-alkylcarbonyl, C_{1-3}-alkylamino-C_{1-4}-alkylcarbonyl, C_{1-3}-alkylamino-C_{1-4}-alkylcarbonylamino, C_{1-4}-alkoxycarbonyl-C_{1-4}-alkyl, C_{1-3}-alkylamino-C_{1-3}-alkyl, C_{1-3}-alkylamino-C_{1-3}-alkoxy, C_{1-3}-alkylamino-C_{1-3}-alkoxy-C_{1-3}-alkoxy, C_{1-4}-alkoxycarbonyl, C_{1-4}-alkoxycarbonylamino-C_{1-4}-alkyl, C_{1-3}-alkylsulfonylamino-

C_{1-3}-alkoxy, C_{1-4}-hydroxyalkyl,  and C_{1-4}-alkoxy;

advantageously, the R^1 substituents are selected from bromo, chloro, fluoro, iodo, nitro, amino, cyano, Boc-aminoethyl, hydroxy, fluorosulfonyl, methylsulfonyl, aminosulfonyl, 4-methylpiperazinylsulfonyl, cyclohexyl, phenyl, phenylmethyl, 4-pyridylmethyl, 4-morpholinylmethyl, 1-methylpiperazin-4-ylmethyl, 1-methylpiperazin-4-ylpropyl, morpholinylpropyl, piperidin-1-ylmethyl, 1-methylpiperidin-4-ylmethyl, 2-methyl-2-(1-methylpiperidin-4-yl)ethyl, 2-methyl-2-(4-pyrimidinyl)ethyl, 2-methyl-2-(5-methyloxadiazol-2-yl)ethyl, 2-methyl-2-(pyrazol-5-yl)ethyl, 2-methyl-2-(1-ethoxycarbonyl-1,2,3,6-tetrahydropyridin-4-yl)ethyl, morpholinylethyl, 1-(4-morpholinyl)-2,2-dimethylpropyl, 1-(4-morpholinyl)-2,2-dimethylethyl, piperidin-4-ylethyl, 1-Boc-piperidin-4-ylethyl, piperidin-1-ylethyl, 1-Boc-piperidin-4-ylethyl, piperidin-4-ylmethyl, 1-Boc-piperidin-4-ylmethyl, piperidin-4-ylpropyl, 1-Boc-piperidin-4-ylpropyl, piperidin-1-ylpropyl, pyrrolidin-1-ylpropyl, pyrrolidin-2-ylpropyl, 1-Boc-pyrrolidin-2-ylpropyl, 1-(pyrrolidin-1-yl)-2-methylpropyl, pyrrolidin-1-ylmethyl, pyrrolidin-2-ylmethyl, 1-Boc-pyrrolidin-2-ylmethyl, pyrrolidinylpropenyl, pyrrolidinylbutenyl, methylcarbonyl, Boc, piperidin-1-ylmethylcarbonyl, pyrrolidin-1-yl-carbonyl, 4-pyridylcarbonyl, 4-methylpiperazin-1-ylcarbonylethyl, CH_3O-C(=O)-CH_2-, methoxycarbonyl, aminomethylcarbonyl, dimethylaminomethylcarbonyl, methylsulfonylamino, dimethylaminomethylcarbonylamino, 1-pyrrolidinyl-CH_2-C(=O)-NH-, 4-morpholinyl-CH_2-C(=O)-NH-, 3-

tetrahydrofuryl-O-C(=O)-NH-, cyclohexyl-N(CH_3)-, (4-pyrimidinyl)amino, (2-methylthio-4-pyrimidinyl)amino, 3-ethoxycarbonyl-2-methyl-fur-5-yl, 4-methylpiperazin-1-yl, 4-methyl-1-piperidyl, 1-Boc-4-piperidyl, piperidin-4-yl, 1-methylpiperidin-4-yl, 1-methyl-(1,2,3,6-tetrahydropyridyl), imidazolyl, morpholinyl, 4-trifluoromethyl-1-piperidinyl, hydroxybutyl, methyl, gem-dimethyl, ethyl, propyl, isopropyl, butyl, tert-butyl, sec-butyl, trifluoromethyl, pentafluoroethyl, nonafluorobutyl, dimethylaminopropyl, 1,1-di(trifluoromethyl)-1-hydroxymethyl, 1,1-di(trifluoromethyl)-1-(piperidinylethoxy)methyl, 1,1-di(trifluoromethyl)-1-(pyrrolidin-2-ylmethoxy)methyl, 1,1-di(trifluoromethyl)-1-(methoxyethoxyethoxy)methyl, 1-hydroxyethyl, 2-hydroxyethyl, trifluoromethoxy, 1-aminoethyl, 2-aminoethyl, 1-(N-isopropylamino)ethyl, 2-(N-isopropylamino)ethyl, 3-tetrahydrofuryloxy, dimethylaminoethoxy, 4-chlorophenoxy, phenyloxy, azetidin-3-ylmethoxy, 1-Boc-azetidin-3-ylmethoxy, 3-tetrahydrofurylmethoxy, pyrrolidin-2-ylmethoxy, 1-methylcarbonyl-pyrrolidin-2-ylmethoxy, 1-Boc-pyrrolidin-2-ylmethoxy, pyrrolidin-1-ylmethoxy, 1-methyl-pyrrolidin-2-ylmethoxy, 1-isopropyl-pyrrolidin-2-ylmethoxy, 1-Boc-piperdin-4-ylmethoxy, (1-pyrrolidinyl)ethoxy, piperdin-4-ylmethoxy, piperdin-3-ylmethoxy, 1-methylpiperdin-4-yloxy, methylsulfonylaminoethoxy, isopropoxy, methoxy and ethoxy;

even more advantageously, the R^1 substituents are selected from chloro, fluoro, acetyl, oxo, methylsulfonyl, 2-methyl-2-(1-methylpiperidin-4-yl)ethyl, piperidine-ethoxy-ditrifluoromethyl-methyl-, 1-methylpiperidin-4-yl, 1-

methylpiperidin-4-yl-methyl, 1-methylpiperidin-4-yl-propyl, pyrrolidin-1-yl-carbonyl, methylsulfonylamino, dimethylaminomethylcarbonylamino, 1-pyrrolidinyl-CH_2-C(=O)- NH-, N-methyl-pyrrolidinyl-CH_2-O-, N-isopropyl-pyrrolidinyl-CH_2-O-, N-pyrrolidinyl-CH_2CH_2O-, pyrrolidinyl-propyl, morpholine-propyl, N-methyl-piperazine, piperazine-methyl, 4N-methylsulfonyl-piperazine-methyl, tetrafluoroethyl-O-, 4-morpholinyl-CH_2-C(=O)-NH-, N-Boc-methyl C(O)-, amino-CH_2-C(O)-, 3-tetrahydrofuryl-C(=O)-, 3-tetrahydrofuryl-O-C(=O)-NH-, 3-tetrahydrofuryl-CH_2-O-, N,N-dimethylamino-CH_2-C(O)-, N,N-dimethylamino-CH_2-C(O)NH-, N,N-dimethylamino-$CH_2CH_2CH_2$-, hydroxyethylamino, methylcyclopropyl, methyl, gem-dimethyl, ethyl, tert-butyl, t-butoxycarbonyl, propyl, isopropyl, methoxy, piperidinemethyl, 1,1-dimethyl-propyl, azetidinyl, trifluoromethyl, pentafluoroethyl, 1,1-di(trifluoromethyl)-1-hydroxymethyl, 1-hydroxy-1,1-di(trifluoromethyl) methyl, 1,1-di(trifluoromethyl)-1-(pyrrolidin-2-ylmethoxy)methyl, 3-tetrahydrofuryloxy, 1-methylcarbonyl-pyrrolidin-2-ylmethoxy, 1-methyl-pyrrolidin-2-ylmethoxy, 2-hydroxy-3-pyrrolidin-propoxy, 1,1-dimethylethylacetyl, 1,1-dimethylacetic acid, and methylsulfonylaminoethoxy, and

yet even more advantageously, the R^1 substituents are selected from methyl, ethyl, isopropyl, t-butyl, 2-methyl-2-(1-ethoxycarbonyl-1,2,3,6-tetrahydropyridin-4-yl)ethyl, 1-(4-morpholinyl)-2,2-dimethylethyl, pyrrolidin-1-yl-carbonyl, CH_3O-C(=O)-CH_2-,

methylsulfonylamino, dimethylaminomethylcarbonylamino, 1-pyrrolidinyl-CH_2-C(=O)-NH-, 4-morpholinyl-CH_2-C(=O)-NH-, 3-tetrahydrofuryl-O-C(=O)-NH-, 1,1-di(trifluoromethyl)-1-(pyrrolidin-2-ylmethoxy)methyl, 3-tetrahydrofuryloxy, 1-methylcarbonyl-pyrrolidin-2-ylmethoxy, and methylsulfonylaminoethoxy;

wherein R^e and R^f are independently selected from H and C_{1-2}-haloalkyl; advantageously $-CF_3$;

wherein R^7 is selected from H, C_{1-3}-alkyl, optionally substituted phenyl, optionally substituted phenyl-C_{1-3}-alkyl, 4-6 membered heterocyclyl, optionally substituted 4-6 membered heterocyclyl-C_1-C_3-alkyl, C_{1-3}-alkoxy-C_{1-2}-alkyl and C_{1-3}-alkoxy-C_{1-3}-alkoxy-C_{1-3}-alkyl; and

wherein R^2 is selected from H, halo, haloalkyl and C_{1-6} alkyl, and advantageously, H, fluoro, chloro, bromo, trifluoromethyl, methyl, ethyl, isopropyl and t-butyl.

In another embodiment, the invention provides a second class of compounds as defined below by Formula II:



II

wherein R is selected from 7-isoquinolinyl, 2-methyl-3-oxo-2,3-dihydroindazol-6-yl, [1,6]-naphthydrin-3-yl, [1,7]-naphthydrin-2-yl, oxo-2,3-dihydrobenzofuranyl, dihydro-benzodioxinyl, 6-quinazolinyl, 2-amino-6-

quinazolinyl, 4-methylamino-6-quinazolinyl, 2,4-diamino-6-quinazolinyl, 3-oxo-3,4-dihydro-1,4-benzoxazin-6-yl, 2,2-difluoro-1,3-benzodioxol-5-yl and 2,2,3,3-tetrafluoro-2,3-dihydro-1,4-benzodioxin-6-yl, each of which is optionally substituted with one or more substitutions selected from halo, haloakyl, C_{1-6} alkyl, C_{2-8} alkenyl, C_{2-8} alkynyl, N-dimethylamino-C_{1-6}-alkyl, N-dimethylamino-C_{1-6}-alkoxy, amino, carbonylamino, morpholino-sulfonyl, amino-sulfonyl, oxazolyl, pyrrolyl, morpholinyl, carboxyl, cyano, and acetyl;

wherein R^1 is selected from unsubstituted or substituted 1,2-dihydroquinolyl, 1,2,3,4-tetrahydroquinolyl, 1,2,3,4-tetrahydro-isoquinolyl, 2-oxo-1,2,3,4-tetrahydroquinolyl, 2-oxo-1,2,3,4-tetrahydroquinolyl, 1-oxo-1,2,3,4-tetrahydro-isoquinolyl, isoquinolyl, quinolyl, indol-6-yl, 6-isoindolyl, 3,4-dihydro-2H-benzo[1,4]oxazin-6-yl, 3-oxo-3,4-dihydro-2H-benzo[1,4]oxazin-6-yl, 2,3-dihydro-1H-indol-6-yl, naphthyridinyl, 2-oxo-3,4-dihydro-1H-[1,8]naphthyridin-7-yl, 3,4-dihydro-[1,8]naphthyridinyl, 1,2,3,4-tetrahydro-[1,8]naphthyridinyl, quinozalinyl,

wherein substituted R^1 is substituted with one or more substituents selected from halo, optionally substituted C_{1-6}-alkyl, optionally substituted C_{3-6}-cycloalkyl, optionally substituted phenyl, optionally substituted phenyl-C_1-C_4-alkylenyl, C_{1-2}-haloalkoxy, optionally substituted phenyloxy, optionally substituted 4-6 membered heterocyclyl-C_1-C_6-alkyl, optionally substituted 4-6 membered heterocyclyl-C_2-C_4-alkenyl, optionally substituted 4-6 membered heterocyclyl, optionally substituted 4-6 membered heterocyclyloxy, optionally substituted 4-6 membered heterocyclyl-C_{1-4}-alkoxy, optionally substituted 4-6 membered heterocyclylsulfonyl, optionally substituted

4-6 membered heterocyclylamino, optionally substituted 4-6 membered heterocyclylcarbonyl, optionally substituted 4-6 membered heterocyclyl-C_{1-4}-alkylcarbonyl, optionally substituted 4-6 membered heterocyclylcarbonyl-C_{1-4}-alkyl, optionally substituted 4-6 membered heterocyclyl-C_{1-4}-alkylcarbonylamino, optionally substituted 4-6 membered heterocyclyl-oxycarbonylamino, C_{1-2}-haloalkyl, C_{1-4}-aminoalkyl, optionally substituted C_{1-4}-aminoalkylcarbonyl, nitro, amino, C_{1-3}-alkylsulfonylamino, hydroxy, cyano, aminosulfonyl, C_{1-2}-alkylsulfonyl, C_{1-2}-alkylsulfonylamino, C_{1-2}-alkylsulfonylamino-C_{1-4}-alkoxy, halosulfonyl, C_{1-4}-alkylcarbonyl, amino-C_{1-4}-alkylcarbonyl, C_{1-3}-alkylamino-C_{1-4}-alkylcarbonyl, C_{1-3}-alkylamino-C_{1-4}-alkylcarbonylamino, C_{1-4}-alkoxycarbonyl-C_{1-4}-alkyl, C_{1-3}-alkylamino-C_{1-3}-alkyl, C_{1-3}-alkylamino-C_{1-3}-alkoxy, C_{1-3}-alkylamino-C_{1-3}-alkoxy-C_{1-3}-alkoxy, C_{1-4}-alkoxycarbonyl, C_{1-4}-alkoxycarbonylamino-C_{1-4}-alkyl, C_{1-3}-alkylsulfonylamino-C_{1-3}-alkoxy, C_{1-4}-hydroxyalkyl,



and C_{1-4}-alkoxy; and

wherein R^e and R^f are independently selected from H and C_{1-2}-haloalkyl;

wherein R^7 is selected from H, C_{1-3}-alkyl, optionally substituted phenyl, optionally substituted phenyl-C_{1-3}-alkyl, 4-6 membered heterocyclyl, optionally substituted 4-6 membered heterocyclyl-C_1-C_3-alkyl, C_{1-3}-alkoxy-C_{1-2}-alkyl and C_{1-3}-alkoxy-C_{1-3}-alkoxy-C_{1-3}-alkyl; and

wherein R^2 is selected from H, halo, haloalkyl and C_{1-6} alkyl.

The compounds of the present invention further include pharmaceutically acceptable derivatives, including salts, of the compounds defined by Formulas I and II.

An exemplary grouping of compounds of interest encompassed within Formulas I and II consist of compounds and pharmaceutically-acceptable derivatives thereof as follows:

2-((2-amino-6-quinazolinyl)amino)-N-(3-methyl-4-(1-methylethyl)phenyl)-3-pyridinecarboxamide;

N-(4,4-dimethyl-1,2,3,4-tetrahydro-7-quinolinyl)-2-(6-quinazolinylamino)-3-pyridinecarboxamide;

N-(4,4-dimethyl-2-oxo-1,2,3,4-tetrahydro-7-quinolinyl)-2-(7-isoquinolinylamino)-3-pyridinecarboxamide;

N-(5-(1,1-dimethylethyl)-3-isoxazolyl)-2-((1-oxo-2,3-dihydro-1H-isoindol-4-yl)amino)-3-pyridinecarboxamide;

N-(5-(1,1-dimethylethyl)-3-isoxazolyl)-2-(7-isoquinolinylamino)-3-pyridinecarboxamide;

N-(1-(N,N-dimethylglycyl)-4,4-dimethyl-1,2,3,4-tetrahydro-7-quinolinyl)-2-(1H-indazol-6-ylamino)-3-pyridinecarboxamide;

N-(1-acetyl-3,3-dimethyl-2,3-dihydro-1H-indol-6-yl)-2-(7-isoquinolinylamino)-3-pyridinecarboxamide;

N-(4,4-dimethyl-1,2,3,4-tetrahydro-7-isoquinolinyl)-2-(7-isoquinolinylamino)-3-pyridinecarboxamide;

5-fluoro-2-(7-isoquinolinylamino)-N-(3-methyl-4-(1-methylethyl)phenyl)-3-pyridinecarboxamide;

N-(4,4-dimethyl-1,2,3,4-tetrahydro-7-quinolinyl)-2-(1H-indazol-6-ylamino)-3-pyridinecarboxamide;

N-(4,4-dimethyl-1,2,3,4-tetrahydro-7-quinolinyl)-2-(7-isoquinolinylamino)-3-pyridinecarboxamide;

N-(3,3-dimethyl-2,3-dihydro-1H-indol-6-yl)-2-(7-isoquinolinylamino)-3-pyridinecarboxamide;

N-(6-(1,1-dimethylethyl)-3-pyridinyl)-2-((1-oxo-2,3-dihydro-1H-isoindol-4-yl)amino)-3-pyridinecarboxamide;

N-(2-glycyl-4,4-dimethyl-1,2,3,4-tetrahydro-7-isoquinolinyl)-2-(7-isoquinolinylamino)-3-pyridinecarboxamide;

2-(7-isoquinolinylamino)-N-(3-methyl-4-(1-methylethyl)phenyl)-3-pyridinecarboxamide;

N-(3-((((2S)-1-methyl-2-pyrrolidinyl)methyl)oxy)-5-(trifluoromethyl)phenyl)-2-((1-oxo-2,3-dihydro-1H-isoindol-4-yl)amino)-3-pyridinecarboxamide;

N-(3,3-dimethyl-1-((2S)-tetrahydro-2-furanylcarbonyl)-2,3-dihydro-1H-indol-6-yl)-2-(7-isoquinolinylamino)-3-pyridinecarboxamide;

N-(4-(1,1-dimethylethyl)phenyl)-2-(6-quinazolinylamino)-3-pyridinecarboxamide;

N-(4,4-dimethyl-1,2,3,4-tetrahydro-7-isoquinolinyl)-2-(6-quinazolinylamino)-3-pyridinecarboxamide;

N-(5,5-dimethyl-7-oxo-5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)-2-(7-isoquinolinylamino)-3-pyridinecarboxamide;

N-(1-acetyl-4,4-dimethyl-1,2,3,4-tetrahydro-7-quinolinyl)-2-(1H-indazol-6-ylamino)-3-pyridinecarboxamide;

2-(7-isoquinolinylamino)-N-(4-(2,2,2-trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl)phenyl)-3-pyridinecarboxamide;

N-(1-acetyl-4,4-dimethyl-1,2,3,4-tetrahydro-7-quinolinyl)-2-((1-oxo-2,3-dihydro-1H-isoindol-4-yl)amino)-3-pyridinecarboxamide;

N-(4,4-dimethyl-2-((2R)-tetrahydro-2-furanylcarbonyl)-1,2,3,4-tetrahydro-7-isoquinolinyl)-2-(7-isoquinolinylamino)-3-pyridinecarboxamide;

N-(5-(1,1-dimethylethyl)-3-isoxazolyl)-2-(6-quinazolinylamino)-3-pyridinecarboxamide;

N-(5,5-dimethyl-7-oxo-5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)-2-(6-quinazolinylamino)-3-pyridinecarboxamide;

N-(4-(1,1-dimethylethyl)phenyl)-2-(7-isoquinolinylamino)-3-pyridinecarboxamide;

N-(4,4-dimethyl-1,2,3,4-tetrahydro-7-isoquinolinyl)-2-(5-isoquinolinylamino)-3-pyridinecarboxamide;

N-(2-acetyl-4,4-dimethyl-1,2,3,4-tetrahydro-7-isoquinolinyl)-2-(7-isoquinolinylamino)-3-

pyridinecarboxamide;
2-(7-isoquinolinylamino)-N-(3-methyl-4-(pentafluoroethyl)phenyl)-3-pyridinecarboxamide;
N-(5-(1,1-dimethylethyl)-3-isoxazolyl)-2-(5-isoquinolinylamino)-3-pyridinecarboxamide;
N-(4-(1,1-dimethylpropyl)phenyl)-2-(7-isoquinolinylamino)-3-pyridinecarboxamide;
2-(7-isoquinolinylamino)-N-(3-(methyloxy)-5-(trifluoromethyl)phenyl)-3-pyridinecarboxamide;
N-(4,4-dimethyl-1,2,3,4-tetrahydro-7-isoquinolinyl)-2-(1,6-naphthyridin-3-ylamino)-3-pyridinecarboxamide;
N-(6-(1,1-dimethylethyl)-3-pyridinyl)-2-(7-isoquinolinylamino)-3-pyridinecarboxamide;
N-(1-(N,N-dimethylglycyl)-4,4-dimethyl-1,2,3,4-tetrahydro-7-quinolinyl)-2-((1-oxo-2,3-dihydro-1H-isoindol-4-yl)amino)-3-pyridinecarboxamide;
N-(4-(1,1-dimethylethyl)phenyl)-2-(5-isoquinolinylamino)-3-pyridinecarboxamide;
2-((1-oxo-2,3-dihydro-1H-isoindol-4-yl)amino)-N-(4-(2,2,2-trifluoro-1-(methyloxy)-1-(trifluoromethyl)ethyl)phenyl)-3-pyridinecarboxamide;
N-(6-(1-methylcyclopropyl)-3-pyridinyl)-2-((1-oxo-2,3-dihydro-1H-isoindol-4-yl)amino)-3-pyridinecarboxamide;
2-(1H-1,2,3-benzotriazol-5-ylamino)-N-(5-(1,1-dimethylethyl)-3-isoxazolyl)-3-pyridinecarboxamide;
2-((1-oxo-2,3-dihydro-1H-isoindol-4-yl)amino)-N-(4-(pentafluoroethyl)-3-(1-piperazinylmethyl)phenyl)-3-pyridinecarboxamide;
2-(7-isoquinolinylamino)-N-(4-(pentafluoroethyl)phenyl)-3-pyridinecarboxamide;
2-(7-isoquinolinylamino)-N-(4-(2,2,2-trifluoro-1-(methyloxy)-1-(trifluoromethyl)ethyl)phenyl)-3-pyridinecarboxamide;
2-(1H-indazol-6-ylamino)-N-(6-(1-methylcyclopropyl)-3-

pyridinyl)-3-pyridinecarboxamide;

N-(4-(1,1-dimethylethyl)phenyl)-2-(1,6-naphthyridin-3-ylamino)-3-pyridinecarboxamide;

2-(7-isoquinolinylamino)-N-(2-methyl-1,3-benzothiazol-5-yl)-3-pyridinecarboxamide;

N-(4-chloro-3-(trifluoromethyl)phenyl)-2-(7-isoquinolinylamino)-3-pyridinecarboxamide;

2-(7-isoquinolinylamino)-N-(4-(trifluoromethyl)phenyl)-3-pyridinecarboxamide;

2-(1,6-naphthyridin-3-ylamino)-N-(4-(2,2,2-trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl)phenyl)-3-pyridinecarboxamide;

1,1-dimethylethyl 4,4-dimethyl-7-(((2-(1,6-naphthyridin-3-ylamino)-3-pyridinyl)carbonyl)amino)-3,4-dihydro-2(1H)-isoquinolinecarboxylate;

N-(3-((4-(methylsulfonyl)-1-piperazinyl)methyl)-4-(pentafluoroethyl)phenyl)-2-((1-oxo-2,3-dihydro-1H-isoindol-4-yl)amino)-3-pyridinecarboxamide;

N-(4,4-dimethyl-1,2,3,4-tetrahydro-7-isoquinolinyl)-2-((1-oxo-1,3-dihydro-2-benzofuran-4-yl)amino)-3-pyridinecarboxamide;

N-(3-(1,1-dimethylethyl)phenyl)-2-((1-oxo-2,3-dihydro-1H-isoindol-4-yl)amino)-3-pyridinecarboxamide;

N-(7-isoquinolinyl)-2-((1-oxo-2,3-dihydro-1H-isoindol-4-yl)amino)-3-pyridinecarboxamide;

N-(4-(1,1-dimethylethyl)phenyl)-2-((2-methyl-3-oxo-2,3-dihydro-1H-indazol-6-yl)amino)-3-pyridinecarboxamide

2-((2,2-difluoro-1,3-benzodioxol-5-yl)amino)-N-(4,4-dimethyl-1,2,3,4-tetrahydro-7-isoquinolinyl)-3-pyridinecarboxamide;

2-((2,4-diamino-6-quinazolinyl)amino)-N-(4-(1,1-dimethylethyl)phenyl)-3-pyridinecarboxamide;

2-((1-oxo-2,3-dihydro-1H-isoindol-4-yl)amino)-N-(6-(trifluoromethyl)-3-pyridinyl)-3-pyridinecarboxamide

N-(6-chloro-3-pyridinyl)-2-((1-oxo-2,3-dihydro-1H-isoindol-4-yl)amino)-3-pyridinecarboxamide;

N-(2-acetyl-4,4-dimethyl-1,2,3,4-tetrahydro-7-isoquinolinyl)-2-((4-(methylamino)-6-quinazolinyl)amino)-3-pyridinecarboxamide;

2-(4-(1,1-dimethylethyl)phenyl)-4-(1H-indazol-6-ylamino)-1,2-dihydro-3H-pyrrolo[3,4-c]pyridin-3-one;

2-(5-isoquinolinylamino)-N-(3-((((2S)-1-methyl-2-pyrrolidinyl)methyl)oxy)-5-(trifluoromethyl)phenyl)-3-pyridinecarboxamide;

N-(1-acetyl-3,3-dimethyl-2,3-dihydro-1H-indol-6-yl)-2-((1-oxo-1,3-dihydro-2-benzofuran-4-yl)amino)-3-pyridinecarboxamide;

N-(4-(phenyloxy)phenyl)-2-((4-(trifluoromethyl)phenyl)amino)-3-pyridinecarboxamide;

N-(3,3-dimethyl-2,3-dihydro-1H-indol-6-yl)-2-((1-oxo-1,3-dihydro-2-benzofuran-4-yl)amino)-3-pyridinecarboxamide;

2-((1-oxo-1,3-dihydro-2-benzofuran-5-yl)amino)-N-(4-(pentafluoroethyl)phenyl)-3-pyridinecarboxamide;

N-(4-(1,1-dimethylethyl)phenyl)-2-((1-oxo-1,3-dihydro-2-benzofuran-4-yl)amino)-3-pyridinecarboxamide;

2-((1-oxo-1,3-dihydro-2-benzofuran-4-yl)amino)-N-(4-(2,2,2-trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl)phenyl)-3-pyridinecarboxamide;

N-(3,3-dimethyl-2,3-dihydro-1H-indol-6-yl)-2-(5-isoquinolinylamino)-3-pyridinecarboxamide;

2-((3-oxo-1,3-dihydro-2-benzofuran-5-yl)amino)-N-(4-(pentafluoroethyl)phenyl)-3-pyridinecarboxamide;

N-(6-(1-azetidinyl)-3-pyridinyl)-2-(7-isoquinolinylamino)-3-pyridinecarboxamide;

N-(5-(1-azetidinyl)-2-pyridinyl)-2-(7-isoquinolinylamino)-3-pyridinecarboxamide;

N-(5-(1,1-dimethylethyl)-3-isoxazolyl)-2-((2,2,3,3-

tetrafluoro-2,3-dihydro-1,4-benzodioxin-6-yl)amino)-3-pyridinecarboxamide;

N-(4-(1,1-dimethylethyl)phenyl)-2-((2,2,3,3-tetrafluoro-2,3-dihydro-1,4-benzodioxin-6-yl)amino)-3-pyridinecarboxamide;

N-(4,4-dimethyl-2-oxo-1,2,3,4-tetrahydro-7-quinolinyl)-2-((2,2,3,3-tetrafluoro-2,3-dihydro-1,4-benzodioxin-6-yl)amino)-3-pyridinecarboxamide;

2-(1H-1,2,3-benzotriazol-5-ylamino)-N-(2-methyl-1,3-benzothiazol-5-yl)-3-pyridinecarboxamide;

2-(1H-1,2,3-benzotriazol-5-ylamino)-N-(4,4-dimethyl-2-oxo-1,2,3,4-tetrahydro-7-quinolinyl)-3-pyridinecarboxamide;

2-(7-isoquinolinylamino)-N-(3-(((2R)-tetrahydro-2-furanylmethyl)oxy)-5-(trifluoromethyl)phenyl)-3-pyridinecarboxamide;

N-(5,5-dimethyl-7-oxo-5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)-2-((3-oxo-3,4-dihydro-2H-1,4-benzoxazin-6-yl)amino)-3-pyridinecarboxamide;

N-(5-(1,1-dimethylethyl)-3-isoxazolyl)-2-((3-oxo-3,4-dihydro-2H-1,4-benzoxazin-6-yl)amino)-3-pyridinecarboxamide;

2-(1H-indazol-6-ylamino)-N-(2-methyl-1,3-benzothiazol-5-yl)-3-pyridinecarboxamide;

ethyl (2S)-2-(4-(((2-(7-isoquinolinylamino)-3-pyridinyl)carbonyl)amino)phenyl)propanoate;

(2S)-2-(4-(((2-(7-isoquinolinylamino)-3-pyridinyl)carbonyl)amino)phenyl)propanoic acid;

2-(7-isoquinolinylamino)-N-(3-oxo-3,4-dihydro-2H-1,4-benzothiazin-6-yl)-3-pyridinecarboxamide; and

N-(4-(1,1-dimethylethyl)phenyl)-2-(5-quinolinylamino)-3-pyridinecarboxamide.

A second exemplary grouping of compounds of interest within Formulas I and II consist of compounds as follows:

N-(4,4-dimethyl-2-oxo-1,2,3,4-tetrahydro-7-quinolinyl)-2-(7-isoquinolinylamino)-3-pyridinecarboxamide;

N-(4,4-dimethyl-1,2,3,4-tetrahydro-7-quinolinyl)-2-(7-isoquinolinylamino)benzamide;

N-(5-(1,1-dimethylethyl)-3-isoxazolyl)-2-(7-isoquinolinylamino)-3-pyridinecarboxamide;

2-(7-isoquinolinylamino)-N-(3-methyl-4-(1-pyrrolidinyl)phenyl)-3-pyridinecarboxamide;

N-(1-acetyl-3,3-dimethyl-2,3-dihydro-1H-indol-6-yl)-2-(7-isoquinolinylamino)-3-pyridinecarboxamide;

N-(4,4-dimethyl-1,2,3,4-tetrahydro-7-isoquinolinyl)-2-(7-isoquinolinylamino)-3-pyridinecarboxamide;

5-fluoro-2-(7-isoquinolinylamino)-N-(3-methyl-4-(1-methylethyl)phenyl)-3-pyridinecarboxamide;

N-(4,4-dimethyl-1,2,3,4-tetrahydro-7-quinolinyl)-2-(7-isoquinolinylamino)-3-pyridinecarboxamide;

N-(3,3-dimethyl-2,3-dihydro-1H-indol-6-yl)-2-(7-isoquinolinylamino)-3-pyridinecarboxamide;

N-(2-glycyl-4,4-dimethyl-1,2,3,4-tetrahydro-7-isoquinolinyl)-2-(7-isoquinolinylamino)-3-pyridinecarboxamide;

N-(3,3-dimethyl-1-((2S)-tetrahydro-2-furanylcarbonyl)-2,3-dihydro-1H-indol-6-yl)-2-(7-isoquinolinylamino)-3-pyridinecarboxamide;

N-(5,5-dimethyl-7-oxo-5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)-2-(7-isoquinolinylamino)-3- pyridinecarboxamide;

N-(4-(1,1-dimethylethyl)phenyl)-2-(7-isoquinolinylamino)benzamide;

2-(7-isoquinolinylamino)-N-(4-(2,2,2-trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl)phenyl)-3-pyridinecarboxamide;

N-(4,4-dimethyl-2-((2R)-tetrahydro-2-furanylcarbonyl)-1,2,3,4-tetrahydro-7-isoquinolinyl)-2-(7-isoquinolinylamino)-3-pyridinecarboxamide;

N-(4-(1,1-dimethylethyl)phenyl)-2-(7-isoquinolinylamino)-3-pyridinecarboxamide;

N-(2-acetyl-4,4-dimethyl-1,2,3,4-tetrahydro-7-isoquinolinyl)-2-(7-isoquinolinylamino)-3-pyridinecarboxamide;

2-(7-isoquinolinylamino)-N-(3-methyl-4-(pentafluoroethyl)phenyl)-3-pyridinecarboxamide;

N-(4-(1,1-dimethylethyl)phenyl)-3-fluoro-2-(7-isoquinolinylamino)benzamide;

2-(7-isoquinolinylamino)-N-(4-(1-methylethyl)phenyl)-3-pyridinecarboxamide;

N-(4-(1,1-dimethylpropyl)phenyl)-2-(7-isoquinolinylamino)-3-pyridinecarboxamide;

2-(7-isoquinolinylamino)-N-(3-(methyloxy)-5-(trifluoromethyl)phenyl)-3-pyridinecarboxamide;

N-(3-chloro-4-methylphenyl)-2-(7-isoquinolinylamino)-3-pyridinecarboxamide;

N-(6-(1,1-dimethylethyl)-3-pyridinyl)-2-(7-isoquinolinylamino)-3-pyridinecarboxamide;

2-(7-isoquinolinylamino)-N-(4-(pentafluoroethyl)phenyl)-3-pyridinecarboxamide;

2-(7-isoquinolinylamino)-N-(4-(2,2,2-trifluoro-1-(methyloxy)-1-(trifluoromethyl)ethyl)phenyl)-3-pyridinecarboxamide;

2-(7-isoquinolinylamino)-N-(2-methyl-1,3-benzothiazol-5-yl)-3-pyridinecarboxamide;

N-(4-chloro-3-(trifluoromethyl)phenyl)-2-(7-isoquinolinylamino)-3-pyridinecarboxamide;

2-(7-isoquinolinylamino)-N-(4-(trifluoromethyl)phenyl)-3-pyridinecarboxamide;

N-(6-(1-azetidinyl)-3-pyridinyl)-2-(7-isoquinolinylamino)-3-pyridinecarboxamide;

N-(5-(1-azetidinyl)-2-pyridinyl)-2-(7-isoquinolinylamino)-3-pyridinecarboxamide;

2-(7-isoquinolinylamino)-N-(3-(((2R)-tetrahydro-2-furanylmethyl)oxy)-5-(trifluoromethyl)phenyl)-3-pyridinecarboxamide;

ethyl (2S)-2-(4-(((2-(7-isoquinolinylamino)-3-pyridinyl)carbonyl)amino)phenyl)propanoate;

(2S)-2-(4-(((2-(7-isoquinolinylamino)-3-pyridinyl)carbonyl)amino)phenyl)propanoic acid;

(2R)-2-(4-(((2-(7-isoquinolinylamino)-3-pyridinyl)carbonyl)amino)phenyl)propanoic acid;

2-(7-isoquinolinylamino)-N-(3-oxo-3,4-dihydro-2H-1,4-benzothiazin-6-yl)-3-pyridinecarboxamide;

2-(7-isoquinolinylamino)-N-(4-((trifluoromethyl)oxy)phenyl)-3-pyridinecarboxamide; and

N-(3-chloro-4-(trifluoromethyl)phenyl)-2-(7-isoquinolinylamino)-3-pyridinecarboxamide.

A third exemplary grouping of compounds of interest within Formulas I and II consist of pharmaceutically-acceptable hydrochloride, sulfate, sulfonate or phosphate salts of the follow compounds:

N-(4,4-dimethyl-2-oxo-1,2,3,4-tetrahydro-7-quinolinyl)-2-(7-isoquinolinylamino)-3-pyridinecarboxamide;

N-(4,4-dimethyl-1,2,3,4-tetrahydro-7-quinolinyl)-2-(7-isoquinolinylamino)benzamide;

N-(5-(1,1-dimethylethyl)-3-isoxazolyl)-2-(7-isoquinolinylamino)-3-pyridinecarboxamide;

2-(7-isoquinolinylamino)-N-(3-methyl-4-(1-pyrrolidinyl)phenyl)-3-pyridinecarboxamide;

N-(1-acetyl-3,3-dimethyl-2,3-dihydro-1H-indol-6-yl)-2-(7-isoquinolinylamino)-3-pyridinecarboxamide;

N-(4,4-dimethyl-1,2,3,4-tetrahydro-7-isoquinolinyl)-2-(7-isoquinolinylamino)-3-pyridinecarboxamide;

5-fluoro-2-(7-isoquinolinylamino)-N-(3-methyl-4-(1-methylethyl)phenyl)-3-pyridinecarboxamide;

N-(4,4-dimethyl-1,2,3,4-tetrahydro-7-quinolinyl)-2-(7-

isoquinolinylamino)-3-pyridinecarboxamide;
N-(3,3-dimethyl-2,3-dihydro-1H-indol-6-yl)-2-(7-isoquinolinylamino)-3-pyridinecarboxamide;
N-(2-glycyl-4,4-dimethyl-1,2,3,4-tetrahydro-7-isoquinolinyl)-2-(7-isoquinolinylamino)-3-pyridinecarboxamide;
N-(3,3-dimethyl-1-((2S)-tetrahydro-2-furanylcarbonyl)-2,3-dihydro-1H-indol-6-yl)-2-(7-isoquinolinylamino)-3-pyridinecarboxamide;
N-(5,5-dimethyl-7-oxo-5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)-2-(7-isoquinolinylamino)-3- pyridinecarboxamide;
N-(4-(1,1-dimethylethyl)phenyl)-2-(7-isoquinolinylamino)benzamide;
2-(7-isoquinolinylamino)-N-(4-(2,2,2-trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl)phenyl)-3-pyridinecarboxamide;
N-(4,4-dimethyl-2-((2R)-tetrahydro-2-furanylcarbonyl)-1,2,3,4-tetrahydro-7-isoquinolinyl)-2-(7-isoquinolinylamino)-3-pyridinecarboxamide;
N-(4-(1,1-dimethylethyl)phenyl)-2-(7-isoquinolinylamino)-3-pyridinecarboxamide;
N-(2-acetyl-4,4-dimethyl-1,2,3,4-tetrahydro-7-isoquinolinyl)-2-(7-isoquinolinylamino)-3-pyridinecarboxamide;
2-(7-isoquinolinylamino)-N-(3-methyl-4-(pentafluoroethyl)phenyl)-3-pyridinecarboxamide;
N-(4-(1,1-dimethylethyl)phenyl)-3-fluoro-2-(7-isoquinolinylamino)benzamide;
2-(7-isoquinolinylamino)-N-(4-(1-methylethyl)phenyl)-3-pyridinecarboxamide;
N-(4-(1,1-dimethylpropyl)phenyl)-2-(7-isoquinolinylamino)-3-pyridinecarboxamide;
2-(7-isoquinolinylamino)-N-(3-(methyloxy)-5-(trifluoromethyl)phenyl)-3-pyridinecarboxamide;

N-(3-chloro-4-methylphenyl)-2-(7-isoquinolinylamino)-3-pyridinecarboxamide;

N-(6-(1,1-dimethylethyl)-3-pyridinyl)-2-(7-isoquinolinylamino)-3-pyridinecarboxamide;

2-(7-isoquinolinylamino)-N-(4-(pentafluoroethyl)phenyl)-3-pyridinecarboxamide;

2-(7-isoquinolinylamino)-N-(4-(2,2,2-trifluoro-1-(methyloxy)-1-(trifluoromethyl)ethyl)phenyl)-3-pyridinecarboxamide;

2-(7-isoquinolinylamino)-N-(2-methyl-1,3-benzothiazol-5-yl)-3-pyridinecarboxamide;

N-(4-chloro-3-(trifluoromethyl)phenyl)-2-(7-isoquinolinylamino)-3-pyridinecarboxamide;

2-(7-isoquinolinylamino)-N-(4-(trifluoromethyl)phenyl)-3-pyridinecarboxamide;

N-(6-(1-azetidinyl)-3-pyridinyl)-2-(7-isoquinolinylamino)-3-pyridinecarboxamide;

N-(5-(1-azetidinyl)-2-pyridinyl)-2-(7-isoquinolinylamino)-3-pyridinecarboxamide;

2-(7-isoquinolinylamino)-N-(3-(((2R)-tetrahydro-2-furanylmethyl)oxy)-5-(trifluoromethyl)phenyl)-3-pyridinecarboxamide;

ethyl (2S)-2-(4-(((2-(7-isoquinolinylamino)-3-pyridinyl)carbonyl)amino)phenyl)propanoate;

(2S)-2-(4-(((2-(7-isoquinolinylamino)-3-pyridinyl)carbonyl)amino)phenyl)propanoic acid;

(2R)-2-(4-(((2-(7-isoquinolinylamino)-3-pyridinyl)carbonyl)amino)phenyl)propanoic acid;

2-(7-isoquinolinylamino)-N-(3-oxo-3,4-dihydro-2H-1,4-benzothiazin-6-yl)-3-pyridinecarboxamide;

2-(7-isoquinolinylamino)-N-(4-((trifluoromethyl)oxy)phenyl)-3-pyridinecarboxamide; and

N-(3-chloro-4-(trifluoromethyl)phenyl)-2-(7-isoquinolinylamino)-3-pyridinecarboxamide.

INDICATIONS

Compounds of the present invention would be useful for, but not limited to, the prevention or treatment of angiogenesis related diseases and physiological conditions. Particularly, the compounds of the invention would inhibit the growth of blood vessels thereby reducing the blood flow to and from a given tumor site, resulting in no net growth to the tumor at that site and reduced or no migration of tumor cells to and from that site. Accordingly, these compounds are useful for an overall reduction in the size of the tumor.

The compounds of the present invention have kinase inhibitory activity, such as VEGFR/KDR inhibitory activity, and are useful in therapy to minimize deleterious effects of VEGF. Accordingly, the compounds of the present invention would be useful, as antineoplasia agents, for the treatment of neoplasia including cancer and metastasis, including, but not limited to: carcinoma such as cancer of the bladder, breast, colon, kidney, liver, lung (including small cell lung cancer), esophagus, gall-bladder, ovary, pancreas, stomach, cervix, thyroid, prostate, and skin (including squamous cell carcinoma); hematopoietic tumors of lymphoid lineage (including leukemia, acute lymphocitic leukemia, acute lymphoblastic leukemia, B-cell lymphoma, T-cell-lymphoma, Hodgkin's lymphoma, non-Hodgkin's lymphoma, hairy cell lymphoma and Burkett's lymphoma); hematopoietic tumors of myeloid lineage (including acute and chronic myelogenous leukemias, myelodysplastic syndrome and promyelocytic leukemia); tumors of mesenchymal origin (including fibrosarcoma and rhabdomyosarcoma, and other sarcomas, e.g. soft tissue and bone); tumors of the central and peripheral nervous system (including astrocytoma, neuroblastoma, glioma and schwannomas); and other tumors (including melanoma, seminoma, teratocarcinoma, osteosarcoma, xenoderoma pigmentosum, keratoctanthoma, thyroid follicular cancer and

Kaposi's sarcoma). Preferably, the compounds are useful for the treatment of neoplasia selected from lung cancer, colon cancer and breast cancer.

The compounds of the present invention also would be useful for treatment of ophthalmological conditions such as corneal graft rejection, ocular neovascularization, retinal neovascularization including neovascularization following injury or infection, diabetic retinopathy, retrolental fibroplasia and neovascular glaucoma; retinal ischemia; vitreous hemorrhage; ulcerative diseases such as gastric ulcer; pathological, but non-malignant, conditions such as hemangiomas, including infantile hemaginomas, angiofibroma of the nasopharynx and avascular necrosis of bone; and disorders of the female reproductive system such as endometriosis. The compounds are also useful for the treatment of edema, and conditions of vascular hyperpermeability.

The compounds of the present invention are useful in therapy of proliferative diseases. These compounds can be used for the treatment of an inflammatory rheumatoid or rheumatic disease, especially of manifestations at the locomotor apparatus, such as various inflammatory rheumatoid diseases, especially chronic polyarthritis including rheumatoid arthritis, juvenile arthritis or psoriasis arthropathy; paraneoplastic syndrome or tumor-induced inflammatory diseases, turbid effusions, collagenosis, such as systemic Lupus erythematosus, poly-myositis, dermato-myositis, systemic sclerodermia or mixed collagenosis; postinfectious arthritis (where no living pathogenic organism can be found at or in the affected part of the body), seronegative spondylarthritis, such as spondylitis ankylosans; vasculitis, sarcoidosis, or arthrosis; or further any combinations thereof. An example of an inflammation related disorder is (a) synovial inflammation,

for example, synovitis, including any of the particular forms of synovitis, in particular bursal synovitis and purulent synovitis, as far as it is not crystal-induced. Such synovial inflammation may for example, be consequential to or associated with disease, e.g. arthritis, e.g. osteoarthritis, rheumatoid arthritis or arthritis deformans. The present invention is further applicable to the systemic treatment of inflammation, e.g. inflammatory diseases or conditions, of the joints or locomotor apparatus in the region of the tendon insertions and tendon sheaths. Such inflammation may be, for example, consequential to or associated with disease or further (in a broader sense of the invention) with surgical intervention, including, in particular conditions such as insertion endopathy, myofasciale syndrome and tendomyosis. The present invention is further especially applicable to the treatment of inflammation, e.g. inflammatory disease or condition, of connective tissues including dermatomyositis and myositis.

The compounds of the present invention can be used as active agents against such disease states as arthritis, atherosclerosis, psoriasis, hemangiomas, myocardial angiogenesis, coronary and cerebral collaterals, ischemic limb angiogenesis, wound healing, peptic ulcer Helicobacter related diseases, fractures, cat scratch fever, rubeosis, neovascular glaucoma and retinopathies such as those associated with diabetic retinopathy or macular degeneration. In addition, some of these compounds can be used as active agents against solid tumors, malignant ascites, hematopoietic cancers and hyperproliferative disorders such as thyroid hyperplasia (especially Grave's disease), and cysts (such as hypervascularity of ovarian stroma, characteristic of polycystic ovarian syndrome (Stein- Leventhal syndrome)) since such diseases require a

proliferation of blood vessel cells for growth and/or metastasis.

Further, some of these compounds can be used as active agents against burns, chronic lung disease, stroke, polyps, anaphylaxis, chronic and allergic inflammation, ovarian hyperstimulation syndrome, brain tumor-associated cerebral edema, high-altitude, trauma or hypoxia induced cerebral or pulmonary edema, ocular and macular edema, ascites, and other diseases where vascular hyperpermeability, effusions, exudates, protein extravasation, or edema is a manifestation of the disease. The compounds will also be useful in treating disorders in which protein extravasation leads to the deposition of fibrin and extracellular matrix, promoting stromal proliferation (e.g. fibrosis, cirrhosis and carpal tunnel syndrome).

The compounds of the present invention are also useful in the treatment of ulcers including bacterial, fungal, Mooren ulcers and ulcerative colitis.

The compounds of the present invention are also useful in the treatment of conditions wherein undesired angiogenesis, edema, or stromal deposition occurs in viral infections such as Herpes simplex, Herpes Zoster, AIDS, Kaposi's sarcoma, protozoan infections and toxoplasmosis, following trauma, radiation, stroke, endometriosis, ovarian hyperstimulation syndrome, systemic lupus, sarcoidosis, synovitis, Crohn's disease, sickle cell anaemia, Lyme disease, pemphigoid, Paget's disease, hyperviscosity syndrome, Osler-Weber-Rendu disease, chronic inflammation, chronic occlusive pulmonary disease, asthma, and inflammatory rheumatoid or rheumatic disease. The compounds are also useful in the reduction of sub-cutaneous fat and for the treatment of obesity.

The compounds of the present invention are also useful in the treatment of ocular conditions such as ocular and

macular edema, ocular neovascular disease, scleritis, radial keratotomy, uveitis, vitritis, myopia, optic pits, chronic retinal detachment, post-laser complications, glaucoma, conjunctivitis, Stargardt's disease and Eales disease in addition to retinopathy and macular degeneration.

The compounds of the present invention are also useful in the treatment of cardiovascular conditions such as atherosclerosis, restenosis, arteriosclerosis, vascular occlusion and carotid obstructive disease.

The compounds of the present invention are also useful in the treatment of cancer related indications such as solid tumors, sarcomas (especially Ewing's sarcoma and osteosarcoma), retinoblastoma, rhabdomyosarcomas, neuroblastoma, hematopoietic malignancies, including leukemia and lymphoma, tumor- induced pleural or pericardial effusions, and malignant ascites.

The compounds of the present invention are also useful in the treatment of diabetic conditions such as diabetic retinopathy and microangiopathy.

The compounds of the present invention may also act as inhibitors of other protein kinases, e.g. Src, Lck, Abl, GSK, Kit, p38, EGFR, CDK-2, CDK-5, IKK, JNK3, bFGFR, PDGFR, RAF and ZAP70. Thus, these compounds may be effective in the treatment of diseases and conditions associated with the function and activity of various other protein kinases, such as those listed above.

Besides being useful for human treatment, these compounds are also useful for veterinary treatment of companion animals, exotic animals and farm animals, including mammals, rodents, and the like. By way of example, these compounds may be used to treat horses, dogs, and cats.

DEFINITIONS

The term "treatment" includes therapeutic treatment as well as prophylactic treatment (either preventing the onset of disorders altogether or delaying the onset of a preclinically evident stage of disorders in individuals).

The term "derivative" is broadly construed herein, and intended to encompass any salt of a compound of this invention, any ester of a compound of this invention, or any other compound, such as a prodrug, which upon administration to a patient is capable of providing (directly or indirectly) a compound of this invention, or a metabolite or residue thereof, characterized by the ability to inhibit angiogenesis.

The term and "pharmaceutically-acceptable derivative" as used herein, denotes a derivative which is pharmaceutically acceptable.

The phrase "therapeutically-effective" is intended to qualify the amount of each agent, which will achieve the goal of improvement in disorder severity and the frequency of incidence over treatment of each agent by itself, while avoiding adverse side effects typically associated with alternative therapies. For example, effective neoplastic therapeutic agents prolong the survivability of the patient, inhibit the rapidly-proliferating cell growth associated with the neoplasm, or effect a regression of the neoplasm.

The term "carrier", as used herein, denotes any pharmaceutically acceptable additive, excipient, adjuvant, or other suitable ingredient, other than the active pharmaceutical ingredient (API), which is typically included for formulation and/or administration purposes.

The term "H" denotes a single hydrogen atom. This radical may be attached, for example, to an oxygen atom to form a hydroxyl radical.

Where the term "alkyl" is used, either alone or within other terms such as "haloalkyl" and "alkylamino", it

embraces linear or branched radicals having one to about twelve carbon atoms. More preferred alkyl radicals are "lower alkyl" radicals having one to about six carbon atoms. Examples of such radicals include methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, *sec*-butyl, *tert*-butyl, pentyl, isoamyl, hexyl and the like. The phrase "one or more alkyl substitutions" embraces, beyond its normal meaning, the instance where a single atom, such as carbon, has two of the same or different substituents attached to it. For example, a "gem-dimethyl" group, which the phrase above embraces, refers to a single carbon atom in a structural moeity having two methyl radicals attached to it. The term "alkylenyl" embraces bridging divalent alkyl radicals such as methylenyl and ethylenyl.

The term "alkenyl" embraces linear or branched radicals having at least one carbon-carbon double bond of two to about twelve carbon atoms. More preferred alkenyl radicals are "lower alkenyl" radicals having two to about six carbon atoms. Examples of alkenyl radicals include ethenyl, propenyl, allyl, propenyl, butenyl and 4-methylbutenyl. The terms "alkenyl" and "lower alkenyl", embrace radicals having "cis" and "trans" orientations, or alternatively, "E" and "Z" orientations.

The term "alkynyl" denotes linear or branched radicals having at least one carbon-carbon triple bond and having two to about twelve carbon atoms. More preferred alkynyl radicals are "lower alkynyl" radicals having two to about six carbon atoms. Most preferred are lower alkynyl radicals having two to about four carbon atoms. Examples of such radicals include propargyl, butynyl, and the like.

The term "halo" means halogens such as fluorine, chlorine, bromine or iodine atoms.

The term "haloalkyl" embraces radicals wherein any one or more of the alkyl carbon atoms is substituted with halo

as defined above. Specifically embraced are monohaloalkyl, dihaloalkyl and polyhaloalkyl radicals including perhaloalkyl. A monohaloalkyl radical, for one example, may have either an iodo, bromo, chloro or fluoro atom within the radical. Dihalo and polyhaloalkyl radicals may have two or more of the same halo atoms or a combination of different halo radicals. "Lower haloalkyl" embraces radicals having 1-6 carbon atoms. Even more preferred are lower haloalkyl radicals having one to three carbon atoms. Examples of haloalkyl radicals include fluoromethyl, difluoromethyl, trifluoromethyl, chloromethyl, dichloromethyl, trichloromethyl, pentafluoroethyl, heptafluoropropyl, difluorochloromethyl, dichlorofluoromethyl, difluoroethyl, difluoropropyl, dichloroethyl and dichloropropyl. "Perfluoroalkyl" means alkyl radicals having all hydrogen atoms replaced with fluoro atoms. Examples include trifluoromethyl and pentafluoroethyl.

The term "hydroxyalkyl" embraces linear or branched alkyl radicals having one to about ten carbon atoms any one of which may be substituted with one or more hydroxyl radicals. More preferred hydroxyalkyl radicals are "lower hydroxyalkyl" radicals having one to six carbon atoms and one or more hydroxyl radicals. Examples of such radicals include hydroxymethyl, hydroxyethyl, hydroxypropyl, hydroxybutyl and hydroxyhexyl. Even more preferred are lower hydroxyalkyl radicals having one to three carbon atoms.

The term "alkoxy" embrace linear or branched oxy-containing radicals each having alkyl portions of one to about ten carbon atoms. More preferred alkoxy radicals are "lower alkoxy" radicals having one to six carbon atoms. Examples of such radicals include methoxy, ethoxy, propoxy, butoxy and *tert*-butoxy. Even more preferred are lower alkoxy radicals having one to three carbon atoms. Alkoxy radicals may be further substituted with one or more halo atoms, such

as fluoro, chloro or bromo, to provide "haloalkoxy" radicals. Even more preferred are lower haloalkoxy radicals having one to three carbon atoms. Examples of such radicals include fluoromethoxy, chloromethoxy, trifluoromethoxy, trifluoroethoxy, fluoroethoxy and fluoropropoxy.

The term "aryl", alone or in combination, means a carbocyclic aromatic system containing one or two rings wherein such rings may be attached together in a fused manner. The term "aryl" embraces aromatic radicals such as phenyl, naphthyl, indenyl, tetrahydronaphthyl, and indanyl. More preferred aryl is phenyl. Said "aryl" group may have 1 to 5 substituents such as lower alkyl, hydroxyl, halo, haloalkyl, nitro, cyano, alkoxy and lower alkylamino. Phenyl substituted with $-O-CH_2-O-$ forms the aryl benzodioxolyl substituent.

The term " heterocyclyl" embraces saturated, partially saturated and unsaturated heteroatom-containing ring radicals, where the heteroatoms may be selected from nitrogen, sulfur and oxygen. It does not include rings containing -O-O-, -O-S- or -S-S- portions. Said "heterocyclyl" group may have 1 to 3 substituents such as oxo (also known as "carbonyl"), hydroxyl, Boc, halo, haloalkyl, cyano, lower alkyl, lower aralkyl, lower alkoxy, amino and lower alkylamino.

Examples of saturated heterocyclic radicals include saturated 3 to 6-membered heteromonocyclic groups containing 1 to 4 nitrogen atoms [e.g. pyrrolidinyl, imidazolidinyl, piperidinyl, pyrrolinyl, piperazinyl]; saturated 3 to 6-membered heteromonocyclic group containing 1 to 2 oxygen atoms and 1 to 3 nitrogen atoms [e.g. morpholinyl]; saturated 3 to 6-membered heteromonocyclic group containing 1 to 2 sulfur atoms and 1 to 3 nitrogen atoms [e.g., thiazolidinyl]. Examples of partially saturated heterocyclyl

radicals include dihydrothienyl, dihydropyranyl, dihydrofuryl and dihydrothiazolyl.

Examples of unsaturated heterocyclic radicals, also termed "heteroaryl" radicals, include unsaturated 5 to 6 membered heteromonocyclyl group containing 1 to 4 nitrogen atoms, for example, pyrrolyl, imidazolyl, pyrazolyl, 2-pyridyl, 3-pyridyl, 4-pyridyl, pyrimidyl, pyrazinyl, pyridazinyl, triazolyl [e.g., 4H-1,2,4-triazolyl, 1H-1,2,3-triazolyl, 2H-1,2,3-triazolyl]; unsaturated 5- to 6-membered heteromonocyclic group containing an oxygen atom, for example, pyranyl, 2-furyl, 3-furyl, etc.; unsaturated 5 to 6-membered heteromonocyclic group containing a sulfur atom, for example, 2-thienyl, 3-thienyl, etc.; unsaturated 5- to 6-membered heteromonocyclic group containing 1 to 2 oxygen atoms and 1 to 3 nitrogen atoms, for example, oxazolyl, isoxazolyl, oxadiazolyl [e.g., 1,2,4-oxadiazolyl, 1,3,4-oxadiazolyl, 1,2,5-oxadiazolyl]; unsaturated 5 to 6-membered heteromonocyclic group containing 1 to 2 sulfur atoms and 1 to 3 nitrogen atoms, for example, thiazolyl, thiadiazolyl [e.g., 1,2,4-thiadiazolyl, 1,3,4-thiadiazolyl, 1,2,5-thiadiazolyl].

The term also embraces radicals where heterocyclic radicals are fused/condensed with aryl radicals: unsaturated condensed heterocyclic group containing 1 to 5 nitrogen atoms, for example, indolyl, isoindolyl, indolizinyl, benzimidazolyl, quinolyl, isoquinolyl, indazolyl, benzotriazolyl, tetrazolopyridazinyl [e.g., tetrazolo [1,5-b]pyridazinyl]; unsaturated condensed heterocyclic group containing 1 to 2 oxygen atoms and 1 to 3 nitrogen atoms [e.g. benzoxazolyl, benzoxadiazolyl]; unsaturated condensed heterocyclic group containing 1 to 2 sulfur atoms and 1 to 3 nitrogen atoms [e.g., benzothiazolyl, benzothiadiazolyl]; and saturated, partially unsaturated and unsaturated condensed heterocyclic group

containing 1 to 2 oxygen or sulfur atoms [e.g. benzofuryl, benzothienyl, 2,3-dihydro-benzo[1,4]dioxinyl, benxo[1,3]dioxyly, dihydrobenzofuryl and dihydroisobenzofuryl]. Preferred heterocyclic radicals include five to ten membered fused or unfused radicals. More preferred examples of heteroaryl radicals include quinolyl, isoquinolyl, imidazolyl, pyridyl, thienyl, thiazolyl, oxazolyl, furyl, and pyrazinyl. Other preferred heteroaryl radicals are 5- or 6-membered heteroaryl, containing one or two heteroatoms selected from sulfur, nitrogen and oxygen, selected from thienyl, furyl, pyrrolyl, indazolyl, pyrazolyl, oxazolyl, triazolyl, imidazolyl, pyrazolyl, isoxazolyl, isothiazolyl, pyridyl, piperidinyl and pyrazinyl.

Particular examples of non-nitrogen containing heteroaryl include pyranyl, 2-furyl, 3-furyl, 2-thienyl, 3-thienyl, benzofuryl, benzothienyl, and the like.

Particular examples of partially saturated and saturated heterocyclyl include pyrrolidinyl, imidazolidinyl, piperidinyl, pyrrolinyl, pyrazolidinyl, piperazinyl, morpholinyl, tetrahydropyranyl, thiazolidinyl, dihydrothienyl, 2,3-dihydro-benzo[1,4]dioxanyl, indolinyl, isoindolinyl, dihydrobenzothienyl, dihydrobenzofuryl, isochromanyl, chromanyl, 1,2-dihydroquinolyl, 1,2,3,4-tetrahydro-isoquinolyl, 1,2,3,4-tetrahydro-quinolyl, 2,3,4,4a,9,9a-hexahydro-1H-3-aza-fluorenyl, 5,6,7-trihydro-1,2,4-triazolo[3,4-a]isoquinolyl, 3,4-dihydro-2H-benzo[1,4]oxazinyl, benzo[1,4]dioxanyl, 2,3-dihydro-1H-1λ'-benzo[d]isothiazol-6-yl, dihydropyranyl, dihydrofuryl and dihydrothiazolyl, and the like.

The term "sulfonyl", whether used alone or linked to other terms such as alkylsulfonyl, denotes respectively divalent radicals $-SO_2-$.

The term "aminosulfonyl" denotes a sulfonyl radical substituted with an amine radical, forming a sulfonamide ($-SO_2NH_2$).

The term "alkylaminosulfonyl" includes "N-alkylaminosulfonyl" where sulfamyl radicals are independently substituted with one or two alkyl radical(s). More preferred alkylaminosulfonyl radicals are "lower alkylaminosulfonyl" radicals having one to six carbon atoms. Even more preferred are lower alkylaminosulfonyl radicals having one to three carbon atoms. Examples of such lower alkylaminosulfonyl radicals include N-methylaminosulfonyl, and N-ethylaminosulfonyl.

The term "carboxy", whether used alone or with other terms, such as "carboxyalkyl", denotes $-CO_2H$.

The term "carbonyl", whether used alone or with other terms, such as "aminocarbonyl", denotes -(C=O)-.

The term "aminocarbonyl" denotes an amide group of the formula $-C(=O)NH_2$.

The terms "N-alkylaminocarbonyl" and "N,N-dialkylaminocarbonyl" denote aminocarbonyl radicals independently substituted with one or two alkyl radicals, respectively. More preferred are "lower alkylaminocarbonyl" having lower alkyl radicals as described above attached to an aminocarbonyl radical.

The terms "N-arylaminocarbonyl" and "N-alkyl-N-arylaminocarbonyl" denote aminocarbonyl radicals substituted, respectively, with one aryl radical, or one alkyl and one aryl radical.

The terms "heterocyclylalkyl" and "heterocyclylalkylenyl" embrace heterocyclic-substituted alkyl and alkylenyl radicals. More preferred heterocyclylalkylenyl radicals are "5- or 6-membered heteroarylalkylenyl" radicals having alkyl portions of one to six carbon atoms and a 5- or 6-membered heteroaryl

radical. Even more preferred are lower heteroarylalkylenyl radicals having alkyl portions of one to three carbon atoms. Examples include such radicals as pyridylmethyl and thienylmethyl.

The terms "aralkyl" and "aryl alkylenyl" embrace aryl-substituted alkyl and alkylenyl radicals. Preferable aralkyl radicals are "lower aralkyl" radicals having aryl radicals attached to alkyl radicals having one to six carbon atoms. Even more preferred are "phenylalkylenyl" attached to alkyl portions having one to three carbon atoms. Examples of such radicals include benzyl, diphenylmethyl and phenylethyl. The aryl in said aralkyl may be additionally substituted with halo, alkyl, alkoxy, halkoalkyl and haloalkoxy.

The term "alkylthio" embraces radicals containing a linear or branched alkyl radical, of one to ten carbon atoms, attached to a divalent sulfur atom. Even more preferred are lower alkylthio radicals having one to three carbon atoms. An example of "alkylthio" is methylthio, (CH_3S-).

The term "haloalkylthio" embraces radicals containing a haloalkyl radical, of one to ten carbon atoms, attached to a divalent sulfur atom. Even more preferred are lower haloalkylthio radicals having one to three carbon atoms. An example of "haloalkylthio" is trifluoromethylthio.

The term "alkylamino" embraces "N-alkylamino" and "N,N-dialkylamino" where amino groups are independently substituted with one alkyl radical and with two alkyl radicals, respectively. More preferred alkylamino radicals are "lower alkylamino" radicals having one or two alkyl radicals of one to six carbon atoms, attached to a nitrogen atom. Even more preferred are lower alkylamino radicals having one to three carbon atoms. Suitable alkylamino radicals may be mono or dialkylamino such as N-methylamino,

N-ethylamino, N,N-dimethylamino, N,N-diethylamino and the like.

The term "arylamino" denotes amino groups, which have been substituted with one or two aryl radicals, such as N-phenylamino. The arylamino radicals may be further substituted on the aryl ring portion of the radical.

The term "heteroarylamino" denotes amino groups, which have been substituted with one or two heteroaryl radicals, such as N-thienylamino. The "heteroarylamino" radicals may be further substituted on the heteroaryl ring portion of the radical.

The term "aralkylamino" denotes amino groups, which have been substituted with one or two aralkyl radicals. More preferred are phenyl-C_1-C_3-alkylamino radicals, such as N-benzylamino. The aralkylamino radicals may be further substituted on the aryl ring portion.

The terms "N-alkyl-N-arylamino" and "N-aralkyl-N-alkylamino" denote amino groups, which have been independently substituted with one aralkyl and one alkyl radical, or one aryl and one alkyl radical, respectively, to an amino group.

The term "aminoalkyl" embraces linear or branched alkyl radicals having one to about ten carbon atoms any one of which may be substituted with one or more amino radicals. More preferred aminoalkyl radicals are "lower aminoalkyl" radicals having one to six carbon atoms and one or more amino radicals. Examples of such radicals include aminomethyl, aminoethyl, aminopropyl, aminobutyl and aminohexyl. Even more preferred are lower aminoalkyl radicals having one to three carbon atoms.

The term "alkylaminoalkyl" embraces alkyl radicals substituted with alkylamino radicals. More preferred alkylaminoalkyl radicals are "lower alkylaminoalkyl" radicals having alkyl radicals of one to six carbon atoms.

Even more preferred are lower alkylaminoalkyl radicals having alkyl radicals of one to three carbon atoms. Suitable alkylaminoalkyl radicals may be mono or dialkyl substituted, such as N-methylaminomethyl, N,N-dimethyl-aminoethyl, N,N-diethylaminomethyl and the like.

The term "alkylaminoalkoxy" embraces alkoxy radicals substituted with alkylamino radicals. More preferred alkylaminoalkoxy radicals are "lower alkylaminoalkoxy" radicals having alkoxy radicals of one to six carbon atoms. Even more preferred are lower alkylaminoalkoxy radicals having alkyl radicals of one to three carbon atoms. Suitable alkylaminoalkoxy radicals may be mono or dialkyl substituted, such as N-methylaminoethoxy, N,N-dimethylaminoethoxy, N,N-diethylaminoethoxy and the like.

The term "alkylaminoalkoxyalkoxy" embraces alkoxy radicals substituted with alkylaminoalkoxy radicals. More preferred alkylaminoalkoxyalkoxy radicals are "lower alkylaminoalkoxyalkoxy" radicals having alkoxy radicals of one to six carbon atoms. Even more preferred are lower alkylaminoalkoxyalkoxy radicals having alkyl radicals of one to three carbon atoms. Suitable alkylaminoalkoxyalkoxy radicals may be mono or dialkyl substituted, such as N-methylaminomethoxyethoxy, N-methylaminoethoxyethoxy, N,N-dimethylaminoethoxyethoxy, N,N-diethylaminomethoxymethoxy and the like.

The term "halosulfonyl" embraces sulfonyl radicals substituted with a halogen radical. Examples of such halosulfonyl radicals include chlorosulfonyl and fluorosulfonyl.

The term "arylthio" embraces aryl radicals of six to ten carbon atoms, attached to a divalent sulfur atom. An example of "arylthio" is phenylthio.

The term "aralkylthio" embraces aralkyl radicals as described above, attached to a divalent sulfur atom. More

preferred are phenyl-C_1-C_3-alkylthio radicals. An example of "aralkylthio" is benzylthio.

The term "aryloxy" embraces optionally substituted aryl radicals, as defined above, attached to an oxygen atom. Examples of such radicals include phenoxy.

The term "aralkoxy" embraces oxy-containing aralkyl radicals attached through an oxygen atom to other radicals. More preferred aralkoxy radicals are "lower aralkoxy" radicals having optionally substituted phenyl radicals attached to lower alkoxy radical as described above.

The term "heterocyclyloxy" embraces optionally substituted heteroaryl radicals, as defined above, attached to an oxygen atom.

The term "heterocyclylalkoxy" embraces oxy-containing heteroarylalkyl radicals attached through an oxygen atom to other radicals. More preferred heteroarylalkoxy radicals are "lower heteroarylalkoxy" radicals having optionally substituted heteroaryl radicals attached to lower alkoxy radical as described above.

The term "cycloalkyl" includes saturated carbocyclic groups. Preferred cycloalkyl groups include C_3-C_6 rings. More preferred compounds include, cyclopentyl, cyclopropyl, and cyclohexyl.

The term "comprising" or "comprises" is meant to be open ended, i.e., including the indicated component but not excluding other elements.

The terms "Formula I and Formula II" include any sub formulas.

The present invention also comprises the use of a compound of the invention, or pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the treatment either acutely or chronically of an angiogenesis mediated disease state, including those described previously. The compounds of the present invention are

useful in the manufacture of an anti-cancer medicament. The compounds of the present invention are also useful in the manufacture of a medicament to attenuate or prevent disorders through inhibition of KDR.

The present invention comprises a pharmaceutical composition comprising a therapeutically effective amount of a compound of Formula I or Formula II in association with a least one pharmaceutically acceptable carrier, adjuvant or diluent.

The present invention also comprises a method of treating angiogenesis related disorders in a subject having or susceptible to such disorder, the method comprising treating the subject with a therapeutically effective amount of a compound of Formula I



I

or a pharmaceutically acceptable derivative thereof, wherein R is a 9- or 10-membered heterocyclyl ring containing at least one nitrogen or oxygen atom, said ring selected from 7-isoquinolinyl, 2-methyl-3-oxo-2,3-dihydroindazol-6-yl, [1,6]-naphthydrin-3-yl, [1,7]-naphthydrin-2-yl, 1-oxo-2,3-dihydrobenzofuran-4-yl, 3-oxo-2,3-dihydrobenzofuran-5-yl, dihydro-benzodioxinyl, 6-quinazolinyl, 2-amino-6-quinazolinyl, 4-methylamino-6-quinazolinyl, 2,4-diamino-6-quinazolinyl, 3-oxo-3,4-dihydro-1,4-benzoxazin-6-yl, 2,2-difluoro-1,3-benzodioxol-5-yl and 2,2,3,3-tetrafluoro-2,3-dihydro-1,4-benzodioxin-6-yl, each

of which is optionally substituted with one or more substitutions selected from halo, haloalkyl, C_{1-6} alkyl, C_{2-8} alkenyl, C_{2-8} alkynyl, N-dimethylamino-C_{1-6}-alkyl, N-dimethylamino-C_{1-6}-alkoxy, amino, alkyl-carbonylamino, morpholino-sulfonyl, amino-sulfonyl, oxazolyl, pyrrolyl, morpholinyl, carboxyl, cyano, and acetyl;

wherein R^1 is selected from unsubstituted or substituted

phenyl,

5-6 membered heteroaryl,

9-10 membered bicyclic heterocyclyl and

11-14 membered tricyclic heterocyclyl,

wherein substituted R^1 is substituted with one or more substituents selected from halo, optionally substituted C_{1-6}-alkyl, optionally substituted C_{3-6}-cycloalkyl, optionally substituted phenyl, optionally substituted phenyl-C_1-C_4-alkylenyl, C_{1-2}-haloalkoxy, optionally substituted phenyloxy, optionally substituted 4-6 membered heterocyclyl-C_1-C_6-alkyl, optionally substituted 4-6 membered heterocyclyl-C_2-C_4-alkenyl, optionally substituted 4-6 membered heterocyclyl, optionally substituted 4-6 membered heterocyclyloxy, optionally substituted 4-6 membered heterocyclyl-C_{1-4}-alkoxy, optionally substituted 4-6 membered heterocyclylsulfonyl, optionally substituted 4-6 membered heterocyclylamino, optionally substituted 4-6 membered heterocyclylcarbonyl, optionally substituted 4-6 membered heterocyclyl-C_{1-4}-alkylcarbonyl, optionally substituted 4-6 membered heterocyclylcarbonyl-C_{1-4}-alkyl, optionally substituted 4-6 membered heterocyclyl-C_{1-4}-alkylcarbonylamino, optionally substituted 4-6 membered heterocyclyl-oxycarbonylamino, C_{1-2}-haloalkyl, C_{1-4}-aminoalkyl, optionally substituted C_{1-4}-aminoalkylcarbonyl, nitro, amino, C_{1-3}-alkylsulfonylamino, hydroxy, cyano,

aminosulfonyl, C_{1-2}-alkylsulfonyl, C_{1-2}-alkylsulfonylamino, C_{1-2}-alkylsulfonylamino-C_{1-4}-alkoxy, halosulfonyl, C_{1-4}-alkylcarbonyl, amino-C_{1-4}-alkylcarbonyl, C_{1-3}-alkylamino-C_{1-4}-alkylcarbonyl, C_{1-3}-alkylamino-C_{1-4}-alkylcarbonylamino, C_{1-4}-alkoxycarbonyl-C_{1-4}-alkyl, C_{1-3}-alkylamino-C_{1-3}-alkyl, C_{1-3}-alkylamino-C_{1-3}-alkoxy, C_{1-3}-alkylamino-C_{1-3}-alkoxy-C_{1-3}-alkoxy, C_{1-4}-alkoxycarbonyl, C_{1-4}-alkoxycarbonylamino-C_{1-4}-alkyl, C_{1-3}-alkylsulfonylamino-C_{1-3}-alkoxy, C_{1-4}-hydroxyalkyl,



and C_{1-4}-alkoxy; and

wherein R^e and R^f are independently selected from H and C_{1-2}-haloalkyl; and

wherein R^7 is selected from H, C_{1-3}-alkyl, optionally substituted phenyl, optionally substituted phenyl-C_{1-3}-alkyl, 4-6 membered heterocyclyl, optionally substituted 4-6 membered heterocyclyl-C_1-C_3-alkyl, C_{1-3}-alkoxy-C_{1-2}-alkyl and C_{1-3}-alkoxy-C_{1-3}-alkoxy-C_{1-3}-alkyl; and

wherein R^2 is selected from H, halo, haloalkyl and C_{1-6} alkyl.

Similarly, the present invention further comprises a method of treating angiogenesis related disorders in a subject having or susceptible to such disorder, the method comprising treating the subject with a therapeutically effective amount of a compound of Formula II, as described herein.

COMBINATIONS

While the compounds of the present invention can be administered as the sole active pharmaceutical agent, they can also be used in combination with one or more compounds of the invention or other agents. When administered as a

combination, the therapeutic agents can be formulated as separate compositions that are administered at the same time or sequentially at different times, or the therapeutic agents can be formulated and administered as a single composition.

The phrase "co-therapy" (or "combination-therapy"), in defining use of a compound of the present invention and another pharmaceutical agent, is intended to embrace administration of each agent in a sequential manner in a regimen that will provide beneficial effects of the drug combination, and is intended as well to embrace co-administration of these agents in a substantially simultaneous manner, such as in a single capsule having a fixed ratio of these active agents or in multiple, separate capsules or other formulations for each agent.

If formulated as a fixed dose, such combination products employ the compounds of this invention within the accepted dosage ranges. Compounds of Formulas I and II may also be administered sequentially with known anticancer or cytotoxic agents when a combination formulation is inappropriate. The invention is not limited in the sequence of administration; compounds of the invention may be administered either prior to, simultaneous with or after administration of the known anticancer or cytotoxic agent.

The administration of compounds, or compositions, of the present invention may be in conjunction with additional therapies known to those skilled in the art in the prevention or treatment of neoplasia, such as with radiation therapy or with cytostatic or cytotoxic agents. In some embodiments, the combination therapy can include a compound, or composition, of the present invention with at least one anti-tumor agent or other conventional therapeutic agent. In some embodiments, the combination comprises a compound, or composition, of the present invention (e.g., an antibody or antigen binding region) in combination with at least one

anti-angiogenic agent. Agents are inclusive of, but not limited to, *in vitro* synthetically prepared chemical compositions, antibodies, antigen binding regions, radionuclides, and combinations and conjugates thereof. An agent can be an agonist, antagonist, allosteric modulator, toxin or, more generally, may act to inhibit or stimulate its target (e.g., receptor or enzyme activation or inhibition), and thereby promote cell death or arrest cell growth.

Currently, standard treatment of primary tumors consists of surgical excision followed by either radiation or IV administered chemotherapy. The typical chemotherapy regime consists of either DNA alkylating agents, DNA intercalating agents, CDK inhibitors, or microtubule poisons. The chemotherapy doses used are just below the maximal tolerated dose and therefore dose limiting toxicities typically include, nausea, vomiting, diarrhea, hair loss, neutropenia and the like.

There are large numbers of antineoplastic agents available in commercial use, in clinical evaluation and in pre-clinical development, which would be selected for treatment of neoplasia by combination drug chemotherapy. Such antineoplastic agents fall into several major categories, namely, antibiotic-type agents, alkylating-type agents, antimetabolite-type agents, hormonal agents, immunological agents, interferon-type agents and a category of miscellaneous antineoplastic agents.

A first family of antineoplastic agents, which may be used in combination with compounds of the present invention, consists of antimetabolite-type/thymidilate synthase inhibitor antineoplastic agents. Suitable antimetabolite-type antineoplastic agents may be selected from, but not limited to, the group consisting of 5-FU-fibrinogen, acanthifolic acid, aminothiadiazole, brequinar sodium, carmofur, Ciba-Geigy CGP-30694, cyclopentyl cytosine,

cytarabine phosphate stearate, cytarabine conjugates, Lilly DATHF, Merrel Dow DDFC, dezaguanine, dideoxycytidine, dideoxyguanosine, didox, Yoshitomi DMDC, doxifluridine, Wellcome EHNA, Merck & Co. EX-015, fazarabine, Daiichi Seiyaku FO-152, isopropyl pyrrolizine, Lilly LY-188011, Lilly LY-264618, methobenzaprim, Wellcome MZPES, norspermidine, NCI NSC-127716, NCI NSC-264880, NCI NSC-39661, NCI NSC-612567, Warner-Lambert PALA, pentostatin, piritrexim, plicamycin, Asahi Chemical PL-AC, Takeda TAC-788, thioguanine, tiazofurin, Erbamont TIF, tyrosine kinase inhibitors, Taiho UFT, uricytin, folic acid analogs such as methotrexate and trimetrexate, pyrimidine analogs such as 5-fluorouracil, N-(2'-furanidyl)-5-fluorouracil, floxuridine, fluorodeoxyuridine, gemcitabine, cytosine arabinoside (AraC, cytarabine), 5-azacytidine, 2,2´-difluorodeoxycytidine and purine analogs such as 6-mercaptopurine, 6-thioguanine, azathioprine, 2'-deoxycoformycin (pentostatin), erythrohydroxynonyladenine (EHNA), fludarabine phosphate, and 2-chlorodeoxyadenosine (cladribine, 2-CdA).

A second family of antineoplastic agents, which may be used in combination with compounds of the present invention, consists of alkylating-type antineoplastic agents. Suitable alkylating-type antineoplastic agents may be selected from, but not limited to, the group consisting of Shionogi 254-S, aldo-phosphamide analogues, alkyl sulfonates such as busulfan, altretamine, anaxirone, Boehringer Mannheim BBR-2207, bestrabucil, budotitane, Wakunaga CA-102, carboplatin, carmustine (BCNU), Chinoin-139, Chinoin-153, chlorambucil, cisplatin, cyclophosphamide, American Cyanamid CL-286558, Sanofi CY-233, cyplatate, Degussa D-19-384, Sumimoto DACHP(Myr)2, diphenylspiromustine, diplatinum cytostatic, Erba distamycin derivatives, Chugai DWA-2114R, ITI E09, elmustine, Erbamont FCE-24517, estramustine, estramustine phosphate, estramustine phosphate sodium, fotemustine,

Unimed G-6-M, Chinoin GYKI-17230, hepsul-fam, ifosfamide, iproplatin, lomustine (CCNU), mafosfamide, mechlorethamine, melphalan, mitolactol, Nippon Kayaku NK-121, nitrogen mustards, NCI NSC-264395, NCI NSC-342215, oxaliplatin, Upjohn PCNU, prednimustine, Proter PTT-119, ranimustine, semustine (methyl-CCNU), SmithKline SK&F-101772, Yakult Honsha SN-22, spiromus-tine, Tanabe Seiyaku TA-077, tauromustine, temozolomide, teroxirone, tetraplatin and trimelamol, ethylenimines/methylmelamine such as thriethylenemelamine (TEM), triethylene, thiophosphoramide (thiotepa), hexamethylmelamine (HMM, altretamine) and triazines such as dacarbazine (DTIC).

A third family of antineoplastic agents which may be used in combination with compounds of the present invention consists of antibiotic-type antineoplastic agents. Suitable antibiotic-type antineoplastic agents may be selected from, but not limited to, the group consisting of Taiho 4181-A, aclarubicin, actinomycin, actinomycin D, actinoplanone, Erbamont ADR-456, aeroplysinin derivative, Ajinomoto AN-201-II, Ajinomoto AN-3, Nippon Soda anisomycins, anthracycline, azino-mycin-A, bisucaberin, Bristol-Myers BL-6859, Bristol-Myers BMY-25067, Bristol-Myers BMY-25551, Bristol-Myers BMY-26605, Bristol-Myers BMY-27557, Bristol-Myers BMY-28438, bleomycins such as bleomycin sulfate, bryostatin-1, Taiho C-1027, calichemycin, chromoximycin, dactinomycin, daunorubicin, daunomycin (rubidomycin), mitoxantrone Kyowa Hakko DC-102, Kyowa Hakko DC-79, Kyowa Hakko DC-88A, Kyowa Hakko DC89-A1, Kyowa Hakko DC92-B, ditrisarubicin B, Shionogi DOB-41, doxorubicin, doxorubicin-fibrinogen, elsamicin-A, epirubicin, erbstatin, esorubicin, esperamicin-A1, esperamicin-A1b, Erbamont FCE-21954, Fujisawa FK-973, fostriecin, Fujisawa FR-900482, glidobactin, gregatin-A, grincamycin, herbimycin, idarubicin, illudins, kazusamycin, kesarirhodins, Kyowa Hakko KM-5539, Kirin Brewery KRN-8602,

Kyowa Hakko KT-5432, Kyowa Hakko KT-5594, Kyowa Hakko KT-6149, American Cyanamid LL-D49194, Meiji Seika ME 2303, menogaril, mitomycin, mitomycinC, mitoxantrone, SmithKline M-TAG, neoenactin, Nippon Kayaku NK-313, Nippon Kayaku NKT-01, SRI International NSC-357704, oxalysine, oxaunomycin, peplomycin, pilatin, pirarubicin, plicamycin (mithramycin), porothramycin, pyrindanycin A, Tobishi RA-I, rapamycin, rhizoxin, rodorubicin, sibanomicin, siwenmycin, Sumitomo SM-5887, Snow Brand SN-706, Snow Brand SN-07, sorangicin-A, sparsomycin, SS Pharmaceutical SS-21020, SS Pharmaceutical SS-7313B, SS Pharmaceutical SS-9816B, steffimycin B, Taiho 4181-2, talisomycin, Takeda TAN-868A, terpentecin, thrazine, tricrozarin A, Upjohn U-73975, Kyowa Hakko UCN-10028A, Fujisawa WF-3405, Yoshitomi Y-25024 and zorubicin.

A fourth family of antineoplastic agents which may be used in combination with compounds of the present invention consists of a miscellaneous families of antineoplastic agents, including tubulin interacting agents, topoisomerase II inhibitors, topoisomerase I inhibitors and hormonal agents, selected from, but not limited to, the group consisting of α-carotene, α-difluoromethyl-arginine, acitretin, Biotec AD-5, Kyorin AHC-52, alstonine, amonafide, amphethinile, amsacrine, Angiostat, ankinomycin, anti-neoplaston A10, antineoplaston A2, antineoplaston A3, antineoplaston A5, antineoplaston AS2-1, Henkel APD, aphidicolin glycinate, asparaginase, Avarol, baccharin, batracylin, benfluron, benzotript, Ipsen-Beaufour BIM-23015, bisantrene, Bristol-Myers BMY-40481, Vestar boron-10, bromofosfamide, Wellcome BW-502, Wellcome BW-773, caracemide, carmethizole hydrochloride, Ajinomoto CDAF, chlorsulfaquinoxalone, Chemes CHX-2053, Chemex CHX-100, Warner-Lambert CI-921, Warner-Lambert CI-937, Warner-Lambert CI-941, Warner-Lambert CI-958, clanfenur, claviridenone, ICN compound 1259, ICN compound 4711, Contracan, Yakult Honsha

CPT-11, crisnatol, curaderm, cytochalasin B, cytarabine, cytocytin, Merz D-609, DABIS maleate, dacarbazine, datelliptinium, didemnin-B, dihaematoporphyrin ether, dihydrolenperone, dinaline, distamycin, Toyo Pharmar DM-341, Toyo Pharmar DM-75, Daiichi Seiyaku DN-9693, docetaxel elliprabin, elliptinium acetate, Tsumura EPMTC, the epothilones, ergotamine, etoposide, etretinate, fenretinide, Fujisawa FR-57704, gallium nitrate, genkwadaphnin, Chugai GLA-43, Glaxo GR-63178, grifolan NMF-5N, hexadecylphosphocholine, Green Cross HO-221, homoharringtonine, hydroxyurea, BTG ICRF-187, ilmofosine, isoglutamine, isotretinoin, Otsuka JI-36, Ramot K-477, Otsuak K-76COONa, Kureha Chemical K-AM, MECT Corp KI-8110, American Cyanamid L-623, leukoregulin, lonidamine, Lundbeck LU-23-112, Lilly LY-186641, NCI (US) MAP, marycin, Merrel Dow MDL-27048, Medco MEDR-340, merbarone, merocyanlne derivatives, methylanilinoacridine, Molecular Genetics MGI-136, minactivin, mitonafide, mitoquidone mopidamol, motretinide, Zenyaku Kogyo MST-16, N-(retinoyl)amino acids, Nisshin Flour Milling N-021, N-acylated-dehydroalanines, nafazatrom, Taisho NCU-190, nocodazole derivative, Normosang, NCI NSC-145813, NCI NSC-361456, NCI NSC-604782, NCI NSC-95580, ocrectide, Ono ONO-112, oquizanocine, Akzo Org-10172, natural antimitotic drugs such as paclitaxel, pancratistatin, pazelliptine, Warner-Lambert PD-111707, Warner-Lambert PD-115934, Warner-Lambert PD-131141, Pierre Fabre PE-1001, ICRT peptide D, piroxantrone, polyhaematoporphyrin, polypreic acid, Efamol porphyrin, ppipodophylotoxins such as etoposide and teniposide, probimane, procarbazine, proglumide, Invitron protease nexin I, Tobishi RA-700, razoxane, Sapporo Breweries RBS, restrictin-P, retelliptine, retinoic acid, Rhone-Poulenc RP-49532, Rhone-Poulenc RP-56976, SmithKline SK&F-104864, Sumitomo SM-108, Kuraray SMANCS, SeaPharm SP-10094, spatol,

spirocyclopropane derivatives, spirogermanium, Unimed, SS Pharmaceutical SS-554, strypoldinone, Stypoldione, Suntory SUN 0237, Suntory SUN 2071, superoxide dismutase, taxotere, Toyama T-506, Toyama T-680, taxol, Teijin TEI-0303, teniposide, thaliblastine, Eastman Kodak TJB-29, tocotrienol, topotecan, Topostin, Teijin TT-82, Kyowa Hakko UCN-01, Kyowa Hakko UCN-1028, ukrain, Eastman Kodak USB-006, vinca alkaloids including vinblastine (VLB), vinblastine sulfate, vincristine, vindesine, vinestramide, vinorelbine, vintriptol and vinzolidine, withanolides, Yamanouchi YM-534, enzymes such as L-asparaginase, biological response modifiers such as G-CSF and GM-CSF, miscellaneous agents including platinium coordination complexes such as cisplatin and carboplatin, anthracenediones such as mitoxantrone, substituted urea such as hydroxyurea, methylhydrazine derivatives including N-methylhydrazine (MIH) and procarbazine, adrenocortical suppressants such as mitotane (o,p´-DDD) and aminoglutethimide, hormones and antagonists including adrenocorticosteroid antagonists such as prednisone and equivalents, dexamethasone and aminoglutethimide, progestin such as hydroxyprogesterone caproate, medroxyprogesterone acetate and megestrol acetate, estrogen such as diethylstilbestrol and ethinyl estradiol equivalents, antiestrogen such as tamoxifen, androgens including testosterone propionate and fluoxymesterone/equivalents, antiandrogens such as flutamide, gonadotropin-releasing hormone analogs and leuprolide, and non-steroidal antiandrogens such as flutamide.

Alternatively, the compounds of the present invention may also be used in co-therapies with other miscellaneous anti-neoplastic agents, such as acemannan, aclarubicin, aldesleukin, alemtuzumab, alitretinoin, altretamine, amifostine, aminolevulinic acid, amrubicin, amsacrine,

anagrelide, anastrozole, ANCER, ancestim, ARGLABIN, arsenic trioxide, BAM 002 (Novelos), bexarotene, bicalutamide, broxuridine, capecitabine, celmoleukin, cetrorelix, cladribine, clotrimazole, cytarabine ocfosfate, DA 3030 (Dong-A), daclizumab, denileukin diftitox, deslorelin, dexrazoxane, dilazep, docetaxel, docosanol, doxercalciferol, doxifluridine, doxorubicin, bromocriptine, carmustine, cytarabine, fluorouracil, HIT diclofenac, interferon alfa, daunorubicin, tretinoin, edelfosine, edrecolomab, eflornithine, emitefur, epirubicin, epoetin beta, etoposide phosphate, exemestane, exisulind, fadrozole, filgrastim, finasteride, fludarabine phosphate, formestane, fotemustine, gallium nitrate, gemcitabine, gemtuzumab zogamicin, gimeracil/oteracil/tegafur combination, glycopine, goserelin, heptaplatin, human chorionic gonadotropin, human fetal alpha fetoprotein, ibandronic acid, idarubicin, (imiquimod, interferon alfa, interferon alfa, natural, interferon alfa-2, interferon alfa-2a, interferon alfa-2b, interferon alfa-N1, interferon alfa-n3, interferon alfacon-1, interferon alpha, natural, interferon beta, interferon beta-1a, interferon beta-1b, interferon gamma, natural interferon gamma-1a, interferon gamma-1b, interleukin-1 beta, iobenguane, irinotecan, irsogladine, lanreotide, LC 9018 (Yakult), leflunomide, lenograstim, lentinan sulfate, letrozole, leukocyte alpha interferon, leuprorelin, levamisole + fluorouracil, liarozole, lobaplatin, lonidamine, lovastatin, masoprocol, melarsoprol, metoclopramide, mifepristone, miltefosine, mirimostim, mismatched double stranded RNA, mitoguazone, mitolactol, mitoxantrone, molgramostim, nafarelin, naloxone + pentazocine, nartograstim, nedaplatin, nilutamide, noscapine, novel erythropoiesis stimulating protein, NSC 631570 octreotide, oprelvekin, osaterone, oxaliplatin, paclitaxel, pamidronic acid, pegaspargase, peginterferon

alfa-2b, pentosan polysulfate sodium, pentostatin, picibanil, pirarubicin, rabbit antithymocyte polyclonal antibody, polyethylene glycol interferon alfa-2a, porfimer sodium, raloxifene, raltitrexed, rasburicase, rhenium Re 186 etidronate, RII retinamide, rituximab, ritromurtide, samarium (153 Sm) lexidronam, sargramostim, sizofiran, sobuzoxane, sonermin, strontium-89 chloride, suramin, tasonermin, tazarotene, tegafur, temoporfin, temozolomide, teniposide, tetrachlorodecaoxide, thalidomide, thymalfasin, thyrotropin alfa, topotecan, toremifene, tositumomab-iodine 131, altreptin, trastuzumab, treosulfan, tretinoin, trilostane, trimetrexate, triptorelin, tumor necrosis factor alpha, natural, ubenimex, bladder cancer vaccine, Maruyama vaccine, melanoma lysate vaccine, valrubicin, verteporfin, vinorelbine, VIRULIZIN, zinostatin stimalamer, or zoledronic acid; abarelix; AE 941 (Aeterna), ambamustine, antisense oligonucleotide, bcl-2 (Genta), APC 8015 (Dendreon), cetuximab, decitabine, dexaminoglutethimide, diaziquone, EL 532 (Elan), EM 800 (Endorecherche), eniluracil, etanidazole, fenretinide, filgrastim SD01 (Amgen), fulvestrant, galocitabine, gastrin 17 immunogen, HLA-B7 gene therapy (Vical), granulocyte macrophage colony stimulating factor, histamine dihydrochloride, ibritumomab tiuxetan, ilomastat, IM 862 (Cytran), interleukin-2, iproxifene, LDI 200 (Milkhaus), leridistim, lintuzumab, CA 125 MAb (Biomira), cancer MAb (Japan Pharmaceutical Development), HER-2 and Fc MAb (Medarex), idiotypic 105AD7 MAb (CRC Technology), idiotypic CEA MAb (Trilex), LYM-1-iodine 131 MAb (Techniclone), polymorphic epithelial mucin-yttrium 90 MAb (Antisoma), marimastat, menogaril, mitumomab, motexafin gadolinium, MX 6 (Galderma), nelarabine, nolatrexed, P 30 protein, pegvisomant, pemetrexed, porfiromycin, prinomastat, RL 0903 (Shire), rubitecan, satraplatin, sodium phenylacetate,

sparfosic acid, SRL 172 (SR Pharma), SU 5416 (SUGEN), TA 077 (Tanabe), tetrathiomolybdate, thaliblastine, thrombopoietin, tin ethyl etiopurpurin, tirapazamine, cancer vaccine (Biomira), melanoma vaccine (New York University), melanoma vaccine (Sloan Kettering Institute), melanoma oncolysate vaccine (New York Medical College), viral melanoma cell lysates vaccine (Royal Newcastle Hospital), or valspodar.

Alternatively, the compounds of the present invention may also be used in co-therapy with anti-tumor and anti-angiogenic agents (both administered as cancer therapy agents). Exemplary anti-tumor agents include HERCEPTIN™ (trastuzumab), which may be used to treat breast cancer and other forms of cancer, and RITUXAN™ (rituximab), ZEVALIN™ (ibritumomab tiuxetan), and LYMPHOCIDE™ (epratuzumab), which may be used to treat non-Hodgkin's lymphoma and other forms of cancer, GLEEVAC™ which may be used to treat chronic myeloid leukemia and gastrointestinal stromal tumors, and BEXXAR™ (iodine 131 tositumomab) which may be used for treatment of non-Hodgkins's lymphoma.

Exemplary anti-angiogenic agents that may be used in combination with compounds of the present invention include ERBITUX™ (IMC-C225), KDR (kinase domain receptor) inhibitory agents (e.g., antibodies and antigen binding regions that specifically bind to the kinase domain receptor), anti-VEGF agents (e.g., antibodies or antigen binding regions that specifically bind VEGF, or soluble VEGF receptors or a ligand binding region thereof) such as AVASTIN™ or VEGF-TRAP™, and anti-VEGF receptor agents (e.g., antibodies or antigen binding regions that specifically bind thereto), EGFR inhibitory agents (e.g., antibodies or antigen binding regions that specifically bind thereto) such as ABX-EGF (panitumumab), IRESSA™ (gefitinib), TARCEVA™ (erlotinib), anti-Ang1 and anti-Ang2 agents (e.g., antibodies or antigen binding regions specifically binding thereto or to their receptors, e.g., Tie2/Tek), and anti-Tie-2 kinase inhibitory agents (e.g., antibodies or antigen binding regions that

specifically bind thereto). The pharmaceutical compositions of the present invention can also include one or more agents (e.g., antibodies, antigen binding regions, or soluble receptors) that specifically bind and inhibit the activity of growth factors, such as antagonists of hepatocyte growth factor (HGF, also known as Scatter Factor), and antibodies or antigen binding regions that specifically bind its receptor "c-met".

Other anti-angiogenic agents that may be used in combination with compounds of the present invention include Campath, IL-8, B-FGF, Tek antagonists (Ceretti et al., U.S. Publication No. 2003/0162712; U.S. Pat. No. 6,413,932), anti-TWEAK agents (e.g., specifically binding antibodies or antigen binding regions, or soluble TWEAK receptor antagonists; see, Wiley, U.S. Pat. No. 6,727,225), ADAM distintegrin domain to antagonize the binding of integrin to its ligands (Fanslow et al., U.S. Publication No. 2002/0042368), specifically binding anti-eph receptor and/or anti-ephrin antibodies or antigen binding regions (U.S. Pat. Nos. 5,981,245; 5,728,813; 5,969,110; 6,596,852; 6,232,447; 6,057,124 and patent family members thereof), and anti-PDGF-BB antagonists (e.g., specifically binding antibodies or antigen binding regions) as well as antibodies or antigen binding regions specifically binding to PDGF-BB ligands, and PDGFR kinase inhibitory agents (e.g., antibodies or antigen binding regions that specifically bind thereto).

Additional anti-angiogenic/anti-tumor agents that may be used in combination with compounds of the present invention include: SD-7784 (Pfizer, USA); cilengitide.(Merck KGaA, Germany, EPO 770622); pegaptanib octasodium, (Gilead Sciences, USA); Alphastatin, (BioActa, UK); M-PGA, (Celgene, USA, US 5712291); ilomastat, (Arriva, USA, US 5892112); emaxanib, (Pfizer, USA, US 5792783); vatalanib, (Novartis, Switzerland); 2-methoxyestradiol, (EntreMed, USA); TLC ELL-12, (Elan, Ireland); anecortave acetate, (Alcon, USA); alpha-D148 Mab, (Amgen, USA); CEP-7055,(Cephalon, USA); anti-Vn Mab, (Crucell, Netherlands) DAC:antiangiogenic, (ConjuChem, Canada); Angiocidin, (InKine Pharmaceutical,

USA); KM-2550, (Kyowa Hakko, Japan); SU-0879, (Pfizer, USA); CGP-79787, (Novartis, Switzerland, EP 970070); ARGENT technology, (Ariad, USA); YIGSR-Stealth, (Johnson & Johnson, USA); fibrinogen-E fragment, (BioActa, UK); angiogenesis inhibitor, (Trigen, UK); TBC-1635, (Encysive Pharmaceuticals, USA); SC-236, (Pfizer, USA); ABT-567, (Abbott, USA); Metastatin, (EntreMed, USA); angiogenesis inhibitor, (Tripep, Sweden); maspin, (Sosei, Japan); 2-methoxyestradiol, (Oncology Sciences Corporation, USA); ER-68203-00, (IVAX, USA); Benefin, (Lane Labs, USA); Tz-93, (Tsumura, Japan); TAN-1120, (Takeda, Japan); FR-111142, (Fujisawa, Japan, JP 02233610); platelet factor 4, (RepliGen, USA, EP 407122); vascular endothelial growth factor antagonist, (Borean, Denmark); cancer therapy, (University of South Carolina, USA); bevacizumab (pINN), (Genentech, USA); angiogenesis inhibitors, (SUGEN, USA); XL 784, (Exelixis, USA); XL 647, (Exelixis, USA); MAb, alpha5beta3 integrin, second generation, (Applied Molecular Evolution, USA and MedImmune, USA); gene therapy, retinopathy, (Oxford BioMedica, UK); enzastaurin hydrochloride (USAN), (Lilly, USA); CEP 7055, (Cephalon, USA and Sanofi-Synthelabo, France); BC 1, (Genoa Institute of Cancer Research, Italy); angiogenesis inhibitor, (Alchemia, Australia); VEGF antagonist, (Regeneron, USA); rBPI 21 and BPI-derived antiangiogenic, (XOMA, USA); PI 88, (Progen, Australia); cilengitide (pINN), (Merck KGaA, German; Munich Technical University, Germany, Scripps Clinic and Research Foundation, USA); cetuximab (INN), (Aventis, France); AVE 8062, (Ajinomoto, Japan); AS 1404, (Cancer Research Laboratory, New Zealand); SG 292, (Telios, USA); Endostatin, (Boston Childrens Hospital, USA); ATN 161, (Attenuon, USA); ANGIOSTATIN, (Boston Childrens Hospital, USA); 2-methoxyestradiol, (Boston Childrens Hospital, USA); ZD 6474, (AstraZeneca, UK); ZD 6126, (Angiogene Pharmaceuticals, UK); PPI 2458, (Praecis, USA); AZD 9935, (AstraZeneca, UK); AZD 2171, (AstraZeneca, UK); vatalanib (pINN), (Novartis, Switzerland and Schering AG, Germany); tissue factor pathway inhibitors, (EntreMed, USA); pegaptanib (Pinn), (Gilead Sciences, USA); xanthorrhizol, (Yonsei University, South

Korea); vaccine, gene-based, VEGF-2, (Scripps Clinic and Research Foundation, USA); SPV5.2, (Supratek, Canada); SDX 103, (University of California at San Diego, USA); PX 478, (ProlX, USA); METASTATIN, (EntreMed, USA); troponin I, (Harvard University, USA); SU 6668, (SUGEN, USA); OXI 4503, (OXiGENE, USA); o-guanidines, (Dimensional Pharmaceuticals, USA); motuporamine C, (British Columbia University, Canada); CDP 791, (Celltech Group, UK); atiprimod (pINN), (GlaxoSmithKline, UK); E 7820, (Eisai, Japan); CYC 381, (Harvard University, USA); AE 941, (Aeterna, Canada); vaccine, angiogenesis, (EntreMed, USA); urokinase plasminogen activator inhibitor, (Dendreon, USA); oglufanide (pINN), (Melmotte, USA); HIF-1alfa inhibitors, (Xenova, UK); CEP 5214, (Cephalon, USA); BAY RES 2622, (Bayer, Germany); Angiocidin, (InKine, USA); A6, (Angstrom, USA); KR 31372, (Korea Research Institute of Chemical Technology, South Korea); GW 2286, (GlaxoSmithKline, UK); EHT 0101, (ExonHit, France); CP 868596, (Pfizer, USA); CP 564959, (OSI, USA); CP 547632, (Pfizer, USA); 786034, (GlaxoSmithKline, UK); KRN 633, (Kirin Brewery, Japan); drug delivery system, intraocular, 2-methoxyestradiol, (EntreMed, USA); anginex, (Maastricht University, Netherlands, and Minnesota University, USA); ABT 510, (Abbott, USA); AAL 993, (Novartis, Switzerland); VEGI, (ProteomTech, USA); tumor necrosis factor-alpha inhibitors, (National Institute on Aging, USA); SU 11248, (Pfizer, USA and SUGEN USA); ABT 518, (Abbott, USA); YH16, (Yantai Rongchang, China); S-3APG , (Boston Childrens Hospital, USA and EntreMed, USA); MAb, KDR, (ImClone Systems, USA); MAb, alpha5 beta1, (Protein Design, USA); KDR kinase inhibitor, (Celltech Group, UK, and Johnson & Johnson, USA); GFB 116, (South Florida University, USA and Yale University, USA); CS 706, (Sankyo, Japan); combretastatin A4 prodrug, (Arizona State University, USA); chondroitinase AC, (IBEX, Canada); BAY RES 2690, (Bayer, Germany); AGM 1470, (Harvard University, USA, Takeda, Japan, and TAP, USA); AG 13925, (Agouron, USA); Tetrathiomolybdate, (University of Michigan, USA); GCS 100, (Wayne State University, USA) CV 247, (Ivy Medical, UK); CKD 732, (Chong Kun Dang, South Korea); MAb, vascular endothelium growth

factor, (Xenova, UK); irsogladine (INN), (Nippon Shinyaku, Japan); RG 13577, (Aventis, France); WX 360, (Wilex, Germany); squalamine (pINN), (Genaera, USA); RPI 4610, (Sirna, USA); cancer therapy, (Marinova, Australia); heparanase inhibitors, (InSight, Israel); KL 3106, (Kolon, South Korea); Honokiol, (Emory University, USA); ZK CDK, (Schering AG, Germany); ZK Angio, (Schering AG, Germany); ZK 229561, (Novartis, Switzerland, and Schering AG, Germany); XMP 300, (XOMA, USA); VGA 1102, (Taisho, Japan); VEGF receptor modulators, (Pharmacopeia, USA); VE-cadherin-2 antagonists , (ImClone Systems, USA); Vasostatin, (National Institutes of Health, USA);vaccine, Flk-1, (ImClone Systems, USA); TZ 93, (Tsumura, Japan); TumStatin, (Beth Israel Hospital, USA); truncated soluble FLT 1 (vascular endothelial growth factor receptor 1), (Merck & Co, USA); Tie-2 ligands, (Regeneron, USA); and, thrombospondin 1 inhibitor, (Allegheny Health, Education and Research Foundation, USA).

Cancer therapy agents that may be used in combination with compounds of the present invention also include polypeptides (peptidal or peptide-like cancer therapy agents), which selectively induce apoptosis in tumor cells, including, but not limited to, the TNF-related polypeptide TRAIL. Certain cancer therapy agents include, but are not limited to: thalidomide and thalidomide analogues (N-(2,6-dioxo-3-piperidyl)phthalimide); tecogalan sodium (sulfated polysaccharide peptidoglycan); TAN 1120 (8-acetyl-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-10-[[octahydro-5-hydroxy-2-(2-hydroxypropyl)-4,10-dimethylpyrano[3,4-d]-1,3,6-dioxazocin-8-yl]oxy]-5,12-naphthacenedione); suradista (7,7'-[carbonylbis[imino(1-methyl-1H-pyrrole-4,2-diyl)carbonylimino(1-methyl-1H- pyrrole-4,2-diyl)carbonylimino]]bis-1,3-naphthalenedisulfonic acid tetrasodium salt); SU 302; SU 301; SU 1498 ((E)-2-cyano-3-[4-hydroxy-3,5-bis(1-methylethyl)phenyl]-N-(3-phenylpropyl)-2-pro penamide); SU 1433 (4-(6,7-dimethyl-2-quinoxalinyl)-

1,2-benzenediol); ST 1514; SR 25989;soluble Tie-2; SERM derivatives, Pharmos; semaxanib (pINN)(3-[(3,5-dimethyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro-2H-indol-2-one); S 836; RG 8803; RESTIN; R 440 (3-(1-methyl-1H-indol-3-yl)-4-(1-methyl-6-nitro-1H-indol-3-yl)-1H-pyrrole-2,5-dione); R 123942 (1-[6-(1,2,4-thiadiazol-5-yl)-3-pyridazinyl]-N-[3-(trifluoromethyl)phenyl]-4-piperidinamine); prolyl hydroxylase inhibitor; progression elevated genes; prinomastat (INN) ((S)-2,2-dimethyl-4-[[p-(4-pyridyloxy)phenyl]sulphonyl]-3-thiomorpholinecarbohydroxamic acid); NV 1030; NM 3 (8-hydroxy-6-methoxy-alpha-methyl-1-oxo-1H-2-benzopyran-3-acetic acid); NF 681; NF 050; MIG; METH 2; METH 1; manassantin B (alpha-[1-[4-[5-[4-[2-(3,4-dimethoxyphenyl)-2-hydroxy-1-methylethoxy]-3-methoxyphenyl]tetrahydro-3,4-dimethyl-2-furanyl]-2-methoxyphenoxy]ethyl]-1,3-benzodioxole-5-methanol); KDR monoclonal antibody; alpha5beta3 integrin monoclonal antibody; LY 290293 (2-amino-4-(3-pyridinyl)-4H-naphtho[1,2-b]pyran-3-carbonitrile); KP 0201448; KM 2550; integrin-specific peptides; INGN 401; GYKI 66475; GYKI 66462; greenstatin (101-354-plasminogen (human)); gene therapy for rheumatoid arthritis, prostate cancer, ovarian cancer, glioma, endostatin, colorectal cancer, ATF BTPI, antiangiogenesis genes, angiogenesis inhibitor, or angiogenesis; gelatinase inhibitor, FR 111142 (4,5-dihydroxy-2-hexenoic acid 5-methoxy-4-[2-methyl-3-(3-methyl-2-butenyl)oxiranyl]-1-oxaspiro[2.5]oct-6-yl ester); forfenimex (pINN) (S)-alpha-amino-3-hydroxy-4-(hydroxymethyl)benzeneacetic acid); fibronectin antagonist (1-acetyl-L-prolyl-L-histidyl-L-seryl-L-cysteinyl-L-aspartamide); fibroblast growth factor receptor inhibitor; fibroblast growth factor antagonist; FCE 27164 (7,7'-[carbonylbis[imino(1-methyl-1H-pyrrole-4,2-diyl)carbonylimino(1-methyl-1H- pyrrole-4,2-

diyl)carbonylimino]]bis-1,3,5-naphthalenetrisulfonic acid hexasodium salt); FCE 26752 (8,8'-[carbonylbis[imino(1-methyl-1H-pyrrole-4,2-diyl)carbonylimino(1-methyl-1H-pyrrole-4,2-diyl)carbonylimino]]bis-1,3,6-naphthalenetrisulfonic acid); endothelial monocyte activating polypeptide II; VEGFR antisense oligonucleotide; anti-angiogenic and trophic factors; ANCHOR angiostatic agent; endostatin; Del-1 angiogenic protein; CT 3577; contortrostatin; CM 101; chondroitinase AC; CDP 845; CanStatin; BST 2002; BST 2001; BLS 0597; BIBF 1000; ARRESTIN; apomigren (1304-1388-type XV collagen (human gene COL15A1 alpha1-chain precursor)); angiopoietin 2; angioinhibin; aaATIII; A 36; 9alpha-fluoromedroxyprogesterone acetate ((6-alpha)-17-(acetyloxy)-9-fluoro-6-methyl-pregn-4-ene-3,20-dione); 2-methyl-2-phthalimidino-glutaric acid (2-(1,3-dihydro-1-oxo-2H-isoindol-2-yl)-2-methylpentanedioic acid); Yttrium 90 labelled monoclonal antibody BC-1; Semaxanib (3-(4,5-Dimethylpyrrol-2-ylmethylene)indolin-2-one)(C15 H14 N2 O); PI 88 (phosphomannopentaose sulfate); Alvocidib (4H-1-Benzopyran-4-one, 2-(2-chlorophenyl)-5,7-dihydroxy-8-(3-hydroxy-1- methyl-4-piperidinyl)- cis-(-)-) (C21 H20 Cl N O5); E 7820; SU 11248 (5-[3-Fluoro-2-oxo-1,2-dihydroindol-(3Z)-ylidenemethyl]-2,4-dimethyl-1H- pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide) (C22 H27 F N4 O2); Squalamine (Cholestane-7,24-diol, 3-[[3-[(4-aminobutyl)aminopropyl]amino]-, 24-(hydrogen sulfate), (3.beta.,5.alpha.,7.alpha.)-) (C34 H65 N3 O5 S); Eriochrome Black T; AGM 1470 (Carbamic acid, (chloroacetyl)-, 5-methoxy-4-[2-methyl-3-(3-methyl-2- butenyl)oxiranyl] -1-oxaspiro[2,5] oct-6-yl ester, [3R-[3alpha, 4alpha(2R, 3R), 5beta, 6beta]]) (C19 H28 Cl N O6); AZD 9935; BIBF 1000; AZD 2171; ABT 828; KS-interleukin-2; TEK/Fc; Uteroglobin; A 6; NSC 639366 (1-[3-(Diethylamino)-2-hydroxypropylamino]-4-

(oxyran-2- ylmethylamino)anthraquinone fumerate) (C24 H29 N3 O4 . C4 H4 O4); ISV 616; anti-ED-B fusion proteins; HUI 77; Troponin I; BC-1 monoclonal antibody; SPV 5.2; ER 68203; CKD 731 (3-(3,4,5-Trimethoxyphenyl)-2(E)-propenoic acid (3R,4S,5S,6R)-4-[2(R)- methyl-3(R)-3(R)-(3-methyl-2-butenyl)oxiran-2-yl]-5-methoxy-1- oxaspiro[2.5]oct-6-yl ester) (C28 H38 O8); IMC-1C11; aaATIII; SC 7; CM 101; Angiocol; Kringle 5; CKD 732 (3-[4-[2-(Dimethylamino)ethoxy]phenyl]-2(E)-propenoic acid)(C29 H41 N O6); U 995; Canstatin; SQ 885; CT 2584 (1-[11-(Dodecylamino)-10-hydroxyundecyl]-3,7-dimethylxanthine)(C30 H55 N5 O3); Salmosin; EMAP II; TX 1920 (1-(4-Methylpiperazino)-2-(2-nitro-1H-1-imidazoyl)-1-ethanone) (C10 H15 N5 O3); Alpha-v Beta-x inhibitor; CHIR 11509 (N-(1-Propynyl)glycyl-[N-(2-naphthyl)]glycyl-[N-(carbamoylmethyl)]glycine bis(4-methoxyphenyl)methylamide)(C36 H37 N5 O6); BST 2002; BST 2001; B 0829; FR 111142; and 4,5-Dihydroxy-2(E)-hexenoic acid (3R,4S, 5S, 6R)-4-[1(R),2(R)-epoxy-1,5- dimethyl-4-hexenyl]-5-methoxy-1-oxaspiro[2.5]octan-6-yl ester (C22 H34 O7).

Exemplary cancers include, but are not limited to, breast cancer, colorectal cancer, gastric carcinoma, glioma, head and neck squamous cell carcinoma, hereditary and sporadic papillary renal carcinoma, leukemia, lymphoma, Li-Fraumeni syndrome, malignant pleural mesothelioma, melanoma, multiple myeloma, non-small cell lung carcinoma, osteosarcoma, ovarian cancer, pancreatic cancer, prostate cancer, small cell lung cancer, synovial sarcoma, thyroid carcinoma, and transitional cell carcinoma of urinary bladder.

Alternatively, the compounds of the present invention may also be used in co-therapies with other anti-neoplastic agents, such as other kinase inhibitors including p38

inhibitors and CDK inhibitors, TNF inhibitors, matrix metalloproteinase inhibitors (MMP), COX-2 inhibitors including celecoxib, rofecoxib, parecoxib, valdecoxib, and etoricoxib, NSAID's, SOD mimics, C-met inhibitors or $\alpha_v\beta_3$ inhibitors.

In some embodiments, the invention includes administration of, in addition to a Tek antagonist, one or more chemotherapeutic agents in combination with the compound(s) or compositions of the invention. Suitable chemotherapeutic agents, including various soluble forms thereof, include, without limitation, Flt3 ligand, CD40 ligand, interleukin-2, interleukin-12, 4-1BB ligand, anti-4-1BB antibodies, TNF antagonists and TNF receptor antagonists including TNFR/Fc, TWEAK antagonists and TWEAK-R antagonists including TWEAK-R/Fc, TRAIL, VEGF antagonists including anti-VEGF antibodies, VEGF receptor (including VEGF-R1 and VEGF-R2, also known as Flt1 and Flk1 or KDR) antagonists, and CD148 (also referred to as DEP-1, ECRTP, and PTPRJ, see Takahashi et al., J. Am. Soc. Nephrol. 10:2135-45, 1999) agonists.

In other embodiments, compounds or compositions of the invention may be combined with agents disclosed in the following patents and publications: U.S. Patent Nos. 5521184, 5747498, 5770599, 5990141, 6235764, 6258812, 6515004, 6630500, 6713485; U.S. Patent Publication No.US20030105091; and PCT application Nos: WO01/37820,WO01/32651, WO0268406, WO0266470, WO0255501, WO0405279, WO0407481, WO0407458, WO0409784, WO0259110, WO9945009, WO9835958, WO0059509, WO9961422, WO0012089 and WO0002871; as well as the following specific compounds: N-(4-chlorophenyl)-4-(4-pyridinylmethyl)-1-phthalazinamine;

4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl-2-pyridinecarboxamide;

N-[2-(diethylamino)ethyl]-5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide;

3-[(4-bromo-2,6-difluorophenyl)methoxy]-5-[[[[4-(1-pyrrolidinyl)butyl]amino]carbonyl]amino]-4-isothiazolecarboxamide;

N-(4-bromo-2-fluorophenyl)-6-methoxy-7-[(1-methyl-4-piperidinyl)methoxy]-4-quinazolinamine;

3-[5,6,7,13-tetrahydro-9-[(1-methylethoxy)methyl]-5-oxo-12H-indeno[2,1-a]pyrrolo[3,4-c]carbazol-12-yl]propyl ester N,N-dimethyl-glycine;

N-[5-[[[5-(1,1-dimethylethyl)-2-oxazolyl]methyl]thio]-2-thiazolyl]-4-piperidinecarboxamide;

N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-6-[5-[[[2-(methylsulfonyl)ethyl]amino]methyl]-2-furanyl]-4-quinazolinamine;

4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-phenyl]benzamide;

N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(4-morpholinyl)propoxy]-4-quinazolinamine;

N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine;

N-(3-((((2R)-1-methyl-2-pyrrolidinyl)methyl)oxy)-5-(trifluoromethyl)phenyl)-2-((3-(1,3-oxazol-5-yl)phenyl)amino)-3-pyridinecarboxamide;

2-(((4-fluorophenyl)methyl)amino)-N-(3-((((2R)-1-methyl-2-pyrrolidinyl)methyl)oxy)-5-(trifluoromethyl)phenyl)-3-pyridinecarboxamide;

N-[3-(Azetidin-3-ylmethoxy)-5-trifluoromethyl-phenyl]-2-(4-fluoro-benzylamino)-nicotinamide;

6-fluoro-N-(4-(1-methylethyl)phenyl)-2-((4-pyridinylmethyl)amino)-3-pyridinecarboxamide;
2-((4-pyridinylmethyl)amino)-N-(3-(((2S)-2-pyrrolidinylmethyl)oxy)-5-(trifluoromethyl)phenyl)-3-pyridinecarboxamide;
N-(3-(1,1-dimethylethyl)-1H-pyrazol-5-yl)-2-((4-pyridinylmethyl)amino)-3-pyridinecarboxamide;
N-(3,3-dimethyl-2,3-dihydro-1-benzofuran-6-yl)-2-((4-pyridinylmethyl)amino)-3-pyridinecarboxamide;
N-(3-((((2S)-1-methyl-2-pyrrolidinyl)methyl)oxy)-5-(trifluoromethyl)phenyl)-2-((4-pyridinylmethyl)amino)-3-pyridinecarboxamide;
2-((4-pyridinylmethyl)amino)-N-(3-((2-(1-pyrrolidinyl)ethyl)oxy)-4-(trifluoromethyl)phenyl)-3-pyridinecarboxamide;
N-(3,3-dimethyl-2,3-dihydro-1H-indol-6-yl)-2-((4-pyridinylmethyl)amino)-3-pyridinecarboxamide;
N-(4-(pentafluoroethyl)-3-(((2S)-2-pyrrolidinylmethyl)oxy)phenyl)-2-((4-pyridinylmethyl)amino)-3-pyridinecarboxamide;
N-(3-((3-azetidinylmethyl)oxy)-5-(trifluoromethyl)phenyl)-2-((4-pyridinylmethyl)amino)-3-pyridinecarboxamide;
N-(3-(4-piperidinyloxy)-5-(trifluoromethyl)phenyl)-2-((2-(3-pyridinyl)ethyl)amino)-3-pyridinecarboxamide;
N-(4,4-dimethyl-1,2,3,4-tetrahydro-isoquinolin-7-yl)-2-(1H-indazol-6-ylamino)-nicotinamide;
2-(1H-indazol-6-ylamino)-N-[3-(1-methylpyrrolidin-2-ylmethoxy)-5-trifluoromethyl-phenyl]-nicotinamide;
N-[1-(2-dimethylamino-acetyl)-3,3-dimethyl-2,3-dihydro-1H-indol-6-yl]-2-(1H-indazol-6-ylamino)-nicotinamide;
2-(1H-indazol-6-ylamino)-N-[3-(pyrrolidin-2-ylmethoxy)-5-trifluoromethyl-phenyl]-nicotinamide;
N-(1-acetyl-3,3-dimethyl-2,3-dihydro-1H-indol-6-yl)-2-(1H-indazol-6-ylamino)-nicotinamide;

N-(4,4-dimethyl-1-oxo-1,2,3,4-tetrahydro-isoquinolin-7-yl)-2-(1H-indazol-6-ylamino)-nicotinamide;
N-[4-(tert-butyl)-3-(3-piperidylpropyl)phenyl][2-(1H-indazol-6-ylamino)(3-pyridyl)]carboxamide;
N-[5-(tert-butyl)isoxazol-3-yl][2-(1H-indazol-6-ylamino)(3-pyridyl)]carboxamide; and
N-[4-(tert-butyl)phenyl][2-(1H-indazol-6-ylamino)(3-pyridyl)]carboxamide.

Specific binding agents to a cancer therapy agent(s) may be administered with the cancer therapy agent, in conjunction with the compound, or composition, of the present invention. Binding agents may be administered prophylactically or therapeutically to prevent or mitigate the disease or condition in question.

Included in the compounds of Formulas I and II are the pharmaceutically acceptable salts of the free-base compounds. The term "pharmaceutically-acceptable salts" embraces salts commonly used to form alkali metal salts and to form addition salts of free acids or free bases. As appreciated by those of ordinary skill in the art, salts may be formed from ionic associations, charge-charge interactions, covalent bonding, complexation, coordination, etc. The nature of the salt is not critical, provided that it is pharmaceutically acceptable. The term pharmaceutically-acceptable" when used with reference to a compound, including a salt or derivative, a carrier, excipient, adjuvant, and other ingredients used for formulation, is intended to refer to a form of the ingredient that is safe for administration. For example, a salt form of a compound of Formula I or of Formula II, which has been approved for mammalian use, via ingestion or by other administrative routes, by a governing body or regulatory agency, such as the Food and Drug Administration (FDA) of the United States, is pharmaceutically acceptable.

Suitable pharmaceutically acceptable acid addition salts of compounds of Formulas I and II may be prepared from an inorganic acid or from an organic acid. Examples of such inorganic acids are hydrochloric, hydrobromic, hydroiodic, hydrofluoric, nitric, carbonic, sulfuric and phosphoric acid. Appropriate organic acids may be selected from aliphatic, cycloaliphatic, aromatic, arylaliphatic, heterocyclic, carboxylic and sulfonic classes of organic acids, examples of which include, without limitation, formic, acetic, adipic, butyric, propionic, succinic, glycolic, gluconic, lactic, malic, tartaric, citric, ascorbic, glucuronic, maleic, fumaric, pyruvic, aspartic, glutamic, benzoic, anthranilic, mesylic, 4-hydroxybenzoic, phenylacetic, mandelic, embonic (pamoic), methanesulfonic, ethanesulfonic, ethanedisulfonic, benzenesulfonic, pantothenic, 2-hydroxyethanesulfonic, toluenesulfonic, sulfanilic, cyclohexylaminosulfonic, camphoric, camphorsulfonic, digluconic, cyclopentanepropionic, dodecylsulfonic, glucoheptanoic, glycerophosphonic, heptanoic, hexanoic, 2-hydroxy-ethanesulfonic, nicotinic, 2-naphthalenesulfonic, oxalic, palmoic, pectinic, persulfuric, 2-phenylpropionic, picric, pivalic propionic, succinic, thiocyanic, undecanoic, stearic, algenic, β-hydroxybutyric, salicylic, galactaric and galacturonic acid. Suitable pharmaceutically-acceptable base addition salts of compounds of Formulas I and II include metallic salts, such as salts made from aluminum, calcium, lithium, magnesium, potassium, sodium and zinc, or salts made from organic bases including, without limitation, primary, secondary and tertiary amines, substituted amines including cyclic amines, such as caffeine, arginine, diethylamine, N-ethyl piperidine, histidine, glucamine, isopropylamine, lysine, morpholine, N-ethyl morpholine, piperazine, piperidine, triethylamine, disopropylethylamine and trimethylamine. All of these salts

may be prepared by conventional means from the corresponding compound of the invention by reacting, for example, the appropriate acid or base with the compound of Formulas I or II.

Also, the basic nitrogen-containing groups can be quaternized with such agents as lower alkyl halides, such as methyl, ethyl, propyl, and butyl chloride, bromides and iodides; dialkyl sulfates like dimethyl, diethyl, dibutyl, and diamyl sulfates, long chain halides such as decyl, lauryl, myristyl and stearyl chlorides, bromides and iodides, aralkyl halides like benzyl and phenethyl bromides, and others. Water or oil-soluble or dispersible products are thereby obtained.

Examples of acids that may be employed to form pharmaceutically acceptable acid addition salts include such inorganic acids as hydrochloric acid, hydrobromic acid, citric acid, sulphuric acid and phosphoric acid and such organic acids as oxalic acid, stearic and, salicylic acid, pamoic acid, gluconic acid, ethanesulfonic acid, methanesulfonic acid, toluenesulfonic acid, tartaric acid, fumaric acid, medronic acid, napsylic acid, maleic acid, succinic acid and citric acid. Other examples include salts with alkali metals or alkaline earth metals such as sodium, potassium, calcium or magnesium, or with organic bases. Preferred salts include hydrochloride, phosphate and edisylate.

In one embodiment of the invention, the compound of Formulas I or II is in the form of a salt, such as a hemi-, mono-, or di-salt complex, wherein the salt is selected from a benzenesulfonate salt, an ethanesulfonate salt, an ethanedisulfonate salt, a methanesulfonate salt, a p-toluenesulfonate salt, a phosphate salt, a hydrobromide salt, a nitrate salt, a hydrochloride salt, a citrate salt, a medronate salt, a tosylate salt, a maleate salt, a

fumarate salt, a napsylate salt, a pamoate salt, a salicylate salt and a stearate salt.

Additional examples of such salts can be found in Berge et al., J. Pharm. Sci., 66, 1 (1977). Conventional methods may be used to form the salts. For example, a phosphate salt of a compound of the invention may be made by combining the desired compound free base in a desired solvent, or combination of solvents, with phosphoric acid in a desired stoichiometric amount, at a desired temperature, typically under mild heat between 40-80 °C (depending upon the boiling point of the solvent). Generally, polar solvents such as alcohols (like EtOH), DMF, DMSO, and the like are used to form salts, as is readily appreciated by those of ordinary skill in the art. The salt can be precipitated upon cooling (slow or fast) and may crystallize (i.e., if crystalline in nature), as appreciated by those of ordinary skill in the art. (See Example 75 for instance) Further, hemi-, mono-, di, tri- and poly-salt forms of the compounds of the present invention are also contemplated herein. Similarly, hemi-, mono-, di, tri- and poly-hydrated forms of the compounds, salts and derivatives thereof, are also contemplated herein.

The present invention further comprises procedures for the preparation of a compound of Formulas I and II.

GENERAL SYNTHETIC PROCEDURES

The compounds of the invention can be synthesized according to the following procedures of Schemes 1-33, wherein the substituents are as defined for Formulas I and II, above, except where further noted. Although schemes 1-33 illustrate procedures for preparing compounds of Formula I (amino-nicotinamides), these schemes are also applicable as exemplary methods for the preparation of corresponding amino-benzamides of Formula II, which are described in more

detail in the "Preparations" immediately following the General Synthetic Procedures.

Scheme 1



1 2 3

Substituted nicotinamides **3** can be prepared from the corresponding halo analogs **1** by the process outlined in Scheme 1. Substituted amino acids **2** are prepared from the corresponding chloro compounds **1** such as by reacting with an amine at a suitable temperature, such as about 80°C. The acid **2** is coupled with an amine, preferably in the presence of a coupling agent such as EDC, to form the corresponding amide **3**.

The amination process can be carried out as an Ullmann type reaction using a copper catalyst, such as copper[0] or a copper[I] compound such as copper[I]oxide, copper[I]bromide or copper[I]iodide in the presence of a suitable base (such as a metal carbonate, for example K_2CO_3 to neutralize the acid generated in the reaction.

This reaction is reviewed in Houben-Weyl "Methoden der Organischen Chemie", Band 11/1, page 32 -33, 1958, in Organic Reactions, 14, page 19-24, 1965 and by J. Lindley (1984) in Tetrahedron, 40, page 1433-1456.

The amount of catalyst is typically in the range of 1 to 20 mole percent. The reaction is carried out in an inert, aprotic solvent such as an ether solvent (for example dimethoxyethane or dioxane) or an amide solvent (for example dimethylformamide or *N*- methylpyrrolidone), under an inert atmosphere in the temperature range of 60-180 °C.

An alternative amination process involves using a Group VIII element, where the metal core of the catalyst should be a zero-valent transition metal, such as palladium or nickel, which has the ability to undergo oxidative addition to the aryl-halogen bond. The zero valent state of the metal may be generated in situ from the M[II] state. The catalyst complexes may include chelating ligands, such as alkyl, aryl or heteroaryl derivatives of phoshines or biphosphines, imines or arsines. Preferred catalysts contain palladium or nickel.

Examples of such catalysts include palladium[II] chloride, palladium[II]acetate, tetrakis(triphenyl-phosphine)palladium[0] and nickel[II]acetylacetonate. The metal catalyst is typically in the range of 0.1 to 10 mole percent. The chelating ligands may be either monodentate, as in the case for example of trialkyphosphines, such as tributylphosphine, triarylphosphines, such as tri-(*ortho*-tolyl)phosphine, and triheteroaryl phosphines, such as tri-2-furylphosphine; or they may be bidentate such as in the case of 2,2'-bis(diphenylphosphino)- 1,1'binaphthyl, 1,2-bis(diphenylphosphino)ethane, 1,1'-bis(diphenylphosphino) ferrocene and 1-(*N,N*-dimethyl-amino)-1'-(dicyclohexylphosphino)biphenyl. The supporting ligand may be complexed to the metal center in the form of a metal complex prior to being added to the reaction mixture or may be added to the reaction mixture as a separate compound. The supporting ligand is typically present in the range 0.01 to 20 mole percent. It is often necessary to add a suitable

base to the reaction mixture, such as a trialkylamine (for example, DIEA or 1,5-diazabicyclo[5,4,0]undec-5-ene), a Group I alkali metal alkoxide (for example potassium *tert*-butoxide) or carbonate (for example cesium carbonate) or potassium phosphate. The reaction is typically carried out in an inert aprotic solvent such as an ether solvent (for example dimethoxyethane or dioxane) or an amide solvent (for example, DMF or *N*-methylpyrrolidone), under an inert atmosphere in the temperature range of 60-180 ºC.

The amination is preferably carried out in an inert, aprotic, preferably anhydrous, solvent or solvent mixture, for example in a carboxylic acid amide, for example DMF or dimethylacetamide, a cyclic ether, for example THF or dioxane, or a nitrile, for example CH_3CN, or in a mixture thereof, at an appropriate temperature, for example in a temperature range of from about 40 ºC to about 180 ºC, and if necessary under an inert gas atmosphere, for example a nitrogen or argon atmosphere.

Scheme 2



Substituted nicotinamides **3** can also be prepared from the corresponding halo analogs **1A** by the process outlined in Scheme 2. The chloro acid **1** (LG is OH) is coupled with an amine, preferably in the presence of a coupling agent such as EDC, to form the corresponding chloro amide **4**. Substituted amino-nicotinamides **3** are prepared from the corresponding chloro compounds **4** such as by reacting with an amine at a suitable temperature, such as about 80 °C. The amination reaction can be run in the presence of an appropriate catalyst such as a palladium catalyst, in the presence of an aprotic base such as sodium *t*-butoxide or cesium carbonate, or a nickel catalyst, or a copper catalyst.

Alternatively, nicotinamides **3** can be prepared from 2-chloro-heterocyclyl acid chloride **1A** (LG is Cl) by coupling first with R^1-NH_2 such as in the presence of base, e.g., $NaHCO_3$, triethylamine (TEA) or other weak base, in a suitable solvent, such as CH_2Cl_2, to form the amide **1B**, then coupling with a primary or secondary amine in the presence of a base, such as LiHMDS or other strong base, to yield the substituted nicotinamide **3**.

Additionally, where A is a pi-electron rich heterocycle, the addition of KF, such as 40% KF on alumina in IpOH, at a temperature over about 100 °C, preferably about 160 °C, can be used in the formation of **3** from **1B**.

Scheme 3



Substituted carboxamides **3** can also be prepared from the corresponding bromo/chloro analogs **5** by the process outlined in Scheme 3. The bromo/chloro acid **5** is coupled with an amine, preferably in the presence of a coupling agent such as EDC, to form the corresponding bromo substituted amide **6**. Suzuki coupling with the bromo amide **6** and suitable boronic acids provides the substituted amide **4**. Substituted amino-amides **3** are prepared from the corresponding chloro compounds **4** as described in Scheme 2.

Scheme 4



Substituted pyridines **12** can be prepared by the procedure described in Scheme 4. A solution of sodium hypobromite is freshly prepared and added to a 2-hydroxynicotinic acid **7** and heated, such as at a temperature of about 50 °C. Additional sodium hypobromide may be added to form the bromo compound **8** as needed. The 5-bromo-2-hydroxynicotinic acid **8** is reacted with thionyl chloride, at suitable temperature, such as at a temperature >RT, and

preferably at about 80 °C, to form the 2-chloro-nicotinic acid analog **9**. The acid is coupled with an amine, preferably in the presence of a suitable coupling agent(s), such as EDC, HOBT, and DIEA, to form the corresponding substituted amide **10**. Suzuki coupling with the bromo nicotinamide **10** and suitable boronic acids, provides the substituted nicotinamide **11**. 2-Amino-nicotinamides **12** are prepared from the corresponding chloro compounds **11** such as by reacting with substituted amines at a suitable temperature, such as about 80 °C.

Scheme 5



13 14 15

2-Amino-nicotinamides can also be prepared by first functionalizing pyridine compounds, as shown by the procedure described in Scheme 5. 2-Fluoropyridine **13** is lithiated by treatment with a lithium base, such as LDA or butyl lithium, at a temperature below about 0 °C, and preferably at about -78 °C, and quenched with a stream of dry CO_2 to form the nicotinic acid **14**. Solid CO_2 (dry ice) can be used, preferably dried with N_2, instead of gaseous CO_2. The acid **14** is converted to the acid halide **15**, such as by treatment with thionyl chloride and heating at a temperature above about 50 °C, and preferably at about reflux.

Scheme 6



Chloro-substituted pyridines **18** are prepared such as by the procedure described in Scheme 6. 2-Chloronicotinic acid **17** is activated with ethyl chloroformate, in the presence of base, such as TEA, at a temperature of about RT, to form the mixed anhydride (not shown). Reaction of the mixed anhydride with an amine produces amide **18**. Alternatively, the amine can be coupled with the acid chloride **16**, such as with polymer-supported DIEA. Excess acid chloride is removed by treating the reaction mixture with polymer-supported trisamine resin, to form amide **18**.

Scheme 7



a: 7-Aminoisoquinoline, $Pd(OAc)_2$, BINAP, Toluene, K_2CO_3

b: (i) LiOH, MeOH, H_2O, THF. (ii)R^1-NH_2, TBTU, N,N-diisopropylethylamine, Methylene chloride.

Amino-isoquinoline-aryl-amides **21** can be prepared such as by the procedure described in Scheme 7. As shown, a halo-benzoic acid ester or nicotinic acid ester **19** can be coupled to an amino-isoquinoline under Buchwald-type palladium coupling conditions, such as with the use of $Pd(OAc)_2$ and BINAP in toluene with a mild base such as a carbonate base (see conditions a). The resulting isoquinolin-7-ylamino-acid ester **20** can be saponified to the corresponding acid using a hydroxide base, such as LiOH, in a suitable solvent, such as in a mixed solvent of MeOH, water and THF, at mild temperature. The acid intermediate (not shown) can then be treated with known, conventional acid activating/coupling reagents, such as TBTU, HBTU, DCC, and the like, in the presence of a mild base, such as a tertiary amine base like DIEA (*N,N*-diisopropylethyl amine), and reacted with a desired amine such as an amino-tetrahydroisoquinoline **22** (below), or suitable other nucleophile (not shown in scheme 7), to afford the amino-isoquinolines **21** as the product. This method is useful for installing the desired isoquinolines prior to modifying the amide moieties of compound **21**.

Scheme 8



Alternatively, amino-isoquinoline (or quinazoline)-aryl-nicotinamides **25** (where R^1 is aryl) can be prepared by the procedure described in Scheme 8, as follows: Amino-isoquinolines **23** can be coupled to benzoic esters or nicotinic esters **19** (scheme 7) after it has been converted to the desired amide **22** (see scheme 7 above), under N_2, by reacting compounds **22** and **23** in the presence of $Pd_2(dba)_3$, a catalytic amount of 2-dicyclohexylphosphino-2'-(N,N-dimethylamino)biphenyl **24** (Cas# 213697-53-1, Strem Chemicals 15-1145,) and 1.0 M $LiNTMS_2$ THF solution, in a pressure-sealed reaction vessel. The reaction vessel is generally stirred at elevated temperatures, as at about 70 °C for a prolonged period of time, such as about 17 hours. After cooling, the product **25** can be recovered by conventional extraction and/or purification methods.

Scheme 9



As an alternative to Scheme 8, amino-naphthydrin-aryl-nicotinamides **28** (see also similar compounds **22**, **25**) can be prepared by the procedure described in Scheme 9, as follows: 2-amino-N-(4-tert-butyl-phenyl)-benzamide **26** (where R^1 is 4-tert-butyl-phenyl) and 2-Chloro-[1,7]naphthyridine **27** can be coupled to form compound **28** using the reagents shown in scheme 8, i.e., $Pd_2(dba)_3$, (2'-dicyclohexylphosphanyl-biphenyl-2-yl)-dimethyl-amine, and 1M solution of $LiN(TMS)_2$ in THF, in a sealed reaction vessel at 70 °C for about 24h. Such a method is useful especially where desired amino-napththydrins, for use in the procedure described in Scheme 8, are not commercially available and/or are difficult to synthesize.

Scheme 10



Nicotinamides **31** can be made under various coupling conditions. For example, and as shown in Scheme 10, nicotinamides **31** can be made by treating a desired fluoro-nicotinamide **29** and a desired 7-aminoisoquinoline (or quinazoline where Z=N) **30** with TFA in a suitable solvent, such as t-BuOH, and stirring the resulting mixture for 24 hours at elevated temperature, such as at 90 ºC.

Various aryl R and R^1 groups of the compounds of the present invention can be prepared as described in the following Schemes 11-25, 27-30 and 32-33.

Scheme 11



32 **33** **34**

Alkylated indazoles can be prepared by the procedure described in Scheme 11. To a solution of 6-nitroindazole **32** in a solvent such as THF is added strong base, such as NaH at a temperature below RT, preferably at about 0 ºC. Alkylhalides, such as where R" is methyl, are added and reacted at a temperature about RT to give 1-alkyl-6-nitro-1H-indazole **33**. The nitro indazole **33** is hydrogenated, such as with an H_2 atmosphere in the presence of a catalyst, such as Pd/C to give the 1-substituted-6-amino-1H-indazole **34**.

Scheme 12



35 **36**

Brominated indazoles can be prepared by the procedure described in Scheme 12. NBS is slowly added to an acidic solution, such as a mixture of TFA:H_2SO_4 (5:1) and *tert*-butyl-4-nitrobenzene **35** at a temperature of about RT to yield the brominated compound **36**.

Scheme 13



37 **38** **39**

Indazolyl ethers **38** can be prepared by the procedure described in Scheme 13. 6-Nitro-1H-2-hydroindazol-3-one **37** is protected such as with Boc_2O and DMAP in CH_2Cl_2 at a temperature of about RT, to give the protected 6-nitro-2-hydroindazol-3-one. The protected 6-nitro-2-hydroindazol-3-one is reacted with an alcohol (where R^x is an appropriate substituent selected from the possible substituents on R^1) and Ph_3P in a solvent, such as THF, and DEAD, at a temperature of about RT, to give the protected 6-nitro(indazol-3-yl) ether. The nitro intermediate is hydrogenated, such as with an H_2 atmosphere in the presence

of a catalyst, such as Pd/C, to give the protected 6-amino(indazol-3-yl) ether **38**. The amine **38** is coupled with 2-chloronicotinic acid in a solvent, such as an alcohol, preferably pentanol, at a temperature above RT, preferably at a temperature above about 75 ºC, and more preferably at a temperature at about 130 ºC to give the coupled and deprotected compound **39**.

Scheme 14



Indolinyl substituted carboxamides **45** can be prepared from the corresponding nitro indoline **40** by the procedure described in Scheme 14. For example, 3,3-dimethyl-6-nitroindoline **40** is alkylated, such as with N-protected-4-formylpiperidine in the presence of $NaHB(OAc)_3$ and acid, such as glacial AcOH, and solvent, such as dichloromethane, at a temperature of about RT, to afford the alkylated indane **41**. Hydrogenation of the alkylated indane **41**, such as with an H_2 atmosphere in the presence of a catalyst, such as Pd/C, in the presence of a solvent, such as an alcohol, preferably MeOH, to give the amino intermediate **42**. Alternatively, other hydrogenation methods can be used, such as Fe powder with NH_4Cl. Coupling of the amine **42**, such as with 2-chloronicotinic acid and DIEA, HOBt and EDC, in a solvent such as CH_2Cl_2 at a temperature of about RT provides the protected carboxamide **43**, which upon deprotection and alkylation yields other compounds of the invention, **44** and **45**, respectively. Alternatively, amine **42** is reacted with 2-fluoronicotinoyl chloride to form a 2-fluoronicotinamide, which can be alkylated such as in Scheme 14.

Scheme 15



Substituted indolines **51** are prepared such as by the procedures described in Scheme 15. Substituted amino-indolines **48** are prepared from the nitroindoline **46** and a ketone in the presence of $NaHB(OAc)_3$ to form the 1-substituted indoline **47**. The nitroindoline **47** is hydrogenated, such as with H_2 in the presence of a catalyst, such as Pd/C, to yield the amino-indoline **48**.

Alternatively, substituted amino-indolines **51** are prepared from the nitroindoline **46**. Nitroindoline **46**, is reacted with an acid chloride to form an amide. Further treatment with a primary or secondary amine, preferably a secondary amine, such as in the presence of NaI, at a temperature above about 50 ºC, and preferably at about 70 ºC yields the nitroindoline **49**. The nitro compound **49** is hydrogenated, such as with H_2 in the presence of a catalyst, such as Pd/C, to yield the amino-indoline) **50**. The carbonyl is reduced, such as with BH_3-THF yields 1-aminoalkyl-indolines **51**.

Scheme 16



52 53 54 55 56 55a

Substituted indolines (**55**, **55a**, and **56**) are prepared such as by the procedures described in Scheme 16. Substituted acetamides **53** are prepared from the coupling of halo-5-nitroanilines **52** (where LG is bromo or chloro, preferably chloro) and an acylating agent, such as acetyl chloride or acetic anhydride, under standard coupling chemistry, such as with DIEA, and DMAP, at a temperature of about RT, in a suitable solvent, such as CH_2Cl_2, DMF and/or DMAC. The N-(2-methylprop-2-enyl)acetamide **54** is prepared from the acetamide **53**, such as by the treatment of base, such as NaH in a suitable solvent such as NMP or anhydrous DMF and a 3-halo-2-methylpropene such as 3-bromo-2-methylpropene or 3-chloro-2-methylpropene, at a temperature between about 0 °C and RT, and preferably at about RT; or with $CsCO_3$ at a temperature above RT, preferably above about 50 °C and more preferably above about 60 °C. Cyclization of the N-(2-methylprop-2-enyl)acetamide **54**, such as by the Heck-type reaction (treatment with $Pd(OAc)_2$ in the presence

of base, for example tetraethyl-ammonium chloride, sodium formate, and NaOAc) at a temperature above about 50 ºC, and preferably at about 80 ºC, yields the protected (3,3-dimethyl-6-nitro-2,3-dihydro-indol-1-yl)ethanone **55**. Deprotection, such as with strong acid such as HCl or AcOH at a temperature above about 50 ºC, and preferably at about 70-80 ºC, yields the 3,3-dimethyl-6-nitro-2,3-dihydro-indol-1-yl **56**. Alternatively, the protected dihydro-6-nitro indoline **55** can be reduced, such as with Fe, or with 10% Pd/C in the presence of an excess of NH_4CO_2H, or with H_2 in the presence of a catalyst to form the protected dihydro-6-amino indoline **55a**.

Scheme 17



7-Amino-isoquinolines **61** can be prepared by the procedure described in Scheme 17. 4-Nitrophenethylamine hydrochloride **57** can be treated with triflic anhydride in the presence of base, such as DIEA, in a suitable solvent, such as CH_2Cl_2, at reduced temperature and stirred at about RT to form the protected amino compound **58**. Treatment of the resulting yellow 2,2,2-trifluoro-N-[2-(4-nitro-phenyl)-ethyl]-acetamide **58** with paraformaldehyde and acid, such as HOAc or a mixture of HOAc with H_2SO_4, slowly under

controlled reaction conditions affords the N-acetyl protected 7-nitro-1,2,3,4-tetrahydroisoquinoline **59**. Isoquinoline-acetamide **59** can then be reduced to 7-nitro-1,2,3,4-tetrahydro-isoquinoline **60** with a hydroxide base, such as LiOH, for example, in solvent such as MeOH, CH_2Cl_2 and H_2O, to cleave the acetamide. The nitro group resulting nitro-tetrahydroisoquinoline **60** can then be reduced to the corresponding 7-amino-isoquinoline **61** with 10%Pd on carbon in diethylene glycol under radiation, such as in a Smith Synthesizer microwave at 220 ºC.

Scheme 18



62 63

N^4-Substituted-quinazoline-4,6-diamines **63** can be prepared by the procedure described in Scheme 18. The nitro group of substituted-(6-nitro-quinazolin-4-yl)-amines **62** can be reduced by conventional hydrogenation methods, such as with palladium on carbon (10 wt%) in suitable solubilizing solvent, such as methanol, under a suitable pressure of hydrogen gas.

Scheme 19



[1,6]Naphthyridin-3-ylamines **68** can be prepared by the procedure described in Scheme 19. 3-Nitro-7,8-dihydro-5H-[1,6]naphthyridine-6-carboxylic acid tert-butyl ester **66** can be prepared by reacting 1-methyl-3,5-dinitro-1H-pyridin-2-one **64** and 4-oxo-piperidine-1-carboxylic acid tert-butyl ester **65** with 2M solution of NH_3 in MeOH in a sealed vessel for 24h at 70 °C. Cooling and concentration of the reaction affords the crude compound **66**, which may be recrystallized from one or more suitable solvents, such as from MeOH. The Boc protecting group of 3-nitro-7,8-dihydro-5H-[1,6]naphthyridine-6-carboxylic acid tert-butyl ester **66** can be removed using standard deprotection chemistry, such as with TFA in solvent, to yield 3-nitro-5,6,7,8-tetrahydro-[1,6]naphthyridine **67**. Compound **67** may be recrystallized from suitable solvents, such as CH_3CN. Hydrogenation of 3-nitro-5,6,7,8-tetrahydro-[1,6]naphthyridine **67** with Pd/C, with simultaneous oxidation under known conditions, such as in a microwave reaction vessel, affords the corresponding amino-naphthydrins **68**.

Scheme 20



1,2,3,6-Tetrahydro-pyridyl substituted anilines **73** are prepared such as by the procedure described in Scheme 20. Nitrobenzenes **69** are brominated, such as with bromine in the presence of acid, H_2SO_4 for example, or with NBS to yield the 3-bromo derivative **70**. Suzuki coupling of the bromo-derivative **70** and a substituted pyridylboronic acid, such as at a temperature above RT, preferably above about 50 °C, and more preferably at about 80 °C, yields the pyridyl derivative **71**. Alkylation of the nitrophenyl-pyridine **71**, such as by treatment with iodomethane, preferably above about 50 ºC, and more preferably at about 80 ºC, yields the pyridinium compound **72**, which upon reduction, such as by $NaBH_4$, yields the tetrahydyropyridine substituted aniline **73**.

A-917 - 92 -

Scheme 21



A series of substituted anilines are prepared such as by the procedure described in Scheme 21. A nitrobenzyl bromide **74** is coupled with morpholine, such as at a temperature at about RT, to yield the heterocyclylmethyl nitrobenzene derivative (not shown). Reduction of the nitro compound (step 2), such as with iron powder, preferably above about 50 ºC, and more preferably at about 80 ºC, yields the heterocyclylmethyl substituted aniline **75**.

Protected alkylamine substituted anilines can be prepared from the nitro free amines **76**, such as with standard protecting agents and chemistry known in the art, such as BOC chemistry. Reduction of the protected nitro compound, such as with iron powder, preferably above about 50 ºC, and more preferably at about 80 ºC, yields the aniline **77**.

Sulfonamide substituted anilines can be prepared from nitrobezenesulfonyl chlorides **78**. Coupling of nitrobezenesulfonyl chlorides **78** with reactive heterocyclic compounds, such as substituted piperazines, piperidines, and the like, in a protic solvent such as EtOH, such as at a temperature about RT, yields the nitrobezenesulfonamides **78**. Reduction of the nitro benzenesulfonamide, such as with iron powder, preferably above about 50 °C, and more preferably at about 80 °C, yields the aniline **79**.

Scheme 22



80 **81** **82**

A series of perhaloalkyl-substituted anilines **82**, where R^Y represents perhaloalkyl radicals, are prepared such as by the procedure described in Scheme 22. 1-Nitro-4-(perfluoroethyl)benzene can be synthesized by the method described in the reference [John N. Freskos, Synthetic Communications, 18(9), 965-972 (1988)]. Alternatively, 1-Nitro-4-(perfluoroalkyl)benzene can be synthesized from the nitro compound, where X^a is a leaving group, such as bromo or iodo, by the method described by W. A. Gregory, et al. [J. Med. Chem., 1990, 33, 2569-2578].

Reduction of the nitrobenzenes **81**, with a metal such as iron powder, at a temperature above about 50 °C, and preferably at about 80 °C, yields the aniline **82**. Hydrogenation, such as with H_2 atmosphere in the presence of a catalyst, such as 10% Pd/C, is also possible.

Scheme 23



Additional series of substituted anilines (**85**, **88** and **91**) are prepared such as by the procedures described in Scheme 23 (where R^x is a substituent selected those available for substituted R^1, preferably haloalkyl and alkyl). 2-Alkoxy substituted anilines **85** are prepared from the corresponding phenol compounds **83** such as by the Mitsunobu reaction, including treatment with a N,N-dialkylethanolamine and PPh_3 and DEAD to give the corresponding nitro compound **84**, followed by hydrogenation, such as with H_2 to give the aniline **85**.

Alternatively, piperazinyl substituted anilines **88** can be prepared by the treatment of an aniline **86** with an N-substituted-bis(2-chloroethyl)amine, base, such as K_2CO_3 and NaI, at a temperature above about 50 °C, preferably above about 100 °C, and more preferably at about 170 °C, to give the piperazinylbenzene compound **87**. Nitration, such as with H_2SO_4 and HNO_3, at a temperature above 0 °C, and preferably

at about RT, followed by hydrogenation, such as with H_2 atmosphere gives the substituted aniline **88**.

Alternatively, piperazinyl substituted anilines **91** can be prepared by the treatment of a fluoro-nitro-substituted aryl compounds **89**. The fluoro-nitro-substituted aryl compounds **89** and 1-substituted piperazines are heated, preferably neat, at a temperature above about 50 °C, and preferably at about 90 °C, to yield the piperazinyl-nitroaryl compounds **90**. Hydrogenation, such as with H_2 atmosphere in the presence of a catalyst, such as 10% Pd/C, gives the substituted aniline **91**.

Scheme 24



Substituted anilines **98** are prepared such as by the procedures described in Scheme 24. Nitrophenyl esters **93** are formed from the acid **92**, such as by treatment with MeOH and acid. Alkylation of the ester **93**, such as by treatment with base, followed by alkyl halide, yields the branched alklyl compounds **94**. Reduction of the ester **94**, such as with BH_3, yields the alcohol **95**. The aldehyde **96** is

prepared from the alcohol **95**, such as by treatment with TPAP in the presence of N-methylmorpholine-N-oxide. Subsequent treatment with methoxymethyltriphenylphosphonium chloride and KHMDS yields **96**. Coupling of the aldehyde **96** and morpholine, such as with $NaBH(OAc)_3$ yields the tertiary amine **97**. Reduction of the nitro group on compound **97**, such as with acid, for example AcOH, and zinc yields the aniline **98**.

Scheme 25



Substituted aniline compounds **101** are prepared such as by the procedure described in Scheme 25 (where R^x is a substituent selected those available for substituted R^1, preferably haloalkyl and alkyl). Alkynyl-aniline **100**, prepared similar to that described in Scheme 26 (below), is hydrogenated such as with H_2 in the presence of a catalyst, such as $Pd(OH)_2$, to yield the substituted alkyl **101**.

Scheme 26



Substituted bromophenyl compounds **103** are prepared such as by the procedure described in Scheme 26. Bromine is added to a optionally substituted nitrobenzene **102**, silver(II)sulfate and acid, such as H_2SO_4, to provide the bromo derivative **103**.

Scheme 27



4-(2,2,2-Trifluoro-1-methoxy-1-trifluoromethyl-ethyl)-phenylamine **105** can be prepared by the procedure decribed in scheme 27, as follows: the hydroxyl group of 2-(4-amino-phenyl)-1,1,1,3,3,3-hexafluoro-propan-2-ol **104** can be activated for displacement by conventional methods, such as by treating **104** with diisopropyl azodicarboxylate in the presence of triphenylphosphine (polymer-bound, excess equivalents) then treated with MeOH and stirred at about reflux.

Scheme 28



Substituted anilines (**106** and **107**) are prepared such as by the procedure described in Scheme 28. Treatment with the haloalkyl alcohol **104** with an alcohol, under Mitsunobu conditions such as in the presence of DEAD and PPh_3 yields the corresponding ether adducts **106** or **107**.

Scheme 29



Substituted indoles **110** are prepared such as by the procedure described in Scheme 29. A nitroindole **108** is coupled with a halo compound, in the presence of base, for example K_2CO_3. Heating at a temperature above about 50 °C, and preferably at about reflux yields the substituted-nitro-1H-indole **109**. Hydrogenation similar to conditions described above yield the amino derivative **110**.

Scheme 30



Amino-substituted indoles **113** are prepared such as by the procedure described in Scheme 30. Nitroindoline **111** is

reacted with N-methyl-4-piperidone in the presence of NaOMe at a temperature above about 50 ºC, and preferably at about reflux, to form the 3-substituted indole **112**. Hydrogenation as previously discussed yields the amino indole **113**.

Scheme 31



114 **115**

Substituted carboxamides **115** can be prepared from the corresponding phenols **114** of the invention, by the procedure described in Scheme 31. A carboxamide **114** is coupled with an alcohol, such as 4-hydroxy-N-methylpiperidine, in the presence of DEAD and triphenylphosphine, in a solvent such as THF, at a temperature of about RT, provides the ether **115**.

Scheme 32



2,3,4,4a,9,9a-Hexahydro-1H-3-aza-fluoren-6-ylamine **121** can be prepared by the procedure described in Scheme 32. Nitrobenzylpyridines **116** are alkylated, such as with MeI, in the presence of TBAI and base to form the pyridinium compound **117**. The pyridinium compounds **117** are halogenated, such as brominated with NBS, to form the brominated pyridinium compounds **118** which are reduced such as with $NaBH_4$, dehalogenated and reduced to form the hexahydro-fluorenes **121.**

Scheme 33



Acylated amino-isoquinoline-tetrahydroisoquinoline-nicotinamides **124** can be prepared by the procedure described in scheme 33. Tetrahydroisoquinoline-quinoline nicotinamides **122** can be treated with Boc-protected glycine **123** in the presence of known acid-activating coupling reagents and combinations of same reagents, such as EDAC and HOBt, with a mild base, such as DIEA, to effect the acylation of compound **122** and provide compound **124**. The glycyl amine can be deprotected or cleaved using dilute HCl to afford the free glycine amine **125**, for subsequent coupling to desired chemical structures. Amides (not shown) of compound **125** can be made by coupling compound **125** with activated carboxylic acid compounds (not shown) such as acid chlorides, or by displacing other suitable leaving groups of desired compounds.

The starting compounds defined in Schemes 1-33 may also be present with functional groups in protected form if necessary, such as BOC-protected glycine, and/or in the form of salts, provided a salt-forming group is present and the reaction in salt form is possible. If so desired, one compound of Formula I or II can be converted into another compound of Formula I or II, or a N-oxide thereof; a compound of Formula I or II can be converted into a salt; a salt of a compound of Formula I or II can be converted into the free compound or another salt; and/or a mixture of

isomeric compounds of Formula I or II can be separated into the individual isomers.

N-Oxides are also contemplated to be included in the present invention. N-oxides can be obtained in a known matter by reacting a compound of Formula I or II with hydrogen peroxide or a peracid, e.g. 3-chloroperoxy-benzoic acid, in an inert solvent, e.g. dichloromethane, at a temperature between about -10-35 °C, such as about 0 °C - RT.

If one or more other functional groups, for example carboxy, hydroxy, amino, or mercapto, are or need to be protected in a compound of Formula I or II or in the preparation of compounds of Formula I or II, because they should not take part in the reaction, these are such groups as are usually used in the synthesis of peptide compounds, and also of cephalosporins and penicillins, as well as nucleic acid derivatives and sugars.

The protecting groups may already be present in precursors and should protect the functional groups concerned against unwanted secondary reactions, such as acylations, etherifications, esterifications, oxidations, solvolysis, and similar reactions. It is a characteristic of protecting groups that they lend themselves readily, i.e. without undesired secondary reactions, to removal, typically by solvolysis, reduction, photolysis or also by enzyme activity, for example under conditions analogous to physiological conditions, and that they are not present in the end-products. The specialist knows, or can easily establish, which protecting groups are suitable with the reactions mentioned above and hereinafter.

The protection of such functional groups by such protecting groups, the protecting groups themselves, and their removal reactions are described for example in standard reference works, such as J. F. W. McOmie,

"Protective Groups in Organic Chemistry", Plenum Press, London and New York 1973, in T. W. Greene, "Protective Groups in Organic Synthesis", Wiley, New York 1981, in "The Peptides"; Volume 3 (editors: E. Gross and J. Meienhofer), Academic Press, London and New York 1981, in "Methoden der organischen Chemie" (Methods of organic chemistry), Houben Weyl, 4th edition, Volume 15/1, Georg Thieme Verlag, Stuttgart 1974, in H.-D. Jakubke and H. Jescheit, "Aminosäuren, Peptide, Proteine" (Amino acids, peptides, proteins), Verlag Chemie, Weinheim, Deerfield Beach, and Basel 1982, and in Jochen Lehmann, "Chemie der Kohlenhydrate: Monosaccharide und Derivate" (Chemistry of carbohydrates: monosaccharides and derivatives), Georg Thieme Verlag, Stuttgart 1974.

In the additional process steps, carried out as desired, functional groups of the starting compounds which should not take part in the reaction may be present in unprotected form or may be protected for example by one or more of the protecting groups mentioned above under "protecting groups". The protecting groups are then wholly or partly removed according to one of the methods described there.

Salts of a compound of Formula I or II with a salt-forming group may be prepared in a manner known *per se*. Acid addition salts of compounds of Formula I or II may thus be obtained by treatment with an acid or with a suitable anion exchange reagent. A salt with two acid molecules (for example a dihalogenide of a compound of formula I) may also be converted into a salt with one acid molecule per compound (for example a monohalogenide); this may be done by heating to a melt, or for example by heating as a solid under a high vacuum at elevated temperature, for example from 130 °C to 170 °C, one molecule of the acid being expelled per molecule of a compound of Formula I or II.

Acid salts can usually be converted to free-base compounds, e.g. by treating with suitable basic agents, for example with alkali metal carbonates, alkali metal hydrogen carbonates, or alkali metal hydroxides, typically potassium carbonate or sodium hydroxide. Similarly, basic salts of compounds may be converted to the corresponding free-base compound by treatment with the desired number of equivalents of a suitable acidic agent, such as HCl, acetic acid, and the like.

A carbonyl group in a compound of Formula I or II may be converted into the respective thiocarbonyl, for example, by using an appropriate sulfur compound, e. g. using reaction with Lawesson's reagent (2,4-bis-(4-methoxyphenyl)2,4-dithioxo-1,2,3,4-dithiaphosphetan) in a halogenated hydrocarbon, such as CH_2Cl_2, or an aprotic solvent, such as toluene or xylene, at temperatures from about 30 °C to reflux.

All process steps described here can be carried out under known reaction conditions, preferably under those specifically mentioned, in the absence of or usually in the presence of solvents or diluents, preferably such as are inert to the reagents used and able to dissolve these, in the absence or presence of catalysts, condensing agents or neutralizing agents, for example ion exchangers, typically cation exchangers, for example in the H+ form, depending on the type of reaction and/or reactants at reduced, normal, or elevated temperature, for example in the range from about -100 °C to about 190 °C, preferably from about -80 °C to about 150°C, for example at about -80°C to about 60°C, at room temperature, at about -20 °C to about 40 °C or at the boiling point of the solvent used, under atmospheric pressure or in a closed vessel, where appropriate under pressure, and/or in an inert atmosphere, for example under argon or nitrogen.

Salts may be present in all starting compounds and transients, if these contain salt-forming groups. Salts may also be present during the reaction of such compounds, provided the reaction is not thereby disturbed.

In certain cases, typically in hydrogenation processes, it is possible to achieve stereoselective reactions, allowing for example easier recovery of individual isomers.

Suitable solvents, which may be selected to carry out the reactions in question, as appreciated by those of ordinary skill in the art. Suitable aqueous, organic and inorganic solvents include, without limitation, water; esters, typically lower alkyl-lower alkanoates, e.g., ethyl acetate; ethers, typically aliphatic ethers, e.g., diethylether, or cyclic ethers, e.g., THF; liquid aromatic hydrocarbons, typically benzene or toluene; alcohols, typically MeOH, EtOH or 1-propanol, IPOH, BuOH, t-BuOH; nitriles, typically CH_3CN; halogenated hydrocarbons, typically CH_2Cl_2, $CHCl_3$; acid amides, typically DMF; bases, typically heterocyclic nitrogen bases, e.g. pyridine; carboxylic acids, typically lower alkanecarboxylic acids, e.g., AcOH; carboxylic acid anhydrides, typically lower alkane acid anhydrides, e.g., acetic anhydride; cyclic, linear, or branched hydrocarbons, typically cyclohexane, hexane, pentane, cyclopentane, or isopentane; and mixtures of such solvents, e.g., aqueous solutions and solvent combinations, unless otherwise stated in the description of the process. Such solvent mixtures may also be used in processing, for example in chromatography, extraction and recystallization.

The invention relates also to those methods of the process in which one starts from a compound obtainable at any stage as a transient and carries out the missing steps, or breaks off the process at any stage, or forms a starting

material under the reaction conditions, or uses said starting material in the form of a reactive derivative or salt, or produces a compound obtainable by means of the process according to the invention and processes the said compound *in situ*. In the preferred embodiment, one starts from those starting materials, which lead to the compounds described above as preferred.

The compounds of Formula I or II, including their derivatives, are also obtainable in the form of salts, hydrates or crystals. A crystalline form, for example, can include the solvent, or solvents, used for crystallization (generally present as solvates).

New starting materials and/or intermediates, as well as processes for the preparation thereof, are likewise the subject of this invention. In the preferred embodiment, such starting materials are used and reaction conditions so selected as to enable the preferred compounds to be obtained.

Starting materials of the invention, are known, are commercially available, or can be synthesized in analogy to or according to methods that are known in the art.

For example, amine compounds, represented in Schemes 11, 18, 20 and 22, can be prepared by reduction of the corresponding nitro precurser. The reduction preferably takes place in the presence of a suitable reducing agent, such as tin(II) chloride or hydrogen in the presence of an appropriate catalyst, such as Raney nickel (then preferably the hydrogen is used under pressure, e.g. between 2 and 20 bar), Pd or PtO_2, in an appropriate solvent, e.g. an alcohol, such as MeOH. The reaction temperature is preferably between about 0 °C and about 80 °C, especially about 15 °C to about 30 °C.

It would also be possible to reduce the nitro compound after forming the other amide linkages, under reaction

conditions analogous to those for the reduction of nitro compounds described above. This would eliminate the need to protect the free amino group as described in various of the schemes above.

In the preparation of starting materials, existing functional groups, which do not participate in the reaction should, if necessary, be protected. Preferred protecting groups, their introduction and their removal are described above or in the examples.

All remaining starting materials are known, capable of being prepared according to known processes, or commercially obtainable; in particular, they can be prepared using processes as described in the examples.

Compounds of the present invention can possess, in general, one or more asymmetric carbon atoms and, therefore, are capable of existing in the form of optical isomers as well as in the form of racemic or non-racemic mixtures thereof. The optical isomers can be obtained by resolution of the racemic mixtures according to conventional processes, *e.g.*, by formation of diastereoisomeric salts, by treatment with an optically active acid or base. Examples of appropriate acids are tartaric, diacetyltartaric, dibenzoyltartaric, ditoluoyltartaric, and camphorsulfonic acid and then separation of the mixture of diastereoisomers by crystallization followed by liberation of the optically active bases from these salts. A different process for separation of optical isomers involves the use of a chiral chromatography column optimally chosen to maximize the separation of the enantiomers. Still another available method involves synthesis of covalent diastereoisomeric molecules by reacting compounds of the invention with an optically pure acid in an activated form or an optically pure isocyanate. The synthesized diastereoisomers can be

separated by conventional means such as chromatography, distillation, crystallization or sublimation, and then hydrolyzed to deliver the enantiomerically pure compound. The optically active compounds of the invention can likewise be obtained by using optically active starting materials. These isomers may be in the form of a free acid, a free base, an ester or a salt.

The compounds of the present invention may contain one or more asymmetric centers and, therefore, occur as racemates and racemic mixtures, scalemic mixtures, single enantiomers, individual diastereomers and diastereomeric mixtures. All such isomeric forms of these compounds are expressly included in the present invention.

The compounds of this invention may also be represented in multiple tautomeric forms, for example, as illustrated below:



The invention expressly includes all tautomeric forms of the compounds described herein.

The compounds of this invention may also occur in cis- or trans- or E- or Z- double bond isomeric forms. All such isomeric forms of such compounds are expressly included in the invention. All crystal forms of the compounds described herein are expressly included in the invention.

Substituents on ring moieties (e.g., phenyl, thienyl, etc.) may be attached to specific atoms, whereby they are intended to be fixed to that atom, or they may be drawn unattached to a specific atom, whereby they are intended to be attached at any available atom that is not already substituted by an atom other than H (hydrogen).

The compounds of this invention may contain heterocyclic ring systems attached to another ring system. Such heterocyclic ring systems may be attached through a carbon atom or a heteroatom in the ring system.

Alternatively, a compound of Formula I or II herein may be synthesized according to any of the procedures described herein. In the procedures described herein, the steps may be performed in an alternate order and may be preceded, or followed, by additional protection/deprotection steps as necessary. The procedures may further comprise use of appropriate reaction conditions, including inert solvents, additional reagents, such as bases (e.g., LDA, DIEA, pyridine, K_2CO_3, and the like), catalysts, and salt forms of the above. The intermediates may be isolated or carried on *in situ*, with or without purification. Purification methods are known in the art and include, for example, crystallization, chromatography (liquid and gas phase, simulated moving bed ("SMB")), extraction, distillation, trituration, reverse phase HPLC and the like. Reactions conditions such as temperature, duration, pressure, and atmosphere (inert gas, ambient) are known in the art and may be adjusted as appropriate for the reaction.

As can be appreciated by the skilled artisan, the above synthetic schemes are not intended to comprise a comprehensive list of all means by which the compounds described and claimed in this application may be synthesized. Further methods will be evident to those of ordinary skill in the art. Additionally, the various synthetic steps described above may be performed in an alternate sequence or order to give the desired compounds. Synthetic chemistry transformations and protecting group methodologies (protection and deprotection) useful in synthesizing the inhibitor compounds described herein are known in the art and include, for example, those such as

described in R. Larock, *Comprehensive Organic Transformations*, VCH Publishers (1989); T.W. Greene and P.G.M. Wuts, *Protective Groups in Organic Synthesis*, 3rd. Ed., John Wiley and Sons (1999); L. Fieser and M. Fieser, *Fieser and Fieser's Reagents for Organic Synthesis*, John Wiley and Sons (1994); A. Katritzky and A. Pozharski, Handbook of Heterocyclic Chemistry, 2nd Ed. (2001); M. Bodanszky, A. Bodanszky: *The practice of Peptide Synthesis* Springer-Verlag, Berlin Heidelberg 1984; J. Seyden-Penne: *Reductions by the Alumino- and Borohydrides in Organic Synthesis*, 2nd Ed., Wiley-VCH, 1997; and L. Paquette, ed., *Encyclopedia of Reagents for Organic Synthesis*, John Wiley and Sons (1995).

The compounds of the present invention may be modified by appending appropriate functionalities to enhance selective biological properties. Such modifications are known in the art and include those which increase biological penetration into a given biological compartment (e.g., blood, lymphatic system, central nervous system), increase oral availability, increase solubility to allow administration by injection, alter metabolism and alter rate of excretion.

The following examples contain detailed descriptions of the methods for the preparation of exemplary compounds of Formula I or II. These detailed descriptions fall within the scope, and serve to exemplify, the above-described General Synthetic Procedures, which form part of the invention. These detailed descriptions are presented for illustrative purposes only and are not intended as a restriction on the scope of the invention.

Unless otherwise noted, all materials were obtained from commercial suppliers and used without further purification. Anhydrous solvents such as DMF, THF, CH_2Cl_2 and toluene were obtained from the Aldrich Chemical Company,

typically available as nitrogen blanketed, sure-sealed bottles. All reactions involving air- or moisture-sensitive compounds were performed under a nitrogen atmosphere. Flash chromatography was performed using Aldrich Chemical Company silica gel (200-400 mesh, 60A) or Biotage pre-packed column. Thin-layer chromatography (TLC) was performed with Analtech gel TLC plates (250 μ). Preparative TLC was performed with Analtech silica gel plates (1000-2000 μ). Preparative HPLC was conducted on a Beckman or Waters HPLC system with 0.1% TFA/H_2O and 0.1% TFA/CH_3CN as mobile phase. The flow rate was at 20 ml/min. and gradient method was used. ^1H NMR spectra were determined with super conducting FT NMR spectrometers operating at 400 MHz or a Varian 300 MHz instrument. Chemical shifts are expressed in ppm downfield from internal standard tetramethylsilane. All compounds showed NMR spectra consistent with their assigned structures. Mass spectra (MS) were determined on a Perkin Elmer - SCIEX API 165 electrospray mass spectrometer (positive and, or negative) or an HP 1100 MSD LC-MS with eletrospray ionization and quadrupole detection. All parts are by weight and temperatures are in Degrees centigrade unless otherwise indicated.

The following abbreviations, which are used in the description of the invention, mean the following:

AcOH -	acetic acid
Ac_2O -	acetic anhydride
AIBN -	2,2'-azobisisobutyronitrile
Ar -	argon
$AgSO_4$ -	silver sulfate
$AlCl_3$ -	aluminum tricloride
ATP -	adenosine triphosphate
BH_3 -	borane
Boc -	*tert*-butyloxycarbonyl
Boc_2O -	Boc anhydride

BOP-Cl - bis(2-oxo-3-oxazolidinyl)phosphinic chloride

Br_2 - bromine

BSA - bovine serum albumin

t-BuOH - tert-butanol

CAN - ammonium cerium(IV) nitrate

CH_3CN, AcCN - acetonitrile

CH_2Cl_2 - dichloromethane

CH_3I, MeI - iodomethane, methyl iodide

CCl_4 - carbon tetrachloride

CCl_3 - chloroform

CO_2 - carbon dioxide

Cs_2CO_3 - cesium carbonate

DIEA - diisopropylethylamine

CuI - copper iodide

CuCN - copper cyanide

DCE - 1,2-dichloroethane

DEAD - diethyl azodicarboxylate

DIEA - diisopropylethylamine

DIPAD - disopropyl azodicarboxylate

dppf - 1,1-diphenylphosphinoferrocene

DMAP - 4-(dimethylamino)pyridine

DMAC - N,N-dimethylacetamide

DMF - dimethylformamide

DMSO - dimethylsulfoxide

DTT - dithiothreitol

EDC, EDAC- 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride

EGTA - ethylene glycol-bis(β-aminoethyl ether)-N,N,N',N'-tetraacetic acid

EtOAc - ethyl acetate

EtOH - ethanol

Et_2O - diethyl ether

Fe - iron

g -	gram
h -	hour
HATU -	O-(7-azabenzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate
H_2 -	hydrogen
H_2O -	water
HCl -	hydrochloric acid
H_2SO_4 -	sulfuric acid
H_2NNH_2 -	hydrazine
$HC(OEt)_3$ -	triethylorthoformate
HCHO, H_2CO -	formaldehyde
HCO_2Na -	sodium formate
HOAc, AcOH -	acetic acid
HOAt -	1-hydroxy-7-azabenzotriazole
HOBt -	hydroxybenzotriazole
IpOH -	isopropanol
KF -	potassium fluoride
K_2CO_3 -	potassium carbonate
KHMDS -	potassium hexamethylsilazane
KNO_3 -	potassium nitrate
KOAc -	potassium acetate
KOH -	potassium hydroxide
LAH, $LiAlH_4$ -	lithium aluminum hydride
LDA -	lithium diisopropylamide
LiCl -	lithium chloride
LiHMDS -	lithium hexamethyldisilazide
MeOH -	methanol
$MgCl_2$ -	magnesium chloride
$MgSO_4$ -	magnesium sulfate
mg -	milligram
ml -	milliliter
$MnCl_2$ -	manganese chloride
NBS -	N-bromosuccinimide
NMO -	4-methylmorpholine, N-oxide

NMP -	N-methylpyrrolidone
Na_2SO_4 -	sodium sulfate
$Na_2S_2O_5$ -	sodium metabisulfite
$NaHSO_3$ -	sodium bisulfite
$NaHCO_3$ -	sodium bicarbonate
Na_2CO_3 -	sodium carbonate
NaCl -	sodium chloride
NaH -	sodium hydride
NaI -	sodium iodide
NaOH -	sodium hydroxide
NaOMe -	sodium methoxide
NaOEt -	sodium ethoxide
$NaCNBH_3$ -	sodium cyanoborohydride
$NaBH_4$ -	sodium borohydride
$NaNO_2$ -	sodium nitrate
$NaBH(OAc)_3$ -	sodium triacetoxyborohydride
NH_4Cl -	ammonium chloride
N_2 -	nitrogen
Pd/C -	palladium on carbon
$PdCl_2(PPh_3)_2$ -	palladium chloride bis(triphenylphosphine)
$PdCl_2$(dppf) -	1,1-bis(diphenylphosphino)ferrocene palladium chloride
$Pd(PPh_3)_4$ -	palladium tetrakis triphenylphosphine
$Pd(OH)_2$ -	palladium hydroxide
$Pd(OAc)_2$ -	palladium acetate
PMB -	para methoxybenzyl
$POCl_3$ -	phosphorus oxychloride
PPh_3 -	triphenylphosphine
PtO_2 -	platinum oxide
RT -	room temperature
SiO_2 -	silica
$SOCl_2$ -	thionyl chloride
TBAI -	tetrabutylammonium iodide

TBTU - O-(1H-benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium tetrafluoroborate

TEA - triethylamine

Tf_2NPh - N-phenyltrifluoromethanesulfonimide

TFA - trifluoroacetic acid

THF - tetrahydrofuran

TPAP - tetrapropylammoniumperruthenate

Tris-HCl - Tris(hydroxymethyl)aminomethane hydrochloride salt

Zn - zinc

PREPARATIONS

The preparation of the following exemplary compounds, intermediates and starting materials should assist in the understanding and appreciation of the invention.

Preparation I - 3-nitro-5-trifluoromethyl-phenol:

1-Methoxy-3-nitro-5-trifluoromethyl-benzene (10g, Aldrich) and pyridine-HCl (41.8g, Aldrich) were mixed together and heated neat at 210 ºC in an open flask. After 2.5 h the mixture was cooled to RT and partitioned between 1N HCl and EtOAc. The EtOAc fraction was washed with 1N HCl (4x), brine (1x), dried with Na_2SO_4, filtered and concentrated in vacuo to form 3-nitro-5-trifluoromethyl-phenol as an off-white solid.

Preparation II - 1-Boc-4-(3-nitro-5-trifluoromethyl-phenoxy)-piperidine:

3-Nitro-5-trifluoromethyl-phenol (8.81g) was dissolved in THF (76 ml). 1-Boc-4-hydroxy-piperidine (8.81 g, Aldrich) and Ph_3P (11.15 g) were added and the solution was cooled to -20 ºC. A solution of DEAD (6.8 ml, Aldrich) in THF (36 ml) was added dropwise, maintaining the temperature between -20 and -10 ºC. The reaction was warmed to RT and stirred

overnight. The reaction was concentrated in vacuo and triturated with hexane. The yellow solid was removed by filtration and washed with Et_2O (25 ml), and hexane. The white filtrate was washed with 1N NaOH (2x), brine (1x) and the hexane layer was dried over Na_2SO_4, filtered and concentrated in vacuo. The crude material was purified with flash chromatography (SiO_2, 5-10% EtOAc/hexane) to obtain 1-Boc-4-(3-nitro-5-trifluoromethyl-phenoxy)-piperidine.

The following compounds were prepared similarly to the procedure outlined above:

a) (S)-1-Boc-[2-(5-nitro-2-trifluoromethylphenoxymethyl]-pyrrolidine
b) (R)-1-Boc-[2-(5-nitro-2-trifluoromethylphenoxymethyl]-pyrrolidine.
c) (R) 1-Boc-2-(3-Nitro-5-trifluoromethyl-phenoxymethyl)-pyrrolidine
d) 4-(2-tert-Butyl-5-nitro-phenoxymethyl)-1-methyl-piperidine.
e) (S) 1-Boc-2-(3-Nitro-5-trifluoromethyl-phenoxymethyl)-pyrrolidine
f) 1-Boc-3-(5-nitro-2-pentafluoroethyl-phenoxymethyl)-azetidine.
g) N-Boc-[2-(5-nitro-2-pentafluoroethyl-phenoxy)-ethyl]amine.
h) (R) 3-(2-tert-Butyl-5-nitro-phenoxymethyl)-1-Boc-pyrrolidine.
i) 3-(2-tert-Butyl-5-nitro-phenoxymethyl)-1-Boc-azetidine.
j) (S)-1-Boc-[2-(5-nitro-2-tert-butylphenoxymethyl]-pyrrolidine
k) (S) 3-(2-tert-Butyl-5-nitro-phenoxymethyl)-1-Boc-pyrrolidine.

l) (R)-1-Boc-[2-(5-nitro-2-tert-butylphenoxymethyl]-pyrrolidine

Preparation III - 1-Boc-4-(3-amino-5-trifluoromethyl-phenoxy)-piperidine:

1-Boc-4-(3-nitro-5-trifluoromethyl-phenoxy)-piperidine (470 mg) was dissolved in MeOH (12 ml) and Pd/C (10 mg) was added. After sparging briefly with H_2, the mixture was stirred under H_2 for 6 H. The catalyst was removed by filtration and the MeOH solution was concentrated in vacuo to yield 1-Boc-4-(3-amino-5-trifluoromethyl-phenoxy)-piperidine as an off-white foam.

The following compounds were prepared similarly to the procedure outlined above:

a) 1-Boc-2-(3-Amino-5-trifluoromethyl-phenoxymethyl)-pyrrolidine.

b) 2-(3-Amino-5-trifluoromethyl-phenoxymethyl)-1-methyl-pyrrolidine.

c) [2-(1-Methylpiperidin-4-yloxy)-pyridin-4-yl]methylamine. ESI (M+H)=222.

d) [2-(2-Morpholin-4-yl-ethoxy)-pyridin-4-yl]methylamine.

e) [2-(2-Morpholin-4-yl-propoxy)-pyridin-4-yl]methylamine.

f) [2-(1-Methyl-pyrrolidin-2-ylmethoxy)-pyridin-4-yl]methylamine. ESI MS: (M+H)=222.

g) (4-Aminomethyl-pyridin-2-yl)-(3-morpholin-4-yl-propyl)-amine. ESI MS: (M+H)=251.

h) 4-tert-Butyl-3-(1-methyl-piperidin-4-ylmethoxy)-phenylamine.

i) 4-tert-Butyl-3-(2-piperidin-1-yl-ethoxy)-phenylamine.

j) 3-(1-Methyl-piperidin-4-ylmethoxy)-4-pentafluoroethyl-phenylamine.

k) 3-(1-Isopropyl-piperidin-4-ylmethoxy)-4-pentafluoroethyl-phenylamine.

l) (S) 3-Oxiranylmethoxy-4-pentafluoroethyl-phenylamine.

m) 3-(2-Pyrrolidin-1-yl-ethoxy)-4-trifluoromethyl-phenylamine.

n) 3-(2-Piperidin-1-yl-ethoxy)-4-trifluoromethyl-phenylamine.

o) (S) 3-(1-Boc-pyrrolidin-2-ylmethoxy)-4-pentafluoroethyl-phenylamine.

p) (R) 3-(1-Boc-pyrrolidin-2-ylmethoxy)-4-pentafluoroethyl-phenylamine.

q) (R) 3-(1-Methyl-pyrrolidin-2-ylmethoxy)-5-trifluoromethyl-phenylamine.

r) (S) 3-(1-Methyl-pyrrolidin-2-ylmethoxy)-5-trifluoromethyl-phenylamine

s) (R) 3-Oxiranylmethoxy-4-pentafluoroethyl-phenylamine.

t) (R) 2-(5-Amino-2-pentafluoroethyl-phenoxy)-1-pyrrolidin-1-yl-ethanol.

u) 3-(1-Boc-azetidin-3-ylmethoxy)-4-pentafluoroethyl-phenylamine.

v) 3-(2-(Boc-amino)ethoxy)-4-pentafluoroethyl-phenylamine.

w) 6-Amino-2,2-dimethyl-4H-benzo[1,4]oxazin-3-one. M+H 193.2. Calc'd 192.1.

x) 2,2,4-Trimethyl-3,4-dihydro-2H-benzo[1,4]oxazin-6-ylamine.

y) 1-(6-Amino-2,2-dimethyl-2,3-dihydro-benzo[1,4]oxazin-4-yl)-ethanone. M+H 221.4. Calc'd 220.3.

z) [2-(1-Benzhydryl-azetidin-3-yloxy)-pyridin-4-yl]-methylamine.

aa) [2-(1-Methyl-piperidin-4-ylmethoxy)-pyridin-4-yl]-methylamine. M+H 236.3. Calc'd 235.2.

ab) 3-(4-Boc-piperazin-1-ylmethyl)-5-trifluoromethyl-phenylamine. M+H 360.3.

ac) 2-Boc-4,4-dimethyl-1,2,3,4-tetrahydro-isoquinolin-7-ylamine.

ad) 3-Morpholin-4-ylmethyl-4-pentafluoroethyl-phenylamine.

ae) 3-(4-Methyl-piperazin-1-ylmethyl)-4-pentafluoroethyl-phenylamine. M+H 410.3. Calc'd 409.4.

af) 7-Amino-2-(4-methoxy-benzyl)-4,4-dimethyl-3,4-dihydro-2H-isoquinolin-1-one. M+H 311.1.

ag) 7-Amino-4,4-dimethyl-3,4-dihydro-2H-isoquinolin-1-one.

ah) (3-Amino-5-trifluoromethyl-phenyl)-(4-Boc-piperazin-1-yl)-methanone. M+H 374.3; Calc'd 373.

ai) 3-(4-Boc-Piperazin-1-ylmethyl)-5-trifluoromethyl-phenylamine.

aj) 1-(7-Amino-4,4-dimethyl-3,4-dihydro-1H-isoquinolin-2-yl)-ethanone. M+H 219.2.

ak) {2-[2-(1-Methylpiperidin-4-yl)ethoxy]-pyridin-4-yl}-methylamine.

al) {2-[2-(1-Pyrrolidinyl)ethoxy]-pyridin-4-yl}-methylamine.

am) {2-[2-(1-Methylpyrrolin-2-yl)ethoxy]-pyridin-4-yl}-methylamine.

an) (2-Chloro-pyrimidin-4-yl)-methylamine.

ao) 3-(1-Boc-azetidin-3-ylmethoxy)-5-trifluoromethyl-phenylamine.

ap) 4-tert-Butyl-3-(1-Boc-pyrrolidin-3-ylmethoxy)-phenylamine. M+H 385.

aq) 4-tert-Butyl-3-(1-Boc-azetidin-3-ylmethoxy)-phenylamine. M+Na 357.

ar) (S) 4-tert-Butyl-3-(1-Boc-pyrrolidin-2-ylmethoxy)-phenylamine. M+Na 371.

as) 3-tert-Butyl-4-(4-Boc-piperazin-1-yl)-phenylamine

at) 3-(1-Methyl-piperidin-4-yl)-5-trifluoromethyl-phenylamine.

au) 3,3-Dimethyl-2,3-dihydro-benzofuran-6-ylamine.

av) 3,9,9-Trimethyl-2,3,4,4a,9,9a-hexahydro-1H-3-aza-fluoren-6-ylamine.

aw) 4-[1-Methyl-1-(1-methyl-piperidin-4-yl)-ethyl]-phenylamine was prepared using EtOH as the solvent.

ax) 4-tert-Butyl-3-(4-pyrrolidin-1-yl-but-1-enyl)-phenylamine.

ay) (R) 3-(1-Boc-pyrrolidin-2-ylmethoxy)-5-trifluoromethyl-phenylamine.

az) (S) 3-(1-Boc-pyrrolidin-2-ylmethoxy)-5-trifluoromethyl-phenylamine.

Preparation IV - 1-Boc-4-{3-[(2-fluoro-pyridine-3-carbonyl)-amino]-5-trifluoromethyl-phenoxy}-piperidine:

1-Boc-4-(3-amino-5-trifluoromethyl-phenoxy)-piperidine (4.37 g) was dissolved in CH_2Cl_2 (100 ml) and $NaHCO_3$ (2.4 g, Baker) was added. 2-Fluoropyridine-3-carbonyl chloride (2.12 g) was added an the reaction was stirred at RT for 2.5 h. The reaction was filtered and concentrated *in vacuo* to yield a yellow foam. (30%) EtOAc/Hexane was added and 1-Boc-4-{3-[(2-fluoro-pyridine-3-carbonyl)-amino]-5-trifluoromethyl-phenoxy}-piperidine precipitated as an off white solid.

The following compounds were prepared similarly to the procedure outlined above:

a) 2-Fluoro-N-[3-(3-piperidin-1-yl-propyl)-5-trifluoromethyl-phenyl]-nicotinamide.

b) N-[4-tert-Butyl-3-(2-piperidin-1-yl-ethoxy)-phenyl]-2-fluoro-nicotinamide.

c) N-[3,3-Dimethyl-1-(1-methyl-piperidin-4-ylmethyl)-2,3-dihydro-1H-indol-6-yl]-2-fluoro-nicotinamide.

d) N-[1-(2-Dimethylamino-acetyl)-3,3-dimethyl-2,3-dihydro-1H-indol-6-yl]-2-fluoro-nicotinamide

e) N-[3,3-Dimethyl-1-(2-(Boc-amino)acetyl)-2,3-dihydro-1H-indol-6-yl]-2-fluoro-nicotinamide.

f) N-(4-Acetyl-2,2-dimethyl-3,4-dihydro-2H-benzo[1,4]oxazin-6-yl)-2-fluoro-nicotinamide. M+H 344.5. Calc'd 343.4.

g) 2-Fluoro-N-(2,2,4-trimethyl-3,4-dihydro-2H-benzo[1,4]oxazin-6-yl)-nicotinamide. M+H 316.2. Calc'd 315.1.

h) N-(2,2-Dimethyl-3-oxo-3,4-dihydro-2H-benzo[1,4]oxazin-6-yl)-2-fluoro-nicotinamide. M+H 316.1. Calc'd 315.10.

i) 2-Fluoro-N-[3-(4-methyl-piperazin-1-ylmethyl)-5-trifluoromethyl-phenyl]-nicotinamide. M+H 481. Calc'd 480.

j) 2-Fluoro-N-(2-Boc-4,4-dimethyl-1,2,3,4-tetrahydro-isoquinolin-7-yl)-nicotinamide. M+H 400.

k) 2-Fluoro-N-[3-(4-methyl-piperazin-1-ylmethyl)-4-pentafluoroethyl-phenyl]-nicotinamide. M+H 447.0. Calc'd 446.

l) 2-Fluoro-N-(3-morpholin-4-ylmethyl-4-pentafluoroethyl-phenyl)-nicotinamide.

m) 2-Fluoro-N-[4-iodophenyl]-nicotinamide.

n) 2-Fluoro-N-(4,4-dimethyl-1-oxo-1,2,3,4-tetrahydro-isoquinolin-7-yl)-nicotinamide. M+H 314.0, Calc'd 311.

o) 2-Fluoro-N-[3-(4-Boc-piperazine-1-carbonyl)-5-trifluoromethyl-phenyl]-nicotinamide. M+H 495.

p) 2-Fluoro-N-[3-(4-Boc-piperazin-1-ylmethyl)-5-trifluoromethyl-phenyl]-nicotinamide. M+H 483.3; Calc'd 482.

q) N-(2-Acetyl-4,4-dimethyl-1,2,3,4-tetrahydro-isoquinolin-7-yl)-2-fluoro-nicotinamide. M+H 430.0.

r) N-[3,3-Dimethyl-1-(1-methyl-piperidin-4-yl)-2,3-dihydro-1H-indol-6-yl]-2-fluoro-nicotinamide. M+H 383.2; Calc'd 382.5.

s) N-(4-tert-Butylphenyl)-2-fluoronicotinamide.

t) N-(4-Trifluoromethylphenyl)-2-fluoronicotinamide.

u) 2-Fluoro-N-[3-(1-Boc-azetidin-3-ylmethoxy)-5-trifluoromethyl-phenyl]-nicotinamide. M-H 468.2; Calc'd 469.16.

v) 2-Fluoro-N-[3-(1-Boc-azetidin-3-ylmethoxy)-4-tert-butyl-phenyl]-nicotinamide.

w) (S) N-[4-tert-Butyl-3-(1-Boc-pyrrolidin-2-ylmethoxy)-phenyl]-2-fluoro-nicotinamide. M+Na = 494.

x) N-[3-(1-Methyl-piperidin-4-yl)-5-trifluoromethyl-phenyl]-2-fluoro-nicotinamide was prepared with K_2CO_3 instead of $NaHCO_3$.

y) N-(3-Bromo-5-trifluoromethyl-phenyl)-2-fluoro-nicotinamide.

z) 2-Fluoro-N-(3,9,9-trimethyl-2,3,4,4a,9,9a-hexahydro-1H-3-aza-fluoren-6-yl)-nicotinamide.

aa) 2-Fluoro-N-{4-[1-methyl-1-(1-methyl-piperidin-4-yl)-ethyl]-phenyl}-nicotinamide

ab) N-[3,3-Dimethyl-1-(1-Boc-piperidin-4-ylmethyl)-2,3-dihydro-1H-indol-6-yl]-2-fluoro-nicotinamide.

Preparation V - 1-Boc-4-{3-[(2-chloro-pyridine-3-carbonyl)-amino]-5-trifluoromethyl-phenoxy}-piperidine:

1-Boc-4-{3-[(2-chloro-pyridine-3-carbonyl)-amino]-5-trifluoromethyl-phenoxy}-piperidine was prepared from 1-Boc-4-(3-amino-5-trifluoromethyl-phenoxy)-piperidine and 2-chloropyridine-3-carbonyl chloride by a procedure similar to that described in the preparation of 1-Boc-4-{3-[(2-fluoro-pyridine-3-carbonyl)-amino]-5-trifluoromethyl-phenoxy}-piperidine.

The following compounds were prepared similarly to the procedure outlined above:

a) N-(4-tert-Butyl-3-nitro-phenyl)-2-chloro-nicotinamide.

b) 2-Chloro-N-[3-(3-piperidin-1-yl-propyl)-5-trifluoromethyl-phenyl]-nicotinamide.

c) 2-Chloro-N-[3-(3-morpholin-4-yl-propyl)-5-trifluoromethyl-phenyl]-nicotinamide.

d) 2-Chloro-N-[3-(1-methylpiperidin-4-yl)-5-trifluoromethyl-phenyl]-nicotinamide.

e) 2-Chloro-N-[3-(1-methyl-piperidin-4-ylmethoxy)-4-pentafluoroethyl-phenyl]-nicotinamide.

f) 2-Chloro-N-[3-(1-isopropyl-piperidin-4-ylmethoxy)-4-pentafluoroethyl-phenyl]-nicotinamide.

g) (S) 2-Chloro-N-[4-(oxiranylmethoxy)-3-pentafluoroethyl-phenyl]-nicotinamide.

h) 2-Chloro-N-[3-(2-pyrrolidin-1-yl-ethoxy)-4-trifluoromethyl-phenyl]-nicotinamide.

i) 2-Chloro-N-[3-(2-piperidin-1-yl-ethoxy)-4-pentafluoroethyl-phenyl]-nicotinamide.

j) (R) 2-Chloro-N-[3-(1-Boc-pyrrolidin-2-ylmethoxy)-4-pentafluoroethyl-phenyl]-nicotinamide.

k) (S) 2-Chloro-N-[3-(1-Boc-pyrrolidin-2-ylmethoxy)-4-pentafluoroethyl-phenyl]-nicotinamide.

l) (R) 2-Chloro-N-[3-(1-methyl-pyrrolidin-2-ylmethoxy)-5-trifluoromethyl-phenyl]-nicotinamide.

m) (S) 2-Chloro-N-[3-(1-methyl-pyrrolidin-2-ylmethoxy)-5-trifluoromethyl-phenyl]-nicotinamide.

n) (R) 2-Chloro-N-[4-(oxiranylmethoxy)-3-pentafluoroethyl-phenyl]-nicotinamide.

o) (R) Acetic acid 2-{5-[(2-chloro-pyridine-3-carbonyl)-amino]-2-pentafluoroethyl-phenoxy}-1-pyrrolidin-1-yl-ethyl ester.

p) 2-Chloro-N-[3-(4-methyl-piperazin-1-ylmethyl)-5-trifluoromethyl-phenyl]-nicotinamide.

q) 2-Chloro-N-[2-(4-methoxy-benzyl)-4,4-dimethyl-1-oxo-1,2,3,4-tetrahydro-isoquinolin-7-yl]-nicotinamide. M+H 450.2. Calc'd 449.

r) 2-Chloro-N-(4,4-dimethyl-1-oxo-1,2,3,4-tetrahydro-isoquinolin-7-yl)-nicotinamide. M+H 330.1, Calc'd 329.

s) 2-Chloro-N-[3-(4-Boc-piperazin-1-ylmethyl)-5-trifluoromethyl-phenyl]-nicotinamide.

t) 2-{3-[(2-Chloro-pyridine-3-carbonyl)-amino]-phenyl}-2-methyl-propionic acid methyl ester. M+H 405

u) N-{4-tert-Butyl-3-[2-(1-Boc-piperidin-4-yl)-ethyl]-phenyl}-2-chloro-nicotinamide. M+Na 524. Calc'd 501.1.

v) N-[3,3-Dimethyl-1,1-dioxo-2,3-dihydro-1H-benzo[d]isothiazol-6-yl]-2-chloro-nicotinamide.

w) N-[1,1,4,4-Tetramethyl-1,2,3,4-tetrahydro-naphth-6-yl]-2-chloro-nicotinamide.

x) 2-Chloro-N-[3,3-dimethyl-2,3-dihydro-benzofuran-6-yl]-2-chloro-nicotinamide.

y) 2-Chloro-N-[3-(1-Boc-piperidin-4-yloxy)-5-trifluoromethyl-phenyl]-nicotinamide.

z) 2-Chloro-N-[3-(1-methyl-piperidin-4-ylmethyl)-5-trifluoromethyl-phenyl]-nicotinamide.

aa) 2-Chloro-N-[3-(3-piperidin-1-yl-propyl)-5-trifluoromethyl-phenyl]-nicotinamide.

ab) N-[4-tert-Butyl-3-(4-pyrrolidin-1-yl-but-1-enyl)-phenyl]-2-chloro-nicotinamide.

ac) (R) 2-Chloro-N-[3-(1-Boc-pyrrolidin-2-ylmethoxy)-5-trifluoromethyl-phenyl]-nicotinamide.

ad) (S) 2-Chloro-N-[3-(1-Boc-pyrrolidin-2-ylmethoxy)-5-trifluoromethyl-phenyl]-nicotinamide.

Preparation VI - 1-Boc-2-{3-[(2-fluoro-pyridine-3-carbonyl)-amino]-5-trifluoromethyl-phenoxymethyl}-pyrrolidine:

1-Boc-2-{3-[(2-Fluoro-pyridine-3-carbonyl)-amino]-5-trifluoromethyl-phenoxymethyl}-pyrrolidine was prepared from 1-Boc-2-(3-amino-5-trifluoromethyl-phenoxymethyl)-pyrrolidine by a procedure similar to that described in the

preparation of 1-Boc-4-{3-[(2-fluoro-pyridine-3-carbonyl)-amino]-5-trifluoromethyl-phenoxy}-piperidine.

Preparation VII - 2-(3-nitro-5-trifluoromethyl-phenoxymethyl)-pyrrolidine:

1-Boc-2-(3-nitro-5-trifluoromethyl-phenoxymethyl)-pyrrolidine (2.35 g) was dissolved in CH_2Cl_2 (60 ml) and TFA (20 ml) was added. After stirring for 1 h at RT, the mixture was concentrated in vacuo to yield 2-(3-nitro-5-trifluoromethyl-phenoxymethyl)-pyrrolidine as an oil that solidified upon standing. The material was used as is without further purification.

The following compounds were prepared similarly to the procedure outlined above:

a) (4-Aminomethyl-pyrimidin-2-yl)-(3-morpholin-4-yl-propyl)-amine.

b) (4-Aminomethyl-pyrimidin-2-yl)-[2-(1-methyl-pyrrolidin-2-yl)-ethyl]-amine.

Preparation VIII - 1-methyl-2-(3-nitro-5-trifluoromethyl-phenoxymethyl)-pyrrolidine:

2-(3-Nitro-5-trifluoromethyl-phenoxymethyl)-pyrrolidine (6 mmol) was dissolved in CH_3CN (20 ml) and formaldehyde (2.4 ml, 37% aqueous) was added. $NaBH_3CN$ (607 mg) was added, an exotherm was observed. The pH is monitored every 15 min and adjusted to ~7 with AcOH. After 45 min, the mixture was concentrated in vacuo and the residue is dissolved in EtOAc, washed with 6N NaOH, 1N NaOH, and 2N HCl (3x). The acid washings were combined, adjusted to ~pH 10 with solid Na_2CO_3 and extracted with EtOAc (2x). The EtOAc fractions were combined, dried with Na_2SO_4, and purified with flash chromatography (SiO_2, 95:5:0.5 CH_2Cl_2:MeOH:NH_4OH) to afford

1-methyl-2-(3-nitro-5-trifluoromethyl-phenoxymethyl)-pyrrolidine.

The following compounds were prepared similarly to the procedure outlined above:

a) 2-(1-Methylpiperidin-4-yl)-ethanol.
b) 2-{3-[(2-Fluoro-pyridine-3-carbonyl)-amino]-5-trifluoromethyl-phenoxymethyl}-1-methylpyrrolidine.

Preparation IX - 4-tert-butyl-3-nitro-phenylamine:

A mixture of 1,3-dinitro-4-tert-butylbenzene (10.0 g) in H_2O (56 ml) was heated to reflux. A mixture of Na_2S (21.42 g) and sulfur (2.85 g) in H_2O (34 ml) was added over 1 h via an addition funnel. The reaction maintained at reflux for 1.5 h then cooled to RT and extracted with EtOAc. The organic extracts were combined and washed with H_2O, brine, dried over $MgSO_4$ and concentrated in vacuo to afford 4-tert-butyl-3-nitro-phenylamine, which was used as is without further purification.

Preparation X - N-(3-bromo-5-trifluoromethyl-phenyl)-acetamide:

3-Bromo-5-(trifluoromethyl)phenylamine (5 g, Alfa-Aesar) was dissolved in AcOH (140 ml) and Ac_2O (5.9 ml, Aldrich) was added. The reaction was stirred at RT overnight. The mixture was added slowly to H_2O (~700 ml) forming a white precipitate. The solid was isolated by filtration, washed with H_2O and dried under vacuum to yield N-(3-bromo-5-trifluoromethyl-phenyl)-acetamide.

Preparation XI - N-[3-(3-piperidin-1-yl-propyl)-5-trifluoromethyl-phenyl]-acetamide:

Allylpiperidine (1.96 g, Lancaster) was degassed under vacuum, dissolved in 0.5 M 9-BBN in THF (31.2 ml, Aldrich), and heated to reflux for 1 h, then cooled to RT. $PD(dppf)Cl_2/CH_2Cl_2$ was added to a degassed mixture of N-(3-bromo-5-trifluoromethyl-phenyl)-acetamide, K_2CO_3 (9.8 g) DMF (32.1 ml and H_2O (3 ml). The allyl piperidine solution was added heated to 60 °C for 3 h. After cooling to RT and reheating at 60 °C for 6 h, the mixture was cooled to RT and poured into H_2O. The mixture was extracted with EtOAc (2x), and the EtOAc portion was washed with 2 N HCl (2x) and brine. The aqueous phases were combined and the pH was adjusted to ~11 with NaOH (15%) forming a cloudy suspension. The cloudy suspension was extracted with EtOAc (2x) and the EtOAc portion was dried with Na_2SO_4, filtered and concentrated in vacuo. The crude material was purified by flash chromatography (SiO_2, 95:5:0.5 CH_2Cl_2:MeOH:NH_4OH) to afford N-[3-(3-piperidin-1-yl-propyl)-5-trifluoromethyl-phenyl]-acetamide as a brown oil that solidified under vacuum.

The following compounds were prepared similarly to the procedure outlined above:

a) N-(3-Morpholin-4-ylpropyl-5-trifluoromethyl-phenyl)-acetamide from 4-allyl-morpholine.

b) N-(3-(1-methylpiperdin-4-ylmethyl-5-trifluoromethyl-phenyl)-acetamide from 1-Methyl-4-methylene-piperidine.

Preparation XII - 3-(3-piperidin-1-yl-propyl)-5-trifluoromethyl-phenylamine:

N-[3-(3-Piperidin-1-yl-propyl)-5-trifluoromethyl-phenyl]-acetamide (1.33 g) was dissolved in EtOH (40 ml) and 12 N

HCl (40 ml) was added. After stirring overnight at 70 ºC and RT, the mixture was concentrated *in vacuo*, affording 3-(3-piperidin-1-yl-propyl)-5-trifluoromethyl-phenylamine as a brown oil.

The following compounds were prepared similarly to the procedure outlined above:

a) 3,3-Dimethyl-6-nitro-2,3-dihydro-1H-indole. M+H 193.1; Calc'd 192.2.

b) 3-(1-Methyl-piperidin-4-ylmethyl)-5-trifluoromethyl-phenylamine.

c) 3-Morpholin-4-ylmethyl-5-trifluoromethyl-phenylamine.

Preparation XIII - 3,3-Dimethyl-6-nitro-1-piperidin-4-ylmethyl-2,3-dihydro-1H-indole:

3,3-Dimethyl-1-(1-Boc-piperidin-4-ylmethyl)-6-nitro-2,3-dihydro-1H-indole was dissolved in HCl/EtOAc and stirred for 2 h. The mixture was concentrated *in vacuo* and partitioned between 1,2-dichloroethane and 1N NaOH. The organic layer was removed, washed with brine, dried (Na_2SO_4) and filtered. The material was used without further purification.

Preparation XIV - N-[3-(3-morpholin-4-yl-propyl)-5-trifluoromethyl-phenyl]-acetamide:

N-[3-(3-Morpholin-4-yl-propyl)-5-trifluoromethyl-phenyl]-acetamide was prepared from allyl morpholine and N-(3-bromo-5-trifluoromethyl-phenyl)-acetamide similar to that described in the preparation of N-[3-(3-piperidin-1-yl-propyl)-5-trifluoromethyl-phenyl]-acetamide.

Preparation XV - 3-(3-morpholin-4-yl-propyl)-5-trifluoromethyl-phenylamine:

3-(3-Morpholin-4-yl-propyl)-5-trifluoromethyl-phenylamine was prepared from N-[3-(3-morpholin-4-yl-propyl)-5-trifluoromethyl-phenyl]-acetamide similar to that described in the preparation of 3-(3-piperidin-1-yl-propyl)-5-trifluoromethyl-phenylamine.

Preparation XVI - 1-methyl-4-methylene-piperidine:

Ph_3PCH_3I (50 g, Aldrich) was suspended in Et_2O (20 ml) and butyllithium (77.3 ml, 1.6 M in hexanes, Aldrich) was added dropwise. The reaction was stirred for 2 h at RT then 1-methylpiperidone (12.3 ml, Aldrich) was added slowly. The mixture was stirred at RT overnight. The solid was removed by filtration, the volume was reduced to ~400 ml and additional solid was removed by filtration. The Et_2O was washed with H_2O (2x) and 2N HCl (4x). The pH of the acid washings was adjusted to ~11 with 6 N NaOH, then they were extracted with CH_2Cl_2 (4x). The CH_2Cl_2 washings were dried over Na_2SO_4 and concentrated cold in vacuo to provide 1-methyl-4-methylene-piperidine, which was used as is.

Preparation XVII - N-[3-(1-methylpiperidin-4-yl)-5-trifluoromethyl-phenyl]-acetamide:

N-[3-(1-Methylpiperidin-4-yl)-5-trifluoromethyl-phenyl]-acetamide was prepared from 1-methyl-4-methylene-piperidine and N-(3-bromo-5-trifluoromethyl-phenyl)-acetamide similar to that described in the preparation of N-[3-(3-piperidin-1-yl-propyl)-5-trifluoromethyl-phenyl]-acetamide.

Preparation XVIII - 3-(1-methylpiperidin-4-yl)-5-trifluoromethyl-phenylamine:

3-(1-Methylpiperidin-4-yl)-5-trifluoromethyl-phenylamine was prepared from N-[3-(1-methylpiperidin-4-yl)-5-

trifluoromethyl-phenyl]-acetamide similar to the procedure described in the preparation of 3-(3-piperidin-1-yl-propyl)-5-trifluoromethyl-phenylamine.

Preparation XIX - 2-(1-methylpiperidin-4-yloxy)-4-pyridylcarbonitrile:

4-Hydroxy-1-methylpiperidine (25.4 g) was dissolved in THF (50 ml) in a 100 mL r.b. flask. NaH/mineral oil mixture (9.58 g) was slowly added to the flask and stirred for 20 min. 2-Chloro-4-cyanopyridine was added to the mixture and stirred at RT until completion. Diluted mixture with EtOAc and added H_2O to quench mixture, then transferred contents to a sep. funnel. The organic phase was collected while the aqueous phase was washed two times with EtOAc. The combined organics were dried over Na_2SO_4, filtered, then concentrated *in vacuo*. Then redissolved mixture in CH_2Cl_2, 10% HCl (300 ml) was added and the mixture was transferred to sep. funnel. The org. was extracted, while EtOAc along with 300 mL 5N NaOH was added to the sep. funnel. The organic phases were collected, dried over Na_2SO_4, filtered and concentrated *in vacuo* affording 2-(1-methylpiperidin-4-yloxy)-4-pyridylcarbonitrile as a brown solid. ESI (M+H) = 218.

The following compounds were prepared similarly to the procedure outlined above:

a) 2-(1-methylpiperidin-4-ylmethoxy)-4-pyridylcarbonitrile. M+H 232.1. Calc'd 231.1.
b) 2-(1-Benzhydryl-azetidin-3-yloxy)-4-pyridylcarbonitrile. M+H 342.2. Calc'd 341.2.
c) 2-(1-methylpiperidin-4-ylethoxy)-4-pyridylcarbonitrile.
d) 2-(1-pyrrolidinylethoxy)-4-pyridylcarbonitrile.
e) 2-(1-methylpyrrolin-2-ylethoxy)-4-pyridylcarbonitrile.
f) 2-[2-(1-Boc-azetidin-3-yl)-ethoxy]-4-pyridylcarbonitrile.

Preparation XX - [2-(1-methylpiperidin-4-yloxy)-pyridin-4-yl]methylamine bis hydrochloride:

[2-(1-Methylpiperidin-4-yloxy)-pyridin-4-yl]methylamine was diluted with Et_2O (50 ml) and 1M HCl/Et_2O (47 ml) was added. The vessel was swirled until precipitate formed.

Preparation XXI - 2-(2-morpholin-4-yl-ethoxy)-4-pyridylcarbonitrile:

2-(2-Morpholin-4-yl-ethoxy)-4-pyridylcarbonitrile was prepared from 2-chloro-4-cyanopyridine and 2-morpholin-4-yl-ethanol by a procedure similar to that described in the preparation of 2-(1-methylpiperidin-4-yloxy)-4-pyridylcarbonitrile. The HCl salt was prepared similar to that described for [2-(1-methylpiperidin-4-yloxy)-pyridin-4-yl]methylamine bis hydrochloride.

Preparation XXII - 2-morpholin-4-yl-propanol:

LAH powder (1.6 g) was added to a flask while under N_2 atmosphere, immediately followed by THF (50 ml). The mixture was chilled to 0°C, methyl 2-morpholin-4-yl-propionate (5 g) was added dropwise to the reaction mixture and stirred at 0°C. After 1 h, the mixture was worked up by adding H_2O (44 mL), 2N NaOH (44 mL), then H_2O (44 mL, 3x). After 30 min of stirring, the mixture was filtered through Celite® and the organic portion was concentrated *in vacuo* providing 2-morpholin-4-yl-propanol as a colorless oil.

The following compounds were prepared similarly to the procedure outlined above:

a) (1-Methyl-piperidin-4-yl)-methanol. M+H 130.2. Calc'd 129.1.

Preparation XXIII - 2-(2-morpholin-4-yl-propoxy)-4-pyridylcarbonitrile:

2-(2-Morpholin-4-yl-propoxy)-4-pyridylcarbonitrile was prepared from 2-chloro-4-cyanopyridine and 2-morpholin-4-yl-propanol by a procedure similar to that described in the preparation of 2-(1-methylpiperidin-4-yloxy)-4-pyridylcarbonitrile.

Preparation XXIV - 2-(1-Methyl-pyrrolidin-2-ylmethoxy)-4-pyridylcarbonitrile:

2-(1-Methyl-pyrrolidin-2-ylmethoxy)-4-pyridylcarbonitrile was prepared from 2-chloro-4-cyanopyridine and 1-methyl-pyrrolidin-2-ylmethanol by a procedure similar to that described in the preparation of 2-(1-methylpiperidin-4-yloxy)-4-pyridylcarbonitrile. ESI MS: (M+H)=218.

Preparation XXV - 2-(3-morpholin-4-yl-propylamino)-4-pyridylcarbonitrile:

To a flask charged with 2-chloro-4-cyanopyridine (2.0 g), was added the aminopropyl morpholine (2.11 ml). The mixture was heated to 79 ºC for 5 h and stirred. After 5 h the reaction was incomplete. The mixture was then heated at 60 ºC overnight. The crude compound was purified on silica gel (1-5% MeOH/CH_2Cl_2 gradient). ESI MS: (M+H)=247, (M-H)=245.

Preparation XXVI - 5-Nitro-2-pentafluoroethylphenol:

Combined 2-methoxy-4-nitro-1-pentafluoroethylbenzene (9.35 g) and pyridine HCl in a round bottom flask and heated at 210 ºC for 1 h then cooled to RT. The mixture was diluted with EtOAc and 2N HCl (>500 ml) until all residue dissolved. The organic layer was removed, washed with 2N HCl (2x) and concentrated *in vacuo*. The residue was dissolved in hexanes and Et_2O, washed with 2N HCl, then brine. Dried organic layer over Na_2SO_4, filtered, concentrated *in vacuo* and dried

under high vacuum to provide 5-nitro-2-pentafluoromethylphenol.

Preparation XXVII - 2-tert-Butyl-5-nitro-aniline:

To H_2SO_4 (98%, 389 mL) in a 500 mL 3-neck flask was added 2-tert-butyl aniline (40.6 mL). The reaction was cooled to -10 ºC and KNO_3 in 3.89 g aliquots was added every 6 min for a total of 10 aliquots. Tried to maintain temperature at -5 ºC to -10 ºC. After final addition of KNO_3, stirred the reaction for five min then it was poured onto ice (50 g). The black mix was diluted with H_2O and extracted with EtOAc. The aqueous layer was basified with solid NaOH slowly then extracted with EtOAc (2x). The combined organic layers were washed with 6N NaOH and then with a mix of 6N NaOH and brine, dried over Na_2SO_4, filtered and concentrated *in vacuo* to obtain crude 2-tert-butyl-5-nitro-aniline as a dark red-black oil which solidified when standing at RT. The crude material was triturated with about 130 mL hexanes. After decanting the hexanes, the material was dried to obtain a dark-red black solid.

Preparation XXVIII - 2-tert-Butyl-5-nitrophenol:

In a 250 ml round bottom flask, 20 mL concentrated H_2SO4 was added to 2-tert-butyl-5-nitro-aniline (7.15 g) by adding 5 mL aliquots of acid and sonicating with occasional heating until all of the starting aniline went into solution. H_2O (84 ml) was added with stirring, then the reaction was cooled to 0 ºC forming a yellow-orange suspension. A solution of $NaNO_2$ (2.792 g) in H_2O (11.2 mL) was added dropwise to the suspension and stirred for 5 min. Excess $NaNO_2$ was neutralized with urea, then the cloudy solution was transferred to 500 ml 3-necked round bottom flask then added 17 mL of 1:2 H_2SO_4:H_2O solution, and heated at reflux. Two additional 5 mL aliquots of 1:2 H_2SO_4:H_2O solution, a 7

mL aliquot of 1:2 H_2SO_4:H_2O solution and another 10 mL of 1:2 H_2SO_4: H_2O were added while heating at reflux. The mixture was cooled to RT forming a black layer floating on top of the aqueous layer. The black layer was diluted with EtOAc (300 mL) and separated. The organic layer was washed with H_2O then brine, dried over Na_2SO_4 and concentrated *in vacuo*. Crude oil was purified on silica gel column with 8% EtOAc/Hexanes. Upon drying under vacuum, the 2-tert-butyl-5-nitrophenol was isolated as a brown solid.

Preparation XXIX - 1-methylpiperidine-4-carboxylic acid ethyl ester:

Piperidine-4-carboxylic acid ethyl ester (78 g) was dissolved in MeOH (1.2 L) at RT then formaldehyde (37%, 90 ml) and acetic acid (42 ml) were added and stirred for 2 h. The mixture was cooled to 0 ºC, $NaCNBH_3$ (70 g) was added, and the mix was stirred for 20 min at 0 ºC, then overnight at RT. The mixture was cooled to 0 ºC then quenched with 6N NaOH. The mixture was concentrated *in vacuo* to an aqueous layer, which was extracted with EtOAc (4x), brine-washed, dried over Na_2SO_4, and concentrated *in vacuo* to provide 1-methylpiperidine-4-carboxylic acid ethyl ester.

The following compounds were prepared similarly to the procedure outlined above:

a) (1-Methyl-piperidin-4-yl)-methanol. M+H 130.2. Calc'd 129.1.

Preparation XXX - N-[4-tert-Butyl-3-(1-methyl-piperidin-4-ylmethoxy)-phenyl]-2-chloro-nicotinamide:

N-[4-tert-Butyl-3-(1-methyl-piperidin-4-ylmethoxy)-phenyl]-2-chloro-nicotinamide was prepared from 4-tert-butyl-3-(1-methyl-piperidin-4-ylmethoxy)-phenylamine by a procedure

similar to that described in the preparation of 1-Boc-4-{3-[(2-chloro-pyridine-3-carbonyl)-amino]-5-trifluoromethyl-phenoxy}-piperidine.

Preparation XXXI - 1-[2-(2-tert-Butyl-5-nitro-phenoxy)-ethyl]-piperidine:

To 2-tert-butyl-5-nitrophenol (1.01 g) and K_2CO_3 (1.72 g) was added acetone (35 ml) and H_2O (10.5 mL), then 1-(2-chloroethyl)piperidine HCl (1.909 g) and TBAI (153 mg). The mixture was stirred at reflux overnight. Additional K_2CO_3 (850 mg) and 1-(2-chloroethyl)-piperidine HCl (950 mg) were added and the mixture was heated at reflux for 6 h. The mixture was concentrated *in vacuo* to an aqueous layer which was acidified with 2N HCl and extracted with EtOAc. The aqueous layer was basified with 6N NaOH and washed with CH_2Cl_2 (3x). The combined organic layers were washed with brine/1N NaOH and dried over Na_2SO_4. Washed the EtOAc layer with 2N NaOH/brine and dried over Na_2SO_4. The crude material was purified by silica gel column chromatography with 15% EtOAc/Hexanes to yield 1-[2-(2-tert-butyl-5-nitro-phenoxy)-ethyl]-piperidine as a light tan solid. (M+1)=307.3.

Preparation XXXII - 1-Boc-Piperidine-4-carboxylic acid ethyl ester:

To a stirred solution of piperidine-4-carboxylic acid ethyl ester (23.5 g) in EtOAc (118 ml) at 0°C was added dropwise Boc_2O in EtOAc (60 ml). The reaction was warmed to RT and stirred overnight. The reaction was washed with H_2O, 0.1N HCl, H_2O, $NaHCO_3$ and brine. The organic layer was dried over Na_2SO_4, filtered and concentrated in vacuo. The liquid was dried under vacuum to provide 1-Boc-piperidine-4-carboxylic acid ethyl ester.

The following compounds were prepared similarly to the procedure outlined above:

a) N-Boc-(2-chloropyrimidin-4-yl)-methylamine.
b) 1-(2-tert-Butyl-4-nitrophenyl)-4-Boc-piperazine.
c) 1-Boc-azetidine-3-carboxylic acid
d) 1-Boc-4-Hydroxymethyl-piperidine using TEA.

Preparation XXXIII - 1-Boc-4-hydroxymethyl-piperidine:

1-Boc-4-Hydroxymethyl-piperidine was prepared from 1-Boc-piperidine-4-carboxylic acid ethyl ester by a procedure similar to that described in the preparation of 2-morpholin-4-yl-propanol.

Preparation XXXIV - 1-Boc-4-Methylsulfonyloxymethyl-piperidine:

Dissolved 1-Boc-4-hydroxymethyl-piperidine in anhydrous CH_2Cl_2 (50 ml) and TEA (4.5 ml) and cooled to 0 °C. Mesyl chloride (840 µl) was added and the mixture was stirred for 15 min then at RT for 45 min. The mixture was washed with brine/1N HCl and then brine, dried over Na_2SO_4, concentrated in vacuo and dried under high vacuum to provide 1-Boc-4-methylsulfonyloxymethyl-piperidine as a yellow orange thick oil.

The following compounds were prepared similarly to the procedure outlined above:

a) 1-Boc-3-methylsulfonyloxymethyl-azetidine.

Preparation XXXV - 1-Boc-4-(3-nitro-6-pentafluoroethyl-phenoxymethyl)-piperidine:

To a slurry of 60% NaH suspension in DMF (30 mL) at RT added a solution of 5-nitro-2-pentafluoroethyl-phenol (3.6 g) in 5

mL DMF. The dark red mixture was stirred at RT for 10 min then added a solution of 1-Boc-4-methylsulfonyloxymethyl-piperidine (3.1 g) in 5 mL DMF. The reaction was stirred at 60 ºC and 95 ºC. After 1 h, added 2.94 g K_2CO_3 and stirred overnight at 105 ºC. After cooling to RT, the reaction was diluted with hexanes and 1N NaOH. Separated layers, and washed organic layer with 1N NaOH and with brine, dried over Na_2SO_4, filtered and concentrated *in vacuo*. Purification with silica gel column chromatography with 8% EtOAc/Hexanes yielded 1-Boc-4-(3-nitro-6-pentafluoroethyl-phenoxymethyl)-piperidine as a light yellow thick oil.

Preparation XXXVI - 4-(3-nitro-6-pentafluoroethyl-phenoxymethyl)-piperidine:

4-(3-Nitro-6-pentafluoroethyl-phenoxymethyl)-piperidine was prepared from 1-Boc-4-(3-nitro-6-pentafluoroethyl-phenoxymethyl)-piperidine by a procedure similar to that described in the preparation of 2-(3-nitro-5-trifluoromethyl-phenoxymethyl)-pyrrolidine.

Preparation XXXVII - 1-methyl-4-(3-nitro-6-pentafluoroethyl-phenoxymethyl)-piperidine:

4-(3-Nitro-6-pentafluoroethyl-phenoxymethyl)-piperidine (316.5 mg) was dissolved in 2.7 mL CH_3CN, then added 37% formaldehyde/H_2O (360 ul) and then $NaBH_3CN$ (90 mg). Upon addition of $NaCNBH_3$ the reaction was found to be slightly exothermic. The reaction was stirred at RT and pH was maintained at ~7 by addition of drops of glacial AcOH. After about 1 h, the mixture was concentrated *in vacuo*, treated with 8 mL 2N KOH and extracted two times with 10 mL Et_2O. The organic layers were washed with 0.5N KOH and then the combined organic layers were extracted two times with 1N HCl. The aqueous layer was basified with solid KOH and extracted two times with Et_2O. This organic layer was then

washed with brine/1N NaOH, dried over Na_2SO_4, filtered, concentrated *in vacuo* and dried under high vacuum to give pure compound.

Preparation XXXVIII - 1-Isopropyl-4-(5-nitro-2-pentafluoroethyl-phenoxymethyl)-piperidine:

Dissolved 4-(5-nitro-2-pentafluoroethyl-phenoxymethyl)-piperidine (646 mg) in 1,2-dichloroethane (6.4 ml), then added acetone (136 ul), $NaBH(OAc)_3$ (541 mg) and finally AcOH (105 ul). Stirred the cloudy yellow solution under N_2 at RT overnight. Added another 130 uL acetone and stirred at RT over weekend. Quenched the reaction with 30 mL N NaOH/H_2O and stirred 10 min. Extracted with Et_2O and the organic layer was brine-washed, dried over Na_2SO_4, filtered and concentrated in vacuo. Dried under high vacuum for several h to obtain 1-isopropyl-4-(5-nitro-2-pentafluoroethyl-phenoxymethyl)-piperidine as a yellow orange solid.

The following compounds were prepared similarly to the procedure outlined above:

a) 3,3-Dimethyl-1-(1-methyl-piperidin-4-yl)-6-nitro-2,3-dihydro-1H-indole was prepared using 1-methyl-piperidin-4-one. M+H 290; Calc'd 289.4.

b) 3,3-Dimethyl-1-(1-Boc-piperidin-4-ylmethyl)-6-nitro-2,3-dihydro-1H-indole using 1-Boc-4-formyl-piperidine.

Preparation XXXIX - 3,3-Dimethyl-1-(1-methyl-piperidin-4-ylmethyl)-6-nitro-2,3-dihydro-1H-indole:

3,3-Dimethyl-1-piperidin-4-ylmethyl-6-nitro-2,3-dihydro-1H-indole was treated with an excess of formaldehyde and $NaBH(OAc)_3$ and stirred overnight at RT. The reaction was quenched with MeOH and concentrated in vacuo. The residue was partitioned between EtOAc and 1N NaOH. The organic layer

was removed, washed with brine, dried (Na_2SO_4), filtered and concentrated to provide the compound.

Preparation XL - (S) 2-(5-Nitro-2-pentafluoroethyl-phenoxymethyl)-oxirane:

Combined 5-nitro-2-pentafluoromethylphenol (2.69 g), DMF (25 ml) K_2CO_3 (3.03 g) and (S) toluene-4-sulfonic acid oxiranyl-methyl ester (2.27 g) and stirred the mixture at 90°C. After about 4 h, the mix was cooled, diluted with EtOAc, washed with H_2O, 1N NaOH (2x), 1N HCl and then with brine. Dried over Na_2SO_4, filtered and concentrated *in vacuo*. Purified the crude on silica gel column with 5% EtOAc/hexane and drying under high vacuum provided the (S)-2-(5-nitro-2-pentafluoroethyl-phenoxymethyl)-oxirane.

The following compounds were prepared similarly to the procedure outlined above:

a) (R)-2-(5-Nitro-2-pentafluoroethyl-phenoxymethyl)-oxirane.

Preparation XLI - (S) 2-Chloro-N-[3-(2-hydroxy-3-pyrrolidin-1-yl-propoxy)-4-pentafluoroethyl-phenyl]-nicotinamide:

(S) 2-Chloro-N-[4-(2-oxiranylmethoxy-)-3-pentafluoroethyl-phenyl]-nicotinamide (1.11 g) in a sealed tube and added pyrrolidine (285 µl). Stirred after sealing tube at 60 °C. After 12 h, the mixture was concentrated *in vacuo* and purified on a silica gel column (5:95:0.5 $MeOH:CH_2Cl_2:NH_4OH$ - 8:92:1, $MeOH:CH_2Cl_2:NH_4OH$). The product fractions were concentrated *in vacuo* and dried under high vacuum to obtain pure compound.

The following compounds were prepared similarly to the procedure outlined above:

a) (R) 1-(5-Nitro-2-pentafluoroethyl-phenoxy)-3-pyrrolidin-1-yl-propan-2-ol.

Preparation XLII - 5-nitro-2-trifluoromethylanisole:

Cooled 140 mL pyridine in a large sealable vessel to -40 ºC. Bubbled in trifluoromethyl iodide from a gas cylinder, which had been kept in freezer overnight. After adding ICF_3 for 20 min, added 2-iodo-5-nitroanisole (24.63 g) and copper powder (67.25 g). Sealed vessel and stirred vigorously for 22 h at 140 ºC After cooling to -50 ºC, carefully unsealed reaction vessel and poured onto ice and Et_2O. Repeatedly washed with Et_2O and H_2O. Allowed the ice - Et_2O mixture to warm to RT. Separated layers, washed organic layer with 1N HCl (3x), then brine, dried over Na_2SO_4, filtered and concentrated in vacuo. Eluted material through silica gel plug (4.5:1 Hex:CH_2Cl_2) to provide 5-nitro-2-trifluoromethylanisole.

Preparation XLIII - 1-[2-(5-nitro-2-trifluoromethylphenoxy)ethyl]pyrrolidine:

1-[2-(5-Nitro-2-trifluoromethylphenoxy)ethyl]-pyrrolidine was prepared from 5-nitro-2-trifluoromethyl-phenol and 1-(2-chloroethyl)pyrrolidine by a procedure similar to that described for 1-[2-(2-tert-butyl-5-nitro-phenoxy)-ethyl]-piperidine.

Preparation XLIV - 1-[2-(5-Nitro-2-pentafluoroethyl-phenoxy)-ethyl]-piperidine:

1-[2-(5-Nitro-2-pentafluoroethyl-phenoxy)-ethyl]-piperidine was prepared from 5-nitro-2-pentafluoroethylphenol and 1-(2-chloroethyl)piperidine by a procedure similar to that described in the preparation of 1-[2-(2-tert-butyl-5-nitro-phenoxy)-ethyl]-piperidine.

Preparation XLV - 3-(1-Boc-pyrrolidin-2-ylmethoxy)-4-pentafluoroethyl-phenylamine:

3-(2-Pyrrolidin-1-yl-methoxy)-4-trifluoromethyl-phenylamine was prepared from 1-[2-(5-nitro-2-trifluoromethylphenoxy)methyl]-pyrrolidine by a procedure similar to that described in the preparation of 1-Boc-4-(3-amino-5-trifluoromethyl-phenoxy)-piperidine.

Preparation XLVI - 2-Chloro-N-[3-(2-pyrrolidin-1-yl-ethoxy)-4-trifluoromethyl-phenyl]-nicotinamide:

2-Chloro-N-[3-(2-pyrrolidin-1-yl-ethoxy)-4-trifluoromethyl-phenyl]-nicotinamide was prepared from 3-(2-pyrrolidin-1-yl-ethoxy)-4-trifluoromethyl-phenylamine and 2-chloropyridine-3-carbonyl chloride by a procedure similar to that described in the preparation of 1-Boc-4-{3-[(2-chloro-pyridine-3-carbonyl)-amino]-5-trifluoromethyl-phenoxy}-piperidine.

Preparation XLVII - (R) Acetic acid 2-(5-nitro-2-pentafluoroethyl-phenoxy)-1-pyrrolidin-1-ylmethyl-ethyl ester:

Dissolved 1-(5-nitro-2-pentafluoroethyl-phenoxy)-3-pyrrolidin-1-yl-propan-2-ol (3.5 g) in CH_2Cl_2 (15 ml), added TEA (2.55 ml) and cooled to 0 °C. Acetyl chloride (781.3 µl) was added dropwise, forming a suspension. The mixture was warmed to RT and stirred for 1.5 h. Additional acetyl chloride (200 µl) was added and the mix was stirred for another h. The mixture was diluted with CH_2Cl_2 and washed with sat. $NaHCO_3$. The organic layer was removed, washed with brine and back extracted with CH_2Cl_2. Dried the combined organic layers over Na_2SO_4, filtered and concentrated in vacuo. The residue was purified over silica gel column (5:94.5:0.5 MeOH: CH_2Cl_2:NH_4OH) to provide acetic acid 2-(5-nitro-2-pentafluoroethyl-phenoxy)-1-pyrrolidin-1-ylmethyl-ethyl ester as a yellow brown oil.

The following compounds were prepared similarly to the procedure outlined above:

a) (R) Acetic acid 2-(5-amino-2-pentafluoroethyl-phenoxy)-1-pyrrolidin-1-yl-methyl-ethyl ester.

b) 1-(2,2-Dimethyl-6-nitro-2,3-dihydro-benzo[1,4]oxazin-4-yl)-ethanone. M-NO_2 206.4; Calc'd 250.1.

Preparation XLVIII - (R) 2-Chloro-N-[3-(2-hydroxy-2-pyrrolidin-1-yl-propoxy)-4-pentafluoroethyl-phenyl]-nicotinamide:

(R) Acetic acid 2-{5-[(2-chloro-pyridine-3-carbonyl)-amino]-2-pentafluoroethyl-phenoxy}-1-pyrrolidin-1-yl-ethyl ester (408 mg) was dissolved in MeOH (15 ml) and NH_4OH (6 ml) was added and the mixture was stirred at RT for 6 h. The reaction was concentrated in vacuo and dried under high

vacuum. The residue was purified over silica gel column (8:92:0.6 MeOH: CH_2Cl_2:NH_4OH). The purified fractions were concentrated in vacuo and dried again to provide (R)-2-chloro-N-[3-(2-hydroxy-2-pyrrolidin-1-yl-ethoxy)-4-pentafluoroethyl-phenyl]-nicotinamide as a white foam.

Preparation XLIX - 2-Dimethylamino-1-(3,3-dimethyl-6-nitro-2,3-dihydro-indol-1-yl)-ethanone

3,3-Dimethyl-6-nitro-2,3-dihydro-1H-indole (5 g) was dissolved in DMF (100 ml) and HOAt (3.89 g) dimethylamino-acetic acid (5.83 g) and EDC (3.89 g) were added. The reaction was stirred overnight. The mixture was diluted with CH_2Cl_2 (1L) and washed with sat'd $NaHCO_3$ (3x200 ml). The organic layer was washed with brine, dried over Na_2SO_4, filtered and concentrated in vacuo. The residue was purified by flash chromatography (SiO_2, EtOAc to 5%MeOH/EtOAc) to afford the title compound.

The following compounds were prepared similarly to the procedure outlined above:

a) 1-(3,3-Dimethyl-6-nitro-2,3-dihydro-indol-1-yl)-2-(N-Boc-amino)-ethanone.

Preparation L - 1-(6-Amino-3,3-dimethyl-2,3-dihydro-indol-1-yl)-2-(N-Boc-amino)-ethanone:

1-(3,3-Dimethyl-6-nitro-2,3-dihydro-indol-1-yl)-2-(N-Boc-amino)-ethanone (3.9 g) was dissolved in EtOH (30 ml) and Fe powder (3.1 g) NH_4Cl (299 mg) and H_2O (5 ml) were added. The reaction was stirred at 80 °C overnight. The reaction was filtered through Celite® and evaporated off the MeOH. The residue was partitioned between CH_2Cl_2 and sat'd $NaHCO_3$. The organic layer was removed, washed with brine, dried over Na_2SO_4, filtered and concentrated *in vacuo*. The residue was

purified by flash chromatography (SiO_2, 25% EtOAc/hexane). The purified fractions were concentrated *in vacuo* to afford the compound as a white powder.

The following compounds were prepared similarly to the procedure outlined above:

a) 1-(6-Amino-3,3-dimethyl-2,3-dihydro-indol-1-yl)-2-dimethylamino-ethanone.
b) 3,3-Dimethyl-1-(1-methyl-piperidin-4-ylmethyl)-2,3-dihydro-1H-indol-6-ylamine.
c) 3-(4-Methyl-piperazin-1-ylmethyl)-4-pentafluoroethyl-phenylamine. M+H 324.2. Calc'd 323.
d) 3,3-Dimethyl-1-(1-methyl-piperidin-4-yl)-2,3-dihydro-1H-indol-6-ylamine. M+H 259.6; Calc'd 259.3.
e) 3,3-Dimethyl-1,1-dioxo-2,3-dihydro-1H-1λ6-benzo[d]isothiazol-6-ylamine
f) 1,1,4,4-Tetramethyl-1,2,3,4-tetrahydro-naphth-6-ylamine.
g) 3,3-Dimethyl-1-(1-Boc-piperidin-4-ylmethyl)-2,3-dihydro-1H-indol-6-ylamine.

Preparation LI - 2-Boc-4,4-dimethyl-7-nitro-1,2,3,4-tetrahydro-isoquinoline:

4,4-Dimethyl-7-nitro-1,2,3,4-tetrahydro-isoquinoline (150 mg) was dissolved with CH_2Cl_2 (3 ml) DIEA (100 ul) DMAP (208 mg and Boc_2O (204 mg) and the mixture was stirred for 6 h at RT. The reaction was diluted with CH_2Cl_2, washed with sat'd $NaHCO_3$ and dried over $MgSO_4$, filtered and concentrated to provide the compound which was used without further purification.

The following compounds were prepared similarly to the procedure outlined above substituting Ac_2O:

a) 1-(4,4-Dimethyl-7-nitro-3,4-dihydro-1H-isoquinolin-2-yl)-ethanone. M+H 249.3.

Preparation LII - 2-Bromo-N-(4-methoxy-benzyl)-5-nitro-benzamide:

PMB-amine (5.35 ml) in CH_2Cl_2 (130 ml) was slowly added to 2-bromo-5-nitro-benzoyl chloride (10.55 g) and $NaHCO_3$ (9.6 g) and the mixture was stirred at RT for 1 h. The mixture was diluted with CH_2Cl_2 (1 L), filtered, washed with diluted HCl, dried, filtered again, concentrated and dried under vacuum to provide the compound as a white solid. M+H 367. Calc'd 366.

Preparation LIII - 2-Bromo-N-(4-methoxy-benzyl)-N-(2-methyl-allyl)-5-nitro-benzamide:

To a suspension of NaH (1.22 g) in DMF (130 ml) was added 2-bromo-N-(4-methoxy-benzyl)-5-nitro-benzamide (6.2 g) in DMF (60 ml) at -78 ºC. The mixture was warmed to 0 ºC, 3-bromo-2-methyl-propene (4.57 g) was added and the mixture was stirred for 2 h at 0 ºC. The reaction was poured into ice H_2O, extracted with EtOAc (2x400 ml), dried over $MgSO_4$, filtered and concentrated to a DMF solution which was used without further purification.

Preparation LIV - of 2-(4-Methoxy-benzyl)-4,4-dimethyl-7-nitro-3,4-dihydro-2H-isoquinolin-1-one:

2-Bromo-N-(4-methoxy-benzyl)-N-(2-methyl-allyl)-5-nitro-benzamide (23.4 mmol) was dissolved in DMF (150 ml) and Et_4NCl (4.25 g), HCO_2Na (1.75 g) and NaOAc (4.99 g) were added. N_2 was bubbled through the solution for 10 min, then $Pd(OAc)_2$ (490 mg) was added and the mixture was stirred overnight at 70 ºC. The mixture was extracted with EtOAc, washed with sat'd NH_4Cl, dried over $MgSO_4$, filtered and

concentrated until the compound precipitated as a white solid.

The following compounds were prepared similarly to the procedure outlined above:

a) 3,3-Dimethyl-6-nitro-2,3-dihydro-benzofuran was prepared from 1-bromo-2-(2-methyl-allyloxy)-4-nitro-benzene.

b) 3,9,9-Trimethyl-6-nitro-4,9-dihydro-3H-3-aza-fluorene was prepared from 4-[1-(2-bromo-4-nitro-phenyl)-1-methyl-ethyl]-1-methyl-1,2,3,6-tetrahydro-pyridine.

Preparation LV - 4,4-Dimethyl-7-nitro-3,4-dihydro-2H-isoquinolin-1-one:

2-(4-Methoxy-benzyl)-4,4-dimethyl-7-nitro-3,4-dihydro-2H-isoquinolin-1-one (2.0 g) was dissolved in CH_3CN (100 ml) and H_2O (50 ml) and cooled to 0 ºC. CAN (9.64 g) was added and the reaction was stirred at 0 ºC for 30 min, then warmed to RT and stirred for 6 h. The mixture was extracted with CH_2Cl_2 (2x300 ml) washed with sat'd NH_4Cl, dried over $MgSO_4$, filtered and concentrated. The crude material was recrystallized in CH_2Cl_2/EtOAc (1:1) to give 4,4-dimethyl-7-nitro-3,4-dihydro-2H-isoquinolin-1-one as a white solid.

Preparation LVI - 4,4-Dimethyl-7-nitro-1,2,3,4-tetrahydro-isoquinoline:

4,4-Dimethyl-7-nitro-3,4-dihydro-2H-isoquinolin-1-one (230 mg) was dissolved in THF (10 ml) and BH_3Me_2S (400 ul) was added and the reaction was stirred overnight at RT. The reaction was quenched with MeOH (10 ml) and NaOH (200 mg) and heating at reflux for 20 min. The mixture was extracted with EtOAc, washed with sat'd NH_4Cl, extracted with 10% HCl (20 ml). The acidic solution was treated with 5N NaOH (15 ml), extracted with EtOAc (30 ml) dried, filtered and

evaporated to give the compound as a yellow solid. M+H 207.2, Calc'd 206.

The following compounds were prepared similarly to the procedure outlined above:

a) 4-Boc-2,2-dimethyl-6-nitro-3,4-dihydro-2H-benzo[1,4]oxazine.

Preparation LVII - 2-Bromomethyl-4-nitro-1-pentafluoroethyl-benzene:

2-Methyl-4-nitro-1-pentafluoroethyl-benzene (2.55 g) was dissolved in CCl_4 (30 ml) and AIBN (164 mg) and NBS (1.96 g) were added. The reaction was heated to reflux and stirred for 24 h. The mix was diluted with CH_2Cl_2, washed with sat'd $NaHCO_3$, dried over $MgSO_4$ and concentrated to give the compound as an oil which was used without further purification.

Preparation LVIII - 1-Methyl-4-(5-nitro-2-pentafluoroethyl-benzyl)-piperazine:

2-Bromomethyl-4-nitro-1-pentafluoroethyl-benzene (2.6 g) was added to N-methylpiperazine (5 ml) and stirred at RT for 3 h. The mixture was filtered and the filtrate was treated with 1-chlorobutane, extracted with 2N HCl (100 ml). The acidic solution was treated with 5N NaOH (6 ml) then extracted with EtOAc. The organic layer was removed, dried over $MgSO_4$ and concentrated to give the compound as an oil.

The following compounds were prepared similarly to the procedure outlined above:

a) 4-(5-Nitro-2-pentafluoroethyl-benzyl)-morpholine.

Preparation LIX - 1-Boc-4-(5-nitro-2-pentafluoroethyl-benzyl)-piperazine.

2-Bromomethyl-4-nitro-1-pentafluoroethyl-benzene (2.5 g) was dissolved in CH_2Cl_2 and added to N-Boc-piperazine (2.5 g) and $NaHCO_3$ (1 g) and stirred at RT overnight. The mixture was diluted with CH_2Cl_2 (100 ml) , washed with sat'd NH_4Cl, dried over $MgSO_4$, filtered and concentrated. The residue was purified by silica gel chromatography (hexane, CH_2Cl_2:hexane 2:8) to give the compound as a yellow solid.

Preparation LX - (4-Boc-piperazin-1-yl)-(3-nitro-5-trifluoromethyl-phenyl)-methanone:

A mixture of 3-nitro-5-trifluoromethyl-benzoic acid (4.13 g), 4-Boc-piperazine (2.97 g), EDC (3.88 g), HOBt (2.74 g) and DIEA (3.33 ml) in CH_2Cl_2 (120 ml) was stirred at RT for 3 h. The mixture was diluted with CH_2Cl_2 (100 ml), washed with sat'd NH_4Cl, dried over $MgSO_4$, filtered and concentrated. The residue was purified by silica gel chromatography (hexane, CH_2Cl_2:hexane 1:2) to give the compound as a white solid.

Preparation LXI - 1-Boc-4-(3-nitro-5-trifluoromethyl-benzyl)-piperazine:

(4-Boc-piperazin-1-yl)-(3-nitro-5-trifluoromethyl-phenyl)-methanone (403 mg) was dissolved in THF (6 ml) and BH_3Me_2S (300 µl) was added and the reaction was stirred for 3 h at 60 ºC and 2 h at RT. The reaction was quenched with MeOH (5 ml) and NaOH (100 mg) and stirred at RT for 1 h. The mixture was concentrated and dissolved in CH_2Cl_2, washed with sat'd $NH_4Cl/NaHCO_3$, dried ($MgSO_4$), filtered and evaporated to give the compound as an oil. M+H 390.3.

Preparation LXII - 2-Ethyl-4-aminomethyl pyridine:

To a solution of 2-ethyl-4-thiopyridylamide (10 g) in MeOH (250 ml) was added Raney 2800 Nickel (5 g, Aldrich) in one portion. The mixture was stirred at RT for 2 days then at 60 °C for 16 h. The mixture was filtered, concentrated to provide the desired compound.

Preparation LXIII - N-Boc-[2-(4-morpholin-4-yl-butyl)-pyrimidin-4-ylmethyl]-amine:

N-Boc-(2-chloropyrimidine)-methylamine (663 mg) and 4-(aminopropyl)morpholine (786 mg) were dissolved in MeOH and concentrated *in vacuo*. The residue was heated at 100 °C for 15 min, forming a solid, which was dissolved in CH_2Cl_2/MeOH then concentrated again and heated 15 min more. The solution was concentrated *in vacuo* and dried under high vacuum, and the resulting solid was triturated with a small amount of IpOH and allowed to settle over a weekend. The solid was filtered, rinsing with a small amount of IpOH, to provide the compound as a white solid.

The following compounds were prepared similarly to the procedure outlined above:

a) (4-Bocaminomethyl-pyrimidin-2-yl)-[2-(1-methyl-pyrrolidin-2-yl)-ethyl]-amine. M+H 336.5; Calc'd 335.45.

Preparation LXIV - 2-fluoronicotinic acid:

In a flame dried 3-necked round bottom flask equipped with a dropping funnel and thermometer, under N_2, THF (250 ml) was added via cannula. LDA (2M in cyclohexane, 54 ml) was added via cannula as the flask was cooled to -78 °C. At -78 °C, 2-fluoropyridine (8.87 ml) was added dropwise over 10 min. The reaction was stirred for 3 h. Condensation was blown off (with N_2) a few cubes of solid CO_2 and they were added to

the mixture. The mixture was warmed to RT once the solution turned yellow, and it was stirred overnight. The reaction was cooled to 0 °C and the pH was adjusted to ~2.5 with 5N HCl. The mixture was concentrated in vacuo and extracted with EtOAc. The EtOAc layer was washed with brine, dried over $MgSO_4$, filtered and concentrated to dryness. The resulting solid was taken into a slurry with EtOAc (100 ml), filtered, washed with cold EtOAc and dried at 50 °C for 1 h to afford 2-fluoronictinic acid. M+H 142.1; Calc'd 141.0.

Preparation LXV - 4-cyano-2-methoxypyridine:

Under a stream of N_2 and with cooling, Na metal (2.7 g) was added to MeOH (36 ml) with a considerable exotherm. After the Na is dissolved, a solution of 2-chloro-4-cyanopyridine (15 g) in dioxane:MeOH (1:1, 110 ml) was added via dropping funnel over a 10 min period. The reaction was heated to reflux for 3.5 h then cooled at ~10 °C overnight. Solid was filtered off and the solid was washed with MeOH. The filtrate was concentrated to ~60 ml and H_2O (60 ml) was added to redissolve a precipitate. Upon further concentration, a precipitate formed which was washed with H_2O. Further concentration produced additional solids. The solids were combined and dried in vacuo overnight at 35 °C to provide 4-cyano-2-methoxypyridine which was used as is.

Preparation LXVI - (2-methoxypyridin-4-yl)methylamine:

4-Cyano-2-methoxypyridine (1.7 g) was dissolved in MeOH (50 ml) and conc. HCl (4.96 ml) was added. Pd/C (10%) was added and H_2 was added and let stand overnight. The solids were filtered through Celite® and the cake was washed with MeOH (~250 ml). Concentration in vacuo produced an oil which was dissolved in MeOH (~20 ml). Et_2O (200 ml) was added and stirred for 1 h. The resulting precipitate was filtered and

washed with Et_2O to afford (2-methoxypyridin-4-yl)methylamine (HCl salt) as an off-white solid.

Preparation LXVII - 2-(4-Amino-phenyl)-2-methyl-propionic acid methyl ester:

2-Methyl-2-(4-nitro-phenyl)-propionic acid methyl ester (2.1 g) was dissolved in THF (70 ml) and AcOH (5 ml) and Zn (10 g) were added. The mixture was stirred for 1 h and filtered through Celite®. The filtrate was rinsed with EtOAc and the organics were evaporated to a residue which was purified on silica gel chromatography (40%EtOAc/hexanes) to provide the desired compound as a yellow oil. M+H 194.

Preparation LXVIII - 1-(2-tert-Butyl-phenyl)-4-methyl-piperazine:

2-tert-Butyl-phenylamine and bis-(2-chloro-ethyl)-methylamine were mixed together with K_2CO_3 (25 g), NaI (10 g) and diglyme (250 mL) and heated at 170 ºC for 8 h. The reaction mixture was cooled, the solid filtered and solvent evaporated. The residue was diluted with EtOAc, washed with $NaHCO_3$ solution, extracted twice more with EtOAc, washed with brine, dried over Na_2SO_4 and evaporated to give the compound as a dark solid.

The following compounds were prepared similarly to the procedure outlined above:

a) 1-Bromo-2-(2-methyl-allyloxy)-4-nitro-benzene was prepared from methallyl bromide.

Preparation LXIX - 3-(1-Methyl-1,2,3,6-tetrahydro-pyridin-4-yl)-5-trifluoromethyl-phenylamine:

3-(5,5-Dimethyl-[1,3,2]dioxaborinan-2-yl)-5-trifluoromethyl-phenylamine (8.8 g, 0.032 mol)was added to trifluoro-

methanesulfonic acid 1-methyl-1,2,3,6-tetrahydro-pyridin-4-yl ester (7.91 g, 0.032 mol)and 2N Na_2CO_3 aqueous solution (25 mL) was bubbled through N_2 for 5 min. $Pd(PPh_3)_4$ (3.7 g, 3.2 mmol) was added and the reaction was heated to 80 ºC for 16 h. The reaction was cooled to RT and diluted with Et_2O (100 mL). The mixture was filtered through Celite® and the filtrate was washed with $NaHCO_3$ aqueous solution (25 ml) followed by brine (25 mL). The organic phase was dried over Na_2SO_4 and concentrated *in vacuo*. The desired compound was isolated by passing through silica gel column chromatography (EtOAc, then (2M NH_3) in MeOH/EtOAc) to provide a yellow oil.

Preparation LXX - 3,3-Dimethyl-6-nitro-2,3-dihydro-benzo[d]isothiazole 1,1-dioxide:

3,3-Dimethyl-2,3-dihydro-benzo[d]isothiazole 1,1-dioxide was added to KNO_3 in H_2SO_4 cooled to 0 ºC and stirred for 15 min. The reaction was warmed to RT and stirred overnight. The mix was poured into ice and extracted with EtOAc (3x), washed with H_2O and brine, dried and evaporated to give the compound which was used without further purification.

The following compounds were prepared similarly to the procedure outlined above:

a) 1,1,4,4-Tetramethyl-6-nitro-1,2,3,4-tetrahydro-naphthalene

Preparation LXXI - 3-(1-Methyl-1,2,3,4-tetrahydro-pyridin-4-yl)-5-trifluoromethyl-phenylamine:

3-(5,5-Dimethyl-[1,3,2]dioxaborinan-2-yl)-5-trifluoromethyl-phenylamine (1.2 g) was added to trifluoro-methanesulfonic acid 1-methyl-1,2,3,6-tetrahydro-pyridin-4-yl ester (1.0 g), LiCl (500 mg, Aldrich), PPh_3 (300 mg, Aldrich) and 2M Na_2CO_3

aqueous solution (6 ml) and was bubbled with N_2 for 5 min. $Pd(PPH_3)_4$ (300 mg, Aldrich) was added and the reaction was heated to 80 ºC for 16 h. The reaction was cooled to RT and diluted with Et_2O (100 mL). The mixture was filtered through Celite® and the filtrate was washed with $NaHCO_3$ aqueous solution (25 ml) followed by brine (25 mL). The organic phase was dried over Na_2SO_4 and concentrated *in vacuo*. The desired compound was isolated by silica gel column chromatography (EtOAc 10% (2M NH_3) in MeOH/EtOAc) to provide yellow oil. M+H 257.2; Calc'd 256.1.

Preparation LXXII - Trifluoromethylsulfonic acid 1-methyl-1,2,3,6-tetrahydro-pyridin-4-yl ester:

In a three-necked round bottom flask equipped with a thermometer and an additional funnel was placed anhydrous THF (200 mL) and 2M LDA (82.8 mL). The solution was cooled to -78 ºC and a solution of 1-methyl-piperidin-4-one (20 mL) in anhydrous THF (70 mL) was added drop-wise. The reaction was warmed to -10 ºC over 30 min and cooled down again to -78 ºC. Tf_2NPh (54.32 g) in 200 mL of anhydrous THF was added through the additional funnel over 30 min and anhydrous THF (30 mL) was added to rinse the funnel. The reaction was warmed to RT and the reaction solution was concentrated in vacuo. The residue was dissolved in Et_2O purified on neutral Al_2O_3 column chromatography (Et_2O as elutant). The compound was obtained as orange oil. (20 g)

Preparation LXXIII - 3-(5,5-Dimethyl-[1,3,2]dioxaborinan-2-yl)-5-trifluoromethyl-phenylamine:

N_2 was bubbled through a solution of 3-bromo-5-trifluoromethyl-phenylamine (2.38 g), 5,5,5',5'-tetramethyl-[2,2']bi[[1,3,2]dioxaborinanyl] (2.24 g, Frontier Scientific) and KOAc (2.92 g), dppf (165 mg, Aldrich) in anhydrous dioxane (50 ml) for 2 min. $PdCl_2$ (dppf)(243 mg,

Aldrich) was added and the reaction was heated to 80°C for 4 h. After cooling to RT, the mix was diluted with 50 mL of Et_2O, filtered through Celite®, and the filtrate was concentrated *in vacuo*. The residue was dissolved in Et_2O (100 mL), washed with sat. $NaHCO_3$ aqueous solution (50 mL) followed by brine (50 mL). The organic phase was dried over Na_2SO_4 and concentrated *in vacuo*. The residue was dissolved in 3:2 Et_2O/Hex (100 mL), filtered through Celite® and the filtrate was concentrated *in vacuo* to afford a dark brown semi-solid.

Preparation LXXIV - 1-Boc-3-Hydroxymethyl-azetidine:

A solution of 1-Boc-azetidine-3-carboxylic acid (1.6 g) and Et_3N (2 ml) in anhydrous THF (60 ml) was cooled to 0°C. Isopropyl chloroformate (1.3 g) was added via a syringe slowly; forming a white precipitate almost immediately. The reaction was stirred for 1 h at 0 ºC and the precipitate was filtered out. The filtrate was cooled to 0 ºC again and aqueous $NaBH_4$ solution (900 mg, 5 ml) was added via pipette and stirred for 1 h. The reaction was quenched with $NaHCO_3$ solution (50 mL) and the compound was extracted with EtOAc (200 mL). The organic phase was washed with brine (50 mL), dried over Na_2SO_4 and concentrated *in vacuo*. The residue was dissolved in EtOAc and passed through a short silica gel pad. Concentrating the filtrate *in vacuo* provided the compound as a light yellow oil.

Preparation LXXV - 1-Boc-3-(3-nitro-5-trifluoromethyl-phenoxymethyl)-azetidine:

A mixture of 1-Boc-3-methylsulfonyloxymethyl-azetidine (1.47 g), 3-nitro-5-trifluoromethyl-phenol (1.15 g) and K_2CO_3 (1.15 g) in DMF (20 ml) at 80 °C was stirred overnight. The reaction was cooled to RT and diluted with 25 mL of sat. $NaHCO_3$ and 50 mL of EtOAc. The organic phase was separated

and washed with brine (25 mL), dried over Na_2SO_4 and concentrated *in vacuo*. The crude compound was purified by column chromatography (50% EtOAc/hex).

Preparation LXXVI - 2,2-Dimethyl-6-nitro-3,4-dihydro-2H-benzo[1,4]oxazine:

2,2-Dimethyl-6-nitro-4H-benzo[1,4]oxazin-3-one was added to BH_3-THF complex (Aldrich) in THF with ice cooling. The mixture was heated to reflux for 2 h then carefully diluted with 12 mL of MeOH and heated to reflux for an additional 1 h. Concentrated HCl (12 mL) was added and heated to reflux for 1 h. The mixture was concentrated and the resulting solid was suspended in a dilute aqueous solution of NaOH (1 M) and extracted with EtOAc (100 mL x 4). The organic layers were washed with H_2O and dried over $MgSO_4$. Evaporation of solvent gave a yellow solid.

Preparation LXXVII - 2,2,4-Trimethyl-6-nitro-4H-benzo[1,4]oxazin-3-one:

2,2-Dimethyl-6-nitro-4H-benzo[1,4]oxazin-3-one (1.1 g) was mixed with MeI (850 mg, Aldrich), K_2CO_3 (1.38 g, Aldrich) and DMF (30 ml, Aldrich) at 40°C for 48 h. The DMF was removed in vacuo and the residue was diluted with EtOAc (80 ml). The organic phase was washed with H_2O (50 ml), aqueous Na_2SO_3 (50 ml) and brine (50 ml). The resulting solution was dried ($MgSO_4$) and concentrated to provide the compound which was used as is for the next reaction step.

Preparation LXXVIII - 2-Bromo-N-(2-hydroxy-5-nitro-phenyl)-2-methyl-propionamide:

2-Amino-4-nitro-phenol (3.08 g, Aldrich) was stirred with THF (30 ml, Aldrich) in an ice bath. 2-Bromo-2-methyl-propionyl bromide (2.47 ml, Aldrich) and Et_3N (2.0 g, Aldrich) was slowly added via syringe. The mixture was

stirred for 45 min then poured into ice. The aqueous phase was extracted by EtOAc(50 mL x 4). The organic layer was dried and concentrated. The desired compound was crystallized from EtOAc (*Chem. Pharm. Bull* 1996, 44(1) 103-114).

Preparation LXXIX - 2,2-Dimethyl-6-nitro-4H-benzo[1,4]oxazin-3-one:

2-Bromo-N-(2-hydroxy-5-nitro-phenyl)-2-methyl-propionamide was mixed with K_2CO_3 in 20 mL of DMF and stirred overnight at 50°C. The reaction mixture was poured into ice H2O. The precipitate was collected by filtration and washed with H_2O. The crude compound was recrystallized from EtOH.

Preparation LXXX -4-[1-(2-Bromo-4-nitro-phenyl)-1-methyl-ethyl]-1-methyl-pyridinium iodide:

1-Methyl-4-[1-methyl-1-(4-nitro-phenyl)-ethyl]-pyridinium (8 g) was dissolved in glacial HOAc (10 ml) then diluted with H_2SO_4 (50 ml), then NBS (3.8 g) was added. After 1 h, additional NBS (1.2 g) was added, 30 min later another 0.5 g of NBS, then 15 min later 200 mg more NBS. After 1 h, the mixture was neutralized with NH_4OH (conc.) with ice bath cooling. The neutralized mixture was then concentrated and used as is.

Preparation LXXXI - 4-[1-(2-Bromo-4-nitro-phenyl)-1-methyl-ethyl]-1-methyl-1,2,3,6-tetrahydro-pyridine:

4-[1-(2-Bromo-4-nitro-phenyl)-1-methyl-ethyl]-1-methyl-pyridiniumiodide was mixed with MeOH (400 ml) and CH_2Cl_2 (200 ml), then treated with $NaBH_4$ (2.5 g) in portions. After stirring at RT for 2 h, the mixture was extracted with CH_2Cl_2 (300 mL x 3). The CH_2Cl_2 layer was washed with brine, dried over Na_2SO_4 and concentrated *in vacuo*, to provide the desired compound.

Preparation LXXXII - 1-Methyl-4-[1-methyl-1-(4-nitro-phenyl)-ethyl]-pyridinium iodide:

4-(4-Nitro-benzyl)-pyridine (4.3 g) was mixed with MeI (4 ml, 9.12 g)/NaOH (5N, 30 ml), Bu_4NI (150 mg) and CH_2Cl_2 (50 ml) and stirred at RT overnight. Additional MeI (2 mL) was added along with 50 mL of NaOH (5N). 6 h later, more MeI (2 mL) was added. The mixture was stirred at RT over the weekend. The mixture was cooled on ice bath and the base was neutralized by conc. HCl (aq) addition dropwise to pH 7. The compound was used as is.

Preparation LXXXIII - 1-Methyl-4-(4-nitro-benzyl)-1,2,3,6-tetrahydro-pyridine:

4-(4-Nitrobenzyl)pyridine (64 g) and TBAI (6 g) were dissolved in CH_2Cl_2 (500 mL) and the solution was suspended with NaOH (aq. 5N, 450 mL) in a 3L 3-necked round bottom flask. With vigorous stirring, CH_3I (213 g) was added and stirred vigorously at RT for 60 h (or until blue color disappears). The reaction was quenched with dimethylamine (100 mL) and MeOH (300 mL) and stirred for 2 h. $NaBH_4$ (19 g) was added to the mixture in small portions. The reaction mixture was stirred for 30 min at RT, then partitioned between CH_2Cl_2/H_2O (500 mL/500 mL). The organic layer was collected and the aqueous layer was washed with CH_2Cl_2 (300 mL x 3). The combined organic layers was washed with brine then concentrated in vacuo. The residue was purified on a silica wash-column (7% TEA in EtOAc). The desired fractions were combined and concentrated under vacuum to give the desired compound as a dark gray solid. (MS: M+1=261).

Preparation LXXXIV - 1-Boc-4-formylpiperidine:

4A Molecular sieves were heated to 100 °C and a vacuum was applied. They were cooled to RT and purged with N_2. CH_2Cl_2

(420 ml) and CH_3CN (40 ml), NMO (40 g) and 1-Boc-4-hydroxymethylpiperidine (50 g) were added and the mix was stirred for 5 min then cooled to 15 °C. TPAP (4.1 g) is added and an exotherm was observed. The reaction was maintained at RT with external cooling. The reaction was stirred at RT for 3 h, filtered, concentrated, diluted with 50% EtOAc/hexanes and purified on a silica gel plug (50%EtOAc/hexanes). The eluant fractions were concentrated to afford a yellow oil.

Preparation LXXXV 2-Chloro-4-cyanopyridine:

2-Chloro-4-cyanopyridine was prepared similar to the method described by Daves et al., J. Het. Chem., 1, 130-32 (1964).

Preparation LXXXVI 4-(2-tert-Butyl-5-nitro-phenyl)-but-3-en-1-ol:

A mix of 1-(tert-butyl)-2-bromo-4-nitrobenzene (3.652 g), TEA (5.92 ml), 3-buten-1-ol (5.48 ml), $Pd(OAc)_2$ (32 mg), $Pd(PPh_3)_4$ (327 mg) and toluene (40 ml) was degassed with nitrogen and heated in a sealed vessel for 16 h at 120 °C. The next day, the reaction mixture was cooled to RT, filtered, and concentrated in vacuo. The crude was eluted on a silica gel column with 15% to 22% EtOAc/hexanes gradient system to yield a yellow-brown oil.

Preparation LXXXVII 4-(2-tert-Butyl-5-nitro-phenyl)-but-3-enal:

4-(2-tert-Butyl-5-nitro-phenyl)-but-3-en-1-ol (1.024 g) was dissolved in 10 ml of CH_2Cl_2 and added dropwise over 5 min to a -78 °C mix of oxalyl chloride (0.645 ml), DMSO (0.583 ml), and 10 ml CH_2Cl_2. The reaction was stirred at -78 °C for 1 h, then treated with a solution of TEA (1.52 ml) in 7 ml CH_2Cl_2 and stirred at -78 °C for an additional 25 min, then warmed to -30 °C for 35 min. The reaction was treated

with 50 ml of saturated aqueous NH_4Cl, diluted with H_2O and extracted with EtOAc. The organic layer was brine-washed, dried over Na_2SO_4, filtered, and concentrated in vacuo to yield a yellow oil which was used as is in Preparation LXXXVIII.

Preparation LXXXVIII 1-[4-(2-tert-Butyl-5-nitro-phenyl)-but-3-enyl]-pyrrolidine:

4-(2-tert-Butyl-5-nitro-phenyl)-but-3-enal (895 mg) was dissolved in 40 ml THF, and to the solution was added pyrrolidine (0.317 ml). To the deep orange solution was added $NaBH(OAc)_3$ (1.151 g) and glacial AcOH (0.207 ml). The reaction was stirred at RT overnight, then treated with saturated aqueous $NaHCO_3$ and diluted with Et_2O and some 1N NaOH. The layers were separated, and the organic layer was extracted with aqueous 2N HCl. The acidic aqueous layer was basified to pH>12 with 6 N NaOH, extracted with Et_2O, brine-washed, dried over Na_2SO_4, filtered, and concentrated in vacuo to provide 1-[4-(2-tert-butyl-5-nitro-phenyl)-but-3-enyl]-pyrrolidine as a orange-brown oil.

Preparation LXXXVIX - N-Boc-(2-chloropyrimidin-4-yl)-methylamine:

To 2-chloropyrimidine-4-carbonitrile [2.5 g, prepared by the procedure of Daves et. al. [*J. Het. Chem.* 1964, *1*, 130-132)] in EtOH (250 ml) under N_2 was added Boc_2O (7.3 g). After the mixture was briefly placed under high vacuum and flushed with N_2, 10% Pd/C (219 mg) was added. H_2 was bubbled though the mixture (using balloon pressure with a needle outlet) as it stirred 4.2 h at RT. After filtration through Celite®, addition of 1.0 g additional Boc_2O, and concentration, the residue was purified by silica gel chromatography (5:1 → 4:1 hexanes/EtOAc) to obtain N-Boc-(2-chloropyrimidin-4-yl)-methylamine.

Preparation XC - Methanesulfonic acid 1-Boc-azetidin-3-ylmethyl ester:

To a solution of (1-Boc-azetidin-3-yl)-methanol (1.06 g, 5.7 mmol), TEA (1.18 mL, 8.52mmol) in CH_2Cl_2 at 0°C was added $MeSO_2Cl$ (0.53 mL, 6.82 mmol) via a syringe. The reaction was warmed to RT over 2 h and stirring was continued at RT for 2 h. The white solid formed was removed by filtration and the filtrate was washed with 25 mL of H_2O. The organic phase was dried over Na_2SO_4, and concentrated *in vacuo* to afford yellow oil.

Preparation XCI - N-(2-bromo-5-nitrophenyl)acetamide:

2-Bromo-5-nitroaniline (10 g) was dissolved in 500 mL of CH_2Cl_2, DIEA (6.6 g) was added to the mixture, followed by DMAP (100 mg). The mixture was cooled to 0 °C in ice bath. Acetyl chloride (4 g in 50 mL CH_2Cl_2) was added dropwise to the reaction mixture. After the mixture was stirred at RT over 3 h, extracted once with saturated $NaHCO_3$ solution and once with brine, the resulting organic layer was dried over $MgSO_4$, filtered and concentrated in vacuo. The crude material was purified by flash chromatography on silica gel with 1:1 EtOAc:Hexane to 100% EtOAc to afford N-(2-bromo-5-nitrophenyl)acetamide as a white solid. MS: 258 (M-1). Calc'd. for $C_8H_7BrN_2O_3$-259.06.

Preparation XCII - N-(2-bromo-5-nitrophenyl)-N-(2-methylprop-2-enyl)acetamide:

A suspension of 2 g NaH (95% powder) in anhydrous DMF (100 mL) was cooled to -78 °C, N-(2-bromo-5-nitrophenyl)acetamide (7 g) in dry DMF (50 mL) was added to the mixture under N_2 atmosphere. After the mixture was warmed to 0 °C, 3-bromo-2-methylpropene (7.3 g in 20 dry DMF) was added to the mixture. The mixture was stirred at RT overnight. The

mixture was poured into a container of ice and extracted between saturated $NaHCO_3$ solution and EtOAc. The resulting organic layer was dried over $MgSO_4$, filtered and concentrated in vacuo. The crude material was purified by flash chromatography on silica gel with 7:2 hexane:EtOAc to afford the title compound as a yellow gum. MS: 314 (M+1). Calc'd. for $C_{12}H_{13}BrN_2O_3$-313.15.

Preparation XCIII - 1-(3,3-dimethyl-6-nitro-2,3-dihydro-indol-1-yl)ethanone:

N-(2-Bromo-5-nitrophenyl)-N-(2-methylprop-2-enyl)acetamide (4.5 g) was dissolved in anhydrous DMF (50 mL), tetraethyl-ammonium chloride (2.5 g), sodium formate (1.2 g), NaOAc (3 g) were added, and the resulting mixture was bubbled with N_2 gas for 10 min. $Pd(OAc)_2$ (350 mg) was added and the mixture was heated at 80 °C under N_2 atmosphere overnight. After the mixture was concentrated in vacuo, it was partitioned between saturated $NaHCO_3$ solution and EtOAc, the resulting organic layer was dried over $MgSO_4$, filtered and concentrated in vacuo. The crude material was purified by flash chromatography on silica gel with 2:1 Hexane:EtOAc to afford the title compound as a yellow gum. MS: 235 (M+1). Calc'd. for $C_{12}H_{14}N_2O_3$-234.25.

Preparation XCIV - 3,3-dimethyl-6-nitroindoline:

1-(3,3-Dimethyl-6-nitro-2,3-dihydro-indol-1-yl)ethanone (1.8 g) was dissolved in EtOH (50 mL), 12N HCl (50 mL) was added and the resulting mixture was heated at 70 °C overnight. After the mixture was concentrated in vacuo, it was partitioned between saturated $NaHCO_3$ solution and EtOAc, the resulting organic layer was dried over $MgSO_4$, filtered and concentrated in vacuo to afford a yellow solid. MS: 193 (M+1). Calc'd. for $C_{10}H_{12}N_2O_2$-192.21.

Preparation XCV - 1-Acetyl-6-amino-3,3-dimethylindoline

1-(3,3-Dimethyl-6-nitro-2,3-dihydro-indol-1-yl)ethanone (250 mg) was dissolved in MeOH (20 mL), the mixture was bubbled with H_2 for 10 min. 10% Pd/C (50 mg) was added and the mixture was stirred under H_2 overnight. The mixture was filtered through Celite® and concentrated in vacuo. The crude material was purified by flash chromatography on silica gel with 1:1 EtOAc:CH_2Cl_2 to afford the title compound as a white crystalline material. MS: 205 (M+1). Calc'd. for $C_{12}H_{16}N_2O$-204.27.

Preparation XCVI - 4-(1,1,2,2,3,3,4,4,4-nonafluorobutyl)phenylamine:

4-Nitro-(1,1,2,2,3,3,4,4,4-nonafluorobutyl)benzene was synthesized by a method analogous to that described by Gregory, W. A. et al. (J. Med. Chem, 1990, 33(9) 2569 - 2578). The mixture of the above nitro intermediate (1.0 mmol), iron powder (5.0 mmol) and NH_4Cl (0.7 mmol) in EtOH (3 mL) and H_2O (3 ml) was stirred for 4 h at 80°C. Filtration and concentration gave the crude title compound, which was used without further purification.

Preparation XCVII - 2-bromo-1-*tert*-butyl-4-nitrobenzene:

NBS (125.0 g, 697.5 mmol, 1.5 eq) was slowly added to a solution of TFA:H_2SO_4 (5:1, 750 mL) and *tert*-butyl-4-nitrobenzene (100.0 g, 558.0 mmol) at RT. The solution was stirred for 24 h and poured over 5 kg of ice. The resulting suspension was filtered and washed with a 1:1 MeOH:H_2O solution (200 mL) and dried in a vacuum oven. MS (ES+): 258.1, 260.1 $(M+H)^+$. Calc'd for $C_{10}H_{12}BrNO_2$: 257.0.

Preparation XCVIII - 4-(2-*tert*-butyl-5-nitrophenyl)pyridine:

To a solution of 2-bromo-1-*tert*-butyl-4-nitrobenzene (8.6 g, 33.3 mmol) and toluene (70 mL) in a 150 mL round bottom

flask, 4-pyridylboronic acid (4.5 g, 36.6 mmol, 1.1 eq), $Pd(PPh_3)_4$ (3.8 g, 3.3 mmol, 0.1 eq) and K_2CO_3 (13.8 g, 99.9 mmol,3 eq) were added. The solution was stirred for 24 h at 80°C before cooling to RT. The solution was filtered through a pad of Celite® and purified by silica flash chromatography (30% EtOAc/Hexanes). This afforded the desired compound as a yellow solid. MS (ES+): 257.2 $(M+H)^+$; (ES-): 255.2 $(M-H)^-$. Calc'd for $C_{15}H_{16}N_2O_2$: 256.1.

Preparation XCIX - 4-(2-*tert*-butyl-5-nitrophenyl)-1-methylpyridinium:

4-(2-*tert*-Butyl-5-nitrophenyl)pyridine (2.0 g, 7.8 mmol) was added to a round-bottom flask and dissolved in EtOH (10 mL). CH_3I (30 mL) was added to the flask which was placed in a 80°C sand bath and heated to reflux. After 6 h, the solution was cooled to RT and the excess CH_3I and EtOH were stripped-off under reduced pressure resulting in the desired compound as a light brown solid. MS (ES+): 271.2 $(M+H)^+$; (ES-): 269.2 $(M-H)^-$. Calc'd for $C_{16}H_{19}N_2O_2^+$: 271.1.

Preparation C - 4-tert-butyl-3-(1-methyl-1,2,3,6-tetrahydropyridin-4-yl)aniline:

4-(2-*tert*-Butyl-5-nitrophenyl)-1-methylpyridinium (2.1 g, 7.8 mmol, Step C) was added to a 100 mL round-bottom flask and dissolved in a 10% H_2O/EtOH mixture. To the flask iron dust (1.31 g, 23.4 mmol, 3 eq) and NH_4Cl (460 mg, 8.6 mmol, 1.1 eq) were added. The flask was placed in a 100°C sand bath and heated to reflux. After 2 h, the solution was cooled to RT and filtered through a pad of Celite®. The resulting solution was stripped down to a yellow solid and redissolved in MeOH (20 mL, anhydrous). The solution was cooled to 0°C by placing it in an ice bath and slowly adding $NaBH_4$ (450 mg, 11.7 mmol, 1.5 eq). After addition of the $NaBH_4$, the solution was cooled to RT and stirred for 30 min.

The solvent was stripped-off under vacuum and the solid was redissolved in CH_2Cl_2 and filtered. The solution was concentrated *in vacuo* to afford an amorphous clear yellow solid. MS (ES+): 245.2 $(M+H)^+$. Calc'd for $C_{16}H_{24}N_2$: 244.2.

Preparation CI - [1-(4-amino-phenyl)-ethyl]carbamic acid tert-butyl ester:

A mixture of 1-(S)-1-(4-nitrophenyl)ethylamine hydrochloride (2 g), Boc_2O (2.6 g) and $NaHCO_3$ (3 g) in $MeOH/H_2O$ (1:1, 200 ml) was stirred at RT overnight. The reaction was extracted with EtOAc twice then washed with H2O followed by brine. The organic layer was dried with Na_2SO_4 and evaporated under reduced pressure to give the protected nitrophenyl ethylamine. Boc-1-(S)-1-(4 nitrophenyl)ethylamine (1 g) was hydrogenated by H_2 atmosphere in the presence of Pd/C (200 mg) to give Boc protected aniline (0.8 g). The intermediate was deprotected with 4N HCl/dioxane to give the title compound as the HCl salt.

Preparation CII - 1-[2-(tert-butyl)-5-aminophenyl]-4-methylpiperazine:

A mixture of 2-t-butylaniline (5.4 g) and methylchlorethylamine hydrochloride (7 g) and K_2CO_3 (5 g) in NaI (2 g) in diglyme (150 m) was heated at 170 ºC for 8 h. The reaction was filtered and the filtrate was evaporated under high vacuum. The residue was mixed with EtOAc (200 ml) and H_2O (200 ml) and extracted with EtOAc twice. The combined organic layer was washed with brine and dried over Na_2SO_4 and evaporated to give crude 1-[2-(tert-butylphenyl]-4-methylpiperazine. The crude 1-[2-(tert-butylphenyl]-4-methylpiperazine (260 mg) was stirred with H_2SO_4 (3 ml) at 0ºC and HNO_3 (1.2 ml, 70%) was slowly added to the reaction. The reaction was warmed to RT, stirred for 30 min, poured on ice and basified with K_2CO_3 slowly. The solution was

extracted with EtOAc three times, washed with H_2O, followed by brine, dried over Na_2SO_4 and evaporated under reduced pressure. The residue was purified by column chromatography to give 1-[2-(tert-butyl)-5-nitrophenyl]-4-methylpiperazine (260 mg), which was hydrogenated under H_2 atmosphere to give 1-[2-(tert-butyl)-5-aminophenyl]-4-methylpiperazine.

The following compounds were prepared similarly to the procedure outlined above:

a) 1-(5-aminophenyl)-4-methylpiperazine

Preparation CIII - 4-(tert-butyl)-2-(4-methylpiperazinyl)phenylamine:

A mixture of 1-(tert-butyl)-2-bromo-4-nitrobenzene (3 g) and N-methylpiperazine (8 g) was heated neat at 130 °C for 4 h. The residue was purified by column chromatography to give 1-[4-bromo-5-(tert-butyl)-2-nitrophenyl]-4-methylpiperazine, which was hydrogenated to furnish 4-(tert-butyl)-2-(4-methylpiperazinyl)-phenylamine.

Preparation CIV - {2-[4-(tert-butyl)-2-aminophenoxy]ethyl}dimethylamine:

DEAD (2.6 ml)was added to a mixture of 2-nitro-4-tert-butylphenol (2 g) and N,N-dimethylethanolamine (1.3 g) and Ph_3P (4 g) in THF (50 ml). The reaction was stirred at RT for 1 h, diluted with EtOAc (50 ml) and washed with 1 N HCl twice. The aqueous layer was basified with $NaHCO_3$, extracted with EtOAc twice and washed with H_2O and brine. The organic layer was dried over Na_2SO_4 and evaporated to give {2-[4-(tert-butyl)-2-nitrophenoxy]ethyl}-dimethylamine. It was hydrogenated under H_2 atmosphere to give {2-[4-(tert-butyl)-2-aminophenoxy]ethyl}-dimethylamine.

The following compounds were prepared similarly to the procedure outlined above:

a) [2-(2-aminophenoxy)ethyl]-dimethylamine.

Preparation CV - 2-amino-5,6,7-trihydro-1,2,4-triazolo[3,4-a]isoquinoline:

7-Nitro-2,3,4-trihydroisoquinolin-1-one (500 mg) was heated in $POCl_3$ (10 ml) to reflux for 8 h. The mixture was evaporated, mixed with toluene and evaporated again. The residue was dissolved in THF, H_2NNH_2 (1 ml) was slowly added to the reaction and stirred for 2 h. The reaction was evaporated, heated with $HC(OEt)_3$ (15 ml) at 115°C for 2 h, extracted with EtOAc and hydrogenated to give 2-amino-5,6,7-trihydro-1,2,4-triazolo[3,4-a]isoquinoline.

Preparation CVI - tert-butyl 4-[(6-nitro-3,3-dimethylindolinyl)methyl]piperidinecarboxylate:

3,3-Dimethyl-6-nitroindoline (450 mg) was dissolved in 20 mL of dichloroethane, N-boc-4-formylpiperidine (750 mg) was added to the mixture, followed by 2 g $NaHB(OAc)_3$ and 1 mL of glacial AcOH. The mixture was stirred at RT overnight. Saturated $NaHCO_3$ solution (20 mL) was added to the reaction mixture and stirred for 1 h. The resulting mixture was separated by separation funnel, the organic layer was extracted once with saturated $NaHCO_3$ solution and once with brine. The resulting organic layer was dried over $MgSO_4$, filtered and concentrated in vacuo. The crude material was purified by flash chromatography on silica gel with 9:1 Hexane:EtOAc to afford an orange oil. MS: 290 (M-99). Calc'd. for $C_{21}H_{31}N_3O_4$ - 389.5.

Preparation CVII - 3,3-dimethyl-1-piperidin-4-ylmethyl-2,3-dihydro-1H-indol-6-ylamine:

tert-Butyl 4-[(6-nitro-3,3-dimethylindolinyl)-methyl]piperidinecarboxylate (900 mg) was dissolved in 10 mL MeOH, the mixture was bubbled with H_2 for 10 min. 10% Pd/C (30 mg) was added and the mixture was stirred under H_2 overnight. The mixture was filtered through Celite® and concentrated *in vacuo*. The crude material was purified by flash chromatography on silica gel with 1:1 Hexane:EtOAc to afford a colorless oil. MS: 360 (M+1). Calc'd. for $C_{21}H_{33}N_3O_2$ - 359.5.

Preparation CVIII - (2-chloro-(3-pyridyl))-N-(4-phenoxyphenyl)carboxamide:

2-Chloronicotinoyl chloride (9.15 g, 0.052 mol) was added to a stirred solution of 4-phenoxyaniline (10 g, 0.054 mol) and DIEA (10 ml, 0.057 mol) in CH_2Cl_2 (100 ml) at RT. The mixture was stirred for 48 h before removal of solvent under reduced pressure. The resulting residue was dissolved in EtOAc and washed several times with saturated $NaHCO_3$ aqueous solution and brine, respectively. The organic layer was dried over Na_2SO_4 and evaporated to leave a solid. This material was re-crystallized from EtOAc/Hexane mixture, followed by filtration and rinsing with Et_2O to give the desired compound as a white solid. MS m/z: 325 (M+1); 323 (M-1).

Preparation CIX - 1-(1-methyl(4-piperidyl))-6-nitroindoline:

6-Nitroindoline (5 g) was dissolved in 200 mL of dichloroethane. N-Methyl-4-piperidone (5 g) was added to the mixture, followed by $NaHB(OAc)_3$ (12 g) and 1 mL of glacial AcOH. The mixture was stirred at RT overnight. A saturated $NaHCO_3$ (200 mL) solution was added to the reaction mixture and stirred for 1 h. The resulting mixture was separated by

separation funnel. The organic layer was extracted once with saturated $NaHCO_3$ solution and once with brine. The resulting organic layer was dried over $MgSO_4$, filtered and concentrated in vacuo. The crude material was purified by flash chromatography on silica gel with 2:1 EtOAc:MeOH to afford orange oil. MS: 262 (M+1). Calc'd. for $C_{14}H_{19}N_3O_2$ - 261.3.

Preparation CX - 1-(1-methyl-4-piperidyl)indoline-6-ylamine:

1-(1-Methyl(4-piperidyl))-6-nitroindoline (3 g) was dissolved in 100 mL MeOH and the mixture was bubbled with H_2 for 10 min. 10% Pd/C (200 mg) was added and the mixture was stirred under H_2 overnight. The mixture was filtered through Celite® and concentrated in vacuo to afford light yellow oil. MS: 232 (M+1). Calc'd. for $C_{14}H_{21}N_3$ - 231.3.

Preparation CXI - N-(2-bromo-5-nitrophenyl)acetamide:

2-Bromo-5-nitroaniline (10 g) was dissolved in CH_2Cl_2 (500 mL), DIEA (6.6 g) was added to the mixture, followed by 100 mg of DMAP. The mixture was cooled to 0 °C in ice bath. Acetyl chloride (4 g in 50 mL CH_2Cl_2) was added dropwise to the reaction mixture, which was then stirred at RT over 3 h, and extracted once with saturated $NaHCO_3$ solution and once with brine. The separated organic layer was dried over $MgSO_4$, filtered and concentrated in vacuo. The crude material was purified by flash chromatography on silica gel with 1:1 EtOAc:Hexane to 100% EtOAc to afford a white solid. MS: 258 (M-1). Calc'd. for $C_8H_7BrN_2O_3$ - 259.1.

Preparation CXII - N-(2-bromo-5-nitrophenyl)-N-(2-methylprop-2-enyl)acetamide:

A suspension of NaH (2 g) (95% powder) in 100 mL anhydrous DMF was cooled to -78 °C, and N-(2-bromo-5-nitrophenyl)acetamide (7 g) in 50 mL dry DMF was added to

the mixture under N_2. After the mixture was warmed to 0°C, 3-bromo-2-methylpropene (7.3 g in 20 dry DMF) was added to the mixture. The mixture was stirred at RT overnight. The mixture was poured into a container of ice and extracted between saturated $NaHCO_3$ solution and EtOAc. The resulting organic layer was dried over $MgSO_4$, filtered and concentrated in vacuo. The crude material was purified by flash chromatography on silica gel with 7:2 Hexane:EtOAc to afford a yellow gum. MS: 314 (M+1). Calc'd. for $C_{12}H_{13}BrN_2O_3$ - 313.1.

Preparation CXIII - 1-(3,3-dimethyl-6-nitro-2,3-dihydro-indol-1-yl)ethanone:

N-(2-Bromo-5-nitrophenyl)-N-(2-methylprop-2-enyl)acetamide (4.5 g) was dissolved in 50 mL anhydrous DMF, 2.5 g tetraethyl-ammonium chloride, 1.2 g sodium formate, 3 g sodium acetate were added, the resulting mixture was bubbled with N_2 gas for 10 min. $Pd(OAc)_2$ (350 mg) was added and the mixture was heated at 80 °C under N_2 overnight. After the mixture was concentrated in vacuo, it was extracted between saturated $NaHCO_3$ solution and EtOAc, the resulting organic layer was dried over $MgSO_4$, filtered and concentrated in vacuo. The crude material was purified by flash chromatography on silica gel with 2:1 Hexane:EtOAc to afford a yellow gum. MS: 235 (M+1). Calc'd. for $C_{12}H_{14}N_2O_3$ - 234.2.

Preparation CXIV - 3,3-dimethyl-6-nitroindoline:

1-(3,3-Dimethyl-6-nitro-2,3-dihydro-indol-1-yl)ethanone (1.8 g) was dissolved in 50 mL EtOH, 50 mL 12N HCl was added and the resulting mixture was heated at 70 °C overnight. After the mixture was concentrated in vacuo, it was extracted between saturated $NaHCO_3$ solution and EtOAc. The resulting organic layer was dried over $MgSO_4$, filtered and

concentrated in vacuo to afford a yellow solid. MS: 193 (M+1). Calc'd. for $C_{10}H_{12}N_2O_2$ - 192.2.

Preparation CXV - 3,3-dimethyl-1-(4-methyl-piperazin-1-yl)-6-nitro-2,3-dihydro-1H-indole:

3,3-Dimethyl-6-nitroindoline (0.8 g) was dissolved in 50 mL of dichloroethane, N-methyl-4-piperidone (1 g) was added to the mixture, followed by 2.5 g $NaHB(OAc)_3$ and 1 mL of glacial AcOH. The mixture was stirred at RT overnight. Saturated $NaHCO_3$ solution (50 mL) was added to the mixture and stirred for 1 h. The resulting mixture was separated by separation funnel, the organic layer was extracted once with saturated $NaHCO_3$ solution and once with brine, the resulting organic layer was dried over $MgSO_4$, filtered and concentrated in vacuo. The crude material was purified by flash chromatography on silica gel with 9:1 EtOAc:MeOH to afford an orange oil. MS: 290 (M+1). Calc'd. for $C_{16}H_{23}N_3O_2$ - 289.4.

Preparation CXVI - 3,3-dimethyl-1-(1-methyl(4-piperidyl))indoline-6-ylamine:

3,3-Dimethyl-1-(4-methyl-piperazin-1-yl)-6-nitro-2,3-dihydro-1H-indole (600 mg) was dissolved in 20 mL MeOH, the mixture was bubbled with H_2 for 10 min. 10% Pd/C (100 mg) was added and the mixture was stirred under H_2. The mixture was filtered through Celite® and concentrated in vacuo to afford an oil. MS: 260 (M+1). Calc'd. for $C_{16}H_{25}N_3$ - 259.4.

Preparation CXVII - 3-(1-methyl-1,2,3,6-tetrahydro-pyridin-4-yl)-5-nitro-1H-indole:

5-Nitroindole (2.6 g) was dissolved in 100 mL anhydrous MeOH, followed by 5 g N-methyl-4-piperidone and NaOMe (5 g) powder. The mixture was heated to reflux under N_2 overnight. The mixture was concentrated in vacuo, and was extracted

between saturated $NaHCO_3$ solution and EtOAc. The resulting organic layer was dried over $MgSO_4$, filtered and concentrated in vacuo to afford a yellow solid. This solid was washed with 5 mL EtOAc and 2 mL MeOH to afford a bright yellow solid. MS: 258 (M+1). Calc'd. for $C_{14}H_{15}N_3O_2$ - 257.29.

Preparation CXVIII - 3-(1-methyl-4-piperidyl)indole-5-ylamine:

3-(1-Methyl-1,2,3,6-tetrahydro-pyridin-4-yl)-5-nitro-1H-indole (2.7 g) was dissolved in 50 mL MeOH, the mixture was bubbled with H_2 for 10 min. 10% Pd/C (150 mg) was added and the mixture and stirred under H_2 overnight. The mixture was filtered through Celite® and concentrated in vacuo to afford a yellow oil. MS: 230 (M+1). Calc'd. for $C_{14}H_{19}N_3$ - 229.3.

Preparation CXIX - {3-[3-amino-5-(trifluoromethyl)phenyl]propynyl}dimethylamine:

A mixture of 3-bromo-5-trifluoromethylaniline (1.4 g, 5.9 mmol), 1-dimethylamino-2-propyne (1.3 mL, 0.76 mmol), $PdCl_2(PPh_3)_2$ (0.26 g, 0.29 mmol) and CuI (114 mg, 0.60 mmol) in 10 mL of TEA was heated at 100 °C in a sealed tube for 3 h. The resulting mixture was filtered over Celite®. The filtrate was concentrated, and the residue was purified by prep-HPLC (reverse phase) to give the aniline. MS (ES+): 243 $(M+H)^+$; (ES-): 241 $(M-H)^-$. Calc'd $C_{12}H_{13}F_3N_2$ - 242.24.

Preparation CXX - {3-[3-amino-5-(trifluoromethyl)phenyl]propyl}dimethylamine:

A mixture of {3-[3-amino-5-(trifluoromethyl)-phenyl]propyl}dimethylamine (7 g, 29 mmol) and $Pd(OH)_2$ (0.5 g)in 250 mL of MeOH was stirred under 50 psi H_2. After 2 h, the resulting mixture was filtered over Celite®. The filtrate was concentrated, and the residue was diluted with aq. 1N HCl. The aq. layer was washed with Et_2O, made basic

with aq. 5N NaOH, and extracted with CH_2Cl_2. The organic solution was dried over Na_2SO_4 and concentrated to give the titled compound. MS (ES+): 386 $(M+H)^+$; (ES-): 384 $(M-H)^-$. Calc'd $C_{18}H_{19}ClF_3N_3O$ - 385.8.

Preparation CXXI - 4,4,5,5-tetramethyl-2-(1-methyl(4-1,2,5,6-tetrahydropyridyl))-1,3,2-dioxaborolane:

To a solution of LiHMDS (25 mL, 25 mmol, 1.0 M in THF) in 35 mL of THF was added 1-methyl-4-piperidinone (3.0 mL, 25 mmol) at -78 °C. The resulting solution was stirred for 2 h, then Tf_2NPh (8.9 g, 25 mmol) was added. The resulting solution was warmed to RT and stirred for 2 h. The mixture was concentrated, and the residue was purified by alumina (neutral) chromatography to give 1-methyl-4-(1,2,5,6-tetrahydro)pyridyl-(trifluoromethyl) sulfonate. A mixture of above triflate (5.0 g, 20 mmol), bis(pinacolato)diboron (5.6 g, 22 mmol), potassium acetate (6.5 g, 66 mmol), $PdCl_2$dppf (0.44g, 0.6mmol), and (dppf)2 (0.33g, 0.6 mmol) in 60 mL of dioxane was heated at 80 °C for 4 h. The resulting mixture was cooled to RT, diluted with Et_2O (150 mL). The ethereal solution was washed with H_2O followed by brine. The organic layer dried over Na_2SO_4, concentrated, and recrystallized in hexane-Et_2O to give the title intermediate.

Preparation CXXII - 5-(1-methyl(4-1,2,5,6-tetrahydropyridyl))-3-(trifluoro-methyl)phenylamine:

To a mixture of 4,4,5,5-tetramethyl-2-(1-methyl(4-1,2,5,6-tetrahydropyridyl))-1,3,2-dioxaborolane (1.0 g, 4.4 mmol), $PdCl_2$pddf (0.16 g, 0.2 mmol)and K_2CO_3 (1.8g, 13.2 mmol) and 3-amino-5-bromobenzotrifluoride (0.8g, 3.3 mmol) in DMF (25 mL) was heated at 80°C for 16 h. The resulting mixture was diluted with EtOAc, washed with H_2O, dried over Na_2SO_4, and concentrated. The residue was purified by SiO_2

chromatography to give the title intermediate. MS (ES+): 257 $(M+H)^+$. Calc'd $C_{13}H_{15}F_3N_2$ - 256.3.

Preparation CXXIII - 4-phenylpiperidine:

4-Cyano-4-phenylpiperidine HCl (10.0 g, 45.0 mmol) was combined with KOH pellets and stirred vigorously under Ar at 160°C for 4 h. The reaction mix was cooled to RT and dissolved into toluene (100 ml) and H_2O (100 ml). After separation of the layers, the aqueous layer was back-extracted two times with toluene. The combined organic layer was dried over Na_2SO_4, concentrated *in vacuo*, and dried under high vacuum, yielding a white solid.

Preparation CXXIV - 1-methyl-4-phenylpiperidine:

To a stirring mixture at RT of 4-phenylpiperidine (5.24 g, 32.48 mmol) in CH_3CN (95 ml) was added a 37% solution of HCHO in H_2O (13 ml). To this mixture was added $NaCNBH_3$ (3.27 g, 51.97 mmol). AcOH was added dropwise every 10 min over the next h to maintain the reaction pH near 7. The reaction volume was then reduced *in vacuo*. The reaction mix was diluted with CH_2Cl_2 and washed with 2N NaOH and then brine. The crude was concentrated *in vacuo* and eluted through a silica gel column with 10% MeOH/CH_2Cl_2. The 1-methyl-4-phenylpiperidine was concentrated *in vacuo*, yielding a clear oil.

Preparation CXXV - 4-(1-methyl-4-piperidyl)phenylamine:

To 1-methyl-4-phenylpiperidine (2.663 g, 15.19 mmol) was added carefully H_2SO_4 (15.2 ml). The reaction was cooled in an ice bath and a solution of H_2SO_4 (1.66 ml) and fuming HNO_3 (0.67 ml, 15.95 mmol) was added dropwise over 45 min. The mix was stirred at 0°C for 3 h then at RT for 1.5 h before being poured over about 90 g ice and basified with 24 g solid NaOH. The mix was extracted with CH_2Cl_2. The organic

layer was washed with H_2O, dried over Na_2SO_4, and concentrated *in vacuo*. The crude was eluted on a silica gel column with a MeOH/CH_2Cl_2 gradient to yield 1-methyl-4-(4-nitrophenyl)piperidine which was hydrogenated under H_2 to furnish the title compound.

Preparation CXXVI - 1-piperidylprop-2-en-1-one:
To a 0°C solution of acryloyl chloride (4.576 g, 50.558 mmol) in CH_2Cl_2 (50 ml) was added dropwise and very carefully piperidine (4.305 g, 50.558 mmol). The reaction flask was vented during the exothermic addition. After the addition was completed, the white slurry was stirred at 0°C for 40 min and at RT for 1 h. The reaction was diluted with 70 ml CH_2Cl_2 and washed first with about 60 ml 2N HCl and then with about 60 ml of a mix of 2N NaOH and brine. The organic layer was dried over Na_2SO_4. The solution was evaporated by heating in a H_2O bath at 60°C without vacuum. Once most solvent had been evaporated off, dried the clear oil under high vacuum at RT for 30 min.

Preparation CXXVII - 1-(tert-butyl)-2-bromo-4-nitrobenzene:
Bromine (17.4 ml) was added dropwise over 40 min to a stirred mixture of 4-tert-butylnitrobenzene (59.5 g, 332 mmol), silver(II)sulfate (56.5 g, 181 mmol), H_2SO_4 (300 ml), and H_2O (33 ml) at RT. The mixture was stirred for a further 3 h and then poured into 0.1 M $Na_2S_2O_5/H_2O$ (1L). The solid was filtered, washed with H_2O, Et_2O, and CH_2Cl_2. The filtrate layers were separated. The aqueous fraction was extracted with Et_2O. The combined organic layers were combined, dried over Na_2SO_4, and concentrated *in vacuo*. The yellow solid was triturated with hexanes to give a pale yellow crystalline solid.

Preparation CXXVIII - (2E)-3-[2-(tert-butyl)-5-nitrophenyl]-1-piperidylprop-2-en-1-one:

1-(tert-Butyl)-2-bromo-4-nitrobenzene (6.885 g, 26.674 mmol), 1-piperidylprop-2-en-1-one (4.827 g, 34.677 mmol), and TEA (7.44 ml, 53.35 mmol) were dissolved in toluene (70 ml). To this solution was added $Pd(OAc)_2$ (60 mg, 0.267 mmol) and $Pd(PPh_3)_4$ (617 mg, 0.5335 mmol). The mix was degassed with N_2 and heated in a sealed vessel at 120 °C for 15 h. The reaction mixture was cooled to RT, filtered, and concentrated *in vacuo*. The dark crude oil was eluted through a silica gel column with 15% to 22% EtOAc/hexanes gradient system to yield a viscous, amber-colored oil as the title compound.

Preparation CXXIX - 3-(5-amino-2-tert-butylphenyl)-1-piperidin-1-yl-propenone:

(2E)-3-[2-(tert-Butyl)-5-nitrophenyl]-1-piperidylprop-2-en-1-one (3.22 g, 10.177 mmol) was dissolved in dioxane (20 ml) and IpOH (40 ml). To the N_2-degassed solution was added Pd/C 10% by weight catalyst (2 g). The mix was placed in a Parr hydrogenator and stirred for 18 h under 60 psi H_2. The reaction was not complete the next day, so the reaction was continued for an additional 20 h with fresh catalyst. The mix was filtered through Celite® and concentrated *in vacuo* to give a foamy oil.

Preparation CXXX - 4-(tert-butyl)-3-(3-piperidylpropyl)phenylamine:

3-(5-Amino-2-tert-butylphenyl)-1-piperidin-1-yl-propenone (2.312 g, 7.619 mmol) was dissolved in THF (100 ml) at RT. To this solution was added $LiAlH_4$ (434 mg, 11.43 mmol). After the exothermic reaction stopped, the reaction mixture was heated at reflux at about 80°C for 4 h. The reaction mixture was cooled to 0°C and treated by dropwise addition

of 0.458 ml H_2O, 0.730 ml 10% aqueous NaOH, and 1.19 ml H_2O, respectively. The mixture was stirred at RT for 1 h. After 40 min about 3 g of Na_2SO_4 was added. The mixture was filtered through Celite® and concentrated *in vacuo*. The crude was eluted through silica gel column with a gradient system of 95:5 to 90:10 CH_2Cl_2/MeOH, to yield a thick, amber-colored oil as the title compound.

The following compounds were prepared similarly to the procedure outlined above:

a) 3-((1E)-4-Pyrrolidinylbut-1-enyl)-4-(tert-butyl)phenylamine.

b) 4-(tert-Butyl)-3-(3-pyrrolidinylpropyl)phenylamine.

c) 4-(tert-Butyl)-3-(3-morpholin-4-ylpropyl)phenylamine.

d) 3-[3-(4-methylpiperazinyl)propyl]phenylamine.

e) 4-[3-(4-methylpiperazinyl)propyl]phenylamine.

Preparation CXXXI - 3-(3-nitrophenyl)-1-(4-methylpiperazinyl)propan-1-one:

A slurry consisting of CH_2Cl_2 (15 ml), 3-nitrocinnamic acid (3.154 g, 16.329 mmol), 1-methylpiperazine (1.487 g, 14.845 mmol) and EDC (3.557 g, 18.556 mmol) were stirred at RT for 60 h. The reaction was diluted with H_2O and EtOAc. The aqueous layer was back-extracted with EtOAc. The combined organic layers were washed with 2N NaOH and then brine, dried over Na_2SO_4, and concentrated *in vacuo*. The crude was eluted through a silica gel column with 5% MeOH/CH_2Cl_2, to yield an off-white solid, mostly trans-olefin compound.

Preparation CXXXII - 3-(3-aminophenyl)-1-(4-methylpiperazinyl)propan-1-one:

To a nitrogen-degassed solution of 3-(3-nitrophenyl)-1-(4-methylpiperazinyl)propan-1-one (3.67 g, 13.330 mmol, Step A) in MeOH (50 ml) was added 10% by weight Pd/C (500 mg). The mix was stirred under H_2 atmosphere for 18 h then filtered through Celite® and concentrated *in vacuo*, yielding a thick amber oil which eventually solidified into a dark pink solid.

The following compounds were prepared similarly to the procedure outlined above:

a) 4-[3-(4-methylpiperazinyl)-3-oxopropyl]phenylamine.

Preparation CXXXIII - 1-(2-morpholin-4-ylethyl)indol-6-ylamine:

K_2CO_3 (5.08 g, 36.726 mmol) was added to a slurry of 6-nitroindole (1.985 g, 12.242 mmol), 4-(2-chloroethyl) morpholine.HCl (2.278 g, 12.242 mmol), and CH_3CN (100 ml). The mix was heated to reflux for 18 h, then cooled to RT, filtered, and concentrated *in vacuo*. The crude was eluted through a silica gel column with a gradient of 3:97 to 5:95 and finally 8:92 MeOH/CH_2Cl_2, to yield upon drying the desired intermediate which was hydrogenated under conditions previously described.

Preparation CXXXIV - methyl 2-methyl-2-(4-nitrophenyl)propanoate:

To a stirred solution of 2-(4-nitrophenyl)propionic acid (9 g, 46 mmol, 1 eq) in MeOH (300 mL) was added HCl (4M in Dioxane, 11.5 mL, 46 mmol, 1 eq). The mixture was stirred at RT overnight and was quenched with aqueous $NaHCO_3$. The mixture was extracted with EtOAc. The organic layer was dried over $MgSO_4$ and evaporated under reduced pressure and

the partial residue (4.34 g, 20.7 mmol, 1eq) at 0°C in THF (100 mL) was added NaH (1.66 g, 41.5 mmol, 2 eq). Mixture was stirred at RT for 1h and CH_3I (2.58 g, 41.5 mmol, 2 eq) was added. Reaction was stirred at RT overnight and was quenched with H_2O. Mixture was extracted with EtOAc. The organic layer was dried over $MgSO_4$ and evaporated under reduced pressure and used for the next step without further purification to give title compound.

Preparation CXXXV - 3-methyl-3-(4-nitrophenyl)butan-1-one: To a stirred solution of methyl 2-methyl-2-(4-nitrophenyl)propionate (5.32 g, 23.8 mmol) in THF (200 mL) at 0°C was added a solution of 1M BH_3 in THF (25.8 mL, 45.8 mmol). The reaction was stirred at RT overnight and was quenched with MeOH. THF was evaporated under reduced pressure and the residue was diluted in EtOAc and aqueous HCl (1M) was added. The mixture was extracted with EtOAc, the organic layer was dried over $MgSO_4$ and evaporated under reduced pressure. Purification by flash chromatography using 40% EtOAc-hexane gave a yellow solid. To the yellow solid (2.08 g, 10.8 mmol) at 0°C in CH_2Cl_2 was added NMO (1.9 g, 16.1 mmol), molecular sieves 4Å and TPAP (76 mg, 0.2 mmol). The reaction was stirred for 1h and filtered on a silica pad. Solvent was evaporated under reduced pressure, forming the crude aldehyde which was used as is. To a suspension of methoxymethyltriphenylphosphonium chloride (6.4 g, 18.6 mmol) in THF (150 mL) was added a solution of KHMDS 0.5 M in toluene (37 mL, 18.5 mmol). The mixture was stirred for 30 min and crude aldehyde was added. The reaction was stirred at RT for 1h and quenched with H_2O. The mixture was extracted with EtOAc, dried and evaporated under reduced pressure. Et_2O was added and a precipitate formed, which was filtered on a silica pad and rinsed with

40% EtOAc-hexane. The solvent was removed and crude material was dissolved in CH_2Cl_2. A solution of TFA-H_2O (1:1, 10 mL) was added and the reaction was stirred for 2 h at RT. Aqueous $NaHCO_3$ was added until pH 7 and the mixture was extracted with CH_2Cl_2. The organic layer was dried, filtered and evaporated. Crude compound was purified by flash chromatography (40% EtOAc-hexane) to give the title compound as a yellow oil.

Preparation CXXXVI - 4-(1,1-dimethyl-3-morpholin-4-ylpropyl)phenylamine: To a stirred solution of 3-methyl-3-(4-nitrophenyl)butan-1-one (509 mg, 2.4 mmol) and morpholine (0.21 mL, 2.4 mmol) in THF (30 mL) was added $NaBH(OAc)_3$ (0.73 g, 3.4 mmol). The mixture was stirred at RT overnight and washed with HCl (1M). CH_2Cl_2 was added and the layers were separated. The aqueous layer was basified to pH 9 using NaOH 1M and extracted with CH_2Cl_2. The organic layer was dried and evaporated the nitro compound. To a solution of the nitro compound (0.50 g, 1.8 mmol) in THF (40 mL) was added AcOH (1.97 mmol, 34.5 mmol) followed by zinc (9.1 g, 137 mmol). The mixture was stirred for 1 h, filtered on Celite®, diluted with H_2O and aqueous $NaHCO_3$, and the THF layer was evaporated. The residue was extracted with EtOAc, dried and evaporated to give the title compound.

Preparation CXXXVII - 4-{2,2,2-trifluoro-1-[2-(2-methoxy)ethoxy]-1-(trifluoromethyl)ethyl}phenylamine: Diethyl azodicarboxylate (366 mg, 2.1 mmol) was added dropwise to a solution of 2-(4-aminophenyl)-1,1,1,3,3,3-hexafluoropropan-2-ol (520 mg, 2 mmol), 2-(2-methoxyethoxy)ethan-1-ol (240 mg, 2 mmol) and PPh_3 (550 mg, 2.1 mmol) in THF (10 mL). The mixture was stirred for 2 h, then partitioned between EtOAc and aqueous $NaHCO_3$ solution. The organic phase was washed with brine. After

concentration in vacuo, the organic residue was purified by flash chromatography on silica to give the compound. MS: 362 (M+1). Calc'd. for $C_{14}H_{17}F_6NO_3$ - 361.29.

Preparation CXXXVIII - 2-fluoropyridine-3-carbonyl chloride: To a solution of 2-fluoropyridine (10 g, 100 mmol) in THF (150 mL) under -78°C was added an LDA solution (2M in heptane/THF/ethylbenzene, 60 mL) dropwise. The mixture was stirred at -78°C for 3 h, then was quenched with a stream of dry CO_2. After warming to RT, the mixture was partitioned between EtOAc (100 mL) and H_2O (200 mL). The aqueous layer was acidified to pH between 3-4, and extracted with EtOAc. The organic solution was collected and washed with brine and dried over Na_2SO_4. After removing the solvent in vacuum, 2-fluoropyridine-3-carboxylic acid was obtained as a brown oil. MS: 140 (M-H). Calc'd. for $C_6H_4FNO_2$ - 141.10. 2-Fluoropyridine-3-carboxylic acid (7 g) was suspended in $SOCl_2$ (100 mL). After heating under reflux for 2 h, the mixture became homogeneous. Access $SOCl_2$ was removed in vacuo to afford a brown solid as desired compound.

Preparation CXXXIX - N-(3-Amino-5-chloro-phenyl)-2-dimethylamino-acetamide: To a solution of 5-chloro-benzene-1,3-diamine (3 g, 21 mmol) and dimethylamino-acetic acid (2.2 g, 21 mmol) in CH_2Cl_2 (300 mL) was added EDC (5 g, 25 mmol), HOBt (2.9 g, 21 mmol), and DIEA (5 mL). The reaction mixture was stirred at RT for overnight. Solvent was removed in vacuum and the residue was purified through flash chromatography on silica gel (0-8% MeOH in EtOAc) to give the desired compound.

Preparation CXL - 2-amino-4-nitro-benzamide: To a solution of 2-amino-4-nitro-benzoic acid (9.1 g, 50 mmol) in CH_2Cl_2 (500 mL) was added EDC (12 gram, 60 mmol),

HOBt (6.8 g, 50 mmol), DIEA (12 mL), and NH_3 in MeOH (2M, 40 mL). The reaction was stirred at RT for overnight, and a precipitation formed. The solid was isolated via vacuum filtration.

Preparation CXLI - 6-nitro-3H-quinazolin-4-one:
2-Amino-4-nitro-benzamide was suspended in triethyl orthoformate (50 mL) and the mixture was heated to 140°C for 5 h. Excess reagent was removed in vacuum. The residue was washed in hexanes to give the compound as a yellow solid.

Preparation CXLII - 6-amino-3H-quinazolin-4-one:
Hydrogenation of 6-nitro-3H-quinazolin-4-one (2 g) in EtOH (200 mL) was catalyzed by Pd/c (10%, 200 mg) under a H2 balloon for 1 h. MeOH (200 mL) was added to the mixture. The suspension was filtered through a layer of Celite® and the filtrate was concentrated in vacuum to give the desired compound.

Preparation CXLIII - (2,4-dinitro-phenyl)-acetic acid methyl ester:
To a solution of (2,4-dinitro-phenyl)-acetic acid (5 g) in MeOH (100 mL) was added concentrated H_2SO_4 (1 mL) and the resulting solution was heated at reflux for overnight. After removing solvent in vacuum, the residue was partitioned between EtOAc and aqueous $NaHCO_3$ (sat.). The organic solution was concentrated in vacuum to give the desired compound which was used without further purification.

Preparation CXLIV - 6-amino-1,3-dihydro-indol-2-one:
An EtOH solution of (2,4-dinitro-phenyl)-acetic acid methyl ester was treated with H2 balloon and catalyzed with Pd/c (10%, 500 mg) at RT. The resulting mixture was filtered

through a layer of Celite® and concentrated in vacuum to afford the desired compound.

Preparation CXLVI - 3-Methyl-but-2-enoic acid (6-bromo-pyridin-2-yl)-amide:

To a solution of 2-amino-6-bromopyridine (3.015 g, 0.017 mol) and Et_3N (2.40 mL, 0.017 mol) in CH_2Cl_2 (20.0 mL), was added 3,3-dimethylacryloylchloride (1.96 mL, 0.017 mol) under N_2 at 0 °C. The mixture was slowly warmed to RT and stirred for 12 h. The reaction was quenched by the addition of H_2O (20.0 mL), the organic layer was separated, dried over Na_2SO_4 and evaporated to dryness to yield crude compound which was used without purification.

Preparation CXLVI - 3-Methyl-but-2-enoic acid (6-amino-pyridin-2-yl)-amide:

To a solution of 3-methyl-but-2-enoic acid (6-bromo-pyridin-2-yl)-amide (4.30 g, 0.017 mol) and copper (0.214 g, 3.372 mmol) in IpOH (20.0 mL), was added NH_4OH (20.0 mL) in a sealed vessel under N_2. The reaction was sealed and heated to 90 °C for 12 h. The reaction mixture was cooled to RT and EtOAc (50.0 mL) was added. The organic layer was separated, and then the aq layer was washed with EtOAc (50.0 mL). Combined organic layers were evaporated to dryness, the resulting residue was dissolved in CH_2Cl_2 (50.0 mL) and washed with H_2O (4 x 30 mL). The organic layer was dried over Na_2SO_4 and evaporated to dryness to yield crude aminopyridine, which was used without purification.

Preparation CXLVII - 7-Amino-4,4-dimethyl-3,4-dihydro-1H-[1,8]naphthyridin-2-one:

To a mixture of aminopyridine (1.12 g, 5.833 mmol) and $AlCl_3$ (3.11 g, 0.023 mol) was added chlorobenzene (10.0 mL) in a sealed vessel under Ar. The reaction was sealed and heated

to 120 °C for 12 h. The reaction mixture was cooled to RT and the mixture was poured over ice/HCl mixture and extracted with EtOAc (3 x 50.0 mL). The aqueous layer was neutralized via addition of solid $NaHCO_3$ and extracted with EtOAc (5 x 50 mL). Combined organic layers were dried over Na_2SO_4 and evaporated to dryness to yield crude compound. Chromatography (Silica gel, CH_2Cl_2:MeOH, 99:1) yielded pure naphthyridin.

Preparation CXLVIII - 2-[1-(3-Amino-phenyl)-2,2,2-trifluoro-1-trifluoromethyl-ethoxymethyl]-pyrrolidine-1-carboxylic acid tert-butyl ester:

To a mixture of 2-(3-amino-phenyl)-1,1,1,3,3,3-hexafluoro-propan-2-ol (1.30 g), 2-hydroxymethyl-pyrrolidine-1-carboxylic acid tert-butyl ester (1.04 g), PPh_3 (2.64 g) and molecular sieves 4 Å in THF (100 mL) was added diethyl diazocarboxylate (1.55 mL) slowly. The reaction was stirred at RT for 4h and at reflux for overnight. After filtration to remove solids, the filtrate was concentrated and the residue was taken into Et_2O. The organic phase was washed with saturated $NaHCO_3$ and brine. The organic layer was dried over $MgSO_4$ and evaporated to give a crude compound as very viscous brown oil, which was purified by chromatography through silica gel (500 g, 30% to 50% EtOAc in hexanes) to afford 2-[1-(3-amino-phenyl)-2,2,2-trifluoro-1-trifluoromethyl-ethoxymethyl]-pyrrolidine-1-carboxylic acid tert-butyl ester as a light brown oil.

Preparation CXLIX - Pyrimidine-4-carbaldehyde oxime:

9.14 g (97.11 mmol) of 4-methylpyrimidine was slowly added to a 0^0C solution of 8.75 g HCl in 40 ml EtOH. To this white suspension was added, over 5 min, 61 ml of a 10-20% by weight solution of ethyl nitrite in EtOH. The reaction was stirred at 0 °C for 10 min and then at RT for 2.5 h. The

white salt was filtered and dried under vacuum. The salt was dissolved into 20 ml H_2O and very slowly treated with about 200 ml saturated aqueous $KHCO_3$. A white solid precipitated out of the purple solution. The solid was filtered and dried under vacuum to yield the titled compound.

Preparation CL - C-Pyrimidin-4-yl-methylamine dihydrogen chloride:

To a solution of 3.549 g (28.82 mmol) pyrimidine-4-carbaldehyde oxime in 200 ml MeOH was added after degassing with Ar, 800 mg of 10% by weight Pd/C. The mix was stirred under H_2 for 4 h, then filtered through a Celite® plug. The solution was concentrated under vacuum to a volume of about 50 ml and then treated carefully with 30 ml of 4N HCl in dioxane. The mix was concentrated and dried under vacuum to yield the titled compound as a pink solid.

Preparation CLI - 2-(2,4-Dinitro-phenyl)-3,3,3-trifluoro-2-trifluoromethyl-propionic acid methyl ester:

A mixture of 7.08 g (38.07 mmol) 2,4-dinitrofluorobenzene, 2.43 g (41.88 mmol) KF, and 0.58 g (2.21 mmol) 18-crown-6-ether in 37 ml sulfolane was added 4.00 g (19.04 mmol) methyl 2-(trifluoromethyl)-3,3,3-trifluoropropionate dropwise over about 7 h via syringe pump. After the addition was complete, another 2.43 g KF, 0.58 g 18-Crown-6-ether were added and then 4.00 g Methyl 2-(trifluoromethyl)-3,3,3-trifluoropropionate were added dropwise over 12 h. The next day, repeated additions using same amounts and setting syringe pump addition over 14 h. The following day, the additions were again repeated, this time using half the amounts as above additions and setting syringe pump addition at 12 h. After addition was completed, the reaction mix was cooled to RT and diluted into Et_2O and 0.5N

aqueous HCl. The layers were separated, and the organic layer was washed with brine, dried over Na_2SO_4, filtered and concentrated under vacuum. The crude was eluted on a silica gel column with EtOAc/hexanes gradient, to yield the titled compound, as a yellow solid.
[See Vlasov et al.; J.Org. Chemistry USSR (Engl. Trans.); 15; 1979; 1953-1964).]

Preparation CLII - 6-Amino-1-hydroxy-3,3-bis-trifluoromethyl-1,3-dihydro-indol-2-one:
To an argon-degassed solution of 5.13 g (13.64 mmol) 2-(2,4-dinitro-phenyl)-3,3,3-trifluoro-2-trifluoromethyl-propionic acid methyl ester in 300 ml EtOH was added 0.5 g of 10% by weight Pd/C. The reaction was stirred under H_2 overnight and filtered through Celite®, concentrated down, and dried under vacuum, yielding the titled compound.

Preparation CLIII - 6-Amino-3,3-bis-trifluoromethyl-1,3-dihydro-indol-2-one:
To a solution of 1.245 g (4.151 mmol) 6-amino-1-hydroxy-3,3-bis-trifluoromethyl-1,3-dihydro-indol-2-one in 80 ml THF was added 3.565 ml (62.27 mmol) glacial AcOH and 19 g (290.6 mmol) Zinc dust (100 mesh). The reaction was stirred 40 min at RT and then 5 h at reflux. The reaction was cooled to RT. The solvent was decanted and concentrated, then dissolved in EtOAc and filtered through Celite®. The EtOAc solution was then washed with saturated aqueous $NaHCO_3$ and brine, dried over Na_2SO_4, filtered, and concentrated and dried under vacuum, to yield the titled compound, as a yellow solid.

Preparation CLIV - N-[3-(2-Amino-ethoxy)-4-pentafluoroethyl-phenyl]-2-chloro-nicotinamide:

To a solution of 500 mg (0.98 mmol) Boc-N-[3-(2-Amino-ethoxy)-4-pentafluoroethyl-phenyl]-2-chloro-nicotinamide in 10 ml CH_2Cl_2 was added 10 ml TFA and stirred for 2 h. The reaction was concentrated down, treated with 6N aqueous NaOH, and extracted 3 times with CH_2Cl_2. The combined organic extracts were dried over Na_2SO_4, filtered, concentrated down, and dried under vacuum, yielding the titled compound.

Preparation CLV - 2-Chloro-N-[3-(2-methanesulfonylamino-ethoxy)-4-pentafluoroethyl-phenyl]-nicotinamide:

To a solution of 381 mg (0.93 mmol) N-[3-(2-amino-ethoxy)-4-pentafluoroethyl-phenyl]-2-chloro-nicotinamide in 10 ml CH_2Cl_2 at 0 °C was added 0.389 ml Et_3N and 0.072 ml (0.93 mmol) methanesulfonylchloride. After 5 min, the reaction was stirred at RT for 30 min. The reaction was diluted with CH_2Cl_2, washed with brine, dried over Na_2SO_4, filtered, concentrated, and dried under vacuum, yielding the titled compound as a white foamy solid.

Preparation CLVI - 2-Methyl-2-(4-nitro-phenyl)-propionic acid:

To a solution of 2-(4-nitro-phenyl)-propionic acid (50 g, 0.26 mole) in 250 mL of MeOH was added 6 mL of concentrated HCl. The resulting solution was heated at reflux for 16 h. Then the resultant mixture was diluted with 200 mL of aq. $NaHCO_3$ and 500 mL of EtOAc. The organic layer was separated, dried over Na_2SO_4, and concentrated. The residue was diluted with 100 mL of THF and added to a suspension of NaH (11.2 g, 0.28 mole, 60% in mineral oil) in 600 mL of THF. To the resulting mixture was added CH_3I (18.3 mL, 0.29 mole) in one portion. The resulting mixture was stirred for

48 h at 40 °C, then was diluted with aq. NH_4Cl solution and EtOAc. The organic layer was separated, dried over Na_2SO4, and concentrated. The residue was used without further purification.

To a solution of the residue (54 g, 0.24 mole) in 500 ml of MeOH was added 5N aq. NaOH (144 mL, 0.72 mole). The mixture was stirred for 16 h at 40 °C. The resulting mixture was concentrated, the residue was diluted with H_2O (500 mL), and acidified with 2N HCl to give a precipitate. The precipitate was filtered and dried to give the titled compound as a yellowish solid. MS: 210 (M+1), Calc'd for $C_{10}H_{12}NO_4$- 210.20.

Preparation CLVII - 2-Methyl-5-[1-methyl-1-(4-nitro-phenyl)-ethyl]-[1,3,4]oxadiazole:

A mixture of 2-methyl-2-(4-nitro-phenyl)-propionic acid (5 g, 24 mmol.) and a few drops of DMF in $SOCl_2$ was stirred at reflux for 16 h. The resulting solution was concentrated to give corresponding acid chloride as a brown solid.

To a mixture of the acid chloride (2.33 g, 10.2 mmol), acetic acid hydrazide (0.91 g, 12.2 mmol.), Et_3N (2.86 mL, 20.2 mmol.) in CH_2Cl_2 (50 mL) was added 2 crystals of DMAP at RT. The mixture was stirred for 16 h and concentrated. A solution of the residue in 50 mL of phosphorous oxychloride was heated at 95°C for 16 h. The mixture was concentrated and diluted with ice-water and EtOAc. The organic layer was washed with saturated aq. $NaHCO_3$ solution twice, dried over Na_2SO_4, and concentrated. The residue was purified by SiO_2 chromatography (hexane: EtOAc=1:1) to give the titled compound as a pale yellow crystal. MS: 248 (M+1), Calc'd for $C_{12}H_{14}N_3O_3$-248.10.

Preparation CLVIII - 2-Methyl-5-[1-methyl-1-(4-amino-phenyl)-ethyl]-[1,3,4]oxadiazole:

A mixture of 2-methyl-5-[1-methyl-1-(4-nitro-phenyl)-ethyl]-[1,3,4]oxadiazole (1.36 g, 5.5 mmol.) and Pd/C (68 mg) in EtOAc (50 mL), was stirred under 1 atm of H_2 for 16 h. The resultant was filtered over Celite®, and the filtrate was concentrated to give the titled compound as a pale yellow crystalline. MS: 218 (M+1) calc'd for $C_{12}H_{16}N_3O$-218.12.

Preparation CLIX - 4-[1-Methyl-1-(4-nitro-phenyl)-ethyl]-pyrimidine:

To a mixture of 1-(4-nitro-phenyl)-propan-2-one (5.32 g, 29.7 mmol.), triethylbenzylammonium chloride (0.34g, 1.5 mmol.), and 13 mL of aq. 5N KOH solution (65.3 mmol.) in CH_2Cl_2 was added CH_3I (4.06 mL, 65.3 mmol.). The resulting mixture was stirred at 40 °C, and then diluted with EtOAc and H_2O. The organic layer was dried and concentrated. To the residue (1.0 g, 4.8 mmol.) in toluene (30 mL) was added dimethylformamide dimethylacetal (1.27 mL, 9.6 mmol.). The resulting mixture was heated at reflux for 6 h then concentrated to give 1-dimethylamino-4-methyl-4-(4-nitro-phenyl)-pent-1-en-3-one as a yellow solid (MS 263 (M+1) Calc'd for $C^{14}H_{19}N_2O_3$-263.13).

A mixture of 1-dimethylamino-4-methyl-4-(4-nitro-phenyl)-pent-1-en-3-one (0.5 g, 1.9 mmol.), formamidine HCl (0.305 g, 3.8 mmol.), and NaOEt (1.29 g, 4.0 mmol) was heated in Smith synthesizer under microwave for 10 min at 150 °C. The resultant mixture was diluted with H_2O and EtOAc. The organic layer was dried, and the residue was used without further purification. MS: 244 (M+1) Calc'd for $C_{13}H_{14}N_3O_2$-244.10.

Preparation CLX - 5-[1-Methyl-1-(4-nitro-phenyl)-ethyl]-1H-pyrazole:

A mixture of 1-dimethylamino-4-methyl-4-(4-nitro-phenyl)-pent-1-en-3-one (0.36 g, 1.4 mmol.) and hydrazine hydrate (1.0 g, 6.25 mmol.) in EtOH was heated at 50°C for 3h. The mixture was concentrated, and the residue was diluted with H_2O and EtOAc. The organic layer was dried over Na_2SO_4 and concentrated to give the titled compound as a yellow solid. MS: 232 (M+1) Calc'd for $C_{12}H_{14}N_3O_2$ -232.10.

Preparation CLXI - 2-tert-Butyl-5-nitro-phenylamine:

Concentrated H_2SO_4 (1 L) was cooled to -10°C with a dry ice IpOH bath in a 2 L 3-neck round bottom flask fitted with a mechanical stirrer and temperature probe. 2-*t*-Butylaniline (109 g, 730 mmol) was added, giving a clumpy solid. Once the temperature of the mixture was stabilized at -10°C, KNO_3 (101 g, 1001 mmol) was added portion-wise, as the solid, over 4 h, maintaining the temperature between -20 and -5°C. Once all of the KNO_3 was added, the reaction was stirred overnight with gradual warming to RT. The reaction was quenched by diluting it with H_2O and extracting it 3x with EtOAc. The EtOAc extracts were washed multiple times with saturated $NaHCO_3$(aq), until gas evolution ceased, then with brine. The EtOAc extracts were combined, dried over anhydrous Na_2SO_4, filtered and concentrated under reduced pressure giving a black oil. The oil was eluted through a 36 x 7 cm column of silica gel with a 5%; 10%; 15%; 25%; and 50% EtOAc:Hexanes step gradient (2 L each step) giving 2-tert-butyl-5-nitro-phenylamine as a red solid.

Preparation CLXII - 2-Bromo-N-(2-tert-butyl-5-nitro-phenyl)-acetamide:

2-tert-Butyl-5-nitro-phenylamine (70 g, 359 mmol) and a catalytic amount of DMAP were dissolved in THF (1.5 L) under

N_2. TEA (109 g, 1077 mmol) was added and the solution was cooled to 0 °C. Bromoacetyl bromide (207 g, 1023 mmol) was added and the reaction was gradually warmed to RT with stirring overnight. The reaction was partially concentrated under reduced pressure, treated with H_2O and extracted with EtOAc (3x). The EtOAc extracts were washed with brine, combined, dried over anhydrous Na_2SO_4, filtered and concentrated under reduced pressure giving a black oil. This oil was eluted through a 38 x 7 cm column of silica gel with 95:5:0.5 CH_2Cl_2:MeOH:$NH_4OH_{(aq)}$ eluant giving 2-bromo-N-(2-tert-butyl-5-nitro-phenyl)-acetamide as a brown solid.

Preparation CLXIII - N-(2-tert-Butyl-5-nitro-phenyl)-2-dimethylamino-acetamide:

2-Bromo-N-(2-tert-butyl-5-nitro-phenyl)-acetamide (80 g, 253 mmol) and K_2CO_3 (70 g, 506 mmol) were combined in a 3-L 3-neck round bottom flask fitted with a mechanical stirrer, N_2 inlet, and pressure equalizing addition funnel. THF (1.75 L) was added and the mixture was cooled to 0 °C under N_2. DMA (400 mL of a 2 *M* solution in THF, 800 mmol) was added to the mixture through the pressure equalizing addition funnel over 30 min. The mixture was gradually warmed to RT with stirring overnight. The reaction was quenched by filtering it under vacuum and then concentrating the filtrate under reduced pressure. The recovered material was eluted through a 36 x 7 cm column of silica gel with 50% EtOAc:Hexanes giving N-(2-tert-butyl-5-nitro-phenyl)-2-dimethylamino-acetamide as a brown solid.

The pyrolidino and morpholino analogs are prepared by substituting the dimethylamine with respectively pyrolidine or morpholine and using the same chemistry as described.

a) N-(2-tert-Butyl-5-nitro-phenyl)-2-pyrrolidin-1-yl-acetamide.

b) N-(2-tert-Butyl-5-nitro-phenyl)-2-morpholin-4-yl-acetamide.

Preparation CLXIV - N-(5-Amino-2-tert-butyl-phenyl)-2-dimethylamino-acetamide:

N-(2-tert-Butyl-5-nitro-phenyl)-2-dimethylamino-acetamide (25.8 g, 92 mmol) was dissolved in EtOH (1.4 L) and 1,4-dioxane (200 mL). The solution was degassed under vacuum with stirring. 10% Pd/C (2.5 g) was added (as a slurry in EtOH). The mixture was degassed again, then the reaction vessel was charged with H_2 gas (balloon) and stirred overnight at RT. The reaction was filtered through Celite® with MeOH and the filtrate was concentrated under reduced pressure. The recovered material was eluted through a 36 x 7 cm column of silica gel with a 97.5:2.5:0.25 and 95:5:0.5 CH_2Cl_2:MeOH:$NH_4OH_{(aq)}$ step gradient giving N-(5-amino-2-tert-butyl-phenyl)-2-dimethylamino-acetamide as a brown solid.

Preparation CLXV - 5-Chloro-1-methyl-1H-pyrazole-4-carboxylic acid (4-tert-butyl-phenyl)-amide:

5-Chloro-1-methyl-1*H*-pyrazole-4-carbonyl chloride (1.0 g, 5.6 mmol) was dissolved in CH_2Cl_2 (100 mL) under N_2 and cooled to 0 °C. 4-*t*-Butylaniline was added and the reaction was stirred with gradual warming to RT overnight. The reaction was quenched with saturated $NaHCO_3$(aq) and extracted 3 x with fresh CH_2Cl_2. The CH_2Cl_2 extracts were washed with brine, combined, dried over anhydrous Na_2SO_4, filtered and concentrated under reduced pressure giving 5-chloro-1-methyl-1H-pyrazole-4-carboxylic acid (4-tert-butyl-phenyl)-amide as a foamy pink solid.

Preparation CLXVI - 1,2-dihydro-3-spiro-1'-cyclopropyl-1*H*-indole:

A solution of 3-(2-bromo-ethyl)-1*H*-indole (5 g) in anhydrous CH_3CN (100 mL) was suspended with oven dried K_2CO_3 (20 g) and

heated to reflux for 10 h. After cooling to RT, the mixture was filtered and the filter cake was washed with EtOH (50 mL). The combined filtrate was treated with $NaBH_4$ (300 mg) and stirred for 3 h at RT. Solvents were removed *in vacuo* and the residue was partitioned between H_2O (160 mL) and EtOAc (60 mL). The organic layer was extracted with aqueous HCl (0.5N, 30 mL X 2). The acid layer was basified with NH_4OH (aq. Conc.) and extracted with EtOAc. The organic phase was washed with brine and dried over Na_2SO_4 and concentrated to give the desired compound as a colorless thin oil.

Preparation CLXVII- 6-nitro-1,2-dihydro-3-spiro-1'-cyclopropyl-1*H*-indole:

1',2'-Dihydrospiro(cyclopropane-1,3'-[3*H*]indole) (1.8 g 12.4 mmol) was added in dropwise over a period of 20 min to a cooled (-5 to -10°C) solution of $NaNO_3$ (1.3 g) in H_2SO_4 (conc., 30 mL). After the addition, the reaction was stirred for another 40 min., then the mixture was poured onto crushed ice (200 g) and the resulting mixture was basified with NH_4OH (aq., conc.) with cooling. The basified mixture was extracted with EtOAc twice and the organic layer was washed with brine then dried over Na_2SO_4. After concentration *in vacuo*, the compound was isolated as a dark gray solid.

Preparation CLXVIII - Ethyl 6-nitro-1,2-dihydro-3-spiro-1'-cyclopropyl-1*H*-indole-1-carbamate:

A solution of 6-nitro-1,2-dihydro-3-spiro-1'-cyclopropyl-1*H*-indole (2.7 g) in CH_2CL_2 (100 mL) was suspended with $NaHCO_3$ (5 g), and ethyl chloroformate was added dropwise with vigorous stirring. After the addition, the reaction was stirred overnight. The mixture was washed with H_2O (100 mL), then dried over Na_2SO_4 and concentrated in vacuo. The

residue was recrystalized in MeOH to give the title compound as a dark gray crystalline.

Preparation CLXIX - Ethyl 6-amino-1,2-dihydro-3-spiro-1'-cyclopropyl-1*H*-indole-1-carbamate:

Ethyl 6-nitro-1,2-dihydro-3-spiro-1'-cyclopropyl-1*H*-indole-1-carbamate (2.1 g) was dissolved in EtOH (200 mL), suspended with Pd/C (10%, 560mg) and equipped with a balloon filled with H_2. The hydrogenation was finished in 3 h. The reaction mixture was filtered through a layer of Celite®. The filtrate was concentrated *in vacuo* to give the desired product as a white solid.

Preparation CLXX - 4-[1-Methyl-1-(4-nitro-phenyl)-ethyl]-3,6-dihydro-2H-pyridine-1-carboxylic acid ethyl ester:

1-Methyl-4-[1-methyl-1-(4-nitro-phenyl)-ethyl]-1,2,3,6-tetrahydro-pyridine (5.2 g) was dissolved in toluene (100 mL) and ethyl chloroformate (2.4 g). The mixture was heated at reflux for overnight and cooled to RT. The toluene solution was washed with $NaHCO_3$ (aq., sat., 100 mL) then brine (100 mL) and dried over Na_2SO_4. The organic phase was concentrated in vacuo to give the desired compound which was used without purification.

Preparation CLXXI - 4-[1-Methyl-1-(4-amino-phenyl)-ethyl]-3,6-dihydro-2H-pyridine-1-carboxylic acid ethyl ester:

4-[1-Methyl-1-(4-nitro-phenyl)-ethyl]-3,6-dihydro-2H-pyridine-1-carboxylic acid ethyl ester was dissolved in EtOH (150 mL) and suspended with Pd/C (10%, 1g). The reaction flask was equipped with a balloon filled with H_2. The hydrogenation was continued for 3 days. The mixture was filtered through a layer of Celite® and concentrated *in vacuo* to provide the desired compound as a light brown oil.

Preparation CLXXII: 3,3-dimethyl-6-nitroindoline 3-Methyl-but-2-enoic acid (3-acetylamino-phenyl)-amide:

3,3-Dimethylacryloyl chloride (3.3 ml, 29.3 mmol) was added to a mixture of 3'-aminoacetanilide (4.40 g, 29.3 mmol) and Et_3N (4.5 ml, 32.2 mmol) in 50 ml of CH_2Cl_2 and 25 ml of THF at 0 °C under N_2. The mixture was stirred at RT overnight, diluted with 100 ml of CH_2Cl_2, washed with aqueous Na_2CO_3, then brine, condensed, and purified by flash column chromatography (15 to 30% of EtOAc in CH_2Cl_2). The titled compound was obtained as an off-white solid. MS (ES^+): 233.1 $(M+H)^+$. Calc'd for $C_{13}H_{16}N_2O_2$ - 232.28.

The following compounds were prepared similarly to the procedure outlined above:

a) 3-Methyl-but-2-enoic acid phenylamide. MS(ES^+): 176.1 $(M+H)^+$. Calc'd for $C_{11}H_{13}NO$ - 175.23.

Preparation CLXXIII - N-(4,4-Dimethyl-2-oxo-1,2,3,4-tetrahydro-quinolin-7-yl)-acetamide:

The mixture of 3,3-dimethyl-6-nitroindoline 3-Methyl-but-2-enoic acid (3-acetylamino-phenyl)-amide (1.05 g, 4.52 mmol) and $AlCl_3$ (5.0 g, 37.5 mmol, Aldrich, 99.99%) in 50 ml of anhydrous chlorobenzene was stirred at 120 °C (oil bath temperature) under N_2 overnight, cooled to RT, poured into 10 ml of ice cold HCl, stirred for 30 min, and extracted with EtOAc. The organic portions were combined, washed with brine, dried with Na_2SO_4, filtered, condensed, and purified by flash column chromatography (1% of MeOH in CH_2Cl_2). The titled compound was obtained as an off-white solid. MS (ES^+): 233.2 $(M+H)^+$. Calc'd for $C_{13}H_{16}N_2O_2$ - 232.28.

The following compounds were prepared similarly to the procedure outlined above:

a) 4,4-Dimethyl-3,4-dihydro-1*H*-quinolin-2-one MS(ES$^+$): 175.6 $(M+H)^+$. Calc'd for $C_{11}H_{13}NO$ - 175.23.

Preparation CLXXIV: 7-Amino-4,4-dimethyl-3,4-dihydro-1*H*-quinolin-2-one:

N-(4,4-Dimethyl-2-oxo-1,2,3,4-tetrahydro-quinolin-7-yl)-acetamide (1.50 g, 6.46 mmol) in 10 ml of HCl (concentrated, 37%) and 30 ml of EtOH was stirred at 75 °C for 4 h. The solvents were removed under reduced pressure. The residue was dissolved in EtOAc/H_2O, neutralized with $NaHCO_3$, washed with brine, dried with Na_2SO_4, filtered, and condensed to give the titled compound as an off-white solid. MS (ES$^+$): 191.2 $(M+H)^+$. Calc'd for $C_{11}H_{14}N_2O$ - 190.24.

Preparation CLXXV - 4,4-Dimethyl-1,2,3,4-tetrahydro-quinolin-7-ylamine:

The mixture of 7-amino-4,4-dimethyl-3,4-dihydro-1*H*-quinolin-2-one (1.07 g, 5.62 mmol) and borane dimethylsulfide complex (1.60 ml, 16.9 mmol)in 40 ml of anhydrous THF was heated at reflux under N_2 for 15 h. The solvents were removed under reduced pressure. The residue was heated at reflux in 20 ml of MeOH for 2 h, then 0.80 g of $NaHCO_3$ was added, and the mixture was heated at reflux for 2 h. The mixture was filtered, condensed, and the residue was purified by flash column chromatography (5 to 10% of EtOAc in CH_2Cl_2). The titled compound was obtained as a viscous oil. MS(ES$^+$): 176.9 $(M+H)^+$. Calc'd for $C_{11}H_{16}N$ - 176.26.

The following compounds were prepared similarly to the procedure outlined above:

a) 4,4-Dimethyl-1,2,3,4-tetrahydroquinoline MS(ES$^+$): 162.5 $(M+H)^+$. Calc'd for $C_{11}H_{15}N$ - 161.24.

Preparation CLXXVI - N-(4,4-Dimethyl-1,2,3,4-tetrahydro-quinolin-7-yl)-2-fluoronicotinamide:

The mixture of 4,4-dimethyl-1,2,3,4-tetrahydro-quinolin-7-ylamine (0.20g, 1.13 mmol), 2-fluoronicotinic acid (0.16g, 1.13 mmol), TBTU (0.36 g, 1.13 mmol), and DIEA (0.24 ml, 1.36 mmol) in 5 ml of DMF was stirred at RT for 3 h, then partitioned between EtOAc and Na_2CO_3 (aq). The organic layer was washed with H_2O, brine, dried with $MgSO_4$, filtered, condensed, and the residue was purified by flash column chromatography (20 to 30% of EtOAc in CH_2Cl_2).
The titled compound was obtained as an off-white solid. MS (ES^+): 300.1 $(M+H)^+$. Calc'd for $C_{17}H_{18}FN_3O$- 299.34.

The following compounds were prepared similarly to the procedure outlined above:

a) N-(4,4-Dimethyl-2-oxo-1,2,3,4-tetrahydro-quinolin-7-yl)-2-fluoronicotinamide, as an off-white solid. MS (ES^+): 314.2 $(M+H)^+$. Calc'd for $C_{17}H_{16}FN_3O_2$- 313.33.
b) N-(1-Ethyl-4,4-dimethyl-1,2,3,4-tetrahydro-quinolin-7-yl)-2-fluoronicotinamide, MS(ES^+): 328.3 $(M+H)^+$. Calc'd for $C_{19}H_{22}FN_3O$ - 327.40.

Preparation CLXXVII - 4,4-Dimethyl-7-nitro-1,2,3,4-tetrahydro-quinoline:

To 13 ml of H_2SO_4 (96%) cooled in a salt ice bath was added dropwise 4,4-dimethyl-1,2,3,4-tetrahydro-quinoline (5.80 g, 36.0 mmol). The resulting slurry was stirred for 30 min, upon when concomitant addition of HNO_3 (90%, 1.70 ml, 36.0 mmol) and H_2SO_4 (96%, 7 ml) was started, the addition was finished in 20 min, the mixture was stirred at 0 °C to 15 °C for 2 h, poured into ice, and extracted with EtOAc. The organic portion was washed with brine, condensed, and

purified by flash column chromatography (0 to 10% of EtOAc in hexanes). The titled compound was obtained as a yellow oil. MS (ES^+): 206.9 $(M+H)^+$. Calc'd for $C_{11}H_{14}N_2O_2$ - 206.24.

Preparation CLXXVIII - 1-Ethyl-4,4-dimethyl-7-nitro-1,2,3,4-tetrahydroquinoline:

The mixture of 4,4-dimethyl-7-nitro-1,2,3,4-tetrahydro-quinoline (0.48g, 2.33 mmol), iodoethane (0.21 ml, 2.56 mmol), and NaH (60%, 0.10g, 2.5 mmol) in 10 ml of DMF was stirred at RT overnight, and partitioned between EtOAc and H_2O. The combined organic portions were washed with brine, dried with $MgSO_4$, filtered, and condensed. The crude compound was purified by flash column chromatography (5 to 10% of CH_2Cl_2 in hexanes). The titled compound was obtained as a yellow oil. MS (ES^+): 235.3 $(M+H)^+$. Calc'd for $C_{13}H_{18}N_2O_2$ - 234.29.

Preparation CLXXIX: 1-Ethyl-4,4-dimethyl-1,2,3,4-tetrahydro-quinolin-7-ylamine:

The mixture of 1-ethyl-4,4-dimethyl-7-nitro-1,2,3,4-tetrahydro-quinoline (0.28 g) and Pd/C (0.060 g, 10% wt) in 10 ml of EtOAc was placed under H_2 which was provided by a balloon and stirred at RT overnight. Then the mixture was filtered through Celite®, condensed, and the residue was purified by flash column chromatography (2% of EtOAc in CH_2Cl_2). The titled compound was obtained as a pink oil. MS(ES^+): 204.8 $(M+H)^+$. Calc'd for $C_{11}H_{16}N$ - 204.31.

Preparation CLXXX - 1-(4-Nitro-phenyl)-cyclopropanecarbonitrile:

NaOH (5.0 N, 80ml) was added to a mixture of 4-nitrophenylacetonitrile (10.0 g, 61.7 mmol), 1,2-dibromoethane (8.0 ml, 92.5 mmol), and tetraethylammonium chloride hydrate (10.2 g, 61.7 mmol) in 200 ml of CH_2Cl_2 at

RT. The resulting mixture was stirred at RT for 24 h, diluted with CH_2Cl_2, and acidified with HCl (10%, aq). The organic layer was separated, washed with brine, condensed, and the crude was purified by flash column chromatography. The titled compound was obtained as a light yellowish solid.

Preparation CLXXXI - C-[1-(4-Nitro-phenyl)-cyclopropyl]-methylamine:

The mixture of 1-(4-nitro-phenyl)-cyclopropanecarbonitrile (3.0 g, 15.9 mmol) and borane THF complex (1.0 M solution in THF, 32 ml, 32 mmol) in 50 ml of anhydrous THF was heated at reflux overnight. The mixture was cooled to RT, quenched with 2.5 ml of 50% AcOH aqueous solution, then partitioned between EtOAc and $NaHCO_3$ (aq). The combined organic portions were washed with brine, dried with $MgSO_4$, filtered, and condensed. The crude was purified by flash column chromatography (1 to 2% of MeOH in CH_2Cl_2). The titled compound was obtained as a light brownish solid. MS (ES^+): 192.9. Calc'd for $C_{10}H_{12}N_2O_2$- 192.2.

Preparation CLXXXII - 2,2,2-Trifluoro-N-[1-(4-nitro-phenyl)-cyclopropylmethyl]-acetamide:

Trifluoroacetic anhydride (5.26 ml, 36.9 mmol) was added to a mixture of C-[1-(4-nitro-phenyl)-cyclopropyl]-methylamine (2.37 g, 12.3 mmol) and triethyl amine (8.6 ml, 61.5 mmol) in 50 ml of CH_2Cl_2 at RT. The resulting mixture was stirred for 2 h. The volatiles were removed under reduced pressure and the residue was partitioned between EtOAc and aqueous $NaHCO_3$. The organic layer was washed with brine, dired with $MgSO_4$, filtered, and condensed. The crude compound was purified by flash column chromatography (10 to 20% of EtOAc in hexanes), and the titled compound was obtained as an off-white solid.

Preparation CLXXXIII - 1-(7-Nitro-4-spiro-1'-cyclopropane-3,4-dihydro-1*H*-isoquinolin-2-yl)-2,2,2-trifluoroethanone:

A mixture of 2,2,2-trifluoro-N-1-(4-nitro-phenyl)-cyclopropylmethyl]-acetamide (3.10 g, 10.7 mmol) and paraformaldehyde (0.54 g, 17.2 mmol) was added to a mixture of 12 ml of glacial AcOH and 20 ml of H_2SO4 at RT. The resulting mixture was stirred at 40 °C for 12 h, poured into ice-water and extracted with EtOAc. The combined organic portion was washed with $NaHCO_3$ (aq), H_2O, brine, then dried with $MgSO_4$, and condensed. The crude compound was purified by flash column chromatography (10 to 20% of EtOAc in hexanes), and the titled compound was obtained as a white solid.

Preparation CLXXXIV - 7-Nitro-4-spiro-1'-cyclopropane-1,2,3,4-tetrahydroisoquinoline:

A mixture of 1-(7-nitro-4-spiro-1'-cyclopropane-3,4-dihydro-1*H*-isoquinolin-2-yl)-2,2,2-trifluoroethanone (0.32 g, 1.07 mmol) and K_2CO_3 (1.50 g, 14.2 mmol) in 7 ml of MeOH and 2 ml of H_2O was stirred at RT overnight. The mixture was filtered, and the filtrate was concentrated. The residue was dissolved in EtOAc, washed with NH_4Cl (aq), brine, dried with $MgSO_4$, filtered, and condensed to give the titled compound as a light yellowish solid. MS (ES^+): 204.9 $(M+H)^+$. Calc'd for $C_{11}H_{12}N_2O_2$ - 204.23.

Preparation CLXXXV - *tert*-Butyl N-[7-nitro-4-spiro-1'-cyclopropane- 3,4-dihydro-1*H*-isoquinoline-2-carbamate:

The mixture of 7-nitro-4-spiro-1'-cyclopropane-1,2,3,4-tetrahydroisoquinoline (0.20g, 0.98 mmol), BOC_2O (0.24 g, 1.08 mmol), DMAP(0.025g, 0.20 mmol), DIEA (0.51 ml, 2.94 mmol) in 10 ml of CH_2Cl_2 was stirred at RT for 2 h. The solvent was removed, the residue was purified by flash

column chromatography (5 to 10% of EtOAc in hexanes), and the titled compound was obtained as a white solid.

Preparation CLXXXVI: *tert*-Butyl N-[7-amino-4-spiro-1'-cyclopropane-3,4-dihydro-1*H*-isoquinoline]carbamate

A mixture of *tert*-butyl N-[7-nitro-4-spiro-1'-cyclopropane-3,4-dihydro-2*H*-isoquinoline-2-carbamate (0.27 g, 0.89 mmol) and Pd/C (0.05 g, 10% wt) in 15 ml of MeOH was placed under H_2 which was provided by a balloon and stirred at RT for 1.5 h. The mixture was filtered through Celite®, and condensed to give the titled compound as a white solid. MS (ES^+): 274.8 $(M+H)^+$. Calc'd for $C_{16}H_{22}N_2O_2$ - 274.36.

Preparation CLXXXVII - 4- methyl-6-[2-(1-methyl-ppyrrolidin-2-yl)-ethyl]-pyrimidin -2-ylamine:

To a solution of (S)-(-)-1-methyl-2-pyrrolidine (320 mg, 2.78 mmol) in dry THF (10 mL) at 0 ^{0}C was added NaH (167 mg, 4.16 mmol). After stirred at RT for 1 h, 2-amino-4-chloro-6-methylpyrimidine (600 mg, 4.16 mmol) in dry THF (10 mL) was added dropwise via the addition funnel. The resulting mixture was heated to reflux under Ar gas for 20 h. The reaction was cooled to RT and quenched with sat. NH_4Cl. Solvent was removed. The residue was partitioned between H_2O and $CHCl_3$. The organic layer was washed with H_2O, brine, dried over $MgSO_4$, and evaporated to dryness. This crude compound was purified in column eluted with CH_2Cl_2:MeOH = 95%:5% to yield the title compound. MS *m/z*: 223.2 (M+H). Calc'd. for $C_{12}H_{20}N_4$ - 222.2.

Preparation CLXXXVIII - (6-bromo-pyridin-2-yl)3-Methyl-but-2-enoic -amide:

To a solution of 2-amino-6-bromopyridine (4, 3.015 g, 0.017 mol) and Et_3N (2.40 mL, 0.017 mol) in CH_2Cl_2 (20.0 mL), was added 3,3-dimethylacryloylchloride (1.96 mL, 0.017 mol)

under N_2 at 0 °C. The reaction mixture was slowly warmed to RT and stirred for 12 h. The reaction was quenched by the addition of H_2O (20.0 mL). The organic layer was separated, dried over Na_2SO_4 and evaporated to dryness to yield crude compound which was used without purification.

Preparation CLXXXIX - (6-amino-pyridin-2-yl) 3-Methyl-but-2-enoic -amide:

To a solution of 2-amino-6-bromopyridine (4.30 g, 0.017 mol) and copper (0.214 g, 3.372 mmol) in IPOH (20.0 mL), was added NH_4OH (20.0 mL) in a sealed vessel under N_2. The reaction was sealed and heated to 90 °C for 12 h. The mixture was cooled to RT and EtOAc (50.0 mL) was added. The organic layer was separated, and the aq layer was washed with EtOAc (50.0 mL). The combined organic layers were evaporated to dryness, the resulting residue was dissolved in CH_2Cl_2 (50.0 mL) and washed with H_2O (4 x 30 mL). The organic layer was dried over Na_2SO_4 and evaporated to dryness to yield crude compound which was used without purification.

Preparation CXC - 7-Amino-4,4-dimethyl-3,4-dihydro-1*H*-[1,8]naphthyridin-2-one:

To a mixture of aminopyridine 6 (1.12 g, 5.833 mmol) and $AlCl_3$ (3.11 g, 0.023 mol) was added chlorobenzene (10.0 mL) in a sealed vessel under Ar. The reaction was sealed and heated to 120 °C for 12 h. The reaction mixture was cooled to RT and the mixture was poured over ice/HCl mixture and extracted with EtOAc (3 x 50.0 mL). The Aq layer was neutralized with solid $NaHCO_3$ and extracted with EtOAc (5 x 50 mL). The combined organic layers were dried over Na_2SO_4 and evaporated to dryness to yield crude compound which was purified by chromatography (Silica gel, CH_2Cl_2:MeOH, 99:1) yielding the title compound.

Preparation CXCI - 2-[1-(3-Amino-phenyl)-2,2,2-trifluoro-1-trifluoromethyl-ethoxymethyl]-pyrrolidine-1-carboxylic acid tert-butyl ester:

To a mixture of 2-(3-amino-phenyl)-1,1,1,3,3,3-hexafluoro-propan-2-ol (1.30 g), 2-hydroxymethyl-pyrrolidine-1-carboxylic acid tert-butyl ester (1.04 g), PPh_3 (2.64 g) and molecular sieves 4 Å in THF (100 mL) was added DEAD (1.55 mL) slowly. The reaction was stirred at RT for 4 h and at reflux overnight. After filtration to remove solids, the filtrate was concentrated and the residue was taken up into Et_2O. The organic phase was washed with saturated $NaHCO_3$ and brine. The organic layer was dried over $MgSO_4$ and evaporated to give a viscous brown oil, which was purified by chromatography through silica gel (500 g, 30% to 50% EtOAc in hexanes) to afford 2-[1-(3-amino-phenyl)-2,2,2-trifluoro-1-trifluoromethyl-ethoxymethyl]-pyrrolidine-1-carboxylic acid tert-butyl ester as a light brown oil.

Preparation CXCII - N-(3-Amino-5-chloro-phenyl)-2-dimethylamino-acetamide:

To a solution of 5-chloro-benzene-1,3-diamine (3 g, 21 mmol) and dimethylamino-AcOH (2.2 g, 21 mmol) in CH_2Cl_2 (300 mL) was added EDC (5 g, 25 mmol), HOBt (2.9 g, 21 mmol), and DIEA (5 mL). The reaction mixture was stirred at RT overnight. Solvent was removed in vacuo and the residue was purified through flash chromatography on silica gel (0-8% MeOH in EtOAc) to give the desired compound.

General Procedure for the preparation of 2,6-diaminopyridines:

To a solution of 2-amino-6-bromopyridine (1.070 g, 6.061 mmol) in 2,4-dimethylphenol (2.0 mL) was added amine (6.667 mmol) and the reaction mixture was heated to 150 °C for 12 h. The mixture was cooled to RT and aq. HCl (2.0 M, 30 mL)

was added. EtOAc (50 mL) was added and the organic layer was separated. The Aq layer was washed with EtOAc (2 x 40 mL) and the combined organic layers were washed with H_2O (50 mL), dried over Na_2SO_4, concentrated under vacuo to yield crude compound which was used without purification.

The following compounds were prepared similarly to the procedure outlined above:

a) 3,4,5,6-Tetrahydro-2*H*-[1,2']bipyridinyl-6'-ylamine:
b) 6-(4-Methyl-piperazin-1-yl)-pyridin-2-ylamine:

Preparation CXCIII - 2-Methyl-2-(4-nitrophenyl)propionic acid:

To a solution of 2-(4-nitrophenyl)propionic acid (50 g, 0.26 mol) in 250 mL of MeOH was added 6 mL of concentrated HCl. The resulting solution was heated at reflux for 16 h. The reaction was diluted with 200 mL of aq. $NaHCO_3$ and 500 mL of EtOAc. The organic layer was separated, dried over Na_2SO_4, and concentrated. The residue was diluted with 100 mL of THF and added to a suspension of NaH (11.2 g, 0.28 mol, 60 % in mineral oil) in 600 mL of THF. To the resulting mixture was added CH_3I (18.3 mL, 0.29 mol) in one portion. The resulting mixture was stirred for 48 h at 40 °C and diluted with aq. NH_4Cl solution and EtOAc. The organic layer was separated, dried over Na_2SO4, and concentrated. The residue was used without further purification.

To a solution of the residue (54 g, 0.24 mol) in 500 mL of MeOH was added 5N aq. NaOH solution (144 mL, 0.72 mol). The mixture was stirred for 16 h at 40°C, then, concentrated, and the residue was diluted with H_2O (500 mL). The aq. solution was acidified with 2N HCl to give a precipitate which was filtered and dried to give the titled

compound as a yellowish solid. MS: (ES+) 210 (M+H). Calc'd for $C_{10}H_{12}NO_4$- 210.20.

Preparation CXCIV - 2-Methyl-5-[1-methyl-1-(4-nitro-phenyl)-ethyl]-[1,3,4]oxadiazole:

A mixture of 2-methyl-2-(4-nitro-phenyl)-propionic acid (5 g, 24 mmol) and a few drops DMF in $SOCl_2$ was stirred at reflux for 16 h. The resulting solution was concentrated to give corresponding acid chloride as a brown solid.

To a mixture of the acid chloride (2.33 g, 10.2 mmol), acetic acid hydrazide (0.91 g, 12.2 mmol), Et_3N (2.86 mL, 20.2 mmol) in CH_2Cl_2 (50 mL) was added 2 crystals of DMAP at RT. The resulting mixture was stirred for 16 h and concentrated. A solution of the residue in 50 mL of $POCl_3$ was heated at 95 °C for 16 h. The resulting mixture was concentrated and diluted with ice-H_2O and EtOAc. The organic layer was washed with saturated aq. $NaHCO_3$ solution twice, dried over Na_2SO_4, and concentrated. The residue was purified by SiO_2 chromatography (hexane: EtOAc=1:1) to give the titled compound as a pale yellow crystalline solid. MS: (ES+) 248 (M+H). Calc'd for $C_{12}H_{14}N_3O_3$ - 248.10.

Preparation CXCV - 2-Methyl-5-[1-methyl-1-(4-amino-phenyl)-ethyl]-[1,3,4]oxadiazole:

A mixture of 2-methyl-5-[1-methyl-1-(4-nitro-phenyl)-ethyl]-[1,3,4]oxadiazole (1.36 g, 5.5 mmol) and Pd/C (68 mg) in EtOAc (50 mL) was stirred under 1 atm of H_2 for 16 h. The resulting slurry was filtered over Celite®, and the filtrate was concentrated to give the titled compound as a pale yellow crystalline solid. MS: (ES+) 218 (M+H). Calc'd for $C_{12}H_{16}N_3O$ - 218.12.

Preparation CXCVI - 4-[1-Methyl-1-(4-nitro-phenyl)-ethyl]-pyrimidine:

To a mixture of 1-(4-nitro-phenyl)-propan-2-one (5.32 g, 29.7 mmol), triethylbenzylammonium chloride (0.34 g, 1.5 mmol), and 13 mL of aq. 5N KOH solution (65.3 mmol) in CH_2Cl_2 was added CH_3I (4.06 mL, 65.3 mmol). The resulting mixture was stirred at 40 °C then diluted with EtOAc and H_2O. The organic layer was dried and concentrated.

To the residue (1.0 g, 4.8 mmol) in toluene (30 mL) was added dimethylformamide dimethylacetal (1.27 mL, 9.6 mmol). The resulting mixture was heated at reflux for 6 h, then concentrated to give 1-dimethylamino-4-methyl-4-(4-nitro-phenyl)-pent-1-en-3-one as a yellow solid. MS: (ES+) 263 (M+H). Calc'd for $C_{14}H_{19}N_2O_3$-263.13.

A mixture of 1-dimethylamino-4-methyl-4-(4-nitro-phenyl)-pent-1-en-3-one (0.5 g, 1.9 mmol), formamidine hydrochloride (0.305 g, 3.8 mmol), and NaOEt (1.29 g, 4.0 mmol) was heated in Smith synthesizer under microwave for 10 min at 150 °C. The resultant was diluted with H_2O and EtOAc. The organic layer was dried, and the residue was used without further purification. MS: (ES+) 244 (M+H). Calc'd for $C_{13}H_{14}N_3O_2$ - 244.10.

Preparation CXCVII - 5-[1-Methyl-1-(4-nitro-phenyl)-ethyl]-1*H*-pyrazole:

A mixture of 1-dimethylamino-4-methyl-4-(4-nitro-phenyl)-pent-1-en-3-one (0.36 g, 1.4 mmol) and hydrazine hydrate (1.0 g, 6.25 mmol) in EtOH was heated at 50 °C for 3h. The mixture was concentrated, and the residue was diluted with H_2O and EtOAc. The organic layer was dried over Na_2SO_4 and concentrated to give the titled compound as a yellow solid. MS: (ES+) 232 (M+H.) Calc'd for $C_{12}H_{14}N_3O_2$ -232.10.

Preparation CXCVIII - 2-Methyl-2-(4-nitro-phenyl)-1-pyrrolidin-yl-propan-1-one:

To a round bottom flask charged with 2-methyl-2-(4-nitro-phenyl)-propionic acid, was added 6.5 ml of $SOCl_2$. The mixture was heated to 80° C, with stirring under inert atmosphere for 3.5 h. The mixture was cooled to RT, and then dried in-vacuo. The residue was placed under high vac. After completely dry, the residue was used without further purification.

To the residue was added 10 ml of CH_2Cl_2, along with Et_3N and the mixture was cooled to 0 °C on an ice/H_2O bath. Pyrrolidine .46 mL (1.25 eq.) was added into the mixture, then stirred to RT under inert atmosphere. After 3 h of stirring, the mixture was quenched with H_2O, diluted with CH_2Cl_2, and transferred to a separatory funnel. The organics were collected, combined, dried over Na_2SO_4 and filtered. The crude was concentrated *in vacuo*. After drying, the title compound was produced as an amorphous solid. MS: 263 (M+1); calc'd for $C_{14}H_{18}N_2O_3$ - 262

Preparation CXCIX - 4-(1,1-Dimethyl-2-pyrrolidin-1-yl-ethyl-phenylamine:

To a 3-neck round bottom flask, charged with 2-Methyl-2-(4-nitro-phenyl)-1-pyrrolidin-yl-propan-1-one was added 66 ml of 1M BH_3/THF soln, while the mixture was maintained at 0° C on an ice/H_2O bath. The mixture was stirred under inert atmosphere overnight. A couple drops of 5N NaOH was added slowly to the reaction mixture for quenching. After stirring an additional 5 min, 22 ml of 5N NaOH was added into the reaction mixture, then stirred vigorously for 3 h. The mixture was diluted with 50 ml of 1N NaOH and 100 ml of EtOAc, then transferred into a sep. funnel. The organics were collected and concentrated *in vacuo*. The residue was dissolved in CH_2CL_2, then $NaHCO_3$ soln. was added into the

mixture the organic extracts were dried over Na_2SO_4, filtered, then concentrated *in vacuo*.

To a round bottom flask charged with Pd/C in MeOH under inert atmosphere, was added 1-[2-methyl-2-(4-nitro-phenyl)-propyl]-pyrrolidine in MeOH and H_2 was added while stirring vigorously overnight. The mixture was filtered through Celite® and concentrated *in vacuo* to yield a light yellow oil. MS: 219 (M+1); calc'd for $C_{14}H_{22}N_2$.

Preparation CC - 1-methyl-1-(4-nitro-phenyl)-ethylamine: To a round bottom flask charged with 2-methyl-2-(4-nitro-phenyl)-propionic acid (10 g; 0.0440 mole), was added $SOCl_2$ (32 ml). The mixture was heated to reflux, until completion of the reaction. After heating, the residual $SOCl_2$ was removed by *in vacuo*, then placed the residue on high vac. The crude was used without further purification.

To the residue, was added 20 ml toluene and stirred. Then slowly NaN_3 (7.14 g; 0.1099 mole) was added into the mixture, and stirred vigorously under inert atmosphere for 1.5 h. The mixture was poured into 50 ml H_2O and transferred into a sep. funnel, with 50 ml EtOAc. The organics were collected, dried, filtered, and concentrated in-vacuo. The residue was dissolved in toluene and heated to 100°C while stirring vigorously under inert atmosphere for 1 h. The solvent was removed in-vacuo, 20% HCl aq was added and the mixture stirred vigorously under reflux conditions at 100°C for 9 h. The mixture was evaporated in-vacuo and to the residue was added 50 ml of 5N NaOH and 80 ml EtOAc, then transferred the mixture to a sep. funnel. The organic layer was collected, dried, filtered, and conc. in-vacuo. The residue was purified on silica-gel column in a solvent gradient of 80% EtOAc/Hexanes to 10% MeOH/ CH_2CL_2 yielding a brown solid resulted. MS: 181 (M+1); calc'd for $C_9H_{12}N_2O_2$-180.

Preparation CCI - [1-(4-Amino-phenyl)-1-methyl-ethyl]-(2-methylsulfanyl-pyrimidin-4-yl)-amine:

To a Personal Chemistry reaction tube, was added 1-methyl-1-(4-nitro-phenyl)-ethylamine, along with 4-chloro-2-methylsulfanyl-pyrimidine, DIEA (2.0 eq) and t-BuOH (0.6 ml). The tube was heated by microwave to 150°C for 10 min. After heating, the crude was diluted with CH_2CL_2 and H_2O, then transferred into a sep. funnel. The organics were collected, dried over Na_2SO_4, then concentrated *in vacuo*. The crude was used without further purification.

To a round bottom flask charged with PtO_2 (12% wt.) in MeOH (5 ml), was added crude nitro-intermediate (.170 g.; 0.0006 mole). The mixture was stirred vigorously under H_2 for 2.5 h. The mixture was filtered through Celite® and concentrated in-vacuo. The desired material was purified by silica-gel chromatography in a solvent gradient of 80% EtOAc/Hexanes to 5% MeOH/CH_2CL_2. After drying in high vac, the title compound resulted as a light yellow amorphous solid.

Preparation CCII - 2-(2,2,2-Trifluoro-ethoxy)-isonicotinonitrile:

To the suspension of NaH (2.78 g, 0.11 mole) in THF 100 mL) 2,2,2-trifluoroethanol (10 g, 0.1 mol) was added slowly. The mixture was stirred at RT till it turned clear. A solution of 2-chloro-isonicotinonitrile (13.8 g, 0.1 mol) in THF (100 mL) was slowly added and stirred at reflux for 3 h. After filtration and concentration, the crude oily compound was purified through column chromatography providing pure compound as an oil.

Preparation CCIII -[2-(2,2,2-Trifluoro-ethoxy)-pyridin-4-yl]-methylamine hydrogen chloride:

A mixture of 2-(2,2,2-trifluoro-ethoxy)-isonicotinonitrile (3.90 g, 19.40 mmol), 12N HCl(8.0 mL) and 10% Pd/C (800 mg) in MeOH (100 ml) was stirred under a balloon of H_2 for 7 h. After filtration, the filtrate was concentrated to give compound as a white solid. MS (ES+): 206.9 $(M+H)^+$. Calc'd. for $C_8H_9F_3N_2O$ - 206.07.

Preparation CCIV - 2-Bromomethyl-3-nitro-benzoic acid methyl ester:

The mixture of methyl 2-methyl-3-nitro benzoate (5.06 g, 25.9 mmol), NBS (5.54 g, 31.1 mmol), and AIBN (0.43 g, 2.59 mmol) in 100 ml of anhydrous CCl_4 was heated at reflux under N_2 for 22 h, cooled to RT, diluted with EtOAc, and washed with Na_2CO_3 (aq). The organic portion was separated, washed with brine, dried with Na_2SO_4, filtered, and condensed. The crude material was purified by flash column chromatography to yield pure product, which was used without further purification.

Preparation CCV - 4-Nitro-2, 3-dihydro-isoindol-1-one:

NH_3 (2.0 M in MeOH, 50 ml) was slowly added to the solution of 2-bromomethyl-3-nitro-benzoic acid methyl ester (4.46 g, contaminated with a small amount of assumed starting material, 16.3 mmol) in 30 ml of MeOH at RT. The resulting mixture was stirred at RT overnight, to provide the title compound as a white solid. MS (ES^+): 179.2 $(M+H)^+$. Calc'd for $C_8H_6N_2O_3$ - 178.14.

Preparation CCVI - 4-Amino-2, 3-dihydro-isoindol-1-one:

To the suspension of 4-nitro-2,3-dihydro-isoindol-1-one (2.40 g, 13.5 mmol) in 100 ml of MeOH was added Pd/C (10 wt%, 0.36 g). The mixture was then placed under H_2 from a

balloon, stirred at RT for 24 h, filtered through Celite®, and condensed to give the titled compound as a light greenish solid. MS (ES^+): 149.1 $(M+H)^+$. Calc'd for $C_8H_8N_2O$ - 148.16.

Preparation CCVII - Pyridin-4-ylmethyl-carbamic acid tert-butyl ester:

Boc anhydride (23 g, 105 mmol) was carefully added to a solution of pyridin-4-yl-methylamine (11 g, 102 mmol) and DMAP (0.5 g, 4 mmole) in CH_2CL_2 (150 mL). The reaction was extended for 1 hr after the addition. The reaction mixture was concentrated *in vacuo* and the residue was recrystallized in EtOAc to afford an off white crystal as the desired compound.

Preparation CCVIII - (1-Oxy-pyridin-4-ylmethyl)-carbamic acid tert-butyl ester:

Pyridin-4-ylmethyl-carbamic acid tert-butyl ester (2.1 g, 10 mmol) was dissolved in a one to one mixture of aqueous MeOH (200 mL) with $NaHCO_3$ (5 g, 60 mmol) and Oxone® (12.3 g, 20 mmol). The mixture was stirred overnight then concentrated *in vacuo* to remove MeOH. The resulted aqueous mixture was diluted with H_2O (150 mL) and filtered. The filter cake was washed with H_2O and dried to afford a white solid as the desired compound.

Preparation CCIX - C-(1-Oxy-pyridin-4-yl)-methylamine:

Oxy-pyridin-4-ylmethyl)-carbamic acid tert-butyl ester (2.1 g, 9.4 mmol) was dissolved in a 4N HCl in dioxane solution (50 mL) and heated to 50 C for 2 h. After removing solvent in vacuo, a white solid was received as an HCl salt of the desired compound.

Preparation CCX - 2-(4-Methoxy-benzylamino)-isonicotinonitrile:

To pyridine (500 mL) were added 2-chloroisonicotinonitrile (22.0 g, 159 mmole), para-methoxybenzylamine (25 g, 114% Meq.), and $NaHCO_3$ (30 g). The mixture was heated under reflux overnight. After cooling to RT, the mixture was filtered and the filter cake was rinsed with CH_2Cl_2. The combined filtrate was concentrated to dryness in vacuum to form a yellow solid. This solid is then recrystalized in EtOAc to give a light yellow crystalline compound and the mother liquor was concentrated and subjected to EtOAc again (repeating three times) to yield the desired compound.

Preparation CCXI - (4-Aminomethyl-pyridin-2-yl)-(4-methoxy-benzyl)-amine:

2-(4-Methoxy-benzylamino)-isonicotinonitrile (12 g, 50 mmole) was dissolved in a mixed solvent of EtOH (800 mL) Et_3N (200 mL) and suspended with 2 g of Pd/C (10%). After removing air with vacuum, the flask was charged with H_2 with a balloon. The H_2 balloon was refilled every morning and evening. Pd/C was recharged twice (1.3 g each) on days 2 and 3. Reaction was completed on the 4^{th} day and the reaction mixture was filtered through a pad of Celite®. The filter cake was rinsed with MeOH and the combined filtrate was concentrated *in vacuo* to give the desired compound as a light brown solid.

Preparation CCXII - 4-Aminomethyl-pyridin-2-ylamine:

(4-Aminomethyl-pyridin-2-yl)-(4-methoxy-benzyl)-amine (12 g, 50 mmole) was dissolved in TFA (150 mL) and heated to reflux for 1 h. After cooling, the reaction mixture was concentrated in vacuum and the residue was partitioned between HCl (1N, aq.) and EtOAc. The aqueous layer was washed with EtOAc then hexanes and concentrated to dryness

in vacuum to give an off white solid as a dihydrochloric salt.

Preparation CCXIII - 2-Methylamino-isonicotinonitrile:

To a solution of 2-chloroisonicotinonitrile (22.0 g, 159 mmole) in pyridine (500 mL) was added methylamine in THF (2N, 160 mL), and $NaHCO_3$ (54 g). The mixture was heated to 120 °C in a sealed vessel for 40 h. After cooled to RT, the mixture was filtered and the filter cake was washed with CH_2Cl_2. The combined filtrated was concentrated *in vacuo* to give a yellow solid (21 g) as the desired compound.

Preparation CCXIV - (4-Aminomethyl-pyridin-2-yl)-methyl-amine:

A suspension of 2-Methylamino-isonicotinonitrile (5.6 g) and Pd/C (10%, 4 g) in EtOH (150 mL) and TEA (40 mL) was placed in a 500 mL Parr Hydrogenation bottle and hydrogenated at or below 60 psi H_2 pressure over night. After filtering through a pad of Celite®, the reaction mixture was concentrated *in vacuo* to give a yellow oil as the desired compound.

Preparation CCXV - 3-Fluoro-pyridine 1-oxide:

3-Chloroperoxybenzoic acid (70%, 35.0 g, 142 mmol) was added to the solution of 3-fluoropyridine (6.90 g, 71.1 mmol) in 200 ml of CH_2Cl_2, the mixture was stirred at RT overnight, washed with a small amount of saturated $NaHCO_3$ solution, dried with Na_2SO_4, filtered, condensed, the crude compound was purified by flash column chromatography (1 to 2% of MeOH in CH_2Cl_2), the titled compound was obtained as a light yellowish solid. MS (ES^+): 114.1 $(M+H)^+$. Calc'd for C_5H_4FNO - 113.09.

Preparation CCXVI - 3-Fluoro-pyridine-2-carbonitrile: The mixture of 3-fluoro-pyridine 1-oxide (0.99 g, 8.75 mmol), trimethylsilyl cyanide (4.80 ml, 35.0 mmol), and triethyl amine (1.84 ml, 13.2 mmol) in 100 ml of CH_3CN was heated at reflux overnight. The solvents were removed, under reduced pressure and the residue was partitioned between EtOAc and saturated $NaHCO_3$. The organic portion was separated, dried with Na_2SO_4, filtered, condensed, the crude compound as purified by flash column chromatography (10 to 20% of EtOAc in hexanes). The titled compound was obtained as a light yellowish solid. MS (ES^+): 123.1 $(M+H)^+$. Calc'd for $C_6H_3FN_2$ - 122.10.

Preparation CCXVII - C-(3-Fluoro-pyridin-2-yl)-methylamine: The mixture of 3-fluoro-pyridine-2-carbonitrile (0.81 g, 6.63 mmol) and Pd/C (0.20 g, 10% wt) in 10 ml of MeOH and 2.7 ml of concentrated HCl was placed under H_2 which was provided by a balloon and stirred at RT for 4 h, filtered through Celite®, condensed, the residue was purified by flash column chromatography, 0.13 g of the titled compound was obtained as a light yellowish oil. MS(ES^+): 127.1 $(M+H)^+$. Calc'd for $C_6H_7FN_2$ - 126.13.

Preparation CCXVIII: 5-Bromo-pyridine-2-carbonitrile: The mixture of 2,5-dibromopyridine (4.74 g, 20.0 mmol), zinc cyanide (1.40 g, 12.0 mmol), zinc dust (0.059 g, 0.90 mmol), and $Pd(dppf)Cl_2.CH_2Cl_2$ (0.36 g, 0.44 mmol) in 25 ml of DMF was heated at reflux for 5 h, cooled to RT, diluted with H_2O, extracted with EtOAc, the organic portion was washed with brine, the solvents were removed, the crude compound was purified by flash column chromatography (5 to 15% of EtOAc in hexanes), the titled compound was obtained as an off-white solid.

Preparation CCXIX - 5-Fluoro-pyridine-2-carbonitrile:
The mixture of 5-bromo-pyridine-2-carbonitrile (0.50 g, 2.73 mmol), and KF (0.48 g, 8.20 mmol) in 10 ml of 1-methyl-2-pyrrolidinone was stirred at 175 °C for 18 h, cooled to RT, diluted with H_2O, extracted with EtOAc, the combined organic portions were washed with H_2O, brine, dried with Na_2SO_4, filtered, condensed, the crude compound was purified by flash column chromatography (5 to 20% of EtOAc in hexanes). The titled compound was obtained as an off-white solid.

Preparation CCXX - C-(5-Fluoro-pyridin-2-yl)-methylamine:
The mixture of 5-fluoro-pyridine-2-carbonitrile (0.16 g, 1.27mmol) and Pd/C (0.030 g, 10% wt) in 15 ml of MeOH and 0.50 ml of concentrated HCl was placed under H_2 which was provided by a balloon and stirred at RT for 4 h, filtered through Celite®, condensed, the residue was purified by flash column chromatography. The titled compound was obtained as a light yellowish solid. MS(ES$^+$): 127.2 (free base) $(M+H)^+$. Calc'd for $C_6H_7FN_2$ (free base)- 126.13.

Preparation CCXXI - 1H-Pyrrolo[2,3-b]pyridine 7-oxide:
To a suspension of 1H-pyrrolo[2,3-b]pyridine (10.0 g) and $NaHCO_3$ (45.2 g) in 1:1 MeOH/H_2O (1000 mL) was added Oxone® (106 g) in potions during 40 min period. The mixture was stirred at RT for 5 h. The sold was removed by filtration and the filtrate was concentrated to 200 mL in volume. This aqueous phase was extracted with CH_2Cl_2 (200 mL X 7) to afford 1H-pyrrolo[2,3-b]pyridine 7-oxide.

Preparation CCXXII - 4-chloro-1H-pyrrolo[2,3-b]pyridine:
To a cooled $POCl_3$ (50 mL) in a dried round bottom flask, 1H-pyrrolo[2,3-b]pyridine 7-oxide (5.73 g, step A) was added in potions. The mixture was heated to reflux for 5 h. After cooled down to RT, $POCl_3$ was evaporated under high vacuum

under gentle heating (40-50 °C) to obtain black residue. 50 mL of H_2O was added slowly and pH was adjusted to 8-9 with Na_2CO_3 (first with solid, then saturated aqueous solution). The resulting priticipate was collected by filtration, washed with cold H_2O and dried in a vacuum oven (50 °C) to give 4-chloro-1H-pyrrolo[2,3-b]pyridine as tan powder.

Preparation CCXXIII - 1-(4-iodo-pyrrolo[2,3-b]pyridin-1-yl)-ethanone:

To a suspension of 4-chloro-1H-pyrrolo[2,3-b]pyridine (3.80 g, step B) and NaI (19.15 g) in CH_3CN (40 mL) was added acetyl chloride (5.0 mL) slowly. The mixture was heated to reflux for overnight. After cooled to RT, 40 mL of 10% Na_2CO_3 and 40 mL of 10% $NaHSO_3$ were added. After stirring for 15 min, the mixture was extracted with EtOAc 4 times. The combined organic phases were washed with brine, dried over MgSO4 and concentrated to give a brown residue as the crude compound, which was purified by chromatography through silica gel (220 g, 5 to15% EtOAc/hexanes to afford 1-(4-iodo-pyrrolo[2,3-b]pyridin-1-yl)-ethanone as white solid.

Preparation CCXXIV - 1-acetyl-1H-pyrrolo[2,3-b]pyridine-4-carbonitrile:

A mixture of 1-(4-iodo-pyrrolo[2,3-b]pyridin-1-yl)-ethanone (4.30 g, step C), CuCN (6.841 g), Pd_2dba_3 (0.729 g), and dppf (1.636 g) in 85 mL of dioxane was heated to reflux for 2 h. Solid was removed by filtration through a pad of Celite®. The filtrate was concentrated to give a yellow solid as crude compound, which was purified by chromatography through silica gel (250 g, 5-30% EtOAc/hexanes, stepwise gradient) to afford 1-acetyl-1H-pyrrolo[2,3-b]pyridine-4-carbonitrile as a white fluffy solid.

Preparation CCXXV - 1-(4-aminomethyl-pyrrolo[2,3-b]pyridin-1-yl)-ethanone:

A mixture of 1-acetyl-1H-pyrrolo[2,3-b]pyridine-4-carbonitrile (0.872 g, step D), 10% Pd/C (0.882 g), 20 mL of Et_3N, and 80 mL of EtOH was stirred at RT under balloon pressure of H_2 for overnight. Solid was removed by filtration through a pad of Celite® and the filtrate was concentrated to yield a cream color residue, which was purified by chromatography through silica gel (70 g, 2 to 5% MeOH/$CHCl_3$ with 1% NH_4OH) to afford 1-(4-aminomethyl-pyrrolo[2,3-b]pyridin-1-yl)-ethanone as a white solid.

Preparation CCXXVI - N-(1-acetyl-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-4-ylmethyl)-acetamide:

To a mixture of 1-acetyl-1H-pyrrolo[2,3-b]pyridine-4-carbonitrile (0.691 g, example 15, step D), 10% Pd/C (0.702 g), 5 mL of Et_3N, and 20 mL of EtOAc was added acetic anhydride (1.0 mL). The mixture was stirred at RT under balloon pressure of H_2 for overnight. Solid was removed by filtration through a pad of Celite® and the filtrate was concentrated to yield a white residue, which was purified by chromatography through silica gel (150 g, 1 to 5% MeOH/$CHCl_3$ with 1% NH_4OH, stepwise gradient) to afford N-(1-acetyl-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-4-ylmethyl)-acetamide (0.50 g) as white solid.

Preparation CCXXVII - C-(2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-4-yl)-methylamine hydrogen chloride salt:

A mixture of N-(1-acetyl-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-4-ylmethyl)-acetamide (0.50 g, step A), HCl (conc., 3 mL) and EtOH (12 mL) was heated to 70 °C for overnight. Additional 3 mL of conc. HCl was added to the reaction and the heating was continued for 3 more days. Solvent was evaporated to give a white residue as crude C-

(2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-4-yl)-methylamine HCl salt, which was used without further purification.

General Procedure for the Preparation of 2-amino-4-methylaminopyridines

Preparation CCXXVIII - 2-aminoisonicotinonitrile:
To a slurry of 2-chloro-4-cyanopyridine (10.00 g, 0.079 mol) and sodiumbicarbonate (19.92 g, 0.237 mol) in amine (0.174 mol) was added pyridine (35.0 mL) and the reaction was heated to 90 °C for 3 h. The reaction was then cooled to RT, diluted with the addition of CH_2Cl_2 (100 mL) and filtered. The solid was washed with EtOAc. Combined washes were concentrated in vacuo. A mixture of MeOH/hexanes was added and kept in the fridge for 12 h. The crystals that formed were filtered and washed with hexanes.

Preparation CCXXIX - 2-amino-4-methylaminopyridine:
To a mixture of 2-aminoisonicotinonitrile (0.043 mol) and Pd/C (10%, 6.00 g) was added Et_3N (40.0 mL) and EtOH (160.0 mL) in a parr bottle and hydrogenated at 50 psi for 12 h. Crude mixture was filtered through Celite®, concentrated under vacuo and dried under high vacuum to yield compound.

Preparation CCXXX - (2-Pyrrolidin-1-yl-pyridin-4-yl)-methylamine:
Prepared according to the general procedure with pyrrolidine as the amine.

Preparation CCXXXI - (2-Morpholin-4-yl-pyridin-4-yl)-methylamine:
Prepared according to the general procedure with morpholine as the amine.

Preparation CCXXXII - 3,9,9-Trimethyl-6-nitro-4,9-dihydro-3H-3-aza-fluorene:

4-[1-(2-Bromo-4-nitro-phenyl)-1-methyl-ethyl]-1-methyl-1,2,3,6-tetrahydro-pyridine (9 g), $Pd(OAc)_2$ (900 mg), and DIEA (15 mL) was dissolved in DMF (300 mL), and heated to 80°C overnight. Solvents were removed *in vacuo*. The residue was partitioned between CH_2Cl_2/$NaHCO_3$(sat, aq.). The CH_2Cl_2 layer was washed with brine, dried over Na_2SO_4 and concentrated *in vacuo*. The residue was purified via flash chromatography on silica to give the desired compound. (MS: M+H=257).

Preparation CCXXXIII - 3,9,9-Trimethyl-2,3,4,4a,9,9a-hexahydro-1H-3-aza-fluoren-6-ylamine(156):

3,9,9-Trimethyl-6-nitro-4,9-dihydro-3H-3-aza-fluorene (700 mg) was dissolved in EtOH (20 mL) with aqueous HCl (1N, 5 mL) and suspended with Pd/C (10%, 100 mg). The flask was capped with a balloon filled with H_2. The reaction was completed in 6 h at RT. The reaction mixture was filtered through a layer of Celite® with MeOH. The combined filtrate was concentrated to give desired compound. (MS: M+H=231).

Preparation CCXXXIV - 2-Chloro-5-nitro-phenol:

A mixture of 2-chloro-4-nitroanisole (10 g, 53.3 mmol) and pyridinium chloride (50 g, 426 mmol) was heated at 200 °C for 3 h. After cooling to RT, the mixture was dissolved in 150 mL of aqueous 2N HCl and 150 mL of EtOAc. The organic phase was separated and was washed with aqueous 2N HCl (2 x 100 mL). The resulting organic phase was dried over $MgSO_4$ and concentrated in vacuo. The title compound was obtained via chromatography (silica gel, 10:1 hexane/EtOAc) as a yellow solid.

Preparation CCXXXV - 3-(5-Amino-2-chloro-phenoxymethyl)-azetidine-1-carboxylic acid tert-butyl ester:

To a solution of 3-(2-chloro-5-nitro-phenoxymethyl)-azetidine-1-carboxylic acid tert-butyl ester (2.5 g, 7.29 mmol) in 60 mL of MeOH/H_2O (1:1) and 3 mL of acetic acid (J.T. Baker) was added Zn powder (2.3 g, 36.47 mmol, Aldrich) at 0 °C. The reaction mixture was stirred at 0 °C for 2 h then stirred at 10 °C for 2 h. The resulting mixture was filtered through a Celite® pad and the filtrate was concentrated *in vacuo*. The residue was treated with 60 mL of saturated aqueous $NaHCO_3$ and extracted with EtOAc (3 x 50 mL). The combined organic layers were washed with brine and dried with $MgSO_4$. The resulting solution was concentrated *in vacuo* and the title compound was obtained by column chromatography (silica gel, EtOAc) as a yellow solid.

Preparation CCXXXVI: 3-(Benzotriazol-1-yloxy)-6-chloro-pyridazine-4-carboxylic acid (4-*tert*-butyl-phenyl)-amide:

A mixture of 3,6-dichloropyridazine-4-carboxylic acid (1.00 g, 5.18 mmol), 4-*tert*-butylaniline (0.92 ml, 5.60 mmol), TBTU (1.75 g, 5.44 mmol), and DIEA (1.80 ml, 10.4 mmol) in 7.5 ml of anhydrous DMF was stirred at RT under N_2 overnight. The mixtrue was diluted with H_2O, extracted with EtOAc, and the combined organic portions were washed with brine, dried with Na_2SO_4, filtered, and condensed. The crude compound was purified by flash column chromatography (hexanes/EtOAc/CH_2Cl_2, 9:0:1 to 7:2:1), to provide the desired compound as a light yellowish solid. MS (ES^+): 423.0 $(M+H)^+$. Calc'd for $C_{21}H_{19}ClN_6O_2$ - 422.87.

Preparation CCXXXVII - 3-Hydroxymethyl-azetidine-1-carboxylic acid benzyl ester:

To a mixture of azetidine-1,3-dicarboxylic acid monobenzyl ester (6.4 g) in THF (200 mL) was added BH_3•THF (6 eq, 163

mL, 1M solution) dropwise via an addition funnel at -40 C under an N_2 atmosphere. The solution was warmed to RT and stirred overnight. To the reaction, 5N NaOH (50 mL) was added and then concentrated under vacuum. The resulting aqueous solution was extracted with Et_2O (3 x 100 mL). The organic layer was dried over Na_2SO_4 and evaporated to give the title compound which was used without further purification.

Preparation CCXXXVIII - 3-Methanesulfonyloxymethyl-azetidine-1-carboxylic acid benzyl ester:
3-Hydroxymethyl-azetidine-1,3-dicarboxylic acid monobenzyl ester (6.6 g) was dissolved in CH_2Cl_2 (100 mL) and brought to -15 C. While stirring, TEA was added (3 eq, 9.43 g) followed by methanesulphonic chloride (2.0 eq, 7.69 g) and allowed to come to RT and stirred for 1 h. The resulting organic solution was extracted with water (3 x 100 mL). The organic layer was dried over Na_2SO_4 and evaporated to give the desired product as a clear oil which was used without further purification.

Preparation CCXXXIX - 3-Nitro-5-trifluoromethyl-phenol:
A flask containing 1-Methoxy-3-nitro-5-trifluoromethyl-benzene (10g) and hydrochloride pyridine (10 eq, 52.0 g) was heated to 210 C and stirred for 12 h. Once complete, the reaction was cooled and the residue was dissolved in CH_2Cl_2 and washed twice with water (100 mL). The organic layer was concentrated under vacuum and then set in the freezer overnight. The resulting crystalline product was filtered off and washed with ether and used as is.

Preparation CCXL - 3-(3-Nitro-5-trifluoromethyl-phenoxymethyl)-azetidine-1-carboxylic acid benzyl ester: A mixture of 3-nitro-5-trifluoromethyl-phenol (750 mg, Step C), K_2CO_3 (3 eq., 1.5 g) and 3-hydroxymethyl-azetidine-1-carboxylic acid benzyl ester (1.1 eq., 1.2 g) in DMF was heated to 80 C for 1 h. The solution was cooled to RT then filtered and concentraced under vacuum. The residue was dissolved in CH_2Cl_2 and washed with H_2O twice, followed by brine. The organic layer was dried over Na_2SO_4 and evaporated under reduced pressure. The residue was purified by column chromatography using 5% MeOH/CH_2Cl_2 to provide the desired compound as a colorless solid.

Preparation CCXLI - 3-(3-amino-5-trifluoromethyl-phenoxymethyl)-azetidine-1-carboxylic acid benzyl ester: To a solution of 3-(3-nitro-5-trifluoromethyl-mg) and NH_4Cl (1.1 eq., 80mg) was added iron dust (3 eq., 220 mg) in a 10% water/EtOH solution. The solution was heated to reflux for 6 h. The solution was cooled, then filtered through a pad of Celite®. The resulting solution was concentrated under vacuum to provide the desired compound as a dark yellow solid and used as is.

Preparation CCXLII - 3-nitro-5-(trifluoromethyl)phenylamine To a solution of 3,5-dinitrobenzotrifluoride (10 g, 42 mmols, 1 eq.) in 150 mL of EtOH was added 17.6 mL (258.3 mmols, 6.15 eq.) of ammonium sulfide in water (50% by weight, Aldrich). The reaction was heated to reflux for 16 h during which time it became orange and a yellow precipitate formed. After cooling the volume was reduced to approximately 50 mL. The solid was removed by filtration and the filtrate evaporated to dryness *in vacuo*. The resulting orange solid was purified by column chromatography

eluting with a step gradient of 20-30% EtOAc:hexane to provide the compound as a yellow/orange solid.

Preparation CCXLIII - N-(3-nitro-5-(trifluoromethyl)phenyl)methanesulfonamide

3-Nitro-5-(trifluoromethyl)phenylamine (2 g, 9.7 mmols, 1 eq) was dissolved in 100 mL of CH_2Cl_2. The yellow solution was cooled to 0 °C. Et_3N (2 mL, 14.55 mmols, 1.5 eq) was added followed by mesyl chloride (0.75 mL, 9.7 mmols, 1 eq). The reaction was stirred for 2 h at 0 °C and warmed to RT. Pyridine (0.785 mL, 9.7 mmols, 1 eq) and a catalytic amount of dimethylamine pyridine were added. The reaction was stirred at RT for 16 h. An additional equivalent of mesyl chloride was added and the reaction was heated to reflux for 24 h. After cooling, the solvent was removed *in vacuo*, and the residue redissolved in CH_2Cl_2. The solution was washed twice with 2 N HCl and once with brine. After drying over Na_2SO_4, the solution was filtered and the solvent removed. The resulting solid was triturated briefly with 10% EtOAc:hexane to provide a white solid that was a mixture of sulfonimide and sulfonimide.

The above mixture was dissolve in 20 mL of MeOH that had been saturated with K_2CO_3. After 30 min the reaction was stripped and the resulting solid portioned between 2 N HCl and CH_2Cl_2. The CH2Cl2 was dryed over Na_2SO_4 and stripped to provide and off-white solid.

Preparation CCXLIV - (3S)-tetrahydro-3-furanyl 3-nitro-5-(trifluoromethyl)phenylcarbamate

3-(S)-Hydroxytetrahydrofuran (4.8 mL, 60.7 mmols, 5 eq) was dissolved in 60 mL of toluene. The solution was cooled to 0 °C and Et_3N (5.1 mL, 36.4 mmols, 3 eq) was added. Trichloromethyl chloroformate (3.65 mL, 30.33 mmols, 2.5 eq) was added slowly. The solurion was stirred at 0 °C for 45

min. 3-Amino-5-ntrobenzotrifluoride (2.5 g, 12.13 mmols, 1 eq) was added dropwise in 20 mL of toluene. The reaction was stirred at 0 °C for 1 h. An additional 5 eq of 3-(S)-hydroxytetrahydrofuran was converted to the chloroformate as described above, and added to the reaction mixture. After an additional h at 0 °C, the reaction was heated to 60 °C for 1 h. The reaction was cooled to RT and concentrated. The residue was dissolved in EtOAc, washed twice with saturated NH_4Cl and once with brine. After being dried over Na_2SO_4 the solution was filtered and the solvent removed *in vacuo*. The crude product was purified using a Biotage chromatography system eluting with a gradient of 5% to 35% EtOAc:hexane to yield the desired compound.

Preparation CCXLV - N-(2-((3-nitro-5-(trifluoromethyl)phenyl)oxy)ethyl)-methanesulfonamide

2-((3-Nitro-5-(trifluoromethyl)phenyl)oxy)ethylamine (4.05 g, 16.2 mmols, 1 eq) was dissolved in 100 mL of CH_2Cl_2. The solution was cooled to 0 °C. Pyridine (2.6 mL, 32.4 mmols, 2 eq) was added followed by mesyl chloride (1.25 mL, 16.2 mmols, 1 eq). The reaction was stirred for 18 h during which time it was warmed slowly to RT. The solvent was removed *in vacuo*, and the residue dissolved in EtOAc. The resulting solution was washed twice with 2 N HCl, once with water, and 3x with brine. After being dried over Na_2SO_4 the solution was filtered and concentrated. The crude was purified by silica gel chromatography eluting with 50% to 60% EtOAc:hexane to yield the desired compound.

Preparation CCXLVI - N-(2-((3-amino-5-(trifluoromethyl)phenyl)oxy)ethyl)methanesulfonamide

N-(2-((3-Nitro-5-(trifluoromethyl)phenyl)oxy)ethyl)-methanesulfonamide (1.7 g, 5.2 mmols, 1 eq) was dissolved in 50 L of MeOH. 10% Pd/C (170 mg, 10 weight %) was added and

the reaction sparged with H_2. The suspension was stirred for 5 h, then filtered trough Celite. The filtrate was stripped to yield the title compound.

The following compounds were prepared similarly to the procedure outlined above:

a) 3-((((2R)-1-acetyl-2-pyrrolidinyl)methyl)oxy)-5-(trifluoromethyl)phenylamine.

b) (3S)-tetrahydro-3-furanyl 3-amino-5-(trifluoromethyl)phenylcarbamate.

c) N-(3-amino-5-(trifluoromethyl)phenyl)-methanesulfonamide

Preparation CCXLVII - (2R)-1-acetyl-2-(((3-nitro-5-(trifluoromethyl)phenyl)oxy)methyl)pyrrolidine

(2R)-2-(((3-nitro-5-(trifluoromethyl)phenyl)oxy)methyl) pyrrolidine (3.46 g, 11.9 mmols, 1 eq) was dissolved in 100 mL of CH_2Cl_2. Et_3N (5 mL, 35.7 mmols, 3 eq) was added followed by Ac_2O (1.2 mL, 13.1 mmols, 1.1 eq). The reaction was stirred at RT for 1.5 h. The solvent was removed *in vacuo* and the residue disolved in EtOAc. The solution was washed once each with saturated NH_4Cl, 1 N HCl, and twice with brine. The organic layer was dried over Na_2SO_4 filtered and concentrated *in vacuo*. The crude material was purified on a Biotage chromatography system eluting with a gradient of 10% to 75% EtOAc:hexane to yield the title compound.

Preparation CCXLVIII - 3-(2-Chloro-5-nitro-phenoxymethyl)-azetidine-1-carboxylic acid tert-butyl ester:

To the mixture of 2-chloro-5-nitro-phenol (1.31 g, 7.54 mmol) and K_2CO_3 (1.57 g, 11.31 mmol) in 20 mL of DMF was added 3-methanesulfonyloxymethyl-azetidine-1-carboxylic acid tert-butyl ester (2.0 g, 7.54 mol). The reaction mixture was stirred at 50 ºC for 1 h. After cooling to RT, the reaction mixture was diluted in 100 mL of EtOAc and quenched with 50 mL of water. The organic layer was separated and the aqueous layer was extracted with EtOAc (2 x 50 mL). The combined organic phases were washed with brine, dried over $MgSO_4$ and concentrated in vacuum. The title compound was obtained via column chromatography (silica gel, 1;1 hexane/EtOAc) as yellow oil with 93% yield.

The following additional preparations for exemplary compounds, intermediates, and starting materials should further assist in the understanding and appreciation of various embodiments, and additional examples (Tables 1-5), of compounds of the present invention.

Example 1

Preparation of 2,2,2-trifluoro-N-[2-(4-nitro-phenyl)-ethyl]-acetamide:

To a solution of 4-nitrophenethylamine hydrochloride (50 g, 0.247 mole), DIEA (128 mL, 0.74 mole, 3 eq.) and CH_2Cl_2 (500 mL) in a 1L round bottom flask equipped with a magnetic stirrer was added $(CF_3CO)_2O$ (52.5 mL, 0.37 mole, 1.5 eq) dropwise at 5-10 ºC (with ice/water bath). After stirring for another 1 h after the addition at RT, the reaction was quenched with water (200 mL) and transferred into a separatory funnel. The organic layer was separated,

washed with water and sat. NH_4Cl, dried over Na_2SO_4, filtered, concentrated to give a brown oil. The crude was triturated with water (300 mL), filtered and dried on vacuum overnight to give the desired 2,2,2-trifluoro-N-[2-(4-nitro-phenyl)-ethyl]-acetamide as a yellow solid. This can be used for next step without further purification. An analytical sample was obtained through recrystallization from CH_3OH/H_2O as a yellow solid.

Example 2

Preparation of 2,2,2-trifluoro-1-(7-nitro-3,4-dihydro-1H-isoquinolin-2-yl)-ethanone:

To the mixture of 2,2,2-trifluoro-N-[2-(4-nitro-phenyl)-ethyl]-acetamide (65 g, 0.25 mole), paraformaldehyde (42.4 g, 0.375 mole, 1.5 eq.) and HOAc (200 mL) in a 1L round bottom flask equipped with a magnetic stirrer and a ice/water bath was added H_2SO_4 (300 mL) slowly while maintaining reaction temperature under 40°C. The resulting mixture was stirred for 2 h at 40 °C, poured into ice, extracted with EtOAc, washed with water, sat. Na_2CO_3 and sat. NH_4Cl, dried over Na_2SO_4, filtered and concentrated to give the title ethanone compound. This can be used in the next step without further purification. An analytical sample was obtained through silica gel column chromatography with eluant of CH_2Cl_2:MeOH (9:1).

Example 3

Preparation of 7-nitro-1,2,3,4-tetrahydro-isoquinoline:

To a mixture of 2,2,2-trifluoro-1-(7-nitro-3,4-dihydro-1H-isoquinolin-2-yl)-ethanone (24 g, 0.087 mole), MeOH (300 mL), CH_2Cl_2 (50 mL) and H_2O (100mL) in a 1L round bottom flask equipped with a magnetic stirrer was added LiOH

(24 g). The reaction was completed after stirring for 10 min at RT. The mixture was concentrated, extracted with CH_2Cl_2, washed with water, dried over Na_2SO_4, filtered, concentrated to give the title isoquinoline compound as an off-white solid. MS: (ES+) 179(M+H). Calc'd. for $C_9H_{10}N_2O_2$ - 178.07.

Example 4

Preparation of 7-amino-isoquinoline:

A mixture of 7-nitro-1,2,3,4-tetrahydro-isoquinoline (1.5g, 8.38 mmole) and 10% Pd/C (300 mg) in diethylene glycol (5 mL) was reacted in a Smith Synthesizer under microwave radiation at 220 °C for 25 min. The resulting mixture was diluted with MeOH and filtered. The filtrate was concentrated and diluted with CH_2Cl_2, washed with sat. aq. NH_4Cl and dried over Na_2SO_4. After filtration and concentration, the title compound was isolated through flash chromatography (eluted with CH_2Cl_2:MeOH 9:1) as an orange solid. MS: (ES+) 145(M+H). Calc'd. for $C_9H_8N_2$ - 144.07.

Example 5

Preparation of N^4-methyl-quinazoline-4,6-diamine:

A mixture of methyl-(6-nitro-quinazolin-4-yl)-amine (0.16 g; see Synthesis of Certain Nitroquinazoline Derivatives Structurally Related to some Chemotherapeutic Agents, Botros, S., et. al., *Egyptian Journal of Pharmaceutical Sciences*, 13(1), 11-21,(1972) for a description of preparing the nitro-quinazoline) and Pd/C (10 wt%, 0.032 g) in 10 ml of MeOH was placed under H_2 from a balloon and stirred at RT for 3 h, filtered through a pad of Celite®. Removal of the solvents afforded the title compound as an off-white solid. MS (MH+) = 175.3; Calc'd for $C_9H_{10}N_4$ - 174.20.

Example 6

Preparation of 3-nitro-7,8-dihydro-5H-[1,6]naphthyridine-6-carboxylic acid tert-butyl ester:

2M solution of NH_3 in MeOH (225 mL, 452.25 mmol) was added to a reaction vessel containing 1-methyl-3,5-dinitro-1H-pyridin-2-one (6 g, 30.15 mmol) and 4-oxo-piperidine-1-carboxylic acid tert-butyl ester (6.6 g, 33.15 mmol). The vessel was then sealed and the reaction was stirred for 24 h at 70 °C. After the resulting mixture was cooled to RT, the solvent was removed to give crude product as yellow solid. After recrystallization in MeOH, the desired title compound was obtained as tan solid. MS (ES^+): 280.1 $(M+H)^+$. Calc'd for $C_{13}H_{17}N_3O_4$ - 279.12.

Example 7

Preparation of 3-nitro-5,6,7,8-tetrahydro-[1,6]naphthyridine:

To the solution of 3-nitro-7,8-dihydro-5H-[1,6]naphthyridine-6-carboxylic acid tert-butyl ester (6.14 g, 22 mmol) in CH_2Cl_2 (60 mL) was added TFA (7 mL). The reaction was stirred for 18h at RT. After evaporation of the solvent, the residue was taken into water and neutralized with saturated $NaHCO_3$ aqueous solution. The solid was filtered and washed with cold water and dried. The solid was recrystallized from CH_3CN to give desired title compound as pale white solid. MS (ES^+): 180.1 $(M+H)^+$. Calc'd for $C_8H_9N_3O_2$ - 179.07.

Example 8

Preparation of [1,6]naphthyridin-3-ylamine:

3-Nitro-5,6,7,8-tetrahydro-[1,6]naphthyridine (1 g, 5.6 mmol), pentanol (2 mL) and Pd/C (300mg) were placed in a microwave reaction vessel and stirred under microwave irradiation at 180 °C for 1 h. After cooling, the mixture was diluted with MeOH and filtered through a pad of Celite. The solvent was removed and the crude was purified by flash column chromatography to give the desired title compound as a yellow solid. MS (ES^+): 146.2 $(M+H)^+$. Calc'd for $C_8H_7N_3$ - 145.06.

Example 9

4-(2,2,2-Trifluoro-1-methoxy-1-trifluoromethyl-ethyl)-phenylamine:

A mixture of 2-(4-amino-phenyl)-1,1,1,3,3,3-hexafluoro-propan-2-ol (1 eq.), DIAD(1.96 eq.), PPh_3 (polymer-bound, 2.36 eq) and MeOH (1.1 eq) in THF (100 mL) was stirred at reflux for 16 h. After filtration and concentration, the crude was purified by flash chromatography (20% EtOAc/CH_2Cl_2) to give the title compound as a white solid. MS (ES^+): 274 $(M+H)^+$. Calc'd for $C_{10}H_9F_6NO$- 273.06.

The following Example 10 was prepared utilizing a starting material made by the method described in Example 9.

Ex.#	Structure	Mol. formula	Calc'd Mass	M+H
10	 2-(Isoquinolin-7-ylamino)-N-[4-(2,2,2-trifluoro-1-methoxy-1-trifluoromethyl-ethyl)-phenyl]-nicotinamide	$C_{235}H_{18}F_6N_4O_2$	520.13	521

Example 11



2-(Isoquinolin-7-ylamino)-N-(4-pentafluoroethyl-phenyl)-nicotinamide

To a mixture of 2-fluoro-N-(4-pentafluoroethyl-phenyl)-nicotinamide (112 mg) and 7-aminoisoquinoline (40 mg) in t-BuOH (0.5 mL) was added TFA (94 µL). The resulting mixture was stirred for 24 h at 90 °C, cooled to RT and purified by flash chromatography (4:1:0.1; MeOH/CH_2Cl_2/MeOH) to give the title compound as a yellow solid. MS (ES^+): 459 $(M+H)^+$. Calc'd for $C_{23}H_{15}F_5N_4O$- 458.12.

The following Examples 12-25 were prepared utilizing a method similar to that described in Example 11.

Ex. #	Structure	Mol. formula	Calc'd Mass	M+H
12	 2-(Isoquinolin-7-ylamino)-N-(4-trifluoromethyl-phenyl)-nicotinamide	$C_{22}H_{15}F_3N_4O$	408.12	409
13	 N-(2-Acetyl-4,4-dimethyl-1,2,3,4-tetrahydro-isoquinolin-7-yl)-2-(isoquinolin-7-ylamino)-nicotinamide	$C_{28}H_{27}N_5O_2$	465.22	466

A-917 - 232 -

14	 N-(4-tert-Butyl-phenyl)-2-(isoquinolin-7-ylamino)-nicotinamide	$C_{25}H_{24}N_4O$	396.20	397
15	 N-(5-tert-Butyl-isoxazol-3-yl)-2-(isoquinolin-7-ylamino)-nicotinamide	$C_{22}H_{21}N_5O_2$	387.17	388
16	 N-(2-Acetyl-4,4-dimethyl-1,2,3,4-tetrahydro-isoquinolin-7-yl)-2-(4-methylamino-quinazolin-6-ylamino)-nicotinamide	$C_{28}H_{29}N_7O_2$	495.58	496

A-917 - 233 -

17	 N-(4-tert-Butyl-phenyl)-2-(1-oxo-1,3-dihydro-isobenzofuran-4-ylamino)-nicotinamide	$C_{24}H_{23}N_3O_3$	401.17	402.1
18	 2-(1-Oxo-1,3-dihydro-isobenzofuran-4-ylamino)-N-[4-(2,2,2-trifluoro-1-hydroxy-1-trifluoromethyl-ethyl)-phenyl]-nicotinamide	$C_{23}H_{15}F_5N_3O_4$	511.10	512.1
19	 N-(3,3-Dimethyl-2,3-dihydro-1H-indol-6-yl)-2-(1-oxo-1,3-dihydro-isobenzofuran-4-ylamino)-nicotinamide	$C_{24}H_{22}N_4O_3$	414.17	415.

A-917 - 234 -

20	 N-(4,4-Dimethyl-1,2,3,4-tetrahydro-isoquinolin-7-yl)-2-(1-oxo-1,3-dihydro-isobenzofuran-4-ylamino)-nicotinamide	$C_{25}H_{24}N_4O_3$	428.18	429.1
21	 N-(1-Acetyl-3,3-dimethyl-2,3-dihydro-1H-indol-6-yl)-2-(1-oxo-1,3-dihydro-isobenzofuran-4-ylamino)-nicotinamide	$C_{26}H_{24}N_4O_4$	456.18	457.
22	 2-(2,2-Difluoro-benzo[1,3]dioxol-5-ylamino)-N-(4,4-dimethyl-1,2,3,4-tetrahydro-isoquinolin-7-yl)-nicotinamide	$C_{24}H_{22}F_2N_4O_3$	452.17	453.

A-917 - 235 -

23	 2-(1H-Benzotriazol-5-ylamino)-N-(2-methyl-benzothiazol-5-yl)-nicotinamide	$C_{20}H_{15}N_7OS$	401.44	402.7
24	 2-(1*H*-1,2,3-benzotriazol-5-ylamino)-N-(4,4-dimethyl-2-oxo-1,2,3,4-tetrahydroquinolin-7-yl)nicotinamide	$C_{23}H_{21}N_7O_2$	427.46	428.

A-917		2-(1H-benzo[d][1,2,3]triazol-5-ylamino)-N-(5-tert-butylisoxazol-3-yl)nicotinamide	$C_{19}H_{19}N_7O_2$	377.16	378

Example 26

2-(isoquinolin-7-ylamino)-benzoic acid ethyl ester:

A mixture of 2-bromo-benzoic acid ethyl ester (458 mg, 2.0 mmol), 7-aminoisoquinoline (144 mg, 1.0 mmol), $Pd(OAc)_2$ (11 mg), BINAP (30 mg) and K_2CO_3 (414 mg) in 1 mL of toluene in a sealed tube was stirred for 16 h at 105 °C. The reaction mixture was then allowed to cool to RT, diluted with 20 ml of CH_2Cl_2, filtered through a Celite® packed funnel and concentrated under reduced pressure. The concentrate was purified by flash column chromatography. The titled compound was obtained as oil. MS (ES^+): 293.3 $(M+H)^+$. Calc'd for $C_{18}H_{16}N_2O_2$- 292.

Example 27



N-(4-tert-Butyl-phenyl)-2-(isoquinolin-7-ylamino)-benzamide

A mixture of 2-(isoquinolin-7-ylamino)-benzoic acid ethyl ester (155 mg, 0.53 mmole) and LiOH monohydrate (67 mg, 1.6 mmol) in a mix solvent of MeOH (1 mL), water (1 mL) and THF (1 mL) was stirred for 14 h at RT. The resulting mixture was concentrated to dryness to the corresponding acid lithium salt as a white solid. The lithium salt obtained was mixed with 4-t-butylaniline (149 mg, 1.0 mmol), TBTU (176 mg, 0.55 mmol) and DIEA (0.04 ml) in 1 ml of DMF and the mixture was stirred at RT for 16 h, then diluted with more CH_2Cl_2. The organic layer was washed with water, brine, dried with $MgSO_4$, filtered, concentrated and the residue was purified by flash column chromatography (0 to 30% of EtOAc in CH_2Cl_2). Upon concentration of the desired fractions, the title compound was obtained as a white solid. MS (ES^+): 396.1 $(M+H)^+$. Calc'd for $C_{26}H_{25}N_3O$- 395.20.

The following Examples 28-41 were prepared utilizing a method similar to that described in Examples 11 and 27.

Ex. #	Structure	Mol. formula	Calc'd Mass	M+H
28	 N-(4,4-Dimethyl-1,2,3,4-tetrahydro-quinolin-7-yl)-2-(isoquinolin-7-ylamino)-benzamide	$C_{27}H_{26}N_4O$	422.52	423
29	 N-(4-tert-Butyl-phenyl)-3-fluoro-2-(isoquinolin-7-ylamino)-benzamide	$C_{26}H_{24}FN_3O$	413.19	414.4
30	 N-(4,4-Dimethyl-1,2,3,4-tetrahydro-quinolin-7-yl)-2-(quinazolin-6-ylamino)-benzamide	$C_{26}H_{25}N_5O$	423.21	424.

A-917 - 239 -

31	 N-(1-Acetyl-3,3-dimethyl-2,3-dihydro-1H-indol-6-yl)-2-(isoquinolin-7-ylamino)-nicotinamide	$C_{27}H_{25}N_5O_2$	451.52	452.3
32	 N-(3,3-Dimethyl-2,3-dihydro-1H-indol-6-yl)-2-(isoquinolin-7-ylamino)-nicotinamide	$C_{25}H_{23}N_5O$	409.48	410.6

33	 2-(Isoquinolin-7-ylamino)-N-(3-methoxy-5-trifluoromethyl-phenyl)-nicotinamide	$C_{23}H_{17}F_3N_4O_2$	438.13	439.1
34	 N-(4-Chloro-3-trifluoromethyl-phenyl)-2-(isoquinolin-7-ylamino)-nicotinamide	$C_{22}H_{14}ClF_3N_4O$	442.08	443.

A-917 - 241 -

35	 N-(4-tert-Butyl-phenyl)-2-([1,6]naphthyridin-3-ylamino)-nicotinamide	$C_{24}H_{23}N_5O$	397.19	398.3
36	 4,4-Dimethyl-7-{[2-([1,6]naphthyridin-3-ylamino)-pyridine-3-carbonyl]-amino}-3,4-dihydro-1H-isoquinoline-2-carboxylic acid tert-butyl ester	$C_{30}H_{22}N_6O_3$	524.25	525.3

A-917 - 242 -

37	 N-(4,4-Dimethyl-1,2,3,4-tetrahydro-isoquinolin-7-yl)-2-([1,6]naphthyridin-3-ylamino)-nicotinamide	$C_{25}H_{24}N_6O$	424.2	425.4
38	 2-([1,6]Naphthyridin-3-ylamino)-N-[4-(2,2,2-trifluoro-1-hydroxy-1-trifluoromethyl-ethyl)-phenyl]-nicotinamide	$C_{23}H_{15}F_6N_5O_2$	507.11	508.1

A-917 - 243 -



39	2-(isoquinolin-7-ylamino)-N-(2-methyl-1,3-benzothiazol-5-yl)nicotinamide	$C_{23}H_{17}N_5O_2S$	411.48	412.3



40	N-(4-chloro-3-methylphenyl)-2-(isoquinolin-7-ylamino)nicotinamide	$C_{27}H_{23}F_5N_4O_3$	508.50	509

Example 41



N-(4,4-Dimethyl-1,2,3,4-tetrahydro-isoquinolin-7-yl)-2-(isoquinolin-7-ylamino)-nicotinamide

Preparation of 7-[(2-chloro-pyridine-3-carbonyl)-amino]-4,4-dimethyl-3,4-dihydro-1H-isoquinoline-2-carboxylic acid tert-butyl ester

To a solution of 2-chloronicotinoyl chloride (3.52 g, 20 mmol, 1.0 eq.) and 7-amino-4,4-dimethyl-3,4-dihydro-1H-isoquinoline-2-carboxylic acid tert-butyl ester (5.52 g, 20 mmol, 1.0 eq.) in CH_2Cl_2 (100 mL) was added $NaHCO_3$ (6.4 g, 80 mmol, 4.0 eq.). The mixture was stirred for 1 h at RT, then filtered and concentrated, followed by drying on a vacuum pump for 3 hours. 7-[(2-Chloro-pyridine-3-carbonyl)-amino]-4,4-dimethyl-3,4-dihydro-1H-isoquinoline-2-carboxylic acid tert-butyl ester was obtained as a white foamy solid. This title compound was used for next step without further purification.

Preparation of 7-{[2-(isoquinolin-7-ylamino)-pyridine-3-carbonyl]-amino}-4,4-dimethyl-3,4-dihydro-1H-isoquinoline-2-carboxylic acid tert-butyl ester:

To a mixture of 7-[(2-chloro-pyridine-3-carbonyl)-amino]-4,4-dimethyl-3,4-dihydro-1H-isoquinoline-2-carboxylic acid tert-butyl ester (20.8 g, 50 mmol, 1.0 eq.), 7-aminoisoquinoline (7.2 g, 50 mmol, 1.0 eq.), $Pd_2(dba)_3$ (915 mg, 1mmol, 0.02 eq), 2-dicyclohexylphosphino-2'-(N,N-dimethylamino)biphenyl (CAS# 213697-53-1, Strem Chemicals cat no. 15-1145; 785 mg, 2 mmol, 0.04 eq) under N_2 in a 250 mL pressure reaction vessel was added 1.0 M $LiNTMS_2$ THF solution (120 mL, 120 mmol, 2.4 eq.). The reaction vessel was sealed with a Teflon screwcap and the mixture was stirred at 70 °C for 17 h. The mixture was then cooled to RT. 100 mL of water was added to the mixture and the mixture was extracted with 500 mL of EtOAc. The organic layer was

washed with sat. NH_4Cl solution, 1M $NaHPO_4$ solution (4x200 mL) then dried over $MgSO_4$. After filtration and concentration, the crude was purified through a silica gel column chromatography, eluting with CH_2Cl_2/EtOAc. The desired title compound was obtained as a yellow solid. MS (ES^+): 524 $(M+H)^+$. Calc'd for $C_{31}H_{33}N_5O_3$- 523.26

Preparation of N-(4,4-Dimethyl-1,2,3,4-tetrahydro-isoquinolin-7-yl)-2-(isoquinolin-7-ylamino)-nicotinamide:

To 14.62 g of the compound in the step above (27.95 mmole) in a 2 L RBF was added 4N HCl in EtOAC (500 mL). The mixture was stirred for 20 h at RT and filtered to collect the product as multi-HCl salt. This solid was dissolved in water (200 mL) and the aqueous layer was extracted with EtOAc. The aqueous layer was acidified to about pH 5 with 2 N NaOH solution. The title compound (as monohydrate and mono HCl salt) was obtained after filtration and drying on vacuum pump for 24 h as a light yellow solid. MS (ES^+): 424 $(M+H)^+$. Calc'd for $C_{26}H_{25}N_5O$- 423.21.

The following examples 42-66 were prepared according to a method similar to that described in Example 41:

Ex. #	Structure	Mol. formula	Calc'd Mass	M+H
42	 N-(6-tert-Butyl-pyridin-3-yl)-2-(isoquinolin-7-ylamino)-nicotinamide	$C_{24}H_{23}N_5O$	397.19	398
43	 2-(Isoquinolin-7-ylamino)-N-[4-(2,2,2-trifluoro-1-hydroxy-1-trifluoromethyl-ethyl)-phenyl]-nicotinamide	$C_{24}H_{16}F_6N_4O_2$	506.12	507

A-917 - 247 -

44	 N-(4-Isopropyl-phenyl)-2-(isoquinolin-7-ylamino)-nicotinamide	$C_{24}H_{22}N_4O$	382.18	383
45	 N-(6-Azetidin-1-yl-pyridin-3-yl)-2-(isoquinolin-7-ylamino)-nicotinamide	$C_{23}H_{20}N_6O$	396.17	397
46	 N-[4-(1,1-Dimethyl-propyl)-phenyl]-2-(isoquinolin-7-ylamino)-nicotinamide	$C_{26}H_{26}N_4O$	410.21	411

A-917 - 248 -

47	 N-(5-Azetidin-1-yl-pyridin-2-yl)-2-(isoquinolin-7-ylamino)-nicotinamide	$C_{23}H_{20}N_6O$	396.17	397
48	 2-(Isoquinolin-7-ylamino)-N-(3-methyl-4-pentafluoroethyl-phenyl)-nicotinamide	$C_{24}H_{17}F_5N_4O$	472.13	473
49	 N-(4-Isopropyl-3-methyl-phenyl)-2-(isoquinolin-7-ylamino)-nicotinamide	$C_{25}H_{24}N_4O$	396.20	397

50	 N-(3-tert-Butyl-isoxazol-5-yl)-2-(quinazolin-6-ylamino)-nicotinamide	$C_{21}H_{20}N_6O_2$	388.16	389
51	 N-(4,4-Dimethyl-1,2,3,4-tetrahydro-isoquinolin-7-yl)-2-(quinazolin-6-ylamino)-nicotinamide	$C_{25}H_{24}N_6O$	424.20	425
52	 2(R,S)-(4-{[2-(Isoquinolin-7-ylamino)-pyridine-3-carbonyl]-amino}-phenyl)-propionic acid ethyl ester	$C_{26}H_{24}N_4O_3$	440.18	441

53		2(R,S)-(4-{[2-(Isoquinolin-7-ylamino)-pyridine-3-carbonyl]-amino}-phenyl)-propionic acid	$C_{24}H_{20}N_4O_3$	412.15	413
54		N-(4,4-Dimethyl-2-oxo-1,2,3,4-tetrahydro-quinolin-7-yl)-2-(isoquinolin-7-ylamino)-nicotinamide	$C_{26}H_{23}N_5O_2$	437.50	438.2
55		2-(isoquinolin-7-ylamino)-N-(3-oxo-3,4-dihydro-2H-1,4-benzothiazin-6-yl)nicotinamide	$C_{23}H_{17}N_5O_2S$	427.49	428.3



56	N-(4-tert-Butyl-phenyl)-2-(quinazolin-6-ylamino)-nicotinamide	$C_{24}H_{23}N_5O$	397.19	398.2



57	N-(4,4-Dimethyl-1,2,3,4-tetrahydro-quinolin-7-yl)-2-(quinazolin-6-ylamino)-nicotinamide	$C_{25}H_{24}N_6O$	424.20	425.4



58	N-(5,5-dimethyl-7-oxo-5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)-2-(isoquinolin-7-ylamino)nicotinamide	$C_{25}H_{22}N_6O_2$	438.49	439.21



59	N-(5,5-dimethyl-7-oxo-5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)-2-(quinazolin-6-ylamino)nicotinamide	$C_{24}H_{21}N_7O_2$	439.49	440.2

60	 N-(3-chloro-4-methylphenyl)-2-(isoquinolin-7-ylamino)nicotinamide	$C_{22}H_{17}ClN_4O$	388.57	389
61	 2-(isoquinolin-7-ylamino)-N-(4-(trifluoromethoxy)phenyl)nicotinamide	$C_{22}H_{15}F_3N_4O_2$	424.38	425.1

62	 2-(isoquinolin-7-ylamino)-N-(3-methyl-4-(pyrrolidin-1-yl)phenyl)nicotinamide	$C_{26}H_{25}N_5O$	423.21	424
63	 2-(2-aminoquinazolin-6-ylamino)-N-(3-methyl-4-(1-methylethyl)phenyl) nicotinamide	$C_{24}H_{24}N_6O$	412.49	413

A-917 - 255 -



64	2-(2-aminoquinazolin-6-ylamino)-N-(3-chloro-4-methylphenyl) nicotinamide	$C_{21}H_{17}N_6ClO$	404.12	405



65	2-(2-aminoquinazolin-6-ylamino)-N-(4-chlorophenyl) nicotinamide	$C_{20}H_{15}N_6ClO$	390.1	391



66	2-(2,4-diaminoquinazolin-6-ylamino)-N-(4-tert-butylphenyl) nicotinamide	$C_{25}H_{24}N_7O$	427.21	428

The following examples 67 - 72 were prepared according to a method similar to that described in Example 43 and scheme 8. Particularly, the starting materials possessed the nucleophile (NH_2) and leaving group (halogen such as Cl) in reverse order, i.e., a chloro-nicotinamide was reacted with an amino-heterocycle to obtain the desired product (scheme 8).



67	N-(4-tert-Butyl-phenyl)-	$C_{25}H_{24}N_4O$	396.49	

	2-(isoquinolin-5-ylamino)-nicotinamide		397.1	
				
68	2-(Isoquinolin-5-ylamino)-N-[3-(1-methyl-pyrrolidin-2-ylmethoxy)-5-trifluoromethyl-phenyl]-nicotinamide	$C_{28}H_{26}F_3N_5O_2$	521.24	522.1
				
69	N-(4,4-Dimethyl-1,2,3,4-tetrahydro-isoquinolin-7-yl)-2-(isoquinolin-5-ylamino)-nicotinamide	$C_{28}H_{25}N_5O_2$	423.52	424.2
				
70		$C_{25}H_{23}N_5O$	409.49	

A-917 - 258 -

	N-(3,3-Dimethyl-2,3-dihydro-1H-indol-6-yl)-2-(isoquinolin-5-ylamino)-nicotinamide 			410.2
71	N-(3-tert-butylisoxazol-5-yl)-2-(isoquinolin-5-ylamino)nicotinamide 	$C_{22}H_{21}N_5O_2$	387.17	388
72	N-(4-(1,1-dimethylethyl)phenyl)-2-(5-quinolinylamino)-3-pyridinecarboxamide	$C_{25}H_{24}N_5O$	396.49	397

Example 73



A-917 - 259 -

[2-(7-{[2-(Isoquinolin-7-ylamino)-pyridine-3-carbonyl]-amino}-4,4-dimethyl-3,4-dihydro-1H-isoquinolin-2-yl)-2-oxo-ethyl]-carbamic acid tert-butyl ester

[2-(7-{[2-(Isoquinolin-7-ylamino)-pyridine-3-carbonyl]-amino}-4,4-dimethyl-3,4-dihydro-1H-isoquinolin-2-yl)-2-oxo-ethyl]-carbamic acid tert-butyl ester (Example no. 68; 423 mg, 1 mmole) was treated with Boc-glycine (193mg, 1.1 mmole, 1.1 eq), EDAC (380 mg, 2 mmole, 2 eq), HOBt (135 mg, 1 mmole, 1.0 eq), and DIEA (500 mL) in CH_2Cl_2 (50 mL). The reaction was stirred over night. The solution was washed with $NaHCO_3$ (Aq., Sat., 50 mL) followed by brine. The CH_2Cl_2 solution was concentrated in vacuo. The residue was purified via HPLC in reverse phase (eluent: MeCN-H_2O:5-95% with 0.1% TFA) to afford the titled compound as a yellow solid. MS: (ES+) 581(M+H). Calc'd. for C33H36N6O4 - 580.68.

The following example 74 was prepared according to a method similar to that described in Example 73:



74	N-[4,4-Dimethyl-2-(tetrahydro-furan-2-carbonyl)-1,2,3,4-tetrahydro-isoquinolin-7-yl]-2-(isoquinolin-7-ylamino)-nicotinamide	$C_{31}H_{31}N_5O_3$	521.61	522

Example 75



N-[2-(2-Amino-acetyl)-4,4-dimethyl-1,2,3,4-tetrahydro-isoquinolin-7-yl]-2-(isoquinolin-7-ylamino)-nicotinamide

The compound above (Example no.73; 200 mg, 0.34 mmole) was treated with saturated HCl in EtOAc (50mL) over night at RT. Vacuum filtration of the reaction provided a yellow crystalline solid as the desired titled compound. MS: (ES+) 481(M+H). Calc'd. for $C_{28}H_{28}N_6O_2$ - 480.56.

Example 76



A-917 - 261 -

N-(4-tert-Butyl-phenyl)-2-([1,7]naphthyridin-2-ylamino)-benzamide

2-Chloro-[1,7]naphthyridine (100 mg, 0.61 mmol), 2-amino-N-(4-tert-butyl-phenyl)-benzamide (164 mg, 0.61 mmol), $Pd_2(dba)_3$ (6 mg, 0.006 mmol), (2'-Dicyclohexylphosphanyl-biphenyl-2-yl)-dimethyl-amine (6 mg, 0.015 mmol), and 1M solution of $LiN(TMS)_2$ in THF (1.83 mL), 1.83 mmol) were added to a reaction vessel. The vessel was sealed and the reaction was stirred at 70 °C for 24h. The mixture was cooled to RT, and solvent was removed under vacuum. The crude was purified by flash column chromatography (gradiant, 0 to 100% EtoAC/Hexane) to give the product as tan solid. MS (ES^-): 397.0 $(M+H)^+$. Calc'd for $C_{25}H_{24}N_4O$ - 396.20.

The following example 77 was prepared according to a method similar to that described in Example 76:



77	N-(4,4-Dimethyl-1,2,3,4-tetrahydro-isoquinolin-7-yl)-2-([1,7]naphthyridin-2-ylamino)-benzamide	$C_{26}H_{25}N_5O$	423.2	424.3

The additional examples in Tables 1-5 will further provide assistance in understanding and appreciating various, specific embodiments of the present invention.

Table 1.



#	R^1	R^2
78.	2-chlorophenyl	H
79.	3-chlorophenyl	H
80.	4-chlorophenyl	H
81.	3-trifluoromethylphenyl	H
82.	4-trifluoromethylphenyl	H
83.	3-chloro-4-trifluoromethylphenyl	H
84.	3-pentafluoroethylphenyl	H
85.	4-pentafluoroethylphenyl	H
86.	3-cyclopropylphenyl	H
87.	4-cyclopropylphenyl	H
88.	2-methylphenyl	H
89.	3-methylpheny	H
90.	4-methylphenyl	H
91.	2-(1-methylethyl)phenyl	H
92.	3-(1-methylethyl)phenyl	H
93.	4-(1-methylethyl)phenyl	H
94.	2-methyl-4-(1-methylethyl)phenyl	H
95.	3-methyl-4-(1-methylethyl)phenyl	H
96.	4-(1-methylethyl)-3-methylphenyl	H
97.	2-t-butylphenyl	H
98.	3-t-butylphenyl	H

99.	4-t-butylphenyl	H
100.	3-(1-hydroxy-1,1-di-trifluoromethyl)methylphenyl	H
101.	4-(1-hydroxy-1,1-di-trifluoromethyl)methylphenyl	H
102.	3-(1,1-dimethyl)propylphenyl	H

Table 1. (cont.)



#	R^1	R^2
103.	4-(1,1-dimethyl)propylphenyl	H
104.	2-methoxyphenyl	H
105.	3-methoxyphenyl	H
106.	4-methoxyphenyl	H
107.	4-phenoxyphenyl	H
108.	2-(1-methyl)cyclopropylphenyl	H
109.	2-((pyrrolidinylmethyl)oxy)phenyl	H
110.	3-((pyrrolidinylmethyl)oxy)phenyl	H
111.	4-((pyrrolidinylmethyl)oxy)phenyl	H
112.	3-(4-piperidinylmethyl)oxy)phenyl	H
113.	4-(4-piperidinylmethyl)oxy)phenyl	H
114.	3-((tetrahydrofuranylmethyl)oxy)phenyl	H
115.	3-(tetrahydrofuranylmethyl)oxy)-3-CF_3phenyl	H
116.	3-(4-piperidinylmethyl)phenyl	H
117.	3-(4-piperidinylmethyl)phenyl	H
118.	3-(glycylamino)phenyl	H
119.	4-(glycylamino)phenyl	H
120.	2-chlorophenyl	5-F
121.	3-chlorophenyl	5-F
122.	4-chlorophenyl	5-F

A-917 - 264 -

123.	3-trifluoromethylphenyl	5-F
124.	4-trifluoromethylphenyl	5-F
125.	3-chloro-4-trifluoromethylphenyl	5-F
126.	3-pentafluoroethylphenyl	5-F

Table 1. (cont.)



#	R^1	R^2
127.	4-pentafluoroethylphenyl	5-F
128.	3-cyclopropylphenyl	5-F
129.	4-cyclopropylphenyl	5-F
130.	2-methylphenyl	5-F
131.	3-methylpheny	5-F
132.	4-methylphenyl	5-F
133.	2-(1-methylethyl)phenyl	5-F
134.	3-(1-methylethyl)phenyl	5-F
135.	4-(1-methylethyl)phenyl	5-F
136.	2-methyl-4-(1-methylethyl)phenyl	5-F
137.	3-methyl-4-(1-methylethyl)phenyl	5-F
138.	4-(1-methylethyl)-3-methylphenyl	5-F
139.	2-t-butylphenyl	5-F
140.	3-t-butylphenyl	5-F
141.	4-t-butylphenyl	5-F
142.	3-(1-hydroxy-1,1-di-trifluoromethyl)methylphenyl	5-F
143.	4-(1-hydroxy-1,1-di-trifluoromethyl)methylphenyl	5-F
144.	3-(1,1-dimethyl)propylphenyl	5-F
145.	4-(1,1-dimethyl)propylphenyl	5-F
146.	2-methoxyphenyl	5-F
147.	3-methoxyphenyl	5-F

148.	4-methoxyphenyl	5-F
149.	2-(1-methyl)cyclopropylphenyl	5-F
150.	2-((pyrrolidinylmethyl)oxy)phenyl	5-F
151.	3-((pyrrolidinylmethyl)oxy)phenyl	5-F

Table 1. (cont.)



#	R^1	R^2
152.	4-((pyrrolidinylmethyl)oxy)phenyl	5-F
153.	3-(4-piperidinylmethyl)oxy)phenyl	5-F
154.	4-(4-piperidinylmethyl)oxy)phenyl	5-F
155.	3-((tetrahydrofuranylmethyl)oxy)phenyl	5-F
156.	3-(tetrahydrofuranylmethyl)oxy)-3-CF_3phenyl	5-F
157.	3-(4-piperidinylmethyl)phenyl	5-F
158.	3-(4-piperidinylmethyl)phenyl	5-F
159.	3-(glycylamino)phenyl	5-F
160.	4-(glycylamino)phenyl	5-F
161.	3-pyridyl	H
162.	4-pyridyl	H
163.	1-isoquinolyl	H
164.	3-isoquinolinyl	H
165.	4-isoquinolyl	H
166.	5-isoquinolyl	H
167.	6-isoquinolyl	H
168.	7-isoquinolyl	H
169.	tetrahydro-7-isoquinolinyl	H
170.	1-oxo-tetrahydro-7-isoquinolinyl	H
171.	2-oxo-tetrahydro-7-isoquinolinyl	H
172.	2-quinolinyl	H

173.	3-quinolinyl	H
174.	4-quinolinyl	H
175.	5-quinolinyl	H
176.	6-quinolinyl	H

Table 1. (cont.)



#	R^1	R^2
177.	7-quinolinyl	H
178.	tetrahydro-7-quinolinyl	H
179.	2-oxo-tetrahydro-7-quinolinyl	H
180.	5-quinozalinyl	H
181.	6-quinozalinyl	H
182.	4-indolyl	H
183.	6-indolyl	H
184.	2,3-dihydro-6-indolyl	H
185.	oxo-dihydro-6-indolyl	H
186.	5-isoindolyl	H
187.	6-isoindolyl	H
188.	2-naphthyridinyl	H
189.	3-naphthyridinyl	H
190.	4-naphthyridinyl	H
191.	5-naphthyridinyl	H
192.	tetrahydro-naphthyridinyl	H
193.	oxo-tetrahydro-naphthyridinyl	H
194.	2-isoxazolyl	H
195.	3-pyrazolyl	H
196.	5-pyrazolyl	H
197.	2-thiazolyl	H

198.	3-thiazolyl	H
199.	6-indazolyl	H
200.	5-indazolyl	H

Table 1. (cont.)



#	R^1	R^2
201.	6-benzothienyl	H
202.	6-benzofuryl	H
203.	5-benzothienyl	H
204.	5-benzofuryl	H
205.	2-benzimidazolyl	H
206.	2-benzoxazolyl	H
207.	2-benzthiazolyl	H
208.	6-benzimidazolyl	H
209.	6-benzoxazolyl	H
210.	3-(6-(1-methylcyclopropyl)pyridyl	H
211.	3-(phenoxy)-6-pyridyl	H
212.	4-(phenylcarbonyl)phenyl	H
213.	4-(phenylamino)phenyl	H
214.	4-(3-thienyl)phenyl	H
215.	4-(pyrazol-3-yl)phenyl	H
216.	4-morpholinylmethylphenyl	H
217.		H

A-917

218.  H

Table 1. (cont.)



#	R^1	R^2
219.		H
220.		H
221.	3-isoquinolinyl	5-F
222.	2-quinolinyl	5-F
223.	3-pyridyl	5-F
224.	4-pyridyl	5-F
225.	3-isoquinolinyl	5-F
226.	4-isoquinolyl	5-F
227.	5-isoquinolyl	5-F
228.	6-isoquinolyl	5-F
229.	7-isoquinolyl	5-F
230.	tetrahydro-7-isoquinolinyl	5-F
231.	1-oxo-tetrahydro-7-isoquinolinyl	5-F
232.	2-oxo-tetrahydro-7-isoquinolinyl	5-F

233.	2-quinolinyl	5-F
234.	3-quinolinyl	5-F
235.	4-quinolinyl	5-F
236.	5-quinolinyl	5-F
237.	6-quinolinyl	5-F

Table 1. (cont.)



#	R^1	R^2
238.	7-quinolinyl	5-F
239.	tetrahydro-7-quinolinyl	5-F
240.	2-oxo-tetrahydro-7-quinolinyl	5-F
241.	5-quinozalinyl	5-F
242.	6-quinozalinyl	5-F
243.	4-indolyl	5-F
244.	6-indolyl	5-F
245.	2,3-dihydro-6-indolyl	5-F
246.	oxo-dihydro-6-indolyl	5-F
247.	5-isoindolyl	5-F
248.	6-isoindolyl	5-F
249.	2-naphthyridinyl	5-F
250.	3-naphthyridinyl	5-F
251.	4-naphthyridinyl	5-F
252.	5-naphthyridinyl	5-F
253.	tetrahydro-naphthyridinyl	5-F
254.	oxo-tetrahydro-naphthyridinyl	5-F
255.	2-isoxazolyl	5-F
256.	3-pyrazolyl	5-F
257.	5-pyrazolyl	5-F

258.	2-thiazolyl	5-F
259.	3-thiazolyl	5-F
260.	6-indazolyl	5-F
261.	5-indazolyl	5-F
262.	6-benzothienyl	5-F

Table 1. (cont.)



#	R^1	R^2
263.	6-benzofuryl	5-F
264.	5-benzothienyl	5-F
265.	5-benzofuryl	5-F
266.	2-benzoxazolyl	5-F
267.	2-benzthiazolyl	5-F
268.	6-benzimidazolyl	5-F
269.	6-benzoxazolyl	5-F
270.	3-(6-(1-methylcyclopropyl)pyridyl	5-F
271.	3-(phenoxy)-6-pyridyl	5-F
272.	4-(phenylcarbonyl)phenyl	5-F
273.	4-(phenylamino)phenyl	5-F
274.	4-(3-thienyl)phenyl	5-F
275.	4-(pyrazol-3-yl)phenyl	5-F
276.	4-morpholinylmethylphenyl	5-F
277.		5-F

278.  5-F

279.  5-F

Table 2a.



#	R^1	R^2
280.	2-chlorophenyl	H
281.	3-chlorophenyl	H
282.	4-chlorophenyl	H
283.	3-trifluoromethylphenyl	H
284.	4-trifluoromethylphenyl	H
285.	3-pentafluoroethylphenyl	H
286.	4-pentafluoroethylphenyl	H
287.	3-cyclopropylphenyl	H
288.	4-cyclopropylphenyl	H
289.	2-methylphenyl	H
290.	3-methylpheny	H
291.	4-methylphenyl	H
292.	2-(1-methylethyl)phenyl	H
293.	3-(1-methylethyl)phenyl	H
294.	4-(1-methylethyl)phenyl	H
295.	2-methyl-4-(1-methylethyl)phenyl	H
296.	3-methyl-4-(1-methylethyl)phenyl	H
297.	4-(1-methylethyl)-3-methylphenyl	H

298.	2-t-butylphenyl	H
299.	3-t-butylphenyl	H
300.	4-t-butylphenyl	H
301.	3-(1-hydroxy-1,1-di-trifluoromethyl)methylphenyl	H
302.	4-(1-hydroxy-1,1-di-trifluoromethyl)methylphenyl	H
303.	3-(1,1-dimethyl)propylphenyl	H
304.	4-(1,1-dimethyl)propylphenyl	H

Table 2a. (cont.)



#	R^1	R^2
305.	2-methoxyphenyl	H
306.	3-methoxyphenyl	H
307.	4-methoxyphenyl	H
308.	4-phenoxyphenyl	H
309.	2-(1-methyl)cyclopropylphenyl	H
310.	2-((pyrrolidinylmethyl)oxy)phenyl	H
311.	3-((pyrrolidinylmethyl)oxy)phenyl	H
312.	4-((pyrrolidinylmethyl)oxy)phenyl	H
313.	3-(4-piperidinylmethyl)oxy)phenyl	H
314.	4-(4-piperidinylmethyl)oxy)phenyl	H
315.	3-((tetrahydrofuranylmethyl)oxy)phenyl	H
316.	3-(tetrahydrofuranylmethyl)oxy)-3-CF_3phenyl	H
317.	3-(4-piperidinylmethyl)phenyl	H
318.	3-(4-piperidinylmethyl)phenyl	H
319.	3-(glycylamino)phenyl	H
320.	4-(glycylamino)phenyl	H

A-917 - 273 -

321.  H

322.  H

Table 2a. (cont.)



#	R^1	R^2
323.		H
324.	2-chlorophenyl	5-F
325.	3-chlorophenyl	5-F
326.	4-chlorophenyl	5-F
327.	3-trifluoromethylphenyl	5-F
328.	4-trifluoromethylphenyl	5-F
329.	3-pentafluoroethylphenyl	5-F
330.	4-pentafluoroethylphenyl	5-F
331.	3-cyclopropylphenyl	5-F
332.	4-cyclopropylphenyl	5-F
333.	2-methylphenyl	5-F
334.	3-methylpheny	5-F
335.	4-methylphenyl	5-F
336.	2-(1-methylethyl)phenyl	5-F

337.	3-(1-methylethyl)phenyl	5-F
338.	4-(1-methylethyl)phenyl	5-F
339.	2-methyl-4-(1-methylethyl)phenyl	5-F
340.	3-methyl-4-(1-methylethyl)phenyl	5-F
341.	4-(1-methylethyl)-3-methylphenyl	5-F
342.	2-t-butylphenyl	5-F
343.	3-t-butylphenyl	5-F
344.	4-t-butylphenyl	5-F
345.	3-(1-hydroxy-1,1-di-trifluoromethyl)methylphenyl	5-F

Table 2a. (cont.)



#	R^1	R^2
346.	4-(1-hydroxy-1,1-di-trifluoromethyl)methylphenyl	5-F
347.	3-(1,1-dimethyl)propylphenyl	5-F
348.	4-(1,1-dimethyl)propylphenyl	5-F
349.	2-methoxyphenyl	5-F
350.	3-methoxyphenyl	5-F
351.	4-methoxyphenyl	5-F
352.	2-(1-methyl)cyclopropylphenyl	5-F
353.	2-((pyrrolidinylmethyl)oxy)phenyl	5-F
354.	3-((pyrrolidinylmethyl)oxy)phenyl	5-F
355.	4-((pyrrolidinylmethyl)oxy)phenyl	5-F
356.	3-(4-piperidinylmethyl)oxy)phenyl	5-F
357.	3-((tetrahydrofuranylmethyl)oxy)phenyl	5-F
358.	3-(tetrahydrofuranylmethyl)oxy)-3-CF_3phenyl	5-F
359.	3-(4-piperidinylmethyl)phenyl	5-F
360.	3-(glycylamino)phenyl	5-F
361.	4-(glycylamino)phenyl	5-F

362.	3-pyridyl	H
363.	4-pyridyl	H
364.	1-isoquinolyl	H
365.	3-isoquinolinyl	H
366.	4-isoquinolyl	H
367.	5-isoquinolyl	H
368.	6-isoquinolyl	H

Table 2a. (cont.)



#	R^1	R^2
369.	7-isoquinolyl	H
370.	tetrahydro-7-isoquinolinyl	H
371.	1-oxo-tetrahydro-7-isoquinolinyl	H
372.	2-oxo-tetrahydro-7-isoquinolinyl	H
373.	2-quinolinyl	H
374.	3-quinolinyl	H
375.	4-quinolinyl	H
376.	5-quinolinyl	H
377.	6-quinolinyl	H
378.	7-quinolinyl	H
379.	tetrahydro-7-quinolinyl	H
380.	2-oxo-tetrahydro-7-quinolinyl	H
381.	5-quinozalinyl	H
382.	6-quinozalinyl	H
383.	4-indolyl	H
384.	6-indolyl	H

385.	2,3-dihydro-6-indolyl	H
386.	oxo-dihydro-6-indolyl	H
387.	5-isoindolyl	H
388.	6-isoindolyl	H
389.	2-naphthyridinyl	H
390.	3-naphthyridinyl	H
391.	4-naphthyridinyl	H
392.	5-naphthyridinyl	H

Table 2a. (cont.)



#	R^1	R^2
393.	tetrahydro-naphthyridinyl	H
394.	oxo-tetrahydro-naphthyridinyl	H
395.	2-isoxazolyl	H
396.	3-pyrazolyl	H
397.	5-pyrazolyl	H
398.	2-thiazolyl	H
399.	3-thiazolyl	H
400.	6-indazolyl	H
401.	5-indazolyl	H
402.	3-(6-(1-methylcyclopropyl)pyridyl	H
403.	6-benzofuryl	H
404.	5-benzothienyl	H
405.	5-benzofuryl	H
406.	2-benzimidazolyl	H
407.	2-benzoxazolyl	H
408.	2-benzthiazolyl	H
409.	6-benzimidazolyl	H

410.	6-benzoxazolyl	H
411.	6-benzthiazolyl	H
412.	3-(phenoxy)-6-pyridyl	H
413.	4-(phenylcarbonyl)phenyl	H
414.	4-(phenylamino)phenyl	H
415.	4-(3-thienyl)phenyl	H
416.	4-(pyrazol-3-yl)phenyl	H
417.	4-morpholinylmethylphenyl	H

Table 2a. (cont.)



#	R^1	R^2
418.		5-F
419.		5-F
420.		5-F
421.	3-isoquinolinyl	5-F
422.	2-quinolinyl	5-F
423.	3-pyridyl	5-F
424.	4-pyridyl	5-F
425.	3-isoquinolinyl	5-F

426.	4-isoquinolyl	5-F
427.	5-isoquinolyl	5-F
428.	6-isoquinolyl	5-F
429.	7-isoquinolyl	5-F
430.	tetrahydro-7-isoquinolinyl	5-F
431.	1-oxo-tetrahydro-7-isoquinolinyl	5-F
432.	2-oxo-tetrahydro-7-isoquinolinyl	5-F
433.	2-quinolinyl	5-F

Table 2a. (cont.)



#	R^1	R^2
434.	3-quinolinyl	5-F
435.	4-quinolinyl	5-F
436.	5-quinolinyl	5-F
437.	6-quinolinyl	5-F
438.	7-quinolinyl	5-F
439.	tetrahydro-7-quinolinyl	5-F
440.	2-oxo-tetrahydro-7-quinolinyl	5-F
441.	5-quinozalinyl	5-F
442.	6-quinozalinyl	5-F
443.	4-indolyl	5-F
444.	6-indolyl	5-F
445.	2,3-dihydro-6-indolyl	5-F
446.	oxo-dihydro-6-indolyl	5-F
447.	5-isoindolyl	5-F
448.	6-isoindolyl	5-F
449.	2-naphthyridinyl	5-F
450.	3-naphthyridinyl	5-F

451.	4-naphthyridinyl	5-F
452.	5-naphthyridinyl	5-F
453.	tetrahydro-naphthyridinyl	5-F
454.	oxo-tetrahydro-naphthyridinyl	5-F
455.	2-isoxazolyl	5-F
456.	3-pyrazolyl	5-F
457.	5-pyrazolyl	5-F
458.	2-thiazolyl	5-F

Table 2a. (cont.)



#	R^1	R^2
459.	3-thiazolyl	5-F
460.	6-indazolyl	5-F
461.	5-indazolyl	5-F
462.	3-(6-(1-methylcyclopropyl)pyridyl	5-F
463.	6-benzofuryl	5-F
464.	5-benzothienyl	5-F
465.	5-benzofuryl	5-F
466.	2-benzoxazolyl	5-F
467.	2-benzthiazolyl	5-F
468.	6-benzimidazolyl	5-F
469.	6-benzoxazolyl	5-F
470.	6-benzthiazolyl	5-F
471.	3-(phenoxy)-6-pyridyl	5-F
472.	4-(phenylcarbonyl)phenyl	5-F
473.	4-(phenylamino)phenyl	5-F
474.	4-(3-thienyl)phenyl	5-F
475.	4-(pyrazol-3-yl)phenyl	5-F

476. 4-morpholinylmethylphenyl H

Table 2b.



#	R^1	R^2
477.	2-chlorophenyl	H
478.	3-chlorophenyl	H
479.	4-chlorophenyl	H
480.	3-trifluoromethylphenyl	H
481.	4-trifluoromethylphenyl	H
482.	3-chloro-4-trifluoromethylphenyl	H
483.	3-pentafluoroethylphenyl	H
484.	4-pentafluoroethylphenyl	H
485.	3-cyclopropylphenyl	H
486.	4-cyclopropylphenyl	H
487.	2-methylphenyl	H
488.	3-methylpheny	H
489.	4-methylphenyl	H
490.	2-(1-methylethyl)phenyl	H
491.	3-(1-methylethyl)phenyl	H
492.	4-(1-methylethyl)phenyl	H
493.	2-methyl-4-(1-methylethyl)phenyl	H
494.	3-methyl-4-(1-methylethyl)phenyl	H
495.	4-(1-methylethyl)-3-methylphenyl	H
496.	2-t-butylphenyl	H
497.	3-t-butylphenyl	H
498.	4-t-butylphenyl	H
499.	3-(1-hydroxy-1,1-di-trifluoromethyl)methylphenyl	H

500. 4-(1-hydroxy-1,1-di-trifluoromethyl)methylphenyl H

501. 3-(1,1-dimethyl)propylphenyl H

Table 2b. (cont.)



#	R^1	R^2
502.	4-(1,1-dimethyl)propylphenyl	H
503.	2-methoxyphenyl	H
504.	3-methoxyphenyl	H
505.	4-methoxyphenyl	H
506.	4-phenoxyphenyl	H
507.	2-(1-methyl)cyclopropylphenyl	H
508.	2-((pyrrolidinylmethyl)oxy)phenyl	H
509.	3-((pyrrolidinylmethyl)oxy)phenyl	H
510.	4-((pyrrolidinylmethyl)oxy)phenyl	H
511.	3-(4-piperidinylmethyl)oxy)phenyl	H
512.	4-(4-piperidinylmethyl)oxy)phenyl	H
513.	3-((tetrahydrofuranylmethyl)oxy)phenyl	H
514.	3-(tetrahydrofuranylmethyl)oxy)-3-CF_3phenyl	H
515.	3-(4-piperidinylmethyl)phenyl	H
516.	3-(6-(1-methylcyclopropyl)pyridyl	H
517.	3-(glycylamino)phenyl	H
518.	4-(glycylamino)phenyl	H
519.	3-pyridyl	H
520.	4-pyridyl	H
521.	1-isoquinolyl	H
522.	3-isoquinolinyl	H
523.	4-isoquinolyl	H
524.	5-isoquinolyl	H

A-917 - 282 -

525. 6-isoquinolyl	H
526. 7-isoquinolyl	H

Table 2b. (cont.)



#	R^1	R^2
527.	tetrahydro-7-isoquinolinyl	H
528.	1-oxo-tetrahydro-7-isoquinolinyl	H
529.	2-oxo-tetrahydro-7-isoquinolinyl	H
530.	2-quinolinyl	H
531.	3-quinolinyl	H
532.	4-quinolinyl	H
533.	5-quinolinyl	H
534.	6-quinolinyl	H
535.	7-quinolinyl	H
536.	tetrahydro-7-quinolinyl	H
537.	2-oxo-tetrahydro-7-quinolinyl	H
538.	5-quinozalinyl	H
539.	6-quinozalinyl	H
540.	4-indolyl	H
541.	6-indolyl	H
542.	2,3-dihydro-6-indolyl	H
543.	oxo-dihydro-6-indolyl	H
544.	5-isoindolyl	H
545.	6-isoindolyl	H
546.	2-naphthyridinyl	H
547.	3-naphthyridinyl	H
548.	4-naphthyridinyl	H
549.	5-naphthyridinyl	H

550.	tetrahydro-naphthyridinyl	H
551.	oxo-tetrahydro-naphthyridinyl	H

Table 2b. (cont.)



#	R^1	R^2
552.	2-isoxazolyl	H
553.	3-pyrazolyl	H
554.	5-pyrazolyl	H
555.		H
556.		H
557.		H
558.		H
559.		H

Table 3.



#	R^1	R^2
560.	2-chlorophenyl	H
561.	3-chlorophenyl	H
562.	4-chlorophenyl	H
563.	3-trifluoromethylphenyl	H
564.	4-trifluoromethylphenyl	H
565.	3-chloro-4-trifluoromethylphenyl	H
566.	3-pentafluoroethylphenyl	H
567.	4-pentafluoroethylphenyl	H
568.	3-cyclopropylphenyl	H
569.	4-cyclopropylphenyl	H
570.	2-methylphenyl	H
571.	3-methylpheny	H
572.	4-methylphenyl	H
573.	2-(1-methylethyl)phenyl	H
574.	3-(1-methylethyl)phenyl	H
575.	4-(1-methylethyl)phenyl	H
576.	2-methyl-4-(1-methylethyl)phenyl	H
577.	3-methyl-4-(1-methylethyl)phenyl	H
578.	4-(1-methylethyl)-3-methylphenyl	H
579.	2-t-butylphenyl	H
580.	3-t-butylphenyl	H
581.	4-t-butylphenyl	H
582.	3-(1-hydroxy-1,1-di-trifluoromethyl)methylphenyl	H
583.	4-(1-hydroxy-1,1-di-trifluoromethyl)methylphenyl	H

A-917 - 285 -

584.	3-(1,1-dimethyl)propylphenyl	H

Table 3. (cont.)



#	R^1	R^2
585.	4-(1,1-dimethyl)propylphenyl	H
586.	2-methoxyphenyl	H
587.	3-methoxyphenyl	H
588.	4-methoxyphenyl	H
589.	4-phenoxyphenyl	H
590.	2-(1-methyl)cyclopropylphenyl	H
591.	2-((pyrrolidinylmethyl)oxy)phenyl	H
592.	3-((pyrrolidinylmethyl)oxy)phenyl	H
593.	4-((pyrrolidinylmethyl)oxy)phenyl	H
594.	3-(4-piperidinylmethyl)oxy)phenyl	H
595.	4-(4-piperidinylmethyl)oxy)phenyl	H
596.	3-((tetrahydrofuranylmethyl)oxy)phenyl	H
597.	3-(tetrahydrofuranylmethyl)oxy)-3-CF_3phenyl	H
598.	3-(4-piperidinylmethyl)phenyl	H
599.	3-(6-(1-methylcyclopropyl)pyridyl	H
600.	3-(glycylamino)phenyl	H
601.	4-(glycylamino)phenyl	H
602.	3-pyridyl	H
603.	4-pyridyl	H
604.	1-isoquinolyl	H
605.	3-isoquinolinyl	H
606.	4-isoquinolyl	H
607.	5-isoquinolyl	H

608. 6-isoquinolyl	H
609. 7-isoquinolyl	H

Table 3. (cont.)



#	R^1	R^2
610.	tetrahydro-7-isoquinolinyl	H
611.	1-oxo-tetrahydro-7-isoquinolinyl	H
612.	2-oxo-tetrahydro-7-isoquinolinyl	H
613.	2-quinolinyl	H
614.	3-quinolinyl	H
615.	4-quinolinyl	H
616.	5-quinolinyl	H
617.	6-quinolinyl	H
618.	7-quinolinyl	H
619.	tetrahydro-7-quinolinyl	H
620.	2-oxo-tetrahydro-7-quinolinyl	H
621.	5-quinozalinyl	H
622.	6-quinozalinyl	H
623.	4-indolyl	H
624.	6-indolyl	H
625.	2,3-dihydro-6-indolyl	H
626.	oxo-dihydro-6-indolyl	H
627.	5-isoindolyl	H
628.	6-isoindolyl	H
629.	2-naphthyridinyl	H
630.	3-naphthyridinyl	H
631.	4-naphthyridinyl	H
632.	5-naphthyridinyl	H

633. tetrahydro-naphthyridinyl H

634. oxo-tetrahydro-naphthyridinyl H

Table 3. (cont.)



#	R^1	R^2
635.	2-isoxazolyl	H
636.	3-pyrazolyl	H
637.	5-pyrazolyl	H
638.		H
639.		H
640.		H
641.		H
642.		H

Table 4.



#	R^1	R^2
643.	3-pyridyl	H
644.	4-pyridyl	H
645.	1-isoquinolyl	H
646.	3-isoquinolinyl	H
647.	4-isoquinolyl	H
648.	5-isoquinolyl	H
649.	6-isoquinolyl	H
650.	7-isoquinolyl	H
651.	tetrahydro-7-isoquinolinyl	H
652.	1-oxo-tetrahydro-7-isoquinolinyl	H
653.	2-oxo-tetrahydro-7-isoquinolinyl	H
654.	2-quinolinyl	H
655.	3-quinolinyl	H
656.	4-quinolinyl	H
657.	5-quinolinyl	H
658.	6-quinolinyl	H
659.	7-quinolinyl	H
660.	tetrahydro-7-quinolinyl	H
661.	2-oxo-tetrahydro-7-quinolinyl	H
662.	5-quinozalinyl	H
663.	6-quinozalinyl	H
664.	4-indolyl	H
665.	6-indolyl	H

666.	2,3-dihydro-6-indolyl	H
667.	oxo-dihydro-6-indolyl	H

Table 4. (cont.)



#	R^1	R^2
668.	5-isoindolyl	H
669.	6-isoindolyl	H
670.	2-naphthyridinyl	H
671.	3-naphthyridinyl	H
672.	4-naphthyridinyl	H
673.	5-naphthyridinyl	H
674.	tetrahydro-naphthyridinyl	H
675.	oxo-tetrahydro-naphthyridinyl	H
676.	2-isoxazolyl	H
677.	3-pyrazolyl	H
678.	5-pyrazolyl	H
679.		H
680.		H
681.		H
682.		H

Table 4. (cont.)



#	R^1	R^2
683.		H
684.	6-indazolyl	H
685.	5-indazolyl	H
686.	3-(6-(1-methylcyclopropyl)pyridyl	H
687.	6-benzofuryl	H
688.	5-benzothienyl	H
689.	5-benzofuryl	H
690.	6-benzthiazolyl	H
691.	2-benzimidazolyl	H
692.	2-benzoxazolyl	H
693.	2-benzthiazolyl	H
694.	6-benzimidazolyl	H
695.	6-benzoxazolyl	H
696.		H
697.		H

Table 4. (cont.)



#	R^1	R^2
698.		H
699.		H
700.		H
701.		H
702.		H

703.  H

Table 4. (cont.)



#	R^1	R^2
704.		H
705.		H
706.		5-F
707.	3-pyridyl	5-F
708.	4-pyridyl	5-F
709.	1-isoquinolyl	5-F
710.	3-isoquinolinyl	5-F
711.	4-isoquinolyl	5-F
712.	5-isoquinolyl	5-F
713.	6-isoquinolyl	5-F
714.	7-isoquinolyl	5-F
715.	tetrahydro-7-isoquinolinyl	5-F

716.	1-oxo-tetrahydro-7-isoquinolinyl	5-F
717.	2-oxo-tetrahydro-7-isoquinolinyl	5-F
718.	2-quinolinyl	5-F
719.	3-quinolinyl	5-F

Table 4. (cont.)



#	R^1	R^2
720.	4-quinolinyl	5-F
721.	5-quinolinyl	5-F
722.	6-quinolinyl	5-F
723.	7-quinolinyl	5-F
724.	tetrahydro-7-quinolinyl	5-F
725.	2-oxo-tetrahydro-7-quinolinyl	5-F
726.	5-quinozalinyl	5-F
727.	6-quinozalinyl	5-F
728.	4-indolyl	5-F
729.	6-indolyl	5-F
730.	2,3-dihydro-6-indolyl	5-F
731.	oxo-dihydro-6-indolyl	5-F
732.	5-isoindolyl	5-F
733.	6-isoindolyl	5-F
734.	2-naphthyridinyl	5-F
735.	3-naphthyridinyl	5-F
736.	4-naphthyridinyl	5-F
737.	5-naphthyridinyl	5-F
738.	tetrahydro-naphthyridinyl	5-F
739.	oxo-tetrahydro-naphthyridinyl	5-F
740.	2-isoxazolyl	5-F

A-917 - 294 -

741.	3-pyrazolyl	5-F
742.	5-pyrazolyl	5-F

Table 4. (cont.)



#	R^1	R^2
743.		5-F
744.		5-F
745.		5-F
746.		5-F
747.		5-F
748.	6-indazolyl	5-F
749.	5-indazolyl	5-F
750.	3-(6-(1-methylcyclopropyl)pyridyl	5-F
751.	6-benzofuryl	5-F

752.	5-benzothienyl	5-F
753.	5-benzofuryl	5-F
754.	6-benzthiazolyl	5-F

Table 4. (cont.)



#	R^1	R^2
755.		5-F
756.		5-F
757.		5-F
758.		5-F
759.		5-F

A-917 - 296 -

760.  5-F

Table 4. (cont.)



#	R^1	R^2
761.		5-F
762.		5-F
763.		5-F
764.		5-F

A-917 - 297 -

765.  5-F

Table 5.



#	R^1	R^2
766.	3-pyridyl	H
767.	3-(6-(1-methylcyclopropyl)pyridyl	H
768.	1-isoquinolyl	H
769.	3-isoquinolinyl	H
770.	4-isoquinolyl	H
771.	5-isoquinolyl	H
772.	6-isoquinolyl	H
773.	7-isoquinolyl	H
774.	tetrahydro-7-isoquinolinyl	H
775.	1-oxo-tetrahydro-7-isoquinolinyl	H
776.	2-oxo-tetrahydro-7-isoquinolinyl	H
777.	2-quinolinyl	H
778.	3-quinolinyl	H
779.	4-quinolinyl	H
780.	5-quinolinyl	H
781.	6-quinolinyl	H
782.	7-quinolinyl	H
783.	tetrahydro-7-quinolinyl	H
784.	2-oxo-tetrahydro-7-quinolinyl	H

785.	5-quinozalinyl	H
786.	6-quinozalinyl	H
787.	4-indolyl	H
788.	6-indolyl	H
789.	2,3-dihydro-6-indolyl	H
790.	oxo-dihydro-6-indolyl	H

Table 5. (cont.)



#	R^1	R^2
791.	5-isoindolyl	H
792.	6-isoindolyl	H
793.	2-naphthyridinyl	H
794.	3-naphthyridinyl	H
795.	4-naphthyridinyl	H
796.	5-naphthyridinyl	H
797.	tetrahydro-naphthyridinyl	H
798.	oxo-tetrahydro-naphthyridinyl	H
799.	2-isoxazolyl	H
800.	3-pyrazolyl	H
801.	5-pyrazolyl	H
802.		H
803.		H

A-917 - 299 -

804.  H

805.  H

Table 5. (cont.)



#	R^1	R^2
806.		H
807.	6-indazolyl	H
808.	5-indazolyl	H
809.	3-(6-chloro)pyridyl	H
810.	6-benzofuryl	H
811.	3-(6-trifluoromethyl)pyridyl	H
812.	5-benzofuryl	H
813.	6-benzthiazolyl	H
814.	2-benzimidazolyl	H
815.	2-benzoxazolyl	H
816.	2-benzthiazolyl	H
817.	6-benzimidazolyl	H
818.	6-benzoxazolyl	H
819.		H

A-917 - 300 -

820.  H

Table 5. (cont.)



#	R^1	R^2
821.		H
822.		H
823.		H
824.		H
825.		H

A-917 - 301 -

826.  H

Table 5. (cont.)



#	R^1	R^2
827.		H
828.		H
829.		5-F
830.	3-pyridyl	5-F
831.	3-(6-(1-methylcyclopropyl)pyridyl	5-F
832.	1-isoquinolyl	5-F
833.	3-isoquinolinyl	5-F
834.	4-isoquinolyl	5-F
835.	5-isoquinolyl	5-F
836.	6-isoquinolyl	5-F
837.	7-isoquinolyl	5-F
838.	tetrahydro-7-isoquinolinyl	5-F

839.	1-oxo-tetrahydro-7-isoquinolinyl	5-F
840.	2-oxo-tetrahydro-7-isoquinolinyl	5-F
841.	2-quinolinyl	5-F
842.	3-quinolinyl	5-F

Table 5. (cont.)



#	R^1	R^2
843.	4-quinolinyl	5-F
844.	5-quinolinyl	5-F
845.	6-quinolinyl	5-F
846.	7-quinolinyl	5-F
847.	tetrahydro-7-quinolinyl	5-F
848.	2-oxo-tetrahydro-7-quinolinyl	5-F
849.	5-quinozalinyl	5-F
850.	6-quinozalinyl	5-F
851.	4-indolyl	5-F
852.	6-indolyl	5-F
853.	2,3-dihydro-6-indolyl	5-F
854.	oxo-dihydro-6-indolyl	5-F
855.	5-isoindolyl	5-F
856.	6-isoindolyl	5-F
857.	2-naphthyridinyl	5-F
858.	3-naphthyridinyl	5-F
859.	4-naphthyridinyl	5-F
860.	5-naphthyridinyl	5-F
861.	tetrahydro-naphthyridinyl	5-F
862.	oxo-tetrahydro-naphthyridinyl	5-F
863.	2-isoxazolyl	5-F

A-917 - 303 -

864.	3-pyrozolyl	5-F
865.	5-pyrazolyl	5-F

Table 5. (cont.)



#	R^1	R^2
866.		5-F
867.		5-F
868.		5-F
869.		5-F
870.		5-F
871.	6-indazolyl	5-F
872.	5-indazolyl	5-F
873.	3-(6-(1-methylcyclopropyl)pyridyl	5-F
874.	6-benzofuryl	5-F

875.	5-benzothienyl	5-F
876.	5-benzofuryl	5-F
877.	6-benzthiazolyl	5-F

Table 5. (cont.)



#	R^1	R^2
878.		5-F
879.		5-F
880.		5-F
881.		5-F
882.		5-F

A-917 - 305 -

883.  5-F

Table 5. (cont.)



#	R^1	R^2
884.		5-F
885.		5-F
886.		5-F
887.		5-F
888.		5-F

Table 5. (cont.)



#	R^1	R^2
889.	2-chlorophenyl	H
890.	3-chlorophenyl	H
891.	4-chlorophenyl	H
892.	3-trifluoromethylphenyl	H
893.	4-trifluoromethylphenyl	H
894.	3-pentafluoroethylphenyl	H
895.	4-pentafluoroethylphenyl	H
896.	3-cyclopropylphenyl	H
897.	4-cyclopropylphenyl	H
898.	2-methylphenyl	H
899.	3-methylpheny	H
900.	4-methylphenyl	H
901.	2-(1-methylethyl)phenyl	H
902.	3-(1-methylethyl)phenyl	H
903.	4-(1-methylethyl)phenyl	H
904.	2-methyl-4-(1-methylethyl)phenyl	H
905.	3-methyl-4-(1-methylethyl)phenyl	H
906.	4-(1-methylethyl)-3-methylphenyl	H
907.	2-t-butylphenyl	H
908.	3-t-butylphenyl	H
909.	4-t-butylphenyl	H
910.	3-(1-hydroxy-1,1-di-trifluoromethyl)methylphenyl	H
911.	4-(1-hydroxy-1,1-di-trifluoromethyl)methylphenyl	H
912.	3-(1,1-dimethyl)propylphenyl	H

Table 5. (cont.)



#	R^1	R^2
913.	4-(1,1-dimethyl)propylphenyl	H
914.	2-methoxyphenyl	H
915.	3-methoxyphenyl	H
916.	4-methoxyphenyl	H
917.	4-phenoxyphenyl	H
918.	2-(1-methyl)cyclopropylphenyl	H
919.	2-((pyrrolidinylmethyl)oxy)phenyl	H
920.	3-((pyrrolidinylmethyl)oxy)phenyl	H
921.	4-((pyrrolidinylmethyl)oxy)phenyl	H
922.	3-(4-piperidinylmethyl)oxy)phenyl	H
923.	4-(4-piperidinylmethyl)oxy)phenyl	H
924.	3-(1-piperizinyl)phenyl	H
925.	4-(1-piperizinyl)phenyl	H
926.	3-(4-piperidinylmethyl)phenyl	H
927.	3-(4-piperidinylmethyl)phenyl	H
928.	3-(glycylamino)phenyl	H
929.	4-(glycylamino)phenyl	H
930.	2-chlorophenyl	5-F
931.	3-chlorophenyl	5-F
932.	4-chlorophenyl	5-F
933.	3-trifluoromethylphenyl	5-F
934.	4-trifluoromethylphenyl	5-F
935.	3-pentafluoroethylphenyl	5-F
936.	4-pentafluoroethylphenyl	5-F
937.	3-cyclopropylphenyl	5-F

Table 5. (cont.)



#	R^1	R^2
938.	4-cyclopropylphenyl	5-F
939.	2-methylphenyl	5-F
940.	3-methylpheny	5-F
941.	4-methylphenyl	5-F
942.	2-(1-methylethyl)phenyl	5-F
943.	3-(1-methylethyl)phenyl	5-F
944.	4-(1-methylethyl)phenyl	5-F
945.	2-methyl-4-(1-methylethyl)phenyl	5-F
946.	3-methyl-4-(1-methylethyl)phenyl	5-F
947.	4-(1-methylethyl)-3-methylphenyl	5-F
948.	2-t-butylphenyl	5-F
949.	3-t-butylphenyl	5-F
950.	4-t-butylphenyl	5-F
951.	3-(1-hydroxy-1,1-di-trifluoromethyl)methylphenyl	5-F
952.	4-(1-hydroxy-1,1-di-trifluoromethyl)methylphenyl	5-F
953.	3-(1,1-dimethyl)propylphenyl	5-F
954.	4-(1,1-dimethyl)propylphenyl	5-F
955.	2-methoxyphenyl	5-F
956.	3-methoxyphenyl	5-F
957.	4-methoxyphenyl	5-F
958.	2-(1-methyl)cyclopropylphenyl	5-F
959.	2-((pyrrolidinylmethyl)oxy)phenyl	5-F
960.	3-((pyrrolidinylmethyl)oxy)phenyl	5-F
961.	4-((pyrrolidinylmethyl)oxy)phenyl	5-F

Table 5. (cont.)



#	R^1	R^2
962.	3-(4-piperidinylmethyl)oxy)phenyl	5-F
963.	4-(4-piperidinylmethyl)oxy)phenyl	5-F
964.	3-(1-piperizinyl)phenyl	5-F
965.	4-(1-piperizinyl)phenyl	5-F
966.	3-(4-piperidinylmethyl)phenyl	5-F
967.	3-(4-piperidinylmethyl)phenyl	5-F
968.	3-(glycylamino)phenyl	5-F
969.	4-(glycylamino)phenyl	5-F

Although the pharmacological properties of the compounds of Formulas I and II vary with structural change, in general, activity possessed by compounds of Formulas I and II may be demonstrated *in vivo*. The pharmacological properties of the compounds of this invention may be confirmed by a number of pharmacological in vitro assays. The exemplified pharmacological assays which follow have been carried out with the compounds according to the invention and their salts. Compounds of the present invention showed inhibition of KDR at doses less than 50 μm.

BIOLOGICAL EVALUATION

HUVEC Proliferation Assay

Human Umbilical Vein Endothelial cells are purchased from Clonetics, Inc., as cryopreserved cells harvested from a pool of donors. These cells, at passage 1, are thawed and expanded in EBM-2 complete medium, until passage 2 or 3. The cells are trypsinized, washed in DMEM + 10% FBS + antibiotics, and spun at 1000 rpm for 10 min. Prior to centrifugation of the cells, a small amount is collected for a cell count. After centrifugation, the medium is discarded, and the cells are resuspended in the appropriate volume of DMEM + 10% FBS + antibiotics to achieve a concentration of $3x10^5$ cells/mL. Another cell count is performed to confirm the cell concentration. The cells are diluted to $3x10^4$ cells/mL in DMEM + 10% FBS + antibiotics, and 100 µL of cells are added to a 96-well plate. The cells are incubated at 37 ºC for 22 h.

Prior to the completion of the incubation period, compound dilutions are prepared. Five-point, five-fold serial dilutions are prepared in DMSO, at concentrations 400-fold greater than the final concentrations desired. 2.5 µL of each compound dilution are diluted further in a total of 1 mL DMEM + 10% FBS + antibiotics (400x dilution). Medium containing 0.25% DMSO is also prepared for the 0 µM compound sample. At the 22-hour timepoint, the medium is removed from the cells, and 100 µL of each compound dilution is added. The cells are incubated at 37 ºC for 2-3 h.

During the compound pre-incubation period, the growth factors are diluted to the appropriate concentrations. Solutions of DMEM + 10% FBS + antibiotics, containing either VEGF or bFGF at the following concentrations: 50, 10, 2, 0.4, 0.08, and 0 ng/mL are prepared. For the compound-

treated cells, solutions of VEGF at 550 ng/mL or bFGF at 220 ng/mL for 50 ng/mL or 20 ng/mL final concentrations, respectively, are prepared since 10 µL of each will be added to the cells (110 µL final volume). At the appropriate time after adding the compounds, the growth factors are added. VEGF is added to one set of plates, while bFGF is added to another set of plates. For the growth factor control curves, the media on wells B4-G6 of plates 1 and 2 are replaced with media containing VEGF or bFGF at the varying concentrations (50 - 0 ng/mL). The cells are incubated at 37°C for an additional 72 h.

At the completion of the 72 h incubation period, the medium is removed, and the cells are washed twice with PBS. After the second wash with PBS, the plates are tapped gently to remove excess PBS, and the cells are placed at -70 °C for at least 30 min. The cells are thawed and analyzed using the CyQuant fluorescent dye (Molecular Probes C-7026), following the manufacturer's recommendations. The plates are read on a Victor/Wallac 1420 workstation at 485 nm/530 nm (excitation/emission). Raw data are collected and analyzed using a 4-parameter fit equation in XLFit. IC_{50} values are then determined.

The compounds of examples 10-16, 22-25, 27-77, 103, 114, 138, 210, 217-220, 638, 639, 690, 694, 696, 697, 773, 800, 805, 809, 811, 819, 820 inhibited VEGF-stimulated HUVEC proliferation at a level below 1.0uM.

Angiogenesis Model

To determine the effects of the present compounds on angiogenesis *in vivo*, selective compounds are tested in the rat corneal neovascularization micropocket model or the angiogenesis assay of Passaniti, Lab. Invest.,67, 519-28 (1992).

Rat Corneal Neovascularization Micropocket Model

In Life Aspects: Female Sprague Dawley rats weighing approximately 250 g were randomized into one of five treatment groups. Pretreatment with the vehicle or compound was administered orally, 24 h prior to surgery and continued once a day for seven additional days. On the day of surgery, the rats were temporarily anesthetized in an Isofluorane gas chamber (delivering 2.5 liters/min oxygen + 5% Isofluorane). An othoscope was then placed inside the mouth of the animal to visualize the vocal cords. A tip-blunted wire was advanced in between the vocal cords and used as a guide for the placement of an endotracheal Teflon tube (Small Parts Inc. TFE-standard Wall R-SWTT-18). A volume-controlled ventilator (Harvard Apparatus, Inc. Model 683) was connected to the endotracheal tube to deliver a mixture of oxygen and 3% Isofluorane. Upon achieving deep anesthesia, the whiskers were cut short and the eye areas and eyes gently washed with Betadine soap and rinsed with sterile saline. The corneas were irrigated with one to two drops of Proparacaine HCl ophthalmic topical anesthetic solution (0.5%) (Bausch and Lomb Pharmaceuticals, Tampa FL). The rat was then positioned under the dissecting microscope and the corneal surface brought into focus. A vertical incision was made on the midline of the cornea using a diamond blade knife. A pocket was created by using fine scissors to separate the connective tissue layers of the stroma, tunneling towards the limbus of the eye. The distance between the apex of the pocket and the limbus was approximately 1.5 mm. After the pocket had been made, the soaked nitrocellulose disk filter (Gelman Sciences, Ann Arbor MI.) was inserted under the lip of the pocket. This surgical procedure was performed on both eyes. rHu-bFGF soaked disks were placed into the right eye, and the rHu-

VEGF soaked disks were placed into the left eye. Vehicle soaked disks were placed in both eyes. The disk was pushed into position at the desired distance from the limbal vessels. Ophthalmic antibiotic ointment was applied to the eye to prevent drying and infection. After seven days, the rats were euthanized by CO_2 asphyxiation, and the eyes enucleated. The retinal hemisphere of the eye was windowed to facilitate fixation, and the eye placed into formalin overnight.

Post Mortem Aspects: After twenty-four hours in fixative, the corneal region of interest was dissected out from the eye, using fine forceps and a razorblade. The retinal hemisphere was trimmed off and the lens extracted and discarded. The corneal dome was bisected and the superfluous cornea trimmed off. The iris, conjunctiva and associated limbal glands were then carefully teased away. Final cuts were made to generate a square 3x3 mm containing the disk, the limbus, and the entire zone of neovascularization.

Gross Image Recording: The corneal specimens were digitally photographed using a Sony CatsEye DKC5000 camera (A.G. Heinz, Irvine CA) mounted on a Nikon SMZ-U stereo microscope (A.G. Heinz). The corneas were submerged in distilled water and photographed via trans-illumination at approximately 5.0 diameters magnification.

Image analysis: Numerical endpoints were generated using digital micrographs collected from the whole mount corneas after trimming and were used for image analysis on the Metamorph image analysis system (Universal Imaging Corporation, West Chester PA). Three measurements were taken: Disk placement distance from the limbus, number of

vessels intersecting a 2.0 mm perpendicular line at the midpoint of the disk placement distance, and percent blood vessel area of the diffusion determined by thresholding.

General Formulations:

0.1% BSA in PBS vehicle: 0.025 g of BSA was added to 25.0 ml of sterile 1X phosphate buffered saline, gently shaken until fully dissolved, and filtered at 0.2 µm. Individual 1.0 ml samples were aliquoted into 25 single use vials, and stored at -20 ºC until use. For the rHu-bFGF disks, a vial of this 0.1% BSA solution was allowed to thaw at room temperature. Once thawed, 10 µl of a 100 mM stock solution of DTT was added to the 1 ml BSA vial to yield a final concentration of 1 mM DTT in 0.1% BSA.

rHu-VEGF Dilutions:
Prior to the disk implant surgery, 23.8 µl of the 0.1% BSA vehicle above was added to a 10 µg rHu-VEGF lyophilized vial yielding a final concentration of 10 µM.

rHu-bFGF: Stock concentration of 180 ng/µl:
R&D rHu- bFGF: Added 139 µl of the appropriate vehicle above to the 25 µg vial lyophilized vial. 13.3 µl of the [180 ng/µl] stock vial and added 26.6 µl of vehicle to yield a final concentration of 3.75 µM concentration.

Nitro-cellulose disk preparation: The tip of a 20-gauge needle was cut off square and beveled with emery paper to create a punch. This tip was then used to cut out ≅0.5mm diameter disks from a nitrocellulose filter paper sheet (Gelman Sciences). Prepared disks were then placed into Eppendorf microfuge tubes containing solutions of either 0.1% BSA in PBS vehicle, 10 µM rHu-VEGF (R&D Systems, Minneapolis, MN), or 3.75 µM rHu-bFGF (R&D Systems,

Minneapolis, MN) and allowed to soak for 45-60 min before use. Each nitrocellulose filter disk absorbs approximately 0.1 µl of solution.

In the rat micropocket assay, compounds of the present invention will inhibit angiogenesis at a dose of less than 50 mg/kg/day.

Tumor model

A431 cells (ATCC) are expanded in culture, harvested and injected subcutaneously into 5-8 week old female nude mice (CD1 nu/nu, Charles River Labs) (n=5-15). Subsequent administration of compound by oral gavage (10 - 200 mpk/dose) begins anywhere from day 0 to day 29 post tumor cell challenge and generally continues either once or twice a day for the duration of the experiment. Progression of tumor growth is followed by three dimensional caliper measurements and recorded as a function of time. Initial statistical analysis is done by repeated measures analysis of variance (RMANOVA), followed by Scheffe post hoc testing for multiple comparisons. Vehicle alone (Ora-Plus, pH 2.0) is the negative control. Compounds of the present invention are active at doses less than 150 mpk.

Rat Adjuvant Arthritis Model:

The rat adjuvant arthritis model (Pearson, Proc. Soc. Exp. Biol. 91, 95-101 (1956)) is used to test the anti-arthritic activity of compounds of the formula 1, or salts thereof. Adjuvant Arthritis can be treated using two different dosing schedules: either (i) starting time of immunization with adjuvant (prophylactic dosing); or from day 15 when the arthritic response is already established

(therapeutic dosing). Preferably a therapeutic dosing schedule is used.

Rat Carrageenan-induced Analgesia Test

The rat carrageenan analgesia test was performed with materials, reagents and procedures essentially as described by Hargreaves, et al., (Pain, 32, 77 (1988)). Male Sprague-Dawley rats were treated as previously described for the Carrageenan Foot Pad Edema test. Three hours after the injection of the carrageenan, the rats were placed in a special plexiglass container with a transparent floor having a high intensity lamp as a radiant heat source, positionable under the floor. After an initial twenty minute period, thermal stimulation was begun on either the injected foot or on the contralateral uninjected foot. A photoelectric cell turned off the lamp and timer when light was interrupted by paw withdrawal. The time until the rat withdraws its foot was then measured. The withdrawal latency in seconds was determined for the control and drug-treated groups, and percent inhibition of the hyperalgesic foot withdrawal determined.

Formulations

Also embraced within this invention is a class of pharmaceutical compositions and medicaments comprising active compounds of Formula I, or Formula II, in association with one or more non-toxic, pharmaceutically-acceptable carriers and/or diluents and/or adjuvants (collectively referred to herein as "carrier" materials) and, if desired, other active ingredients. The term "pharmaceutical composition" as used herein, is intended to be synonymous with the term "medicament", for purposes of preparation, administration and/or use, as is readily appreciated by those of ordinary skill in the art. The compositions which

comprise the active compounds, may be administered by any suitable route, preferably in the form of a pharmaceutical composition adapted to such a route, and in a dose effective for the treatment intended. The compositions may, for example, be administered orally, mucosally, topically, rectally, pulmonarily such as by inhalation spray, or parentally including intravascularly, intravenously, intraperitoneally, subcutaneously, intramuscularly intrasternally and infusion techniques, in dosage unit formulations containing conventional pharmaceutically acceptable carriers, adjuvants, and vehicles.

The pharmaceutically active compounds of this invention can be processed in accordance with conventional methods of pharmacy to produce medicinal agents for administration to patients, including humans and other mammals.

For oral administration, the pharmaceutical composition may be in the form of, for example, a tablet, capsule, suspension or liquid. The pharmaceutical composition or medicament is preferably made in the form of a dosage unit containing a particular amount of the active ingredient. Examples of such dosage units are tablets or capsules. For example, these may contain an amount of active ingredient from about 1 to 2000 mg, preferably from about 1 to 500 mg or 5 to 1000 mg. A suitable daily dose for a human or other mammal may vary widely depending on the condition of the patient and other factors, but, once again, can be determined using routine methods.

The amount of compounds which are administered and the dosage regimen for treating a disease condition with the compounds and/or compositions of this invention depends on a variety of factors, including the age, weight, gender and medical condition of the subject, the type of disease, the severity of the disease, the route and frequency of

administration, and the particular compound employed. Thus, the dosage regimen may vary widely, but can be determined routinely using standard methods. A daily dose of about 0.01 to 500 mg/kg, preferably between about 0.1 and about 50 mg/kg, and more preferably about 0.1 and about 20 mg/kg body weight may be appropriate. The daily dose can be administered in one to four doses per day.

For therapeutic purposes, the active compounds of this invention are ordinarily combined with one or more adjuvants appropriate to the indicated route of administration. If administered per dose, the compounds may be admixed with suitable excipients, including lactose, sucrose, starch powder, cellulose esters of alkanoic acids, cellulose alkyl esters, talc, stearic acid, magnesium stearate, magnesium oxide, sodium and calcium salts of phosphoric and sulfuric acids, gelatin, acacia gum, sodium alginate, polyvinylpyrrolidone, and/or polyvinyl alcohol, and then tableted or encapsulated for convenient administration. Such capsules or tablets may contain a controlled-release formulation as may be provided in a dispersion of active compound in hydroxypropylmethyl cellulose.

In the case of psoriasis and other skin conditions, it may be preferable to apply a topical preparation of compounds of this invention to the affected area two to four times a day.

Formulations suitable for topical administration include liquid or semi-liquid preparations suitable for penetration through the skin (*e.g.*, liniments, lotions, ointments, creams, or pastes) and drops suitable for administration to the eye, ear, or nose. A suitable topical dose of active ingredient of a compound of the invention is 0.1 mg to 150 mg administered one to four, preferably one or two times daily. For topical

administration, the active ingredient may comprise from 0.001% to 10% w/w, *e.g.*, from 1% to 2% by weight of the formulation, although it may comprise as much as 10% w/w, but preferably not more than 5% w/w, and more preferably from 0.1% to 1% of the formulation.

When formulated in an ointment, the active ingredients may be employed with either paraffinic or a water-miscible ointment base. Alternatively, the active ingredients may be formulated in a cream with an oil-in-water cream base. If desired, the aqueous phase of the cream base may include, for example at least 30% w/w of a polyhydric alcohol such as propylene glycol, butane-1,3-diol, mannitol, sorbitol, glycerol, polyethylene glycol and mixtures thereof. The topical formulation may desirably include a compound which enhances absorption or penetration of the active ingredient through the skin or other affected areas. Examples of such dermal penetration enhancers include DMSO and related analogs.

Compounds of the invention can also be administered to a subject by a transdermal device. Preferably transdermal administration will be accomplished using a patch either of the reservoir and porous membrane type or of a solid matrix variety. In either case, the active agent is delivered continuously from the reservoir or microcapsules through a membrane into the active agent permeable adhesive, which is in contact with the skin or mucosa of the recipient. If the active agent is absorbed through the skin, a controlled and predetermined flow of the active agent is administered to the recipient. In the case of microcapsules, the encapsulating agent may also function as the membrane.

The oily phase of the emulsions of this invention may be constituted from known ingredients in a known manner. While the phase may comprise merely an emulsifier, it may comprise a mixture of at least one emulsifier with a fat or

an oil or with both a fat and an oil. Preferably, a hydrophilic emulsifier is included together with a lipophilic emulsifier which acts as a stabilizer. It is also preferred to include both an oil and a fat. Together, the emulsifier(s) with or without stabilizer(s) make-up the so-called emulsifying wax, and the wax together with the oil and fat make up the so-called emulsifying ointment base which forms the oily dispersed phase of the cream formulations. Emulsifiers and emulsion stabilizers suitable for use in the formulation of the present invention include Tween 60, Span 80, cetostearyl alcohol, myristyl alcohol, glyceryl monostearate, sodium lauryl sulfate, glyceryl distearate alone or with a wax, or other materials well known in the art.

The choice of suitable oils or fats for the formulation is based on achieving the desired cosmetic properties, since the solubility of the active compound in most oils likely to be used in pharmaceutical emulsion formulations is very low. Thus, the cream should preferably be a non-greasy, non-staining and washable product with suitable consistency to avoid leakage from tubes or other containers. Straight or branched chain, mono- or dibasic alkyl esters such as di-isoadipate, isocetyl stearate, propylene glycol diester of coconut fatty acids, isopropyl myristate, decyl oleate, isopropyl palmitate, butyl stearate, 2-ethylhexyl palmitate or a blend of branched chain esters may be used. These may be used alone or in combination depending on the properties required. Alternatively, high melting point lipids such as white soft paraffin and/or liquid paraffin or other mineral oils can be used.

Formulations suitable for topical administration to the eye also include eye drops wherein the active ingredients are dissolved or suspended in suitable carrier,

especially an aqueous solvent for the active ingredients. The active ingredients are preferably present in such formulations in a concentration of 0.5 to 20%, advantageously 0.5 to 10% and particularly about 1.5% w/w.

Formulations for parenteral administration may be in the form of aqueous or non-aqueous isotonic sterile injection solutions or suspensions. These solutions and suspensions may be prepared from sterile powders or granules using one or more of the carriers or diluents mentioned for use in the formulations for oral administration or by using other suitable dispersing or wetting agents and suspending agents. The compounds may be dissolved in water, polyethylene glycol, propylene glycol, ethanol, corn oil, cottonseed oil, peanut oil, sesame oil, benzyl alcohol, sodium chloride, tragacanth gum, and/or various buffers. Other adjuvants and modes of administration are well and widely known in the pharmaceutical art. The active ingredient may also be administered by injection as a composition with suitable carriers including saline, dextrose, or water, or with cyclodextrin (ie. Captisol), cosolvent solubilization (ie. propylene glycol) or micellar solubilization (ie. Tween 80).

The sterile injectable preparation may also be a sterile injectable solution or suspension in a non-toxic parenterally acceptable diluent or solvent, for example as a solution in 1,3-butanediol. Among the acceptable vehicles and solvents that may be employed are water, Ringer's solution, and isotonic sodium chloride solution. In addition, sterile, fixed oils are conventionally employed as a solvent or suspending medium. For this purpose any bland fixed oil may be employed, including synthetic mono- or diglycerides. In addition, fatty acids such as oleic acid find use in the preparation of injectables.

For pulmonary administration, the pharmaceutical composition may be administered in the form of an aerosol or with an inhaler including dry powder aerosol.

Suppositories for rectal administration of the composition can be prepared by mixing the pharmaceutically active ingredients (including compounds of Formula I, also commonly referred to as "drug") with one or more suitable non-irritating excipients such as cocoa butter and polyethylene glycols that are solid at ordinary temperatures but liquid at the rectal temperature and will therefore melt in the rectum and release the drug.

The pharmaceutical compositions may be subjected to conventional pharmaceutical operations such as sterilization and/or may contain conventional adjuvants, such as preservatives, stabilizers, wetting agents, emulsifiers, buffers etc. Tablets and pills can additionally be prepared with enteric coatings. Such compositions may also comprise adjuvants, such as wetting, sweetening, flavoring, and perfuming agents.

The foregoing is merely illustrative of the invention and is not intended to limit the invention to the disclosed compounds. Variations and changes which are obvious to one skilled in the art are intended to be within the scope and nature of the invention which are defined in the appended claims.

From the foregoing description, one skilled in the art can easily ascertain the essential characteristics of this invention, and without departing from the spirit and scope thereof, can make various changes and modifications of the invention to adapt it to various usages and conditions.



2005267161 30 Jan 2009

THE CLAIMS DEFINING THE INVENTION ARE AS FOLLOWS:-

1. A compound, wherein the compound is 2-(7-isoquinolinylamino)-N-(3-methyl-4-(1-methylethyl)phenyl)-3-pyridinecarboxamide, or a pharmaceutically acceptable salt or derivative thereof.

2. A compound of the following formula:



,

or a pharmaceutically acceptable salt thereof.

3. The compound according to claim 1 or claim 2, wherein the salt is selected from a benzenesulfonate salt, an ethanesulfonate salt, an ethanedisulfonate salt, a methanesulfonate salt, a p-toluenesulfonate salt, a phosphate salt, a hydrobromide salt, a nitrate salt, a hydrochloride salt, a citrate salt, a medronate salt, a tosylate salt, a maleate salt, a fumarate salt, a napsylate salt, a pamoate salt, a salicylate salt, a stearate salt, a sulfate salt and a sulfonate salt.

4. The compound according to claim 3 wherein the salt is selected from a phosphate salt, a hydrochloride salt, a sulfate salt and a sulfonate salt.

5. A pharmaceutical composition comprising a compound according to any one of claims 1 to 4 and a pharmaceutically acceptable carrier.

6. A method of treating cancer in a subject, said method comprising administering to the subject an effective amount of a compound according to any one of claims 1 to 4 or a pharmaceutical composition according to claim 5.

7. The method according to claim 6 wherein the compound or pharmaceutical composition is administered in combination with one or more compounds selected from an anti-neoplastic agent, an anti-angiogenic agent, a chemotherapeutic agent and a peptidal cancer therapy agent.

8. The method according to claim 7 wherein the anti-neoplastic agent is selected from an antibiotic-type agent, an alkylating agent, an anti-metabolite agent, a hormonal agent, an immunological agent, an interferon-type agent, a kinase inhibitor, a miscellaneous agent and combinations thereof.

9. A method of treating angiogenesis in a subject, said method comprising administering to the subject an effective amount of a compound according to any one of claims 1 to 4 or a pharmaceutical composition according to claim 5.

10. A method of treating a VEGFR-related disorder in a subject, said method comprising administering to the subject an effective amount of a compound according to any one of claims 1 to 4 or a pharmaceutical composition according to claim 5.

11. A method of treating a proliferation-related disorder in a subject, said method comprising administering to the subject an effective amount of a compound according to any one of claims 1 to 4 or a pharmaceutical composition according to claim 5.

12. The method according to claim 11 wherein the disorder is inflammation or an inflammation-related disorder.

13. A method of reducing blood flow in a tumor in a subject, said method comprising administering to the subject an effective amount of a compound according to any one of claims 1 to 4 or a pharmaceutical composition according to claim 5.

14. A method of reducing tumor size in a subject, said method comprising administering to the subject an effective amount of a compound according to any one of claims 1 to 4 or a pharmaceutical composition according to claim 5.

15. A method of treating diabetic retinopathy in a subject, said method comprising administering to the subject an effective amount of a compound according to any one of claims 1 to 4 or a pharmaceutical composition according to claim 5.

16. Use of a compound according to any one of claims 1 to 4 for the preparation of a medicament for treating cancer.

17. Use of a compound according to any one of claims 1 to 4 for the preparation of a medicament for treating angiogenesis.

18. Use of a compound according to any one of claims 1 to 4 for the preparation of a medicament for treating a VEGFR-related disorder.

19. Use of a compound according to any one of claims 1 to 4 for the preparation of a medicament for treating a proliferation-related disorder.

20. Use of a compound according to any one of claims 1 to 4 for the preparation of a medicament for reducing blood flow in a tumor.

21. Use of a compound according to any one of claims 1 to 4 for the preparation of a medicament for reducing tumor size.

22. Use of a compound according to any one of claims 1 to 4 for the preparation of a medicament for treating diabetic retinopathy in a subject.

23. A compound; a pharmaceutical composition; a method of treatment; a method of reducing blood flow in a tumor; a method of reducing tumor size; or use of a compound, substantially as herein described with reference to any one or more of the examples but excluding comparative examples.